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1 Introduction
About 800 receptors in the human body are G protein-coupled receptors (GPCRs)which represent the largest receptor family.1 They represent one of the most im-portant classes of targets for drug development, and about 30% of all marketeddrugs target GPCRs.2 Many of the most important drug classes, including beta-adrenergic blockers, antihistamines, opioids and dopamine receptor agonists actvia GPCRs. Some GPCRs cannot only be activated by small molecules, but also bypeptides, proteins and even by light. In the human body they are involved in variousphysiological and pathological processes. Neurotransmission, hormone regulation,sensory functions, chemotaxis, cell growth and differentiation, to name a few, aremediated by GPCRs. The award of the Nobel Prize to Brian Kobilka and Robert J.Lefkowitz in 2012 for their research on GPCRs highlights their unique importance.
1.1 G protein-coupled receptors
1.1.1 Receptor pharmacologyReceptors are cellular macromolecules which selectively bind a specific compoundwhich induces a cellular response. This process can be metaphorically describedas a "key lock principle" where the so-called ligand like a key perfectly fits into thebinding pocket of the receptor, the lock. Receptors can thereby be stabilized in anactive or an inactive conformation. Ligands which activate the receptor by stabiliz-ing its active conformation are called agonists. The activation of the receptor resultsin a further signal transduction cascade in the cell and finally in a physiological orpathological effect. On the other hand, antagonists are ligands that block the recep-tor and prevent the binding of an agonist but do not induce a signal transduction.Inverse agonists are a specific type of antagonists that stabilize the inactive con-formation of the receptor.3 The part of the receptor where the endogenous ligand
1
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binds is the orthosteric binding pocket. Besides, there may be additional bindingsites, which are upon ligand binding also able to influence the binding or effects oforthosteric ligands. Those ligands are called allosteric modulators.4
1.1.2 Structure and classification of G protein-coupled receptorsG protein-coupled receptors consist of seven α-helical transmembrane domains thatare connected by three intracellular and three extracellular loops. They display anextracellular N-terminal domain and an intracellular C-terminal domain. That is whythey are also called 7-transmembrane receptors 7-transmembrane receptors (7TM-receptors) (Figure 1.1).
Figure 1.1: General structure of a G protein-coupled receptor shown on the crystalstructure of the dopamine D3 receptor. The figure was taken and modified from Ka-tritch et al.5
In 1994 Kolakowski et al. grouped all known GPCRs in 6 classes from A to F whereasmost of the human GPCRs can be found in classes A-C.6Based on the GRAFS classification system, which was developed in 2003 by Fredriks-son et al. using phylogenetic analyses, the GPCRs can be grouped into 5 classes,the rhodopsin (class A), secretin (class B), glutamate (class C), adhesion, and friz-zled/taste classes.
2
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GPR84
Figure 1.2: Phylogenetic tree of GPCRs with a special view on orphan receptors of theδ-branch of class A. The figure was taken and modified from Stevens et al.7
3
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The secretin receptor family is named after its first member, the secretin receptor. Inthis class the N-terminus is important for the binding of the ligands. Well-known andpharmacologically relevant members of this family are among others the calcitoninreceptor (CALCR), the corticotropin-releasing hormone receptors (CRHRs), and theglucagon receptor (GCGR).The adhesion receptor family contains adhesion-like motifs in the N terminus whichare likely to participate in cell adhesion.The glutamate receptor family includes eight metabotropic glutamate receptors(GRMs), two γ-aminobutyric acid (GABA) receptors and a calcium-sensing recep-tor (CASR).The frizzled/taste receptor family is a small receptor class with currently only limitedrelevance for pharmaceutical research.The rhodopsin (class A) receptors are the largest receptor class. The class is namedafter the bovine rhodopsin and can be further subdivided into 4 groups, α , β, γ,and δ . The α-branch contains prostaglandin receptors, amine receptors, melatoninreceptors, and the melanocortin, endothelial differentiation sphingolipid, cannabi-noid, adenosine (MECA) receptor cluster. The β-branch mainly includes peptidereceptors. The γ-branch contains the somatostatin, chemokine, galanin (SOG) re-ceptor cluster, the melanin-concentrating hormone (MCH) receptor cluster, and thechemokine receptors.The δ-branch is subdivided into 4 subbranches: MAS-related receptor cluster, gly-coprotein receptor cluster, purine receptor cluster, and the olfactory receptor clus-ter.1 It contains also the P2Y-receptor related orphan GPCRs GPR17, GPR55 andGPR35, and the orphan receptor GPR84 (Figure 1.2). Those receptors will be furtherinvestigated in this study.
1.1.3 Signal transduction pathways of G protein-coupled receptorsThe name "G protein-coupled receptor" is based on the fact that this receptor classacts via a guanine nucleotide-binding protein, the so called G protein. It was firstobserved by Martin Rodbell in 1971 in the context of glucagon action.8 The G proteinis a heterotrimeric structure which consists of an α and a heterodimeric βγ subunit.The binding of an agonist to the receptor results in a conformational change of the
4
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receptor which now is able to interact with the heterotrimeric G protein complex. Itfunctions as a guanosine triphosphate exchange factor (GEF), replacing guanosinediphosphate (GDP) by guanosine triphosphate (GTP). This results in dissociationof the Gα subunit from the Gβγ subunit which both can activate different signalingcascades.9 The kind of signaling pathway, which is activated, is mainly dependingon the type of the Gα subunit (Figure 1.3).
G⍺s G⍺i Gβγ G⍺q G⍺12/13
AC PLC
ATP				cAMP↑
β-arrestin
RhoGEF
RhoAPIP2 IP3 DAG
PKCCa2+↑
PI3K
PKB
Figure 1.3: Signal transduction cascades of G proteins.
The Gαs proteins activate adenylate cyclases (ACs) which catalyze the reactionof adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Anincrease of cAMP results in an activation of protein kinase A (PKA) which is aserine/threonine kinase. It is able to phosphorylate the transcription factor cAMPresponsive element binding protein (CREB) in the nucleus. By activation of phos-phorylase kinase B (PKB), PKA can also regulate glycolysis. Further effects of PKAactivation are lipolysis and relaxation of smooth muscles. Gα i proteins inhibit ACand the subsequent signaling pathway.Gαq proteins activate phospholipase C (PLC) which hydrolyzes phosphatidylinosi-tol-4,5-bisphosphate (PIP2) to inositol trisphosphate (IP3) and diacylglycerol (DAG).IP3 mediates the opening of intracellular calcium channels which results in a calciumincrease in the cytosol. Calcium activates the Ca2+/calmodulin-dependent proteinkinase (CAMK) pathway. DAG activates protein kinase C (PKC). Both pathways are
5
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involved in the regulation of smooth muscle cells and further secretion of mediators.10Gα12/13 proteins activate Rho guanine nucleotide exchange factors (RhoGEF) whichexchange GDP by GTP at RhoA. This results in an activation of RhoA. RhoA regu-lates the actin cytoskeleton, cell shape, cell polarity, microtubule dynamics, mem-brane transport pathways, gene transcription, cell adhesion, cell migration, neuriteextension/retraction and cell growth.11Not only the Gα subunit is able to activate signaling pathways. Also the Gβγprotein is able to activate the PLC pathway. Furthermore it activates PKB via thephosphoinositide-3-kinase pathway resulting in the effects described above.10The termination of the signal cascades can on the one hand be caused by an elim-ination of the bound agonist. But it was also observed, that on the other hand, theactivated receptor itself stops its activity after a certain time. One distinguishesbetween homologous desensitization, where only the agonist-bound receptor is de-sensitized, and heterologous desensitization, which affects also other GPCRs.
Figure 1.4: The life cycle of a G protein-coupled receptor. The figure was taken andmodified from Stadel et al.12
6
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Heterologous desensitization is mostly caused by phosphorylation of the GPCRsby second messenger-dependent protein kinases such as PKA and PKC. Homolo-gous desensitization is induced by G protein-coupled receptor-kinases (GRKs) whichphosphorylate serine and threonine residues of activated GPCRs. Furthermore thephosphorylated receptor presents new binding sites for the so-called arrestin pro-teins which completely desensitize the GPCR.13 This occurs when β2-adaptin (AP-2)and clathrin bind to arrestins. A so-called "clathrin-coated pit" is formed which re-sults in the formation of a vesicle. The desensitized receptors finally can be eitherrecycled by dephosphorylation or can undergo degradation in the lysosomes (Fig-ure 1.4).12In conclusion, GPCR signaling is a complex process in which various signaling cas-cades are involved. Dependent on the type of G protein, ligands can trigger a broadrange of effects in the cell which can influence essential physiological functions inthe human body.
1.1.4 Orphan G protein-coupled receptorsIn the past receptors were mainly identified by the ligands that bind to them. Mod-ern genetic technologies and especially the decoding of the whole human genomeas part of the human genome project made it possible to identify new receptors bythe comparison of genetic sequences with sequences of known receptors. To someof these new receptors no specific endogenous ligand could be assigned. This iswhy those receptors are called orphan receptors. According to International Unionof Basic and Clinical Pharmacology (IUPHAR) about 100 GPCRs exist whose en-dogenous ligand has not been identified or at least has not been confirmed yet.Most of them belong to the rhodopsin-like, class A GPCR family.14 The deorpha-nization of those receptors is of great interest for pharmaceutical research becausethey represent potential drug targets. Studies with knockout mice and also theirexpression in tissues related to diseases like cancer indicate a physiological orpathological relevance. However the deorphanization of GPCRs is challenging. Inthe beginning orphan GPCRs were matched with known neurotransmitters. The firstreceptor which was deorphanized in this way was the 5-hydroxytryptamine recep-tor (5HT1A receptor) which binds 5-hydroxytryptamine.15 As the number of orphanGPCRs soon exceeded the number of known neurotransmitters it emerged that there
7
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must be also unidentified neurotransmitters that have to be identified. A second ideawas that some neurotransmitters do not exclusively bind to only one target. TodayGPCR deorphanization is linked also to neurotransmitter identification. As GPCRsbind to chemically diverse compounds such as peptides, small molecules and alsolipids, deorphanization is often difficult. The characterization of the binding pocketwith surrogate ligands as pharmacological tools has become more and more im-portant. High-throughput screenings combined with medicinal chemistry currentlydominates the research field of orphan GPCRs.16
1.1.5 Purinergic signallingThe history of purinergic signalling began in 1929 when the German researcherKarl Lohmann discovered adenosine ATP.17 Despite its function as an intracellularenergy source, in 1972 Geoffrey Burnstock identified ATP also as a neurotrans-mitter and cotransmitter.18 Initially ridiculed, the concept of purinergic signallingtoday is generally accepted and an interesting and promising research field alsowith regard to drug development. Because of the fact that receptors and enzymeswhich are involved in the purinergic signalling system have various physiologicaland pathological functions in the human body, they represent potential drug targetsfor the treatment of various diseases.
1.1.6 Purinergic receptorsIn 1987 Burnstock proposed the first classification of purinergic receptors by subdi-viding them into P1 and P2 receptors. P1 receptors can be activated by adenosinewhereas P2 receptors are activated by ATP or adenosine 5’-diphosphate (ADP).19P1 receptors are G protein-coupled and can be subdivided into four subtypes, A1,A2A, A2B and A3. Adenosine A1 and A3 receptors are Gi/o-coupled and A2A and A2Bare coupled to the Gs proteins.20The P2 receptors are subdivided into the G protein-coupled P2Y receptors andthe ligand-gated ion channel P2X receptors. P2X receptors are subdivided intoseven receptor subtypes P2X1-P2X7. For the P2Y receptors eight receptors havebeen identified which can be activated by different nucleotides such as uridinetriphosphate (UTP), ATP and ADP (Figure 1.5).21
8
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Purinergic receptors
P0
(GPCR)
P1
(GPCR) P2
P2Y
(GPCR)
P2X1-7
Ligand-gated
ion channels
P2Y1 P2Y2 P2Y4 P2Y6 P2Y11 P2Y12/13 P2Y14
Ade1 Ade2 A1 A2BA2A A3
Figure 1.5: Purinergic receptors.
Recently a novel receptor class which is activated by adenine, named P0 receptors,was identified.22,23
1.1.7 P2Y purinoceptorsThe P2Y purinoceptors are phylogenetically grouped into the δ-branch of the classA (rhodopsin) GPCRs which contains also many orphan GPCRs (Figure 1.2). EightP2Y receptors have been identified so far which differ in their endogenous agonistsand their second messenger system. P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 are Gq-coupled whereas P2Y12, P2Y13, and P2Y14 are Gi/o-coupled. P2Y1, P2Y12, and P2Y13are activated by ADP, P2Y2 and P2Y11 by ATP, P2Y2 and P2Y4 by UTP, and P2Y6and P2Y14 by uridine diphosphate (UDP). P2Y14 is also activated by UDP-glucoseand UDP-galactose.24
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Figure 1.6: Nucleotides that can activate P2Y receptor subtypes.
P2Y receptors are present in almost every cell of the human body and are involvedin many physiological and pathological processes. The widely used drug clopidogrelfor example blocks platelet aggregation via the P2Y14 receptor. But the receptorsalso play a role in the nervous system and have been identified as potential targetsfor alzheimer’s disease.25,26
1.1.8 The orphan receptor GPR17Demyelinization by immune dysregulation is one of the major pathological hallmarksof multiple sclerosis (MS).27 Myelin is formed by oligodendrocytes in the central ner-
10
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vous system (CNS) and enables the saltatory conduction of electric signals alongnerves. Damage of this layer of insulation of nerves results in symptoms like co-ordination problems, blindness or muscle weakness. To date, MS therapy is basedon immunosuppression (corticosteroids, methotrexate etc.) and immune modulation(natalizumab, glatiramer acetate, β-interferons etc.) to prevent damage of the myelinsheats. However no drug is on the market yet, which can induce remyelination.28There is some evidence that purinergic signalling and especially the orphan GPCRGPR17 play a role in this remyelination process and therefore represent interestingpotential drug targets for neurodegenerative diseases like MS.29GPR17 (initially named R12) was first cloned in 2006 by Rapodo et al. upon search-ing for new chemokine receptors. They identified homologies of R12 to the P2Ypurinoreceptors.30 Upon screening of a complementary DNA (cDNA) library usingdegenerate RT-PCR searching for P2Y homologous sequences two years later Blä-sius et al. identified two splice variants of GPR17/R12 located in the brain. Thelonger isoform has a 28 amino acids longer N-terminus than the short isoform.31Phylogenetically GPR17 is located at an intermediate position between the P2Yand the cysteinyl-leukotriene receptors (CysLTs) cysteinyl-leukotriene receptor 1(CysLT1) and cysteinyl-leukotriene receptor 2 (CysLT2), all of which are class AGPCRs.32 P2Y receptors consist of 8 receptor subtypes: P2Y1, P2Y2, P2Y4, P2Y6,P2Y11, P2Y12, P2Y13, and P2Y14. They are stimulated by different nucleotides suchas ATP, ADP, UTP, UDP and UDP-glucose and can be found in almost all regions ofthe body.33 CysLT1 and CysLT2 bind cysteinyl-leukotrienes which act as mediatorsof inflammation, and the receptors are involved in allergic reactions like asthmabronchiale.34
1.1.8.1 The endogenous ligand of GPR17The question about the endogenous ligand of GPR17 has been controversially dis-cussed. Ciana et al. described the receptor as a dual receptor activated by bothCysLTs (leukotriene D4 (LTD4) and leukotriene C4 (LTC4) in the nM range) anduracil derivatives (UDP, UDP-glucose, and UDP-galactose in the µM range) (de-termined by [35S]GTPγS binding at 1321N1-, COS7-, CHO-, and HEK293-cells).The receptor is coupled to Gi and Gq proteins and through its activation the cAMPlevel decreases whereas the calcium level increases.35, 36 Meakawa et al. did not
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detect significant calcium mobilziation in GPR17 expressing cells (1321N1, CHO,and HEK-293T) with LTC4, LTD4, or leukotriene E4 (LTE4) and also not with UDP-glucose (1321N1 cells). Instead they postulated that GPR17 negatively regulatesCysLT1 function. Co-expression of CysLT1 with GPR17 resulted in decreased LTD4-initiated calcium mobilization in a variety of cell lines, inhibited CysLT1-mediatedextracellular-signal regulated kinase (ERK) phosphorylation in response to LTD4and supressed [3H]LTD4 binding. They also observed a co-localization of GPR17and CysLT1 in human monocytes.37 Benned-Jensen and Rosenkilde confirmed thatUDP activates the short isoform, human GPR17-S, dose-dependently in the lowmicromolar range, and the long isoform, human GPR17-S, in the high micromolarrange. However they did not observe an inhibition of human GPR17-S and humanGPR17-L by LTD4.38 In 2013 Qi et al. also tried to verify the identity of the en-dogeous ligands for GPR17. However they did not observe any activation of thereceptor, neither by UDP-glucose, UDP-galactose or UDP, nor by CysLTs in hu-man GPR17-transfected C6, 1321N1 astrocytoma, CHO, COS-7, and HEK293 cells(cAMP accumulation, inositol phosphate production, and monitoring of Ca2+ mobi-lization).39 In the laboratory of E. Kostenis and also in our laboratory no interactionof nucleotides or cysteinyl leukotrienes with GPR17 has been observed so far de-spite considerable efforts.40
1.1.8.2 Physiological and pathophysiological role of GPR17Ciana et al. showed that GPR17 is located in organs undergoing ischemic dam-age,35 but Lecca et al. were the first who connected GPR17 with brain damage andsuggested the receptor as a novel target for brain repair. It was previously shownby Maisel et al. that the GPR17 gene is expressed on hippocampus-derived neuro-progenitor cells (NPCs).41 Lecca et al. showed that GPR17 is present on neuronsand on a subset of quiescent oligodendrocyte precursor cells. Especially in neu-rons expressing the stress marker heat shock protein 70, GPR17 was up-regulated.Knock-down of GPR17 prevented brain infarct evolution and was identified on mi-croglia/macrophages infiltrating the lesioned area at later times of the ischemia.This indicates that the receptor forces neuronal death during the ischemic attackbut also plays a role in the remodeling of the damaged brain areas.42,43 Cerutiet al. investigated GPR17 as a potential drug target for spinal cord injury (SCI).The results of their studies were consistent with the ones by Lecca et al.. SCI in-
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duced a dramatic and rapid death of GPR17+ neurons and oligodendrocytes insidethe lesioned area. Blocking of GPR17 by injection of a specific GPR17 antisenseoligonucleotide into the spinal cord improved improved healing of the tissue dam-ages derived from SCI. Another fact is that GPR17 is expressed by spinal cord cellswhich supports the hypothesis that GPR17 is a mediator for cell differentiation.44Chen et al. found that GPR17 is regulated by the basic helix-loop-helix (bHLH) tran-scription factor Olig1 which plays an important role in oligodendrocyte myelinationand remyelination.45 They found that GPR17 over-expression results in a blockageof the differentiation of neural progenitor cells into oligodendrocytes and an inhi-bition of terminal differentiation of primary oligodentrocyte precursor cells (OPCs).Vice versa a knock-out of GPR17 accelerated OPC maturation. In Olig1 null miceGPR17 was dramatically downregulated which indicated an interdependence.46 Therole of GPR17 in cell differentiation is supported by the observation that GPR17agonists together with neuronal growth factor (NGF) promote neurite outgrowth inPC12 cells and activate the intracellular phosphorylation of both ERK 1/2 and p38kinases.47 The same effect was shown by Huber et al. who blocked GPR17 withmontelukast and observed increased neural stem and progenitor cell proliferation.48Fumagalli et al. described the signalling pathway of GPR17 as follows: The high-est level of receptor expression can be found in immature preoligodendrocytes. Itis also expressed on early NG2+ polydendrocytes but is completely downregulatedon fully mature MAG+ or MBP+ oligodendrocytes. GPR17 inhibition by small in-terfering RNAs (SiRNAs) hindered the differentiation of OPCs whereas activationwith UDP led to OPC maturation. They postulated that regarding differentiationof OPCs GPR17 has a positive effect in early stage OPCs but a negative role inlate OPCs.49 This was Coppi et al. found that GPR17 regulates K+ currents whichcould activate oligodendrocyte differentiation.50 The same results were obtained byHennen et al. who stimulated GPR17 with the agonist MDL29,951.51An interesting study recently showed that mice, treated with the GPR17 antago-nist montelukast showed reduced neuroinflammation and an elevated hippocampalneurogenesis. Additionally the mice had an improved ability to learn and an im-proved memory which makes GPR17 also a potential target for dementia.52 However,montelukast is only a very weak GPR17 antagonist, and it is much more potent atCysLT1 receptors.Meakawa et al. showed that GPR17 negatively regulates CysLT1 receptor func-
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tions regarding the antigen presentation and the downstream phases of allergicpulmonary inflammation and is therefore proposed as a potential target for allergicasthma.53A completely different functional role for GPR17 was described by Ren et al.. Theyfound that Gpr17 knockout mice (Agrp-Gpr17(-/-)) showed reduced food intake.GPR17 seems to be a FoxO1 target which is involved in gluconeogenesis. Theyalso found that GPR17 regulates the sensitivity to insulin and leptin. In conse-quence GPR17 might be a target for the treatment of obesity.54, 55 In contrast to thatMastaitis et al. did not observe any differences in food intake comparing GPR17knock-out mice to the wild-type animals.56When considering the results described in this section we have always to keepin mind that some of the studies partly contain experiments that were performedwith GPR17 ligands that never could be confirmed. Rather the majority of researchgroups, including our group, could show that neither nucleqotides nor CysLTs dointeract with GPR17. The conclusions of all studies, where the receptor was stim-ulated with this ligands, therefore have to be seen in a very critical light.
1.1.8.3 Synthetic ligands for GPR17Several synthetic ligands are known for GPR17. First of all some purinergic andleukotriene antagonists were found to be antagonists at GPR17. Cangrelor57 (P2Y12/-P2Y13 antagonist) and MRS217958 (P2Y1 antagonist) were reported to be GPR17antagonists but could never be confirmed. Pranlukast and montelukast59, 60 (CysLT1antagonists) were identified and confirmed as antagonists at GPR17.35 MDL29,95140and its tritiated form [3H]PSB-1215061 are agonists for GPR17 (Figure 1.7).The human and the rat orthologue share an amino acid sequence similarity of 89%.35The mouse orthologue shares an amino acid sequence similarity of 90 and 98% withthe human and the rat orthologue, respectively.42 Therefore ligands developed forthe human receptor may also be suitable compounds for animal studies. Howevernone of the ligands developed so far is specific for GPR17 since they were originallydesigned for other targets except for MDL-29.951 which is quite selective for GPR17.We therefore have to continue working on the development of novel potent andselective ligands.
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1.1.8.4 ConclusionIn summary GPR17 is an interesting target for the treatment of diseases causedby myelin damage because by blocking the receptor it could be possible to induceneurorepair. Additionally it seems also to have an effect in organs undergoingischemic damage. However only few synthetic and drug-like ligands are known forthis poorly studied receptor. It will be necessary to develop potent ligands whichpass the blood-brain-barrier because the target is located in the brain. All ligandsdeveloped so far contain polar functionalities such as carboxylic acids which mayprevent CNS penetration. It is therefore necessary to determine structure-activityrelationships (SARs) to further characterize the binding pocket of GPR17 and todesign suitable drugs.
1.1.9 The orphan receptor GPR35The orphan receptor GPR35 gene was first discovered in 1998 by O’Dowd et al.encoding a receptor of 309 amino acids.62 In 2004 Okomura et al. identified twodifferent splice variants of the receptor which differ in 31 amino acids at the N-terminal domain. GPR35a is the short isoform and GPR35b the longer one.63 Thehuman GPR35 is closely related to the orphan receptor GPR55 (34% amino acididentity),64 to lysophosphatidic acid receptors, P2Y receptors62 and hydroxycar-
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boxylic acid receptors.65 Interestingly the receptor shows a high species diversity.The amino acid sequence identity between the human and the rodent orthologuesis only moderate with about 70%.66 GPR35 belongs to the class A, rhodopsin likeGPCRs.Wang et al. were able to show that the signal transduction of GPR35 is mediatedby the pertussis toxin sensitive Gi/o protein.67 This findings could be confirmed byseveral groups. Guo et al. showed that the treatment of GPR35 with the agonistszaprinast or kynurenic acid inhibited N-type calcium channels. This effect could beblocked by pertussis toxin.68 Jenkins et al. showed that GPR35 also interacts withthe G13-protein.69 The receptor can furthermore recruit β-arrestins.69,70
1.1.9.1 Expression profile and therapeutic potential of GPR35GPR35 was first found to be expressed in the intestine of the rat62 by Northernblot analysis. The rat GPR35 is also expressed in the uterus, lung and dorsalroot ganglion.71 Okumura et al. detected GPR35 in human gastric cancer cells.Interestingly the expression of the longer splice form GPR35b in gastric cancercells and also stomach cells was higher than the expression of GPR35a.63 Wang etal. detected the human GPR35 also in peripheral leukocytes and spleen. However,also in human it is highly expressed in the small intestine, colon and stomach. Asimilar situation had been found for the mouse GPR35 which was detected in spleenand the gastrointestinal tract.67 Low levels of GPR35 have also been found in theliver.67,71The expression profile of GPR35 indicates a potential role in the pathology of thegastrointestinal tract. GPR35 is overexpressed in gastric cancer cells in comparisonto healthy tissue. Furthermore the introduction of GPR35-cDNA into a NIH3T3 cellline (embryonal mouse fibroblast cells) resulted in a transformation of the cells.63Imielinski et al. identified a single nucleotide polymorphism (SNP) which linksGPR35 to ulcerative colitis and inflammatory bowel disease (IBD).72Min et al. connected GPR35 to cardiovascular diseases. GPR35 knock-out miceshowed a significantly higher blood pressure than the wild-type mice. The groupalso compared the GPR35 expression of healthy patients and heart failure patientsand detected a higher expression of GPR35 in the diseased patients.73 Sun et al.postulated a relation of a Ser294Arg SNP in the GPR35 gene to artherosclerotic
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changes.74 GPR35 could also function as a marker for myocardial infarction as itwas upregulated in hypoxic tissue.75The expression of GPR35 on various immune cells such as spleen, peripheral leuko-cytes,76 monocytes,77 mast cells and eosinophils78 and not at least on invariantnatural killer T cells (iNKTs)79 indicates a potential role of the receptor in thepathology of immune-related diseases. Barth et al. postulated a potential role ofthe receptor in the context of leukocyte recruitment to inflamed tissue. They couldshow that the GPR35 agonist kynurenic acid induces the adhesion of monocytesto the endothelium, which starts the process of leukocyte recruitment.77 The factthat a range of mast cell stabilizers like nedocromil or cromolyn function as GPR35agonists and the expression of GPR35 on mast cells indicate a therapeutic potentialof GPR35 for the treatment of asthma.78A connection of GPR35 to diabetes is also discussed in the literature. Horikawa etal. identified SNPs of GPR35 that correlate with diabetes type 2.80Moreover GPR35 is also a potential target for the treatment of pain. The receptoris colocalized in dorsal root ganglionic neurons, which also express the transientreceptor potential vanilloid 1 (TRPV1) channel. This compound is known to beinvolved in nociception, so GPR35 is a potential target for analgesia.81 Cosi et al.observed an antinociceptive effect when mice were treated with the GPR35 agonistskynurenic acid and zaprinast.82In conclusion, due to its expression profile it is very likely that GPR35 plays a rolein gastrointestinal diseases. However various effects in other regions of the bodyrelated to GPR35 have been observed, that are poorly studied yet.
1.1.9.2 Ligands for GPR35Endogenous ligandsThe first ligand that was identified for GPR35 was the tryptophan metabolite ky-nurenic acid. Due to the fact that it is present in tissue which expresses GPR35 itwas proposed to be the endogenous ligand for GPR35. However it is much morepotent at the rat GPR35 than at the human orthologue. For an activation of thehuman receptor micromolar concentrations of kynurenic acid are needed.67Oka et al. identified lysophosphatidic acids (LPAs), especially 2-acyl-LPAs as fur-
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ther potential endogenous agonists of GPR35. In contrast to kynurenic acid theywere able to activate the human receptor in nanomolar concentrations.83Recently Maravillas-Montero et al. reported that GPR35 is activated by the che-mokine CXCL17 in nanomolar concentrations. They suggested to rename GPR35 inCXCR8 according to the chemokine nomenclature.84 However also this result has tobe confirmed, and the receptor is still not deorphanized.Synthetic agonistsThe phosphodiesterase (PDE)-inhibitor zaprinast was the first synthetic agonistdescribed for GPR35. It is more potent at the human receptor than kynurenic acidbut still much more potent at the rodent orthologues.71 Besides zaprinast manyother small molecules were found to act as GPR35 agonists.Especially notable is that many mast cell stabilizers are agonists at GPR35. Theexact mode of action of these drugs is not clear, so the effect could be GPR35-mediated. Members of this class are the chromones cromoglicic acid and nedocromil,which are more potent at the human receptor than at the rodent receptors78 and therecently identified bufrolin and lodoxamide, which are the first agonists of GPR35that can activate both, the human and the rat receptor, in the low nanomolar range.85One interesting agonist of GPR35 is pamoic acid, which was assumed to be biolog-ically completely inactive. Because of its properties it is used as an excipient whichis present in many marketed drugs. Zhao et al. found that it is a selective agonistfor the human GPR35.70Deng et al. identified a broad range of GPR35 agonists, including aspirin metabo-lites,86 tyrphostin analogs,87 benserazide, catechol and pyrogallol,88 natural phe-nols,89 nitrophenols,90 D-luciferin,91 2-(4-methylfuran-2(5H)-ylidene)malononitrileand thieno[3,2-b]thiophene-2-carboxylic acid derivatives,92 gallic acid and wede-lolactone.93Yang identified the common loop diuretic drugs bumetanide and furosemide asGPR35 agonists.94Recently, a very potent and selective class of GPR35 agonists was identified inour group. 8-Benzamidochromen-4-one-2-carboxylic acids are able to activate thereceptor in the low nanomolar range.95 The first radioligand for GPR35, 6-bromo-8-(4-[3H]methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid, is based on thisscaffold.65
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Synthetic AntagonistsOnly few antagonists for GPR35 are known so far. The most common and widelyused one is CID2745687, which was discovered in 2010 by Zhao et al.70
1.1.9.3 ConclusionGPR35 is an interesting target for drug research but poorly investigated so far. Itsphysiological function as well as its endogenous agonist still remain unclear. Al-though several physiological agonists of GPR35 have been identified most of themactivate the receptor only at high concentrations. It is questionable if these com-pounds are present in adequate concentrations in the body to activate the receptor.LPAs and the chemokine CXCL17 are more potent but test results have not beenconfirmed yet. These proposed agonists are not suitable as tool compounds or asdrug candidates because they are too expensive and, what is more important, be-cause of their inappropriate physiochemical properties. Therefore it is necessary toput further effort into the development of synthetic GPR35 ligands with drug-likeproperties, high selectivity and increased stability.
1.1.10 The orphan receptor GPR55The endocannabinoid system is a part of the nervous system originally based on thetwo GPCRs CB1 and CB2 which bind constituents of the plant Cannabis sativa, theso called cannabinoids. Besides the cannabinoids derived from plants, there are alsoendogenous ligands for the two receptors includingN-arachidonylethanolamide alsoknown as anandamide (AEA) and 2-arachidonylglycerol (2-AG). The endocannabi-noid system is pharmacologically related to movement, memory, appetite, nausea,pain, cancer and also immune diseases.97 The endocannabinoids AEA and 2-AGhave also been described to bind to the orphan GPCR GPR55. It is therefore dis-cussed wether GPR55 could represent a third cannabinoid (CB) receptor, however,sequence homology is low.98The GPR55 gene was first identified in 1999 by Sawzdargo et al. from an expressedsequence tag (EST) database encoding a receptor of 319 amino acids. Its closestrelatives are P2Y5 (29%), GPR23 (30%), GPR35 (27%) and CCR4 (23%).64 It sharesonly an amino acid sequence identity of about 14% with the two CB-receptors CB1
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and CB2.99
1.1.10.1 Pharmacology of GPR55GPR55 belongs to the class A (rhodopsin-like) GPCRs.1 In 2007 Ryberg et al. re-ported that GPR55 is coupled to Gα13. They observed an activation of RhoA duringan activation with AEA and this effect was blocked by cannabidiol.98 Lauckner et al.observed an increase of intracellular calcium in HEK293 cells and postulated thatGPR55 could couple to Gαq or Gα12.100 The Gα12/13 coupling could be confirmed byHenstridge et al. in 2009.101
1.1.10.2 Expression profile and therapeutic potential of GPR55When GPR55 was identified in 1999, Sawzdargo et al. already defined an expressionprofile of the receptor performed by Northern blot analysis. It turned out that it isabundantly expressed in the brain, especially in caudate nucleus and putamen.64Later on Ryberg et al. analysed the GPR55 expression in mouse using quantitativepolymerase chain reaction (PCR) and detected GPR55 messenger RNA (mRNA)in the gastrointestinal tract and the brain.98 There is also evidence for GPR55expression in the liver and adipose tissue.102 Furthermore GPR55 can be found inosteoblasts and osteoclasts.103The expression of GPR55 in metabolically relevant tissues and the relation to CB-receptors, which are known to be involved in the regulation of food intake, indicatea therapeutic potential of the receptor for the treatment of metabolic disorders likediabetes or obesity.104 Moreno-Navarrete et al. observed a correlation of GPR55and lysophosphatidylinositol (LPI), a GPR55 agonist, with several metabolic para-meters like weight, body mass index (BMI), and percent fat mass.102 Meadows et al.investigated GPR55 knock-out mice regarding body weight and insulin resistance.They found that the body weight of GPR55 deficient mice was not increased signifi-cantly whereas the percentage of fat and the insulin resistance was. The movementof the knock-out mice was decreased.105 Very recently Liu et al. postulated thatGPR55 regulates the insulin secretion of the islets of Langerhans.106GPR55 is an interesting target for the treatment of cancer. In 2000 the GPR55agonist LPI was first identified as a marker for ovarian cancer.107 Sutphen et al.
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confirmed this results.108 In 2011 it was shown that GPR55 plays a role in theregulation of proliferation and anchorage-independent growth of ovarian cancer andalso of prostate cancer cells.109 Andradas et al. showed that GPR55 promotescancer cell proliferation via ERK and the receptor was found to be associated totumor growth in glioblastoma110 and to enhance skin cancer growth.111 A furtherinteresting fact is that CB2 and GPR55 form heteromers in cancer cells which displaymodified signalling.112 Recently it was reported by the same group that GPR55expression in human tumors is associated with the aggressive basal/triple-negativebreast cancer population. The authors found that an activation of GPR55 promotesmetastasis in this cancer type.113 Also in colon cancer GPR55 promotes adhesionand migration.114As previously described GPR55 is also expressed in bone cells. It was shown thatLPI is able to inhibit osteoclast formation On the other hand it increased theiractivity. A modulation of GPR55 therefore could be starting point for the treatmentof osteoporosis.103A proinflammatory role of GPR55 especially in the gastrointestinal tract is also dis-cussed. Stancic et al. induced a colitis in mice by adding 2.5% dextran sulfate sodium(DSS) supplemented to the drinking water, or by application of trinitrobenzenesulfonic acid (TNBS). Then the mice where treated with the GPR55 antagonistCID16020046115 which reduced the inflammation.116The physiological role of GPR55 is diverse. There is strong evidence that it is apotential target for the treatment of cancer. Furthermore its role in the context ofmetabolic diseases, osteoporosis and inflammation has to be further investigated.
1.1.10.3 Ligands for GPR55The idea that GPR55 is a new CB receptor was mainly based on the fact thatinitially known endocannabinoids were found to bind to GPR55.98 But GPR55 doesnot have the classical CB binding pocket.117 Ryberg et al. identified AEA, 2-AG andCBD as GPR55 agonists98 and Johns et al. found that O-1602 stimulates GPR55.118
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Lauckner et al. identified further agonist for GPR55: tetrahydrocannabinol (THC),the aminoalkylindole JWH015, the eicosanoids AEA and methanandamide (MEA),
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and the endogenous lipid LPI increased the calcium level in HEK293 cells andlarge dorsal root ganglion (DRG) neurons, but they did not observe an effect withCP55,940, WIN55,2122, and 2-AG.100 However, Whyte et al. found that CBD func-tions as an GPR55 antagonist103 which was confirmed by Rempel et al. who foundthat THC and CP55.940 act as antagonists in the β-arrestin recruitment assay.119In 2007 Oka et al. identified 2-AG-LPI as a possible endogenous ligand for GPR55([35S]GTPγS binding assay in HEK293 cells; EC50 = 200 nM).123 In 2009 the samegroup found that the activity of 2-arachidonoyl-LPI is about 3 times higher thanLPI.121 Ryberg et al. identified AM251, which is known a CB1-antagonist, to bean agonist at GPR55.98 This finding could be reproduced by Yin et al. who per-formed a β-arrestin PathHunter assay at a large number of orphan GPCRs includingGPR55. Besides AM251 they also identified the cannabinoid antagonist rimona-bant (SR141716A) and LPI as strong agonists but did not observe any effect withendogenous cannabinoids.120 The same results were repoduced by Kapur et al. whoidentified CP55949, which is also a CB agonist, as a partial agonist at GPR55, andby Henstridge et al. who observed an agonistic effect of LPI but also an agonisticeffect for AM251.124 , 101Lauckner et al. described rimonabant as a GPR55 antagonist. Heynen-Genel et al.from the NIH did a high throughput screening to identify small molecule agonistsas well as antagonists for GPR55. They identified 3 different chemical scaffolds:morpholinosulfonylphenylamide, ML186 (CID15945391) (305 nM), tricyclic triazo-loquinoline, ML185 (CID1374043) (658 nM) and piperazine, ML184 (CID2440433)(263 nM).125 They also identified antagonists: quinoline aryl sulfonamide ML193(CID1261822) (221 nM), thienopyrimidine ML192 (CID1434953) (1080 nM) and pi-peradinyloxadiazolone ML191 (23612552) (160 nM).115 Rempel et al. identifiedtetrahydromagnolol and later on also coumarins (PSB-SB-489) as lead structuresfor new GPR55 antagonists.119 , 122 In the last year several groups started to workon the optimization of ligands for GPR55. Hess et al. identified constituents ofspice as weak GPR55 antagonists,126 Yrjölä et al. synthesized N-(4-sulfamoyl-phenyl)thiourea derivatives as GPR55 agonists127 and Meza-Aviña et al. designedpiperidine-substituted 1,3,4-oxadiazol-2-ones as GPR55 antagonists.128In conclusion the cognate agonist of GPR55 still lacks confirmation. LPI turned outto be a GPR55 agonist and it is therefore used as a standard agonist. Although abroad range of synthetic agonists and antagonists have been identified in the last
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years there is still a need for more drug-like and also more potent compounds.
1.1.11 The orphan receptor GPR84GPR84 was discovered in 2001 by Wittenberger et al. by an EST data mining strat-egy.129 In the same year Yousefi et al. identified EX33 (GPR84) as a novel geneusing degenerate primer reverse transcription polymerase chain reaction (RT-PCR).Performing Northern blot analysis they could show that EX33 (GPR84) is abun-dantly expressed in bone marrow, lung, and peripheral blood leukocytes, especiallyin neutrophils and eosinophils.130 67Venkataraman et al. were the first to generate GPR84-deficient mice. The prolifera-tion of T and B cells in those mice was normal, but T-cells stimulated with anti-CD3produced an increased level of interleukin-12 (IL-12). The IL-12 level in Th2 effec-tor cells isolated from these knock-out mice was also higher compared to the onesgenerated from wild-type mice.131 The first ligands for GPR84 were discovered byWang et al.. medium-chain free fatty acid (MCFFA) with chain lengths from C9-C14showed agonistic activity at GPR84. short-chain free fatty acids (SCFFAs) which areknown to activate GPR41 and GPR43132 and long-chain free fatty acids (LCFFAs)which activate GPR40133 were not able to activate GPR84. Capric acid (C10), unde-canoic acid (C11) and lauric acid (C12) were the most potent MCFFAs in the cAMPassay (EC50-values of 4, 8, and 9 µM, respectively). The same group also postulatedthat GPR84 activation by MCFFAs is coupled to a pertussis toxin-sensitive Gi/opathway. Furthermore they found that an activation of GPR84 by the surrogate lig-and diindolylmethane (DIM) in the presence of lipopolysaccharides (LPSs) leads toan up-regulation of interleukin (IL)-12 p40 mRNA. Thus GPR84 amplifies the LPS-stimulated production of IL-12 p40.67 In mice suffering from endotoxemia GPR84 isalso expressed in microglia and in peripheral macrophages134 and monocytes in-duced by proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) andIL-1. The same group also showed GPR84 expression during experimental autoim-mune encephalomyelitis (EAE), a model of multiple sclerosis, which is induced by theinjection of various proteins.135 Perry et al. demonstrated the existence of a GPR84homologue in Xenopus laevis where it seems to be involved in eye/lens formation.136Interestingly GPR84 is also expressed in 3T3-L1 adipocytes and is up-regulated inthe adipose tissue from high-fat chow (HFC)-induced obese mice.
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Figure 1.10: Selected GPR84 agonists.
They also showed that RAW264, TNF-α and LPS stimulated the GPR84 expressionin 3T3-L1 adipocytes and human adipose-derived stem cell (ADSC) adipocytes. Itmay be concluded that GPR84 plays a role in the pathogenesis of diabetes andobesity.139A further agonist at GPR84 is the natural product embelin (2,5-dihydroxy-3-undecyl-
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[1,4]benzoquinone) which was studied as a modulator for the treatment of atheroscle-rosis and mcp-1- (monocyte chemoattractant protein-1) related diseases.140 Suzukiet. al. identified also the hydroxy-MCFFAs 2-hydroxycapric acid (C10), 3-hydroxycapricacid (C10), 2-hydroxylauric acid (C12), and 3-hydroxylauric acid (C12) and the sur-rogate ligand 6-n-octylaminouracil (6-OAU)141 as agonists for GPR84.They also confirmed what previous studies had indicated: GPR84 seems to be apro-inflammatory receptor because it amplifies LPS-stimulated IL-8 production inpolymorphonuclear neutrophil (PMN) and TNF-α production in macrophages.137Research on the homologue in the zebrafish (zGPR84) where the receptor is mainlyexpressed in tissues of intestine, heart and liver supported these findings.142As reported by Dietrich et al. GPR84 is a regulator of β-catenin, a signallingmolecule for the differentiation of leukemic stem cells (LSCs). It induces the G1-phase cell-cycle arrest in pre-LSCs and reduces LSC frequency. GPR84 is further-more up-regulated in acute myeloid leukemia (AML) LSCs and in mixed lineageleukemia (MLL) AML, which is a very aggressive and almost untreatable type ofAML.143 Madeddu et al. found that GPR84 is upregulated in the CNS followingvirus infection.144Nikaido et al. performed the first mutagenesis study and investigated the twoGPR84 agonists capric acid and DIM. As a result they postulated that DIM is apositive allosteric modulator (PAM) at GPR84.145A study published in 2015 in "Brain, Behavior, and Immunity" associated GPR84 withAlzheimer’s disease (AD). It was observed that GPR84 is up-regulated in microglia ofAPP/PS1 transgenic mice, a model of AD. Knock-down of GPR84 in these mice hasa negative effect on cognition and the number of microglia. The authors postulatedthat GPR84 could be a signaling molecule for a yet unknown ligand that promotesmicroglia recruitment and may have a positive effect in amyloid pathologies.146Recently Nicol et al. investigated the role of GPR84 in association with pain.They found that GPR84 does not affect acute pain but it seems to have an effecton mechanical and thermal behavioral hypersensitivity in mice after partial sciaticnerve ligation (PNL) which was reduced in GPR84 knock-out mice. GPR84 mRNAwas increased in the sciatic nerve and spinal cord after PNL. Thus GPR84 mightplay a role in chronic pain including neuropathic pain.147GPR84 also has a potential role in the pathology of gastroesophageal reflux disease
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(GERD) being involved in the regulation of the immune answer in the inflammatoryprocess at esophageal cells.148 Zhang et al. recently identified and further optimized2-alkylpyrimidine-4,6-diols and 6-alkylpyridine-2,4-diols as potent GPR84 agonists(Figure 1.10).106,138So far only one class of antagonists for GPR84 is described in a patent and in-vestigated in a first-in-human single dose and multiple dose clinical study for thetreatment of ulcerative colitis. However the dihydropyrimidinoisoquinolinones didnot meet the endpoints for efficacy (Figure 1.11).149
N
N
R2
R1
O
R3
O
dihydropyrimidinoisoquinolinones core structure
IC50 = 0.1 - 100 nM ([35S]GTPγS)Figure 1.11: Core structure of dihydropyrimidinoisoquinolinone-based antagonists.149
Summing up the research that has been done so far on the field of GPR84 there arestrong indications that the receptor plays a role in the immune system and thereforeis of considerable interest as a target for the development of new drugs. However thereceptor has been poorly investigated so far and its physiological/pathophysiologicalrole is not completely understood. There is strong evidence that it is involved ininflammation and immune responses, in metabolic diseases, CNS diseases and evenin reflux disease. It is therefore necessary to develop potent ligands to furtherinvestigate the receptor pharmacology in more detail.
1.2 Nucleotide-metabolizing ecto-enzymesExtracellular nucleotides that activate purinergic receptors undergo a sequence ofhydrolyses producing adenosine which is subsequently deaminated to inosine andfurther hydrolyzed to hypoxanthine. A broad range of specific extracelluar enzymesis involved in this process.
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Figure 1.12: The metabolic hydrolysis cascade of extracellular nucleotides. The figurewas taken from G. Yegutkin150
ecto-nucleotide pyrophosphatases/phosphodiesterases (eNPPs), ecto-nucleoside triphos-phate diphosphohydrolases (eNTPDases), alkaline phosphatase (AP) and ecto-5’-nucleotidase (eN) are able to hydrolyse nucleotides yielding adenosine which canbe further hydrolysed by ecto-adenosine deaminase (ADA) and purine nucleosidephosphorylase (PNP) (Figure 1.12).
1.2.1 Ecto-nucleotide pyrophosphatases/phosphodiesterases(eNPPs)The eNPP family consists of seven members numbered from NPP1-NNP7. Threemembers of this enzyme family are able to hydrolyze nucleotides: NPP1 (PC-1),NPP2 (autotaxin), and NPP3 (gp130RB13-6, B10, phosphodiesterase 1β). They areable to degradate nucleoside triphosphates (NTPs) directly to nucleoside monophos-phates (NMPs).151
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1.2.2 Ecto-nucleoside triphosphate diphosphohydrolases(eNTPDase)The eNTPDases hydrolyse nucleoside tri- and diphosphates to the correspondingNMPs in the presence of Ca2+ or Mg2+ at physiological pH.151 Only four out of theeight subtypes (NTPDase1 (CD39, ATPDase, ectoapyrase), NTPDase2 (CD39L1,ecto-ATPase), NTPDase3 (CD39L3, HB6), and NTPDase8 (hATPDase)) are locatedextracellularly and therefore function as ectonucleotidases. They differ in theirsubstrate specificity: NTPDase2 is selective for NTPs, NTPDase3 and NTPDase8have a preference for NTPs and NTPDase1 hydrolyses both NTPs and nucleosidediphosphates (NMPs) without any preference.152
1.2.3 Alkaline phosphatasesAlkaline phosphatases are able to hydrolyze ATP via ADP and adenosine 5’-mono-phosphate (AMP) to adenosine.151
1.2.4 Ecto-5’-nucleotidase (CD73)The ecto-5’-nucleotidase (eN, CD73) hydrolyzes NMPs. The preferred enzymatic re-action is the degradation of 5’-AMP to adenosine.153 eN is a Zn2+-binding glycosyl-phosphatidylinositol (GPI)-anchored homodimeric protein. Adenosine, the productof the CD73 enzyme reaction, can activate P1-receptors (A1, A2A, A2B, and A3).151eN was first isolated in 1987 by Grondal et al. from the electric organ of the electricray Torpedo marmorata. They found that is has a Km value of 38 µM for AMP. Theenzyme consists of an N-terminal domain, which contains the metal ion binding site,and a C-terminal domain, which contains the substrate binding site and to whichthe GPI anchor is linked (Figure 1.13. Besides the anchored form a soluble form ofthe enzyme exists.
30
1.2 Nucleotide-metabolizing ecto-enzymes Dissertation, Universität Bonn 2016
Figure 1.13: Crystal structures of ecto-5’-nucleotidase in the open form (with adeno-sine) and the closed form (with the inhibitor α ,β-methylene-ADP). The picture wastaken from Knapp et al.154
Human eN exists as a noncovalent homodimer which is connected via the C-terminaldomains. Rotation of the N-terminal domain results in a change of the enzyme fromthe open to the closed form and vice versa. This domain motion determines thesubstrate selectivity of eN towards NMPs, and the inhibitory properties of NMPsand NTPs.154
1.2.4.1 Therapeutical potential of ecto-5’-nucleotidaseThe physiological and pathological functions of eN expression in the human body aremostly related to adenosine formation which is regulated by the enzyme. Adenosineis able to activate P1-receptors, and an important mediator of the purinergic system.eN is expressed in various tissues and organs such as colon, liver,155 kidney,156 brain,heart, cardiovascular system, immune cells and lung.151,157It is known to play a role in the context of immune responses. By hydrolysis of pro-inflammatory ATP to the anti-inflammatory adenosine milieu CD73 modulates theimmune response. It is therefore a potential target for immune related diseases.158The expression of eN by tumor cells and the immunosuppressive effects identifiedin last years caused great interest in eN as a target for anticancer therapy.159Mikhailov et al. found that eN is involved in the multiresistance of different can-cer types. The apoptosis-resistant T cell leukemia clone (A4) showed a high CD73
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surface expression and significant eN activity.160 Stagg et al. also found that CD73knock-out mice have a reduced growth of tumors and an increased antitumor im-munity. Also metastasis was reduced in the CD73-deficient mice. This effects couldalso be observed when mice where treated with CD73 antibodies.161,162 Yegutkin etal. treated mice with the known CD73 inhibitor α ,β-methylene-ADP (AOPCP) whichresulted in retarded tumor progression. They also showed that CD73-deficient micehave a higher immunity against tumors.163 These effects could be explained becauseit is known that adenosine in contrast to ATP is a negative regulator of immune cellsin protecting normal tissues from inflammatory damage. An activation of adenosinereceptors in the tumor has the same effect, protecting the tumor from immune at-tack.164 Taken together there is strong evidence that eN is a potential target for theimmunotherapy of cancer.
1.2.4.2 Inhibitors of ecto-5’-nucleotidaseThe first inhibitors that were identified for eN were the nucleotides ADP and ATP.They block the enzyme in the micromolar range.151,152
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Figure 1.14: Selected inhibitors of ecto-5’-nucleotidase.
The ADP-analogue AOPCP was identified as a more potent eN inhibitor, with im-proved properties regarding stability compared to the endogenous inhibitors.166 Be-sides this compound anthraquinones,167 sulfonamides,168 various polyphenols,169 andsome polyoxometalates (POMs)170 were found to inhibit CD73. Recently the widelyused inhibitor AOPCP was structurally optimized and a series of analogues with in-hibitory potencies in the low nanomolar range have been developed in our group.171
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2 Aims of the study
2.1 Development of potent and selective ligands fororphan G protein-coupled receptorsAbout 100 of the roughly 800 members of the human G protein-coupled receptor(GPCR) family are so-called orphan GPCRs whose endogenous ligand is not knownor not confirmed yet. As the orphan receptors might qualify as drug targets thereis an enormous potential in this poorly studied group of receptors. Our aim is todevelop and optimize synthetic ligands for several promising orphan receptors of theδ-branch of class A GPCRs. Such ligands will be useful as pharmacological toolsto study receptor functions and explore their potential application for the treatmentof diseases. Our second aim is to optimize the compounds with regard to theirphysiochemical properties.Funke et al. identified 8-benzamidochromen-4-one-2-carboxylic acids as potent andselective agonists for the human orthologue of the orphan receptor GPR35.95 In thisstudy we aim to further optimize the structure of the 8-benzamidochromen-4-one-2-carboxylic acids regarding their activity as GPR35 agonists. A limitation of theGPR35 agonists developed so far is their species selectivity for the human receptor.A second objective is to develop potent and selective agonists for the rodent ortho-logues of GPR35. Those compounds would be important tools to perform animalstudies which can give insights into the functions of the receptor in vivo. Further-more it will be interesting to determine structure-activity relationships (SARs) forthe different orthologues to find out which structural elements are important fororthologue selectivity. This is a point that has been poorly investigated for GPR35so far.Some of the compounds, which were originally based on the structure of the cys-teinylleukotriene receptor-1 antagonist pranlukast also showed weak activity at the
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orphan receptors GPR84 and GPR17.172 However the compounds are not very potentand are thereby not suitable as pharmacological tools to further study those orphanreceptors. We plan to modify the structure of the moderately potent compounds todetermine SARs and to develop more potent GPR17 and GPR84 antagonists.Besides the optimization of the compounds regarding their potency at the differ-ent targets the selectivity of the compounds should be preserved or enhanced.Structure-activity relationships (SARs) have to be determined for each receptor,which will provide information about the shape of the binding pocket. We may alsobe able to gain information about structural elements of the endogenous agonistbased on the structure-activity relationship (SAR) analysis.Moreover, it will be of interest to test the chromen-4-ones for their activity at ad-ditional targets, like the GPR35-related GPR55 which is still lacking potent andselective ligands.
2.2 Biological evaluation of potent and selectiveecto-5’-nucleotidase inhibitorsThe objective of a second project is the biological evaluation of selected ecto-5’-nucleotidase (eN) inhibitors which were developed in our group.171 They show in-hibitory potencies in the nanomolar range at the rat enzyme but have not beentested at the human enzyme so far. We want to perform a comprehensive study withthe most potent compounds using a broad range of techniques in several biologicalsystems including the recombinant human enzyme, human blood serum, and differ-ent cell lines and tissues to further characterize the compounds. This will provideinformation on how the compounds will behave in vivo, for example in animal studies.We can further determine whether species differences exist, between the murine andthe human enzyme.
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3 Results and discussion
3.1 Synthesis of chromen-4-one-2-carboxylic acidderivatives
3.1.1 IntroductionChromones represent privileged scaffolds for the synthesis of new drugs.173 Thecysteiny leukotriene receptor antagonist pranlukast, which contains the chromen-4-one core structure, was identified as a moderately potent GRP17 antagonist.35 Thecompound was further modified by Mario Funke to increase its inhibitory potencyat GPR17. This led to the discovery of agonists for the orphan receptor GPR35based on the chromen-4-one structure.95,172 Moreover 8-benzamidochromen-4-one-2-carboxylic acids with long lipophilic residues were found to be weak antagonistsat the orphan receptor GPR84.172 We therefore decided to develop new ligandsbased on this promising core structure for several class A orphanG protein-coupledreceptors (GPCRs). A large number of modifications were realized at the chromen-4-one heterocycle and at various side-chains (Figure 3.1).We mainly targeted 4 structural elements of the scaffold. Firstly the 5-, 6-, and7-position of the chromen-4-one were modified. Here we mainly focused on the6-position which was substituted with small groups including halogen atoms, butalso with larger phenyl residues or longer alkyl chains. The second modification atthe chromen-4-one core was the replacement of the oxygen atom at the 4-positionby sulfur. At the 8-position we introduced many different side chains, from smallcarboxylic acids up to large lipophilic residues containing one or more phenyl rings,and alkyl chains of different length. Finally, the linker which connects the side chainto C8 of the chromen-4-one core was modified in several ways (see below).
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Figure 3.1: Structural modifications of pranlukast
3.1.2 Syntheses3.1.2.1 Synthesis of ethyl 8-amino-4-oxo-4H-chromene-2-carboxylatesThe preparation of ethyl 8-amino-4-oxo-4H-chromene-2-carboxylates began withthe nitration of commercially available 2-hydroxyacetophenones with various sub-stituents (R1 - R3) as shown in Scheme 3.1 based on a method from Burdeska.174
R3R1
R2
OOH
R3R1
R2
OOH
O2NCH3COOH, HNO3, 120 min, rt
1 - 7
42 - 95 %
Scheme 3.1: Synthesis of 1-(2-hydroxy-3-nitrophenyl)ethanones. For R1 - R3 see Ta-ble 3.1.
The starting material was dissolved in glacial acetic acid. Then a mixture of fumingnitric acid and glacial acetic acid was slowly added to the 2-hydroxyacetophenoneand the reaction mixture was stirred for 120 min at room temperature (rt). Afterpouring it onto ice the product precipitated as yellow solid and could be isolated ingood yields ranging from 42 - 95% as shown in Table 3.1.174 Only mononitration at
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the desired position 3 was observed.
Table 3.1: Yields of 1-(2-hydroxy-3-nitrophenyl)ethanones
OH
CH3
O
O2N
R3
R2
R1
compound R1 R2 R3 yield[%]
mp(lit. mp)[◦C] puritya[%]1175 H OCH3 H 62 (112-114) 100.02 H OCF3 H 42 87-88 100.03176 H ethyl H 92 (124-126) 92.74176 H F H 50 (93-94) 99.45 H Br methyl 95 163-164 80.06177 methyl methyl H 84 (143-144) 87.07 H O-TBDMS H 62 87-89 74.0a Purity was determined by HPLC-UV (254 nm)-ESI-MS
The ring closure was performed by a modified Claisen condensation which wasrecently developed in our group.95 Therefore compounds 1 - 7 were reacted withdiethyl oxalate and potassium tert-butoxide in dry dichlormethane (DMF) under anargon atmosphere to get the diketone, as shown in Scheme 3.2. Since the diketoneis not stable it was immediately reacted with concd. HCl in EtOH without furtherpurification to perform the ring closure with an overall yield from 53-98%.All in all we synthesized 9 chromen-4-ones. The ring closure did not work forcompound 7 which has a tert-butyldimethylsilyl (TBDMS) protected hydroxy groupat the 5-position, probably because of steric hinderance.The next step was the reduction of the nitro group to the corresponding amine.Since the reduction with H2 and Pd/C resulted in a debromination at position 6 ofthe chromen-4-one it was decided to use SnCl2 x 2 H2O and 2N HCl in EtOH forreduction.178 The amine could be isolated in good yields ranging from 57 - 95 % andwith high purities (Table 3.2).
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Scheme 3.2: Synthesis of ethyl 8-amino-4-oxo-4H-chromene-2-carboxylates. For R2and R3 see Table 3.2.
Table 3.2: Yields of ethyl 4-oxo-4H-chromene-2-carboxylates
O
R2
R3
R1
O
CO2Et
substitution pattern R1 = NO2 R1 = NH2
R2 R3 compd. yield[%]
mp(lit. mp)[◦C]
puritya[%] compd. yield[%]
mp(lit. mp)[◦C]
puritya[%]
Br H 8179 93 (141-142) 95.3 17180 95 (161-162) 99.4OCF3 H 9 53 120-121 91.3 18 57 100-102 90.0H H 1032 89 (122-123) 99.0 19181 91 (153-154) 100.0ethyl H 11 65 116-117 90.1 20 76 132-133 98.2F H 1295 68 (112-113) 90.2 2195 60 (164-165) 98.8Cl H 13182 98 (126-127) 85.6 2295 62 (150-151) 99.2methyl H 14183 69 (148-151) 95.4 23183 91 (127-132) 98.0OCH3 H 1565 78 (175-176) 98.4 24184 95 (144-145) 98.5Br methyl 16 63 204-205 91.5 25 92 164-166 97.5
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a Purity was determined by HPLC-UV (254 nm)-ESI-MS
3.1.2.2 Modifications of the ethyl 8-amino-4-oxo-4H-chromene-2-carboxylatesThe amine 17 (see Scheme 3.2 and Table 3.2) was the key intermediate for furthermodifications at the 6-position of the chromen-4-one. Especially for the receptorsGPR35 and GPR84 it seemed that there was a lot of space in the binding pocketat this position since a large halogen atom like bromine was beneficial for theactivity of the compounds. Thus we decided to introduce a phenyl substituent atthat position.In the literature some chromen-4-ones with a phenyl substituent at the 6-positionwere described by Witiak et. al.185 The synthesis starts with the biphenylace-tophenone which is reacted in a Claisen condensation with diethyl oxalate to thecorresponding ethyl 4-oxo-6-phenyl-4H-chromene-2-carboxylate (Scheme 3.3).
O
O
CO2EtOH
O Claisen
condensation
Scheme 3.3: Synthesis of ethyl 4-oxo-6-phenyl-4H-chromene-2-carboxylates byWitiak et. al.185
Ethyl 4-oxo-6-phenyl-4H-chromene-2-carboxylates with a nitro group at position 8are not described yet in the literature. A nitration of the 8-position of the chromen-4-one after the Claisen condensation carries the risk of many undesired by-productsand as a consequence tedious purification steps and low yields. It was thereforenecessary to introduce the nitro group before the ring closure.In the literature two pathways are described for the synthesis of ethyl 8-nitro-4-oxo-6-phenyl-4H-chromene-2-carboxylates (Scheme 3.4). Burdeska et al. started with aFries rearrangement of the [1,1’-biphenyl]-4-yl acetate to get the 1-(4-hydroxy-[1,1’-biphenyl]-3-yl)ethanone (Scheme 3.4 - pathway 1).174 However the Fries rearrange-ment reaction entails many disadvantages: the reaction is catalyzed by strong Lewisacids such as AlCl3, which are used in excess of the stoichiometric amount. Thosecatalysts are hazardous, corrosive and react violently with water which makes them
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inconvenient. Secondly the Fries rearrangement does not work with many substi-tuted starting compounds which makes it unsuitable for the synthesis of more com-plex structures. Alonso et al. started from 1-(5-bromo-2-hydroxyphenyl)ethanonereacting it via Suzuki coupling to the 1-(4-hydroxy-[1,1’-biphenyl]-3-yl)ethanone(Scheme 3.4 - pathway 2).186
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direct Suzuki coupling at 17 allows the introduction of various phenyl substituents in only 1 step!
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Scheme 3.4: Strategies for the introduction of phenyl substituents at the 6-position ofthe chromen-4-one scaffold.
This method is much better suitable since it avoids the use of hazardous chemicalsand has no limitations regarding highly substituted starting compounds. This couldrepresent a suitable method for our purpose if we would start from 1-(5-bromo-2-hydroxy-3-nitrophenyl)ethanone. However what both methods have in common is
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the large number of steps in case of introducing a larger number of phenyl sub-stituents with various substitution patterns. Due to the fact that the phenyl sub-stituent has to be coupled at such an early stage we would always have to run thewhole linear synthesis route for each product which is not efficient.We therefore decided to develop a method which allows to perform the Suzukicoupling reaction of compound 17 which could easily be synthesized in a largescale of up to 15 mmol per reaction (Scheme 3.4 - pathway 3). Another advantage isthe good solubility of compound 17 due to the amino group compared to derivativeswith a nitro group. We started with a standard procedure for Suzuki couplingusing palladium acetate/triphenylphosphine as a catalyst in EtOH containing 2 Maquaous (aq.) Na2CO3 solution.187
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Scheme 3.5: Suzuki coupling with ethyl 8-amino-6-bromo-4-oxo-4H-chromene-2-car-boxylate. For R see Table 3.3
The mixture was then refluxed under an argon atmosphere for 1 hour. The problemthat occurred was a hydrolysis of the chromen-4-one ring due to the basic aqueousconditions. We therefore changed the solvent to toluene containing a small amountof DMF, which increases the solubility of 17 significantly. The best catalyst in thenew solvent turned out to be tetrakis(triphenylphosphine)palladium(0) in combina-tion with K2CO3 as a base. To increase the yield we degassed the reaction mixturefor 5 min in an ultrasonic bath to remove all oxygen which would react with thecatalyst. The new method worked fine in the microwave oven (150 ◦C, 45 min, 120Watt, 6 bar) but also in an ACE R© pressure tube (120 ◦C, overnight) in larger batches.
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The product could not be separated from the starting material on a column of silicagel because of similar polarities of starting material and product. Therefore it wasabsolutely necessary to run the reaction until 100% of the starting material wasconverted.We successfully developed an efficient method to introduce different phenyl sub-stituents into the hydrogenolytically unstable chromen-4-ones. It allowed us tosynthesize a set of compounds with differently substituted phenyl residues at the6-position which represent important intermediates.
Table 3.3: Yields of ethyl 4-oxo-6-phenyl-4H-chromene-2-carboxylates
O
O
CO2Et
NH2
R
compound R yield[%] mp[◦C] puritya[%]26 H 89 138-139 99.127 Cl 46 183-184 94.828 methyl 59 127-128 97.129 OCH3 75 162-163 95.330 F 74 176-177 98.331 O-TBDMSb 64 155-157 97.732 N-Boc 60 222-223 99.5a Purity was determined by HPLC-UV (254 nm)-ESI-MSb O-TBDMS = tert-butyldimethylsilyl
We were also interested in the introduction of alkyl substituents at the 6-position ofthe chromen-4-one. Methyl- or ethyl-substituted acetophenones were commerciallyavailable, but for longer alkyl substituents like butyl, which could be interesting forobtaining GPR35 agonists, we had to find a synthetic method. In the literaturealkylated acetophenones are described to be synthesized by acetylation followedby the Fries rearrangement reaction. The disadvantages of the Fries rearrangementreaction have already been discussed, and it was pointed out that this common waywas not an option for our purposes. In the literature there are also proceduresdescribed for Suzuki coupling reactions with alkylboronic acids, so we decided to
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optimize our method with regard to the coupling of butylboronic acid. We found thatthe reaction worked with a mixture of PdCl2(PPh3)2 and triphenylphosphine as acatalyst. However the yield was very low. Nevertheless we could isolate sufficientamounts of product 33 for the next reaction steps.
O
O
Br
NH2
CO2Et
+ H3C B
OH
OH O
O
NH2
CO2Et
H3C
PdCl2(PPh3)2, PPh3, 
K2CO3, toluene, 
DMF, 120 °C, 
overnight
17%
17 33
Scheme 3.6: Suzuki coupling with butylboronic acid.
Using the new Suzuki coupling method with butylboronic acid we successfully syn-thesized ethyl 8-amino-6-butyl-4-oxo-4H-chromene-2-carboxylate 33 which is animportant intermediate for the development of GPR35 agonists.For the determination of further structure-activity relationships (SARs) we replacedthe ketone function in the 4-position of chromen-4-one by a thioketone. Lawesson’sreagent188 was used, which is a commercially available, mild and effective reagent forthe thioation of ketones. For the reaction, the amines 17, 21 and 22 were dissolvedin toluene, and Lawesson’s reagent was added to the mixture which was heated at100 ◦C for 16 hours. The mechanism is similar to a Wittig reaction (Scheme 3.7).
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MeO
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S
S
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S
OMe
MeO
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S
2
MeO
P S
S
2
O
O
R
NH2
CO2Et
O
R
NH2
CO2Et
O P
OMe
S
S
O
S
R
NH2
CO2Et
+
MeO
P
S
O
Lawesson's reagent
40 - 68%
34 - 3617, 21, 22
Lawesson's reagent, 
toluene, 100 °C, 16 h
Scheme 3.7: Synthesis of ethyl 4-thioxo-4H-chromene-2-carboxylates using Lawes-son’s reagent. For R see Table 3.4.
We successfully synthesized three different ethyl 4-thioxo-4H-chromene-2-carbo-xylates in satisfactory yields of 40-68% (Table 3.4).
Table 3.4: Yields of ethyl 4-thioxo-4H-chromene-2-carboxylates
O
S
CO2Et
R
NH2
compound R yield[%] mp[◦C] puritya[%]34 Br 63 176-177 84.935 Cl 40 190-192 98.136 F 68 175-177 84.0a Purity was determined by HPLC-UV (254 nm)-ESI-MS
The commercial availability of acetophenones with substitutents at the 4- and 6-position is limited because their synthesis can be complex due to directing effects of
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other substituents. We therefore introduced bromine atoms at the 5- and 7-positionof the chromen-4-ones which could be further modified. Compound 37 was dissolvedin benzene and DMF and after the addition of N-bromosuccinimide (NBS) and acatalytic amount of azobisisobutyronitrile (AIBN), it was heated to reflux for 6 h(Scheme 3.8).
O
OBr
Cl
Br
NH2
CO2EtO
O
Cl
NH2
CO2Et
benzene, DMF, 
NBS, AIBN, 
reflux, 6 h
20%
37 38
Scheme 3.8: Bromination of 37 with NBS/AIBN
Compound 38 was isolated only in a low yield and was found to display an extremelylow solubility which made further modifications impossible.The same problem of low solubility occurred when the ethyl ester at the 2-positionof 17 was reacted to a carboxyamide by dissolving it in MeOH and adding ammoniasolution.189 The product 39 could be isolated in an excellent yield of 95% but waspractically insoluble in all common solvents (Scheme 3.9).
O
O
Br
NH2
O
O
Br
NH2
CO2Et
MeOH, NH3, 
rt, 24 h
95%
NH2
O
17 39
Scheme 3.9: Conversion of the ethyl ester at position 2 to a carboxamide.
We also synthesized a chromen-4-one with an aldehyde at position 3. Therefore wereacted 1-(2-hydroxy-3-nitrophenyl)ethanone with POCl3 in DMF in a Vilsmeier-Haack reaction.190 We isolated the product 40 in a good yield of 68% (Scheme 3.10).However it was not possible to reduce the nitro group because the aldehyde wasinsoluble in all common solvents.
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NO2
OH
O
O
CHO
O
NO2
DMF, POCl3,
0-5 °C --> rt,
overnight
68%
replacements
40
Scheme 3.10: Synthesis of 8-nitro-4-oxo-4H-chromene-3-carbaldehyde.
Compound 17 turned out to be a perfect intermediate for structural modificationsof the chromen-4-one core structure. It shows a good solubility in contrast to thenitro analogue, which is an essential property for most reactions. Furthermore itcan be synthesized on large scale which avoids multiple reaction steps. However itis hydrogenolytically unstable under basic conditions, so it is absolutely requiredto work under dry conditions. By developing new methods it was possible to intro-duce phenyl and alkyl residues at position 6 of the chromen-4-one, and the ketoneat position 4 was replaced by a thioketone. Those compounds represent importantintermediates for the development of ligands for the targeted orphan GPCRs. How-ever, the introduction of bromine at position 5 and 7 as well as the replacement ofthe ester at position 2 by an amide and the introduction of an aldehyde at position3 resulted in compounds with extremely low solubility which could not be furtherreacted.
3.1.2.3 Synthesis of benzoic acid derivativesFor the synthesis of precursors for side-chains to be introduced in position 8 westarted from the commercially available N-alkylcarboxylic acids. In the first stepthey were reduced with LiAlH4 in tetrahydrofurane (THF) to the corresponding al-cohols.191 The alcohol was subsequently brominated without further purification tothe alkyl bromide using PBr3 (Scheme 3.11).192
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CO2H OH Brn n n
LiAlH4, THF,
 rt, 4 h
PBr3, toluene, 
0-5 °C, 30 min, 
reflux, 120 min
85-93%
(crude product)
86%
(crude product)
n = 4-5
41, 42 43, 44
Scheme 3.11: Synthesis of alkyl bromides.
Alkyl bromides 43 and 42 (Table 3.5) were used without further purification for thenext reaction steps.
Table 3.5: Yields of n-alkyl alcohols and n-alkyl bromides
R
n
R = OH R = Brn compound yield [%] compound yield [%]5 41193 93 43193 864 42193 85 44193 86
In the next reaction step the alkyl bromides were coupled with methyl hydroxyben-zoates via a Williamson ether synthesis. This was performed using K2CO3 as a basein DMF as a solvent.194 The products could be mostly isolated in excellent yieldsof higher than 80% except for compound 45 of which only 37% were formed. Thiscould be due to impurities in the alkyl bromide which was used without any priorpurification.
MeO2C
OH
MeO2C
O
R HO2C
O
R
K2CO3, DMF,
115 °C, 4 h
Method 1: 
microwave, MeOH,
KOH, 100 °C, 30 min
Method 2:
pressure tube, MeOH,
KOH, 120 °C, 4 h
37-100% 23-97%
Scheme 3.12: Synthesis of benzyloxybenzoic acids and alkyloxybenzoic acids. Forstructures see Table 3.6 and Table 3.7.
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Subsequently the protecting methyl ester was hydrolyzed yielding the desired car-boxylic acid. We started to perform the reaction in the microwave oven for obviousreasons. The microwave allows an optimal energy transfer which results in shortreaction times. However a big disadvantage for our purpose was, that the vol-ume of the microwave tube was limited. We needed large amounts of benzoic acidintermediates because they should be coupled to different chromen-4-ones.
Table 3.6: Yields of methyl (benzyloxy)benzoates and (benzyloxy)benzoic acids
O
R1
R3
R2
O
R3
R1
O
R1
F46 - 59 60 - 71 72 - 73substitution pattern R1 = CO2Me R1 = CO2HR2 R3 compound yield compound yieldmeta para [%] [%]H H F 46195 88 47196 85H F F 48197 89 49 96Cl H F 50197 86 51 96Cl F F 52198 88 53199 92F H F 54 92 55200 86OCH3 H F 56201 90 57 93Br H F 58 91 59 90- H F 60202 86 61196 86- H Br 62203 87 63196 89- H Cl 64204 82 65196 94- Br H 66 97 67 72- H methyl 68 88 69205 95- H H 70206 91 71196 8272207 85 73196 97*For melting points see chapter 5.
We therefore modified our method by changing the reaction device from the mircow-ave to a pressure tube which still allowed us to perform the reaction under pressureresulting in short reaction times. With this method we were able to hydrolyze anamount of 7 mmol instead of 2 mmol (by microwave) in one reaction. Although thereaction time increased from 30 min in the microwave up to 4 h in the pressure tube,
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it was still time-saving with regard to the overall yield. The yields for both methodswere comparable and mostly above 90% (Table 3.6 and Table 3.7).
Table 3.7: Yields of alkoxybenzoates and alkoxybenzoic acids
R1
OR
2
OR
2
R1
74 - 79 45, 80 - 102
R2 R1 = CO2Me R1 = CO2H
compound yield [%] puritya[%] compound yield[%] puritya[%]5-phenylpentyl 74208 92 97.7 7532 23 98.04-cyclohexylbutyl 76 77 99.1 77 91 100.05-cyclohexylpentyl 78 47 100.0 79 60 99.72-phenylethyl 80 64 97.0 81196 90 99.83-phenylpropyl 82 79 92.0 83 84 98.54-phenylbutyl 84 90 78.5 85209 23 98.05-phenylpentyl 86 88 90.5 87 86 100.0n-hexyl 88210 67 98.2 89196 73 100.0n-heptyl 90 64 63.4 91196 84 99.5n-octyl 92 87 93.3 93196 72 99.01-cyclohexylmethyl 94211 46 98.8 95212 91 100.02-cyclohexylethyl 96 90 95.9 97196 82 99.63-cyclohexylpropyl 98 53 98.0 99 94 97.04-cyclohexylbutyl 100 58 94.9 101 63 100.05-cyclohexylpentyl 45 37 95.4 102 97 99.1a Purity was determined by HPLC-UV (254 nm)-ESI-MS*For melting points see chapter 5.
We synthesized 29 benzoic acid derivatives which have structural similarities tofatty acids because of their lipophilic side chains. They can now on the one handbe coupled with amines, but on the other hand they may also be tested as potentialligands for fatty acid receptors.
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3.1.2.4 Synthesis of ethyl 8-benzamido-4-oxo-4H-chromene-2-carboxylatesFor the synthesis of the final compounds we coupled the amines with benzoic acidderivatives via an amide coupling reaction. We started by synthesizing the acidchlorides using thionyl chloride in dichloromethane (DCM) which was then directlyreacted with the amine in a mixture of DCM, THF and N,N-diisopropylethylamine(DIPEA) to form the amide (Scheme 3.13).95
O CO2Et
X
R1
NH2
O CO2Et
X
R1
NH
R2
O
R2
O OH
R2
O Cl
+
DCM, THF, 
DIPEA, argon,
rt, 1-3 d
DCM, DMF,
SOCl2,argon,
rt, 30 min
9-99%
Scheme 3.13: Amide coupling reaction. For exact structures see Table 3.8, Table 3.9,Table 3.10 and Table 3.11.
The yield varied from 9 to 99% but was mostly within a good range of at least 50%.We coupled a broad range of benzoic acid derivatives with the amines 17 - 36 andfinally isolated 73 amide derivatives (Table 3.8 - Table 3.11).
Table 3.8: Yields of ethyl 8-benzamido-4-oxo-4H-chromene-2-carboxylates
O
O
NH
CO2Et
O
O
S
R1
NH
CO2Et
O
R1
R2 R2
103 - 118 119
substitution patterncompound R1 R2 yield mp (lit.mp) purityaortho meta para [%] [◦C] [%]10395 Br H H OCH3 78 (251-252) 100.010465 Br F H OCH3 64 (216-217) 100.0
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10565 Br di-F H OCH3 51 (262-263) 98.610665 Br H F OCH3 74 (251-252) 97.210765 methyl H H OCH3 81 (219-220) 98.210865 OCH3 H H OCH3 85 (217-218) 98.9109 Br OCH3 H OCH3 69 284-285 99.5110 OCF3 H H OCH3 17 176-177 100.0111 phenyl H H OCH3 95 237-238 100.0112 ethyl H H OCH3 90 168-170 97.9113 Br H H ethyl 91 208-210 95.9
114 p-chloro-phenyl H H OCH3 86 250-251 96.4115 Br H H SCH3 50 231-232 99.9116 phenyl di-F H OCH3 55 210-211 99.0117 H H H CO2Et 80 201-202 99.0118 Br H H CO2Et 88 207-208 96.0119 Br H H OCH3 47 231-232 85.9a Purity was determined by HPLC-UV (254 nm)-ESI-MS
Table 3.9: Yields of ethyl 8-(2-ethoxy-2-oxoacetamido)-4-oxo-4H-chromene-2-carbox-ylates
O
O
NH
CO2Et
O
OEtO
O
S
R
NH
CO2Et
O
OEtO
R
120 - 127 128
compound R yield [%] mp [◦C] puritya [%]120 Br 73 172-173 98.7121 H 99 174-175 97.6122 phenyl 77 158-159 99.8123 F 74 164-166 99.3124 Cl 23 148-150 99.4125 methoxy 23 147-149 99.8126 methyl 39 133-135 97.6127 ethyl 39 133-135 99.4
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128 Br 29 171-173 91.6a Purity was determined by HPLC-UV (254 nm)-ESI-MS
Compound 129 and compound 130 were protected with TBDMS and tert-butyloxy-carbonyl (Boc), respectively. After the amide coupling reaction we therefore had toremove the protecting groups. The TBDMS was cleaved by refluxing the compound129 with concd. HCl in THF, and product 131 could be isolated in a good yieldof 89%. The Boc group was removed by stirring compound 130 with solution of 4NHCl in dioxane in THF as a solvent and we isolated the amine 132 in an excellentyield of 95% (Scheme 3.14).
O
O
CO2Et
NH
O
O
O
F
TBDMS
O
O
CO2Et
NH
H
N
O
O
F
Boc
O
O
CO2Et
NH
HO
O
O
F
O
O
CO2Et
NH
H2N
O
O
F
concd. HCl, 
THF, reflux,
4h
89%
4N HCl in dioxan,
THF, rt, overnight
95%
129 131
130 132
Scheme 3.14: Removal of the protecting groups TBDMS and Boc.
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Table 3.10: Yields of ethyl 8-((benzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxy-lates
O
O
CO2Et
NH
R1
O
O
R3
R4
R2
O
O
CO2Et
NHO
O
R3
R4
R2
R1
O
O
CO2Et
NH
R1
O
O
R2
O
O
CO2Et
NH
R1
O
O
R2
R3
133 - 135 129 - 132, 136 - 145 146 - 152 153
compound R1 R2 R3 R4 yield[%] mp[◦C] puritya[%]133 OCH3 H F H 79 253-254 100.0134 methyl H F H 78 234-235 63.0135 ethyl H F H 73 210-211 97.4136 H H F H 91 246-247 86.3137 H H F F 69 215-218 63.9138 Cl H F H 85 247-248 93.6139 H Cl F H 45 242-243 99.3140 F H F H 62 219-220 93.3141 OCH3 H F H 75 225-226 99.5142 methyl H F H 82 223-224 87.4143 F H F F 55 223-224 98.1144 F Cl F F 75 210-212 88.6
129 O-TBDMS H F H 82 172-173 83.7145 H F F H 72 249-250 89.0130 N-Boc H F H 72 232-233 96.9131 OH H F H 89 291-292 89.3132 NH2 H F H 95 215-216 99.1146 Br F - - 35 186-187 100.0147 Br Br - - 46 195-196 99.3148 Br Cl - - 33 186-187 100.0149 H methyl H - 36 196-198 98.5150 Br methyl H - 14 194-196 95.8
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151 H H Br - 63 175-176 100.0152 Br H Br - 74 198-200 96.5153 Br F - - 56 190-191 100.0a Purity was determined by HPLC-UV (254 nm)-ESI-MS
Table 3.11: Yields of ethyl 4-oxo-8-((alkylloxy)benzamido)-4H-chromene-2-carboxylates
O
O
NH
CO2Et
O
R1
O R
2
O
O
NH
CO2Et
O
R1
O R2
O
S
NH
CO2Et
O
R1
O R
2
154 - 171 172 - 179 180
compound R1 R2 yield[%] mp[◦C] puritya[%]154 H 1-cyclohexylmethyl 86 199-201 99.2155 H 2-cyclohexylethyl 78 150-151 100.0156 H 3-cyclohexylpropyl 48 129-130 85.1157 Cl 3-cyclohexylpropyl 58 129-130 95.2158 F 3-cyclohexylpropyl 53 147-148 98.7159 H 4-cyclohexylbutyl 61 148-149 98.1160 Cl 4-cyclohexylbutyl 48 147-148 94.2161 F 4-cyclohexylbutyl 48 147-148 93.1162 H 5-cyclohexylpentyl 85 144-145 99.4163 Cl 5-cyclohexylpentyl 72 148-149 100.0164 F 5-cyclohexylpentyl 63 148-149 99.6165 Cl hexyl 9 149-150 93.9166 Cl heptyl 54 153-155 97.0165 Cl octyl 70 151-153 97.5167 H 1-phenylmethyl 67 195-197 99.7168 H 2-phenylethyl 49 168-169 99.5169 H 3-phenylpropyl 41 157-159 98.9170 H 4-phenylbutyl 94 136-137 92.0171 H 5-phenylpentyl 37 137-138 100.0
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172 Br 3-cyclohexylpropyl 37 268-271 98.4173 OCH3 4-cyclohexylbutyl 40 174-175 100.0174 methyl 4-cyclohexylbutyl 64 165-166 92.0175 Cl 4-cyclohexylbutyl 50 62-163 99.6176 F 4-cyclohexylbutyl 60 151-152 99.1177 ethyl 4-cyclohexylbutyl 86 147-148 99.3178 H 5-cyclohexylpentyl 60 186-188 100.0179 Br 5-phenylpentyl 44 176-177 94.7180 F 3-cyclohexylpropyl 30 145-147 78.0a Purity was determined by HPLC-UV (254 nm)-ESI-MS
3.1.2.5 Modification of the amide linkerTo reach a higher diversity we also modified the amide linker for some selectedcompounds. The first idea was to methylate the amide linker to determine wetherremoving the proton has any effect on the potency of the compounds. We chose thecommon way for methylation using methyl iodide in DMF and K2CO3 as a base andisolated compound 181 in a good yield of 76% (Scheme 3.15).
O
O
CO2Et
Br
NHO
OCH3
O
O
CO2Et
Br
NO
OCH3
CH3
DMF, CH3I,
K2CO3, argon,
rt, 2 d
76%
103 181
Scheme 3.15: Methylation of the amide linker.
A further linker we inserted in our products was the urea linker. Compound 19 wasreacted it with triphosgene in DCM and DIPEA which formed the isocyanate. Thisintermediate was then further reacted without prior purification with p-hydroxyanilinein DCM and DIPEA yielding urea 182 in a good yield of 66% over two steps.
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O
O
CO2Et
NH2
O
O
CO2Et
N C O
O
O
CO2Et
NHO
HN
OH
Triphosgene, DCM, 
DIPEA, argon,
0-5 °C, 95 min
NH2
HO
DIPEA, DCM,
argon, rt,
overnight
66% overall yield19 182
Scheme 3.16: Synthesis of the urea linker.
Finally we also wanted to insert a thiourea linker into a potential GPR17 ligand.To synthesize the amino side chain we performed the Williamson ether synthe-sis with alkyl bromide 44 and p-nitrophenol as previously described. The nitrogroup was then reduced with Pd/C and hydrogen in MeOH to the correspondingamine 183, which was subsequently further reacted with the isothiocyanate 184in THF obtained from compound 19 by treatment with thiophosgene in ethyl ac-etate (EtOAc). The thiourea derivative 185 could be isolated in a satisfactory yieldof 40% (Scheme 3.17).
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O
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CO2Et
NH2
O
O
CO2Et
N C S
O
O
CO2Et
NHS
HN
O
1.Thiophosgene, EtOAc, 
TEA argon, -78 °C, 
15 min
2. THF, rt, overnight
THF, DCM,
argon, rt,
overnight
NO2
HO
Br
+
NO2
O
NH2
O
+
65%DMF, K2CO3,115 °C, 4h
Pd/C,H2, 45 psi,
MeOH, rt, 1 h
82%
94% 40%
44
186 187
19 184
185
Scheme 3.17: Synthesis of thiourea derivative 185.
In summary, we successfully modified the amide linker by synthesizing methylatedamide, urea and thiourea derivatives, which extends our knowledge on the SARs ofthe chromenone derivatives as ligands of orphan GPCRs.
3.1.2.6 Synthesis of 4-oxo-4H-chromene-2-carboxylic acids - the final productsFor the synthesis of our final products we had to perform the deprotection of theethyl ester function at position 2 of the chromen-4-ones. This was achieved in amixture of EtOH, H2O and THF in the presence of K2CO3 as a base (Scheme 3.18).
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O
X
R1
CO2Et
R2
O
X
R1
CO2H
R2
K2CO3, H2O, THF, 
EtOH, rt, overnight
30-99%
Scheme 3.18: Synthesis of free carboxylic acids. For exact structures see Table 3.12,Table 3.13, Table 3.14, Table 3.15 and Table 3.16.
For most of the compounds we reached an excellent yield of more than 80% and apurity of more than 98% (Table 3.12 - Table 3.16).
Table 3.12: Yields of 8-(2-ethoxy-2-oxoacetamido)-4-oxo-4H-chromene-2-carboxylicacids
O
O
NH
CO2H
O
OHO
O
S
R
NH
CO2H
O
OHO
R
188 - 196 197
compound R yield [%] mp [◦C] puritya [%]188 Br 96 246-247 98.5189 H 81 245-249 97.9190 phenyl 79 > 300 97.6191 F 85 254-256 99.4192 Cl 83 242-244 98.6193 methoxy 82 245-247 99.7194 methyl 76 250-252 99.4195 ethyl 93 246-248 99.4196 butyl 78 224-225 85.1197 Br 48 > 300 95.6a Purity was determined by HPLC-UV (254 nm)-ESI-MS
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Table 3.13: Yields of 8-benzamido-4-oxo-4H-chromene-2-carboxlic acids
O
O
NH
CO2H
O
O
S
R1
NH
CO2H
O
R1
R2 R2
O
O
R1
N
CO2H
O
R2
CH3198 - 210
211
212
substitution patterncompound R1 R2 yielda mp purityortho meta para [%] [◦C] [%]19865 Br F H OCH3 95 289-290 100.019965 Br di-F H OCH3 91 296-297 100.020065 Br H F OCH3 75 296-297 99.820165 methyl H H OCH3 86 283-284 99.720265 OCH3 H H OCH3 93 276-277 100.0203 Br OCH3 H OCH3 82 284-285 99.5204 OCF3 H H OCH3 96 270-271 99.3205 phenyl H H OCH3 96 270-272 100.0206 ethyl H H OCH3 86 277-278 100.0207 Br H H ethyl 94 297-298 100.0
208 p-chloro-phenyl H H OCH3 84 291-292 99.3209 Br H H SCH3 80 285-286 98.7210 phenyl di-F H OCH3 95 267-268 96.4211 Br H H OCH3 99 146-148 100.0212 Br H H OCH3 87 272-273 98.7a Purity was determined by HPLC-UV (254 nm)-ESI-MS
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Table 3.14: Yields of 8-((benzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acids
O
O
CO2H
NH
R1
O
O
R3
R4
R2
O
O
CO2H
NHO
O
R3
R4
R2
R1
O
O
CO2H
NH
R1
O
O
R2
O
O
CO2H
NH
R1
O
O
R2
R3
213 - 215 216 - 226 227 - 233 234
compound R1 R2 R3 R4 yield[%] mp[◦C] puritya[%]213 OCH3 H F H 87 274-278 100.0214 methyl H F H 63 260-261 100.0215 ethyl H F H 95 258-259 100.0216 H H F H 98 155-156 99.2217 H H F F 68 281-282 100.0218 Cl H F H 87 264-265 98.3219 H Cl F H 89 259-260 99.7220 F H F H 87 264-265 100.0221 OCH3 H F H 91 264-265 100.0222 methyl H F H 91 268-269 99.9223 F H F F 91 276-277 99.3224 F Cl F F 85 276-277 99.4225 OH H F H 85 > 300 99.2226 H F F H 94 262-263 97.0227 Br F - - 71 258-259 99.3228 Br Br - - 30 232-233 100.0229 Br Cl - - 72 202-203 100.0230 H methyl H - 57 229-231 99.8231 Br methyl H - 75 245-246 99.0232 H H Br - 99 256-257 99.9233 Br H Br - 85 253-254 100.0234 Br F - - 65 257-258 98.4a Purity was determined by HPLC-UV (254 nm)-ESI-MS
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Table 3.15: Yields of 8-(3-alkylbenzamido)-4-oxo-4H-chromene-2-carboxylic acids
O
O
NH
CO2H
O
R1
O R
2
O
O
NH
CO2H
O
R1
O R2
O
S
NH
CO2H
O
R1
O R
2
235 - 253 254 - 261 262
compound R1 R2 yield[%] mp[◦C] puritya[%]235 H 1-cyclohexylmethyl 95 254-255 99.8236 H 2-cyclohexylethyl 97 230-231 100.0237 H 3-cyclohexylpropyl 62 220-221 98.9238 Cl 3-cyclohexylpropyl 65 239-240 99.5239 F 3-cyclohexylpropyl 58 230-231 99.6240 H 4-cyclohexylbutyl 83 201-202 99.8241 Cl 4-cyclohexylbutyl 80 219-220 99.7242 F 4-cyclohexylbutyl 36 254-255 99.8243 H 5-cyclohexylpentyl 91 239-240 99.2244 Cl 5-cyclohexylpentyl 92 230-231 99.8245 F 5-cyclohexylpentyl 87 227-228 99.8246 Cl hexyl 95 228-230 99.8247 Cl heptyl 50 222-224 99.8248 Cl octyl 95 228-230 95.0249 H 1-phenylmethyl 87 243-244 99.9250 H 2-phenylethyl 87 230-231 99.2251 H 3-phenylpropyl 80 222-223 99.9252 H 4-phenylbutyl 81 213-214 98.5253 H 5-phenylpentyl 93 206-207 99.6254 Br 3-cyclohexylpropyl 90 246-247 100.0255 OCH3 4-cyclohexylbutyl 92 223-224 99.8256 methyl 4-cyclohexylbutyl 95 223-225 99.9257 Cl 4-cyclohexylbutyl 94 219-220 99.7258 F 4-cyclohexylbutyl 82 243-244 98.5
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259 ethyl 4-cyclohexylbutyl 96 220-221 100.0260 H 5-cyclohexylpentyl 79 231-232 100.0261 Br 5-phenylpentyl 89 223-224 99.7262 F 3-cyclohexylpropyl 56 212-214 95.0a Purity was determined by HPLC-UV (254 nm)-ESI-MS
The isolation of the urea derivative 263 turned out to be difficult because it did notcrystallize from the solution. This could be due to the high polarity of the compound.
Table 3.16: Yields of urea and thiourea derivatives
O
O
NH
CO2H
HN
O
OH
O
O
CO2H
NHS
HN
O
compound yield[%] mp[◦C] puritya[%]263 8 240-241 99.0264 56 148-150 98.0a Purity was determined by HPLC-UV (254 nm)-ESI-MS
All in all we synthesized 79 final products which are based on the chromen-4-onecore structure representing new potential ligands for GPCRs.
3.1.2.7 Synthesis of a tetrazole derivativeTo increase the water-solubility of our compounds we wanted introduce a tetra-zoleate into the 8-position the chromenone. We started from commercially available5-bromo-2-hydroxybenzonitrile which was first acetylated with acetic anhydride inthe presence of a catalytic amount of concd. H2SO4. Then we performed a solvent-free Fries rearrangement using dry AlCl3. The reaction mixture was heated to 160◦C. It was necessary to use absolutely dry and fresh AlCl3 because otherwise noproduct was formed. We could isolate the desired acetophenone 265 in a low yieldof 27% comparable to literature yields. The ring closure was carried out under the
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previously described reaction conditions for the Claisen condensation, and the ester266 was hydrolyzed as described before yielding the corresponding carboxylic acid267. The tetrazole was finally synthesized dissolving cyano derivative 267 in DMFand adding NH4Cl and NaN3. Product 268 could be isolated in a moderate yield of49% (Scheme 3.19). The compound showed an improved water-solubility comparedto the corresponding carboxylic acid 188.
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Scheme 3.19: Synthesis of the tetrazole derivative.
3.1.2.8 Synthesis of phenanthroline derivativesTo decrease the flexibility of our compounds we decided to perform a second ring clo-sure yielding phenanthroline derivatives. Those were synthesized according a modi-fied procedure described by Hall et. al.213 The diethyl 2-((2-(ethoxycarbonyl)-4-oxo-4H-chromen-8-yl)amino)maleates 270 and 271 were synthesized using the amines17 and 23 respectively, which were reacted with diethyl acetylene dicarboxylate inMeOH. The ring closure was performed in the high-boiling solvent Dowtherm R© A(mixture of 26.5% biphenyl and 73.5% diphenyl oxide). This reaction step was crit-ical because we observed a decarboxylation when the reaction time was too long.It was therefore necessary to permanently monitor the progress of the reaction bythin-layer chromatography (TLC) und directly stop it when the starting material was
64
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converted. Another important point was the amount of solvent. If we used too muchsolvent the product did not precipitate and could not be separated from the solvent.It we used too little of the solvent the product was not formed, maybe because thetemperature could not be reached. An amount of 2 mL/g of starting material turnedout to be optimal. Finally the ethyl ester had be hydrolyzed. Our previous methodfor deprotection of the carboxylic acid did not work in this case because the sol-ubility of the phenanthroline derivatives was extremely low. The challenge was tofind a method which was strong enough to cleave the ester but did not cleave thechromen-4-one structure that was also unstable under basic conditions. Using 1NNaOH as a base in a mixture of EtOH and THF as solvent for a reaction time of notlonger than 5 min the ester was quantitatively hydrolyzed without destruction of thechromen-4-one core structure. It should be noticed that this method was superiorto the previous method because of the short reaction time of only 5 min. Finallywe successfully synthesized two phenanthroline derivatives 272 and 273 which will,because of their reduced flexibility, give us further SAR information (Scheme 3.20).
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Scheme 3.20: Synthesis of the phenanthroline derivatives.
We decided to further synthesize a phenanthroline derivate which is not based
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on a chromen-4-one but on a quinolone scaffold. We used the same synthesisprocedure than described before starting from 2,4-aminotoluene which was reactedwith dimethyl acetylendicarboxylate. The ring closure of product 276 was thenperformed in boiling Dowtherm A R© for 30 min. The yield was extremely low becausethe second ring closure occured only after 30 min. After that reaction time someof the intermediate product (after one ring closure) was already destroyed becauseof the extremely high temperature that had to be applied. We isolated only a verysmall amount of product and therefore decided to perform the ester cleavage withoutfurther purification or analysis of the product. The quinolone is more stable thanthe chromen-4-one and therefore the methyl ester could be hydrolyzed in pure 1NNaOH. We isolated product 277 in an extremely low yield of 1% over two steps(Scheme 3.21).
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Scheme 3.21: Synthesis of the phenanthroline derivative 277.
All phenanthroline derivatives share an extremely low solubility but an increasedstability towards basic condition. For drug development they are an alternativescaffold to our chromen-4-ones.
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3.2 Pharmacological evaluation of chromenones atGPR35
3.2.1 IntroductionIn 2013 Funke et al. published 8-benzamidochromen-4-one-2-carboxylic acids aspotent and selective agonists for the human GPR35.95 Subsequently a radioligandbased on this structural class was developed, [3H]PSB-13253, which is the triti-ated version of 6-bromo-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylicacid.65 However the radioligand displays a high degree of species selectivity for thehuman receptor being not very potent at the rat and the mouse orthologue. It istherefore necessary to further modify the structure to increase activity at the rodentreceptors. This phenomenon of orthologue selectivity of GPR35 ligands was alreadydiscussed by many groups.214We synthesized a broad range of structurally diverse chromen-4-one derivativesthat were tested regarding their potency at the different GPR35 orthologues usingthe Pathhunter R© β-arrestin recruitment assay. This assay is a universal tool fororphan G protein-coupled receptor (GPCR) analysis as it is independent of secondmessenger pathways. For the assay a small peptide, the ProLink, is fused to thetarget GPCR. A larger complementing fragment, the enzyme acceptor (EA) is linkedto the arrestin. When the receptor is activated by an agonist the arrestin binds tothe GPCR and both peptide fragments will join forming an enzymatically active β-galactosidase. After addition of a substrate a chemiluminescent reaction product canbe measured. An advantage of this technology is that we can selectively measurethe activity of the fused GPCR.We also further optimized the agonists regarding their potency at the human GPR35.As we have a radioligand available for this target we were also able to determinethe binding of the ligands to the human receptor. In radioligand binding studiesthe ability of a compound to displace the radioligand from its binding site at thereceptor is measured radiometrically.
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3.2.2 ResultsThe pharmacological evaluation of the compounds was performed by Dr. DominikThimm in our group.
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Table 3.17: Potency and affinity of chromen-4-one-2-carboxylic acids at human GPR35, mouse GPR35 and rat GPR35.Functional β-arrestin recruitment experiments were performed using CHO β-arrestin cells expressing human, rat or mouseGPR35. Affinity was determined in radioligand binding experiments using membrane preparations of CHO cells recombinantlyexpressing the human GPR35. Compounds were tested in binding studies versus the radioligand [3H]PSB-13253.
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188 - 196 197 272 - 273 277 268compd. R Human GPR35 Rat GPR35 Mouse GPR35EC50 ± SEM (µM) Ki ± SEM (µM) EC50 ± SEM (µM) EC50 ± SEM (µM)
(% effecta ± SEM) (% inhibitionb ± SEM) (% effectc ± SEM) (% effecta ± SEM)
Standard compoundsdZaprinast 1.96 ± 0.2465 0.401 ± 0.015172 0.0611 ± 0.0061172 1.60 ± 0.04172Cromoglicic acid 1.26 ± 0.1765 2.34 ± 0.0465 0.986 ± 0.126172 4.84 ± 0.60172Pranlukast > 10 (12 ± 2)172 0.0407 ± 0.0073172 0.480 ± 0.036172 > 10 (58 ± 1)172PSB-13253 0.0111 ± 0.003165 0.00518 ± 0.0003365 4.17 ± 0.3365 > 10 (35 ± 2)65188 Br 0.0118 ± 0.0015 0.0138 ± 0.0015 0.0451 ± 0.0065 1.88 ± 0.44189 H 0.246 ± 0.017 0.396 ± 0.036 0.779 ± 0.097 > 10 (37 ± 4)190 phenyl 0.00968 ± 0.00048 0.00319 ± 0.00056 0.154 ± 0.015 0.494 ± 0.083191 F 0.106 ± 0.011 0.0426 ± 0.0111 0.263 ± 0.034 4.76 ± 0.32192 Cl 0.0293 ± 0.0015 0.00716 ± 0.00012 0.0800 ± 0.0031 1.71 ± 0.46193 methoxy 0.0938 ± 0.0087 0.0335 ± 0.0051 0.851 ± 0.102 4.71 ± 0.53 (88%)194 methyl 0.104 ± 0.003 0.0635 ± 0.0208 0.406 ± 0.036 2.38 ± 0.74 (77%)69
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compd. R human GPR35 rat GPR35 mouse GPR35EC50 ± SEM (µM) Ki ± SEM (µM) EC50 ± SEM (µM) EC50 ± SEM (µM)(% effecta ± SEM) (% inhibitionb ± SEM) (% effectc ± SEM) (% effecta ± SEM)195 ethyl 0.0275 ± 0.0025 0.0179 ± 0.0014 0.0750 ± 0.0020 1.00 ± 0.30196 butyl 0.0318 ± 0.0053 0.00897 ± 0.0015 0.0297 ± 0.0040 0.399 ± 0.083197 Br 0.00847 ± 0.00072 0.00271 ± 0.00032 0.0209 ± 0.0023 0.174 ± 0.019272 Br 0.037 ± 0.0021 0.0149 ± 0.0031 0.487 ± 0.064 0.910 ± 0.120273 methyl 0.0295 ± 0.0046 0.00836 ± 0.00075 0.470 ± 0.042 (87%) 0.955 ± 0.229277 methyl 0.0214 ± 0.0021 0.0062 ± 0.00065 0.0263 ± 0.0023 0.105 ± 0.015268 Br 3.00 ± 0.590 0.925 ± 0.080 1.91 ± 0.270 5.84 ± 0.37Initial screens were performed at a concentration of 10 µM. Effects were normalized to the signal induced by a30 µM (humanand mouse) or c10 µM (rat) of zaprinast corresponding to a maximal response at the respective receptor. bRadioligandbinding studies. dFor structures of the standard compounds see Figure 1.8.
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Table 3.18: Potency and affinity of chromen-4-one-2-carboxylic acids at human GPR35, mouse GPR35 and rat GPR35. Functionalβ-arrestin recruitment experiments were performed using CHO β-arrestin cells expressing human, rat or mouse GPR35. Affinitywas determined in radioligand binding experiments using membrane preparations of CHO cells recombinantly expressing thehuman GPR35. Compounds were tested in binding studies versus the radioligand [3H]PSB-13253.
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substitution pattern Human GPR35 Rat GPR35 Mouse GPR35compd. R1 R2 EC50 ± SEM Ki ± SEM EC50 ± SEM EC50 ± SEMortho meta para (µM) (µM) (µM) (µM)(% effecta ± SEM) (% inhibitionb ±SEM) (% effectc ± SEM) (% effecta ±SEM)MF37465 Cl F H OCH3 0.00606 ± 0.00088 0.00192 ± 0.00012 0.374 ± 0.033 n.d.MF33895 Br H H OCH3 0.0111 ± 0.0031 0.00518 ± 0.00033 4.17 ± 0.33 > 10 (35 ± 2)MF356172 Br H H OH 0.716 ± 0.085 n.d. 0.349 ± 0.020 1.07 ± 0.12MF31095 F H H OCH3 0.112 ± 0.011 0.0254 ± 0.0023 1.76 ± 0.08 > 10 (30 ± 4)MF25795 Cl H H OCH3 0.0168 ± 0.0021 0.00550 ± 0.00012 1.83 ± 0.27 > 10 (34 ± 3)MF_AM1195 H H H OCH3 0.346 ± 0.037 0.221 ± 0.020 2.16 ± 0.22 (85%) 5.03 ± 0.67 (66%)19865 Br F H OCH3 0.00446 ± 0.00030 0.00137 ± 0.00011 0.234 ± 0.040 2.71 ± 0.3419965 Br di-F H OCH3 0.00554 ± 0.00029 0.000589 ±0.000076 0.199 ± 0.039 2.85 ± 0.4120065 Br H F OCH3 0.00437 ± 0.00048 0.00164 ± 0.00018 0.769 ± 0.038 (84%) 3.52 ± 0.7620165 methyl H H OCH3 0.0377 ± 0.0036 0.0428 ± 0.0032 1.20 ± 0.26 (79%) 3.82 ± 0.70 (88%)71
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substitution pattern human GPR35 rat GPR35 mouse GPR35compd. R1 R2 EC50 ± SEM Ki ± SEM EC50 ± SEM EC50 ± SEMortho meta para (µM) (µM) (µM) (µM)(% effecta ± SEM) (% inhibitionb ±SEM) (% effectc ± SEM) (% effecta ±SEM)20265 OCH3 H H OCH3 0.0255 ± 0.0027 0.0205 ± 0.0022 1.52 ± 0.12 (77%) 2.69 ± 0.39203 Br OCH3 H OCH3 0.0162 ± 0.0009 0.00824 ± 0.0006 0.493 ± 0.081(78%) 2.52 ± 0.56 (82%)204 OCF3 H H OCH3 0.0104 ± 0.0017 0.00724 ± 0.00043 0.345 ± 0.043 2.64 ± 0.25 (87%)205 phenyl H H OCH3 0.00548 ± 0.00089 0.00172 ± 0.00009 0.195 ± 0.010 0.459 ± 0.104206 ethyl H H OCH3 0.0306 ± 0.0074 0.0228 ± 0.0016 0.428 ± 0.056 1.83 ± 0.04207 Br H H ethyl 0.0570 ± 0.0055 0.0828 ± 0.0081 0.857 ± 0.211 (76%) 3.14 ± 0.23 (89%)208 p-chloro-phenyl
H H OCH3 0.00821 ± 0.00189 0.00139 ± 0.00010 0.263 ± 0.034(88%) 0.724 ± 0.140
209 Br H H SCH3 0.0150 ± 0.0009 0.0235 ± 0.0023 0.748 ± 0.045(80%) 3.29 ± 0.37 (88%)210 phenyl di-F H OCH3 0.00108 ± 0.00011 0.000426 ±0.000037 0.157 ± 0.013 0.293 ± 0.042211 Br H H OCH3 > 10 (28 ± 7) > 10 (23 ± 3) >10 (6 ± 1) > 10 (1 ± 1)212 Br H H OCH3 0.00362 ± 0.00066 0.00125 ± 0.00006 0.552 ± 0.042(73%) 1.31 ± 0.07263 H H H OH 1.87 ± 0.08 1.55 ± 0.126 0.288 ± 0.034(76%) 1.54 ± 0.26 (89%)Initial screens were performed at a concentration of 10 µM. Effects were normalized to the signal induced by a30 µM (human andmouse) or c10 µM (rat) of zaprinast corresponding to a maximal response at the respective receptor. bRadioligand binding studies.
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Table 3.19: Potency and affinity of chromen-4-one-2-carboxylic acids at human GPR35, mouse GPR35 and rat GPR35.Functional β-arrestin recruitment experiments were performed using CHO β-arrestin cells expressing human, rat or mouseGPR35. Affinity was determined in radioligand binding experiments using membrane preparations of CHO cells recombinantlyexpressing the human GPR35. Compounds were tested in binding studies versus the radioligand [3H]PSB-13253.
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213 - 215 216 - 226 227 - 233 234compd. substitution pattern Human GPR35 Rat GPR35 Mouse GPR35R1 R2 R3 R4 EC50 ± SEM Ki ± SEM EC50 ± SEM EC50 ± SEM(% effecta ± SEM) (% inhibitionb ±SEM) (% effectc ± SEM) (% effecta ± SEM)213 OCH3 H F H > 10 (33 ± 6) 1.06 ± 0.058 > 10 (52 ± 9) 1.28 ± 0.38 (76%)214 methyl H F H > 10 (21 ± 1) 0.835 ± 0.058 0.977 ± 0.051 (82%) 1.77 ± 0.09215 ethyl H F H 7.47 ± 1.38 0.432 ± 0.037 0.417 ± 0.018 1.16 ± 0.33216 H H F H > 10 (40 ± 4) 0.186 ± 0.009 0.540 ± 0.078 (64%) 1.42 ± 0.11 (70%)217 H H F F > 10 (8 ± 5) 0.354 ± 0.049 0.527 ± 0.055 (58%) 1.61 ± 0.29 (78%)218 Cl H F H > 10 (4 ± 2) > 10 (30 ± 3) > 10 (43 ± 5) 2.77 ± 0.26 (65%)219 H Cl F H > 10 (48 ± 7) 0.317 ± 0.019 > 10 (50 ± 5) 1.81 ± 0.21 (64%)220 F H F H > 10 (13 ± 3) > 10 (28 ± 2) > 10 (44 ± 4) 1.52 ± 0.28 (70%)221 OCH3 H F H > 10 (20 ± 2) 0.263 ± 0.050 > 10 (43 ± 4) 1.25 ± 0.11 (64%)222 methyl H F H > 10 (5 ± 2) > 10 (41 ± 2) > 10 (30 ± 3) 3.22 ± 0.44 (60%)73
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compd. substitution pattern human GPR35 rat GPR35 mouse GPR35R1 R2 R3 R4 EC50 ± SEM Ki ± SEM EC50 ± SEM EC50 ± SEM
(% effecta ± SEM) (% inhibitionb ±SEM) (% effectc ± SEM) (% effecta ± SEM)223 F H F F > 10 (1 ± 2) > 10 (32 ± 3) > 10 (39 ± 3) 2.76 ± 0.46 (70%)224 F Cl F F > 10 (2 ± 2) > 10 (37 ± 2) > 10 (37 ± 4) 2.27 ± 1.05 (55%)225 OH H F H 0.583 ± 0.086 0.0299 ± 0.0028 0.140 ± 0.022 0.218 ± 0.059226 H F F H 0.381 ± 0.021 0.218 ± 0.022 0.435 ± 0.036 (86%) 1.13 ± 0.06 (86%)227 Br F - - > 10 (7 ± 2) 0.573 ± 0.050 0.726 ± 0.066 (75%) 2.36 ± 0.36228 Br Br - - > 10 (6 ± 1) 0.372 ± 0.031 > 10 (47 ± 3) 2.10 ± 0.19 (88%)229 Br Cl - - > 10 (16 ± 1) 0.383 ± 0.027 > 10 (50 ± 5) 2.77 ± 0.21 (79%)230 H methyl H - > 10 (40 ± 5) 2.11 ± 0.280 > 10 (48 ± 3) 1.36 ± 0.21231 Br methyl H - > 10 (35 ± 7) 1.50 ± 0.130 > 10 (43 ± 2) 4.27 ± 1.19 (75%)232 H H Br - > 10 (27 ± 6) 0.667 ± 0.032 0.512 ± 0.020 (79%) 0.784 ± 0.145233 Br H Br - > 10 (4 ± 5) 4.28 ± 0.250 0.699 ± 0.079 (69%) 1.41 ± 0.06 (84%)234 Br F - - > 10 (-2 ± 1) 1.58 ± 0.080 > 10 (53 ± 9) 4.90 ± 0.62 (80%)Initial screens were performed at a concentration of 10 µM. Effects were normalized to the signal induced by a30 µM (humanand mouse) or c10 µM (rat) of zaprinast corresponding to a maximal response at the respective receptor. bRadioligandbinding studies.
74
3.2PharmacologicalevaluationofchromenonesatGPR35
Dissertation,UniversitätBonn2016
Table 3.20: Potency and affinity of chromen-4-one-2-carboxylic acids at human GPR35, mouse GPR35 and rat GPR35. Functionalβ-arrestin recruitment experiments were performed using CHO β-arrestin cells expressing human, rat or mouse GPR35. Affinitywas determined in radioligand binding experiments using membrane preparations of CHO cells recombinantly expressing thehuman GPR35. Compounds were tested in binding studies versus the radioligand [3H]PSB-13253.
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compd. R1 R2 Human GPR35 Rat GPR35 Mouse GPR35EC50 ± SEM Ki ± SEM EC50 ± SEM EC50 ± SEM
(% effecta ± SEM) (% inhibitionb ±SEM) (% effectc ± SEM) (% effecta ± SEM)235 H 1-cyclohexylmethyl > 10 (23 ± 7) 1.26 ± 0.170 1.25 ± 0.08 (73%) 0.790 ± 0.058236 H 2-cyclohexylethyl > 10 (8 ± 5) 0.930 ± 0.022 1.48 ± 0.27 (58%) 1.71 ± 0.23237 H 3-cyclohexylpropyl > 10 (-7 ± 1) 0.585 ± 0.070 > 10 (41 ± 0) 2.43 ± 0.73 (82%)238 Cl 3-cyclohexylpropyl > 10 (-5 ± 2) > 10 (39 ± 6) > 10 (17 ± 8) 3.43 ± 0.29 (55%)239 F 3-cyclohexylpropyl > 10 (-4 ± 1) 1.59 ± 0.360 > 10 (33 ± 5) 2.98 ± 0.23 (81%)240 H 4-cyclohexylbutyl > 10 (-3 ± 3) 0.474 ± 0.043 > 10 (37 ± 4) 2.58 ± 0.31 (54%)241 Cl 4-cyclohexylbutyl > 10 (-6 ± 1) 1.94 ± 0.11 > 10 (27 ± 3) > 10 (41 ± 2)242 F 4-cyclohexylbutyl > 10 (-6 ± 1) 1.32 ± 0.090 > 10 (29 ± 9) 2.90 ± 0.52 (45%)243 H 5-cyclohexylpentyl > 10 (-2 ± 4) > 10 (34 ± 10) > 10 (8 ± 4) 3.37 ± 1.99 (50%)244 Cl 5-cyclohexylpentyl > 10 (-8 ± 2) 2.67 ± 0.590 > 10 (3 ± 4) > 10 (30 ± 7)75
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compd. R1 R2 human GPR35 rat GPR35 mouse GPR35EC50 ± SEM Ki ± SEM EC50 ± SEM EC50 ± SEM
(% effecta ± SEM) (% inhibitionb ±SEM) (% effectc ± SEM) (% effecta ± SEM)245 F 5-cyclohexylpentyl > 10 (-9 ± 3) 2.22 ± 0.210 > 10 (15 ± 5) > 10 (48 ± 2)246 Cl hexyl > 10 (5 ± 0) 1.30 ± 0.210 > 10 (45 ± 4) 2.25 ± 0.23 (78%)247 Cl heptyl > 10 (-1 ± 1) 1.13 ± 0.180 > 10 (47 ± 5) 2.63 ± 0.23 (66%)248 Cl octyl > 10 (-1 ± 1) 1.62 ± 0.180 > 10 (37 ± 4) > 10 (49 ± 2)249 H 1-phenylmethyl 4.20 ± 0.57 2.94 ± 0.310 0.983 ± 0.095 1.35 ± 0.28
250 H 2-phenylethyl > 10 (40 ± 0) 2.39 ± 0.170 0.561 ± 0.052(85%) 1.07 ± 0.19251 H 3-phenylpropyl > 10 (14 ± 4) 1.08 ± 0.170 1.72 ± 0.53 (59%) 1.38 ± 0.04252 H 4-phenylbutyl > 10 (22 ± 2) 1.00 ± 0.030 > 10 (12 ± 6) 1.82 ± 0.10253 H 5-phenylpentyl > 10 (11 ± 2) 0.490 ± 0.007 > 10 (20 ± 13) 1.25 ± 0.21 (72%)254 Br 3-cyclohexylpropyl > 10 (20 ± 4) 0.179 ± 0.036 > 10 (4 ± 2) > 10 (21 ± 8)255 OCH3 4-cyclohexylbutyl > 10 (35 ± 4) 0.012 ± 0.005 > 10 (9 ± 1) 2.78 ± 0.27 (63%)256 methyl 4-cyclohexylbutyl > 10 (31 ± 2) 0.0172 ± 0.0002 > 10 (2 ± 3) > 10 (18 ± 3)257 Cl 4-cyclohexylbutyl > 10 (3 ± 1) 0.0646 ± 0.0063 > 10 (4 ± 1) > 10 (23 ± 4)258 F 4-cyclohexylbutyl > 10 (-2 ± 1) 0.0364 ± 0.0018 > 10 (4 ± 4) > 10 (13 ± 2)259 ethyl 4-cyclohexylbutyl 0.791 ± 0.228 > 10 (39 ± 6) > 10 (5 ± 7) > 10 (46 ± 2)260 H 5-cyclohexylpentyl > 10 (12 ± 4) 0.0155 ± 0.0012 > 10 (22 ± 3) > 10 (21 ± 5)261 Br 5-phenylpentyl > 10 (22 ± 2) 0.0833 ± 0.0040 > 10 (12 ± 6) > 10 (39 ± 10)262 F 3-cyclohexylpropyl > 10 (2 ± 1) 3.17 ± 0.180 > 10 (9 ± 2) > 10 (36 ± 7)264 H 4-cyclohexylbutyl 1.87 ± 0.08 0.132 ± 0.0012 0.288 ± 0.034 3.86 ± 0.91 (66%)
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compd. R1 R2 human GPR35 rat GPR35 mouse GPR35EC50 ± SEM Ki ± SEM EC50 ± SEM EC50 ± SEM
(% effecta ± SEM) (% inhibitionb ±SEM) (% effectc ± SEM) (% effecta ± SEM)Initial screens were performed at a concentration of 10 µM. Effects were normalized to the signal induced by a30 µM (humanand mouse) or c10 µM (rat) of zaprinast corresponding to a maximal response at the respective receptor. bRadioligandbinding studies.
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3.2.3 Structure-activity relationships3.2.3.1 IntroductionThe phenomenon of orthologue selectivity at the orphan receptor GPR35 was al-ready discussed in the introduction. It was therefore necessary to test the com-pounds not only at the human receptor but also at the rodent receptors because thepotency of ligands at the human receptor cannot be easily translated to the rodentorthologues. In the following paragraphs the results will first be discussed for eachreceptor separately and then analyzed regarding orthologue selectivity.
3.2.3.2 Human GPR35A broad range of chromen-4-one derivatives had already been synthesized in ourgroup. In the course of these studies the side-chain at the 8-position of the chromen-4-one was modified extensively. A phenyl which was substituted in the para-positionwith a methoxy group linked to the chromen-4-one via an amide turned out to bethe best substituent. It could also be observed that fluorine substitutions at thephenyl-ring were beneficial for potency.65,95For the present study we wanted to further investigate the importance of the 6-position. So far it has only been substituted with hydrogen, bromine, chlorine, andfluorine. The results identified bromine as the best substituent at this position sofar.95 For the modifications of the 6-position we chose compound MF_AM1195 asa lead structure. The most potent compounds contain halogens at the 6-positionand show the following rank order of potency: bromine (MF33895 EC50 = 0.0111 ±0.0031 µM) ≈ chlorine (MF25795 EC50 = 0.0168 ± 0.0021 µM) > fluorine (MF31095EC50 = 0.112 ± 0.011 µM) ≈ hydrogen (MF_AM1195 EC50 = 0.346 ± 0.037 µM).The introduction of a methoxy group, which is also a hydrogen bond acceptor likethe halogens, decreased the potency compared to bromine and chlorine substituents(20265 EC50 = 0.0255 ± 0.0027 µM) but resulted still in a higher potency comparedto fluorine and hydrogen. The replacement of the methyl ether by a trifluoromethylether, which has a higher electronegativity and lipophilicity, resulted in an increasein potency (204 EC50 = 0.0104 ± 0.0017 µM) comparable to the one of the brominecompound MF338.95 To determine whether electronegativity or lipophilicity havethe higher impact on the potency we introduced alkyl chains of different lengthsat the 6-position. The potency of the resulting compounds was between the one
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of the fluorine and the chlorine compounds. The length of the chain did not makea significant difference. The longer ethyl chain (206 EC50 = 0.0306 ± 0.0074 µM)seemed to be equallly potent as a methyl group (27865 EC50 = 0.0377 ± 0.0036µM). Besides the electronegativity and lipophilicity also the size of this residuecould play an important role, which would be a further explanation for the goodpotency of the trifluoromethoxy compound 204. We therefore decided to introducea large phenyl substitutent in this position. The phenyl derivative showed a 2-foldhigher potency compared to the bromine and the trifluoromethoxy compound (205EC50 = 0.00548 ± 0.00089 µM). To further increase the size of the compound andto increase 6-substituent’s electronegativity we additionally added a chlorine inthe para-position of the phenyl-ring. However the resulting compound (208 EC50 =0.00821 ± 0.00189 µM) was less active than the unsubstituted phenyl derivative butstill more potent than the bromine and the trifluoromethyl derivatives (Table 3.18).We designed a second series of compounds with a different side-chain where the6-position was again modified extensively (Table 3.17). These compounds weresubstituted at the 8-position with a 2-amino-2-oxoacetic acid. The structure-activityrelationships (SARs) of the 6-position were mostly comparable to the previouslydescribed series of compounds. The rank order of substituents was as follows:phenyl (190 EC50 = 0.00967 ± 0.00048 µM) ≈ bromine (123 EC50 = 0.118 ± 0.0015µM) > ethyl (195 EC50 = 0.0275 ± 0.0025 µM) ≈ chlorine (192 EC50 = 0.0293 ±0.0015 µM) > butyl (196 EC50 = 0.0318 ± 0.0053 µM) > methoxy (193 EC50 =0.0938 ± 0.0087 µM) ≈ methyl (194 EC50 = 0.104 ± 0.003 µM) > hydrogen (189EC50 = 0.246 ± 0.017 µM). One remarkable difference was that the ethyl and thebutyl substituent are better tolerated in this series of compounds whereas methoxyis not well tolerated. Still fluorine and hydrogen as small, more polar atoms are nottolerated and the phenyl substituent is the best one. SAR results are depicted inFigure 3.2.
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Figure 3.2: Structure-activity relationships of substituents at the 6-position of chromen-4-one derivatives determined for the human GPR35. The pEC50 values ± SEM werecalculated from EC50 values that were determined by β-arrestin recruitment assay. Twoscaffolds (A and B) were analyzed.
Besides the modification of the 6-position many other modifications of the linker,
80
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the side-chain, and the chromen-4-one core structure itself were performed. Themost remarkable one was the replacement of the oxygen at the 4-position of thechromen-4-one by a sulfur atom. The C=S bond is less polarized than the C=Obond and sulfur has a lower ability to form hydrogen bonds. The sulfur was welltolerated. Compound 197 (EC50 = 0.00847 ± 0.00072 µM) appeared to be evenslightly more potent than the corresponding oxygen analogue 188 (EC50 = 0.0118± 0.0015 µM). The same was observed for the second series of compounds. Alsohere the sulfur analogue (212, EC50 = 0.00362 ± 0.00066 µM) was almost 3-foldmore potent than the keto-derivative (MF33895 EC50 = 0.0111 ± 0.0031 µM).We also performed some modifications of the linker. The methylation of the primaryamide to a secondary amide and thereby the abolishment of the ability to formhydrogen bonds resulted in a complete loss of potency in compound 211. A urealinker was also not beneficial for the potency (263 EC50 = 1.87 ± 0.08 µM).Regarding the side-chain, the substitution of the phenyl ring was already inves-tigated comprehensively.65,95 Because a fluorine substitution seemed to be ben-eficial for the potency we also performed different fluorine substitutions at themethoxyphenyl group in the 8-position of the chromen-4-one. The potency of thecompounds with ortho-substitution (19865 EC50 = 0.00446 ± 0.0030 µM) was al-most comparable to the di-ortho-(19965 EC50 = 0.00554 ± 0.00029 µM) and themeta-substituted (20065 EC50 = 0.00437 ± 0.00048 µM) derivatives. All compoundswere about 2.5-fold more potent than the unsubstituted MF338. However the affin-ity determined in radioligand binding studies was slightly different. The affinityof 199 (Ki = 0.000589 ± 0.000076 µM) was more than 2-fold higher compared tothe mono-substituted compounds (198 Ki = 0.00137 ± 0.00011 µM and 200 Ki =0.00164 ± 0.00018 µM).An ortho-methoxy substitution (203 EC50 = 0.0162 ± 0.0009 µM) as well as thereplacement of the para-methoxy group by either ethyl (207 EC50 = 0.0570 ± 0.0055µM) or thiomethyl (209 EC50 = 0.0150 ± 0.0009 µM) did not result in compoundswith improved potency.Also the compounds with the 2-amino-2-oxoacetic acid side chain and the tetrazolein the 8-position were not more potent at hGPR35 than the phenyl derivatives. Thelarger compounds displayed in Table 3.19 and Table 3.20, which were originallydesigned for other orphan receptors, did not activate GPR35 at all. They are too
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big and too lipophilic. However there are two exceptions (Figure 3.3). Compound225 (EC50 = 0.583 ± 0.086 µM) and 226 (EC50 = 0.381 ± 0.021 µM) were ableto activate the receptor in the higher nanomolar range. Regarding 225 this couldbe explained by the hydroxy group in the para-position of the phenyl ring in the6-position. The compound binds to the the receptor in a different binding mode andthe hydroxy group might interact in the same binding pocket where the methoxygroup of the side chain phenyl ring normally binds. The activity of compound 226could be explained by the additional fluorine substituent in the side-chain. Wepreviously identified a fluorine in the meta-position as an enhancer of the potencyof the compounds (Figure 3.3).
O CO2H
NH
O
O
O
F
F
O CO2H
NH
O
O
OCH3
The additional flourine atom at 
the side-chain of 226 
enhances the potency of the 
compound compared to 216.
O CO2H
NH
O
O
O
F
F
200 
EC50 = 0.00437 ± 0.0048 µM
Ki = 0.000426 ± 0.000037 µM
226 
EC50 = 0.381 ± 0.021 µM
Ki = 0.218 ± 0.022 µM
216
EC50  > 10 µM
Ki = 0.186 ± 0.009 µM
O CO2H
NH
O
O
O
F
HO
225
EC50 = 0.583 ± 0.086 µM
Ki = 0.0299 ± 0.0028 µM
The hydroxy-substituent at the phenyl-ring 
at the 6-position of compound 225 
enhances the potency compared to 216.
F
Figure 3.3: Small structural modifications convert the inactive compound 216 to GPR35agonists with moderate potency.
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Combining the ortho-difluoro-4-methoxyphenyl side chain with the phenyl substi-tuted chromen-4-one core structure resulted in the most potent hGPR35 agonistknown to date (210, EC50 = 0.00108 ± 0.00011 µM) (Figure 3.4).
O CO2H
O
NHO
F F
OCH3
210
EC50 = 1.08 ± 0.11 nM
Ki = 0.426 ± 0.037 nMFigure 3.4: Compound 210 - the most potent agonist at human GPR35 known to dateis able to activate the receptor with a high potency and binds with nanomolar affinity.
We also performed a ring closure which was inspired by the bufrolin derivative277. Bufrolin (Figure 3.8) had been identified as a potent agonist at human andrat GPR35.215 Like our compound series displayed in Table 3.17 it has 2 carboxylicacids but the scaffold is a phenanthroline derivative which is built up of three rings.We therefore decided to perform a ring closure also at our chromen-4-ones insteadof the side chain. However the resulting compounds (272 EC50 = 0.037 ± 0.0021µM and 273 EC50 = 0.0295 ± 0.0046 µM) were less active than the correspondingopen form. It seems not to fit perfectly into the binding pocket and some flexibilityor less planarity is required. Surprisingly the compound which has methyl in the6-position was a little bit more active than the bromine-substituted compound. Thebufrolin derivative 277 also was 20 fold less potent than the most potent compound210.All SARs determined for the human GPR35 are illustrated in Figure 3.5.
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Figure 3.5: Structure-activity relationships determined for human GPR35.
We can conclude that a large, electron-rich substituent is beneficial at the 6-position. The 4-methoxyphenyl side-chain connected with an unsubstituted amidelinker and substituted with fluorine atoms turned out to be optimal at the 8-position.Furthermore the replacement of the oxygen at position 4 by a sulfur atom slightlyincreased the potency of the compounds.
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3.2.3.3 Affinity of chromenones at the human GPR35The affinity of chromen-4-ones at the human GPR35 was determined by radioli-gand binding experiments using the radioligand [3H]PSB-1325365 which had beendeveloped in our group. The affinity of GPR35 agonists mostly correlated with thepotency determined in β-arrestin assays. Compounds that showed high agonisticpotency at GPR35 also showed a high affinity. However we observed some notabledifferences.When we analyzed the 6-position we saw that the rank order of affinity was com-parable to that we observed for the previously determined potency. Earlier studiesindicated that halogen atoms have a larger effect on the affinity than on the po-tency compared to a methoxy group or an alkyl-chain.65 This could not be confirmed.However the chlorine atom in the 6-position increased the affinity on a higher levelthan the potency (192, EC50 = 0.0293 ± 0.0015 µM; Ki = 0.00716 ± 0.00012 µM).The most potent agonist at the human GPR35, compound 210 also showed thehighest affinity of all tested chromen-4-ones (EC50 = 0.00108 ± 0.00011 µM; Ki =0.000426 ± 0.000037 µM).The results of the binding studies with the larger chromenones shown in Table 3.19and Table 3.20 were more surprising. These compounds mostly did not show ag-onistic activity at GPR35 in the β-arrestin recruitment assays. In the radioligandbinding experiments however some of the compounds showed high affinities. Todetermine if they were antagonists at GPR35, they were tested in the β-arrestinrecruitment assay for antagonism with the result that surprisingly none of the com-pounds showed antagonistic activity at GPR35. These compounds are able to dis-place the binding of [3H]PSB-13253 at GPR35 with high affinity but they are notable to activate or block the β-arrestin signalling pathway. These compounds maybe so-called "biased agonists" with a functional selectivity for the G protein. Biasedagonists are interesting tools as they avoid the functional antagonism which is aresult of the recruitment of arrestins which results in receptor internalization. As aconsequence they could be able to activate the receptor permanently. However thehypothesis that the compounds are biased agonists, has to be confirmed by furtherstudies with functional assays that are able to measure the activity of the G proteinindependently from β-arrestin. One possibility would be the performance of assaysusing chimeric G proteins.
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The SARs for the potential biased agonists were interesting. First of all the com-pounds were much larger and more lipophilic than the full agonists shown in Ta-ble 3.17 and Table 3.18. Large side-chains at the 8-position were well tolerated.Thereby a substitution of the phenyl-amide at the 8-position in the para-positionresulted in higher affinities than the substitution in the meta- or in the ortho-position. The affinity increased with the length of the side-chain. At the end ofthe side-chain a cyclohexyl-ring as well as a phenyl-ring were well tolerated. Thecompounds shown in Table 3.19, whose side-chain had a length of only one C-atomshowed moderate affinities in the higher nanomolar range. However there was oneexception. Compound 225, which showed also a moderate potency at the humanGPR35, showed a high affinity at the human GPR35 in the lower nanomolar range(EC50 = 0.583 ± 0.0086 µM; Ki = 0.0299 ± 0.0028 µM). The introduction of a hy-droxy group in the para-position of the phenyl-ring in position 6 resulted in a 6-foldincrease in affinity compared to the hydrogen-substituted compound 216 (EC50 >10 µM; Ki = 0.186 ± 0.009 µM). Whereas the introduction of a fluorine atom at thefirst phenyl-ring of the side-chain showed a high effect on the potency, it did nothave any effect on the affinity (279, EC50 = 0.381 ± 0.021 µM; Ki = 0.218 ± 0.022µM) (Figure 3.3).
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Figure 3.6: Potential biased agonists for the human GPR35 with high affinity and po-tential functional selectivity for the G protein.
Compounds with longer alkyl side-chains in the meta-position of the phenyl-amideshowed only moderate affinities at the human GPR35 in the high nanomolar ormicromolar range. However, when the side-chain was moved to the para-position
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the affinity was extremely increased. The substituent in the 6-position thereby didnot have a significant effect on the affinity, apart from an ethyl group which resultedin a complete loss of affinity. The effect of the length of the side-chain could not bedetermined due to the lack of a series of structures with comparable substituentsin the 6-position.The potential biased agonists with the highest affinity were compounds 255 (EC50> 10 µM; Ki = 0.012 ± 0.005 µM), 256 (EC50 > 10 µM; Ki = 0.0172 ± 0.0002µM), and 260 (EC50 > 10 µM; Ki = 0.0155 ± 0.0012 µM) which showed affinities inthe low nanomolar range but were completely inactive in the β-arrestin recruitmentassays (Figure 3.6).
3.2.3.4 Rat GPR35The SARs determined for the rat GPR35 were different from the ones at the humanreceptor. When we analyzed the 6-position of the compounds we saw that the rankorder of potency for the halogens and hydrogen is comparable to that observedat the human receptor. The methoxy substituent however was not tolerated andcomparable to hydrogen. The next interesting point are alkyl chains of differentlengths. We observed an increase in potency which is connected to an increase inthe number of C-atoms. As a result we get the following rank order of substituents:butyl (196 EC50 = 0.0297 ± 0.0040 µM) > bromine (188 EC50 = 0.0451 ± 0.0065µM) > ethyl (195 EC50 = 0.0750 ± 0.0020 µM) ≈ chlorine (192 EC50 = 0.0800 ±0.0031 µM) > phenyl (190 EC50 = 0.154 ± 0.015 µM) > fluorine (191 EC50 = 0.263± 0.034 µM) > methyl (194 EC50 = 0.406 ± 0.036 µM) > hydrogen (189 EC50 =0.779 ± 0.097 µM) ≈ methoxy (193 EC50 = 0.851 ± 0.102 µM).
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Figure 3.7: Structure-activity relationships of substituents at the 6-position of chromen-4-one derivatives determined for the rat GPR35. The pEC50 values ± SEM were calcu-lated from EC50 values that were determined by β-arrestin recruitment assay.
The binding pocket of the rat GPR35 is different from the one of the human receptor.There seems to be a lot of space so that big groups like bromine are beneficial.However lipophilicity appears to be more important because long alkyl chains arethe best substituents in this position.When we look at the second series of compounds which contains a phenyl ring in-stead of the second carboxylic acid at the 8-substituent, we cannot clearly determineSARs because the potency of the compounds was very low. The bromine-substitutedcompound (MF33895 EC50 = 4.17 ± 0.020 µM) only activates the receptor in the mi-cromolar range. However phenyl (205 EC50 = 0.195± 0.010 µM) and p-chlorophenyl(208 EC50 = 0.263 ± 0.034 µM) are well tolerated at the 6-position. Also OCF3 (204EC50 = 0.345 ± 0.043 µM) and ethyl (206 EC50 = 0.428 ± 0.056 µM) increased thepotency of the compounds compared to hydrogen (MF_AM1195 EC50 = 2.16 ± 0.22µM). Methyl (20165 EC50 = 1.20 ± 0.26 µM) and methoxy (20265 EC50 = 1.52 ±0.12 µM) were not tolerated as well which matches to our previous results. One ex-planation for the differences in SARs at the 6-position could be that the compoundsbind to the receptor in a different orientation. This should be further investigatedusing computational methods.As we also had observed for the human receptor the replacement of the oxygen at
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the 4-position of the chromen-4-one by sulfur resulted in an increase in potency.Compound 197 (EC50 = 0.0209 ± 0.0023 µM) was about 2-fold more potent thancompound 188 (EC50 = 0.0451 ± 0.0065 µM) and compound 212 (EC50 = 0.552 ±0.042 µM) was even almost 8-fold more potent than compound MF33895 EC50 =4.17 ± 0.020 µM).It is noticeable that the introduction of fluorine atoms at the side chain significantlyincreased the potency of the compounds. Especially the ortho-substitution had anenormous effect. The mono-substituted compound 198 (EC50 = 0.234 ± 0.040 µM) isalmost 20-fold more potent than the unsubstituted derivative (MF33895 EC50 = 4.17± 0.020 µM). Di-substitution resulted in an even higher potency (199 EC50 = 0.199± 0.039 µM) whereas meta-substitution had the smallest effect (200 EC50 = 0.769± 0.038 µM). These results were corroborated by a second pair of compounds: theortho-difluoro derivative 205 (EC50 = 0.157 ± 0.013 µM) was more potent than theunsubstituted compound 205 (EC50 = 0.195 ± 0.010 µM). These results correspondto the results determined for the human receptor.Interestingly also an ortho-substitution with methoxy was beneficial (203 EC50 =0.493 ± 0.081 µM) and increased the potency by about 8-fold.The effect of the replacement of para-methoxy by other groups was also investigated.Both, ethyl (207 EC50 = 0.857 ± 0.211 µM) and thiomethyl (209 EC50 = 0.748 ±0.045 µM) were preferred by the receptor.The modification of the amide linker also resulted in interesting SARs. The methyla-tion of the amide was absolutely not tolerated and completely abolished the activityof the compound (compound 211). In contrast to that the thiourea linker increasedpotency significantly. Compound (264 EC50 = 0.288 ± 0.034 µM) showed an unex-pectedly high potency in the nanomolar range although it is much larger and morelipophilic compared to the other active compounds. Due to the lack of directly cor-responding compounds we could not draw clear conclusions about the urea linker,but it seems to be about equally beneficial as the amide linker as we could notobserve any remarkable effect.The most active compounds so far were the compounds which contain two carboxylicacid functions. We performed a ring closure for some compounds of this serieswhich did not have any negative but also no positive effect on the potency of thecompounds (272 EC50 = 0.487 ± 0.064 µM and 273 EC50 = 0.470 ± 0.042 µM). The
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bufrolin derivative 277 however was much more potent (EC50 = 0.0263 ± 0.0023µM). If we compare the structure of the compounds it is obvious that the directionof the ketone next to the 8-position of the chromen-4-one is really important for thepotency (Figure 3.8).
N
H
O
CO2HHN
OHO2C
N
H
H3C
O
CO2HHN
OHO2C
O
H3C
O
CO2H
NH
O
CO2H
O
Br
O
CO2H
NH
O
CO2H
O
H3C
O
CO2H
O NH
CO2H
O
Br
O
CO2H
O NH
CO2H
O
O
CO2H
O NH
CO2H
Bufrolin
Ring closure at the chromen-4-one
 was not well tolerated
Prolongation of the 
side-chain at the
chromen-4-one 
was beneficialShortening of the side-chainof bufrolin was tolerated
EC50 = 12.8 ± 0.7 nMa
277
EC50 = 26.3 ± 2.3 nM
196
EC50 = 29.7 ± 4.0 nM
188
EC50 = 45.1 ± 6.5 nM
272
EC50 = 487 ± 64 nM
273
EC50 = 470 ± 42 nM
194
EC50 = 406 ± 36 nM
Figure 3.8: Structure-activity relationships determined for the rat GPR35 agoniststhat share substructures with the GPR35 agonist bufrolin. aBufrolin was tested byMacKenzie et al. using the Pathhunter R© β-arrestin recruitment assay.85
The last modification was the replacement of the acetic acid in the side chain bya tetrazole which is also acidic. However the tetrazole is not able to interact withthe receptor in the same way which resulted in a loss of potency (268 EC50 = 1.91± 0.270 µM). This could also be explained by the lack of the amide, especially
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the oxygen, which was previously identified as an important factor for the potency.The 1H-tetrazole is a frequently used bioisosteric modification in drug design as itshows a similar clogP than the carboxylic acid.216All SARs determined for rat GPR35 are illustrated in Figure 3.9. All compound whichdid not show agonistic activity were also tested for antagonism at the rGPR35 butnone of the compounds showed any antagonistic activity in the β-arrestin recruit-ment assays.
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In conclusion the SARs determined for rat GPR35 differ in some regions from thosedetermined for the human receptor. This issue will be discussed in section 3.2.5..The most potent agonist for the rat GPR35 is 197 with an EC50-value of 0.0209 ±0.0023 µM (Figure 3.10).
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EC50 = 26.3 ± 2.3 nMFigure 3.10: The most potent agonists at rat GPR35.
Based on the results of this study, further optimizations can be done to increasethe potency of the GPR35 agonist at the rat orthologue. The replacement of theoxygen at the 4-position of 196 by sulfur could be beneficial. A modification ofthe alkyl side-chain at position 6 has also to be investigated. A prolongation or thereplacement by branched alkyl side-chains as well as the introduction of bromoalkylresidues would be interesting.
3.2.3.5 Mouse GPR35The SARs of chromen-4-ones for the mouse GPR35 are hard to determine. Onefact is that almost all compounds which were tested activated the receptor in themicromolar range although they were structurally completely different. Only fewcompounds were able to activate the receptor at lower concentrations. But whatwe still definetely can see is that the smaller and less lipophilic compounds fromseries one (Table 3.17) and series two (Table 3.18) were usually more potent.The SARs for the 6-position corresponded well to the SARs for the rat orthologue.Long aliphatic alkyl chains were found to be beneficial, the longer the better. Alsophenyl was a suitable substitutent followed by the halogens bromine and chlorine.Fluorine, methoxy and hydrogen resulted in a loss of potency. As a result we gotthe following rank order of potency: butyl (196, EC50 = 0.399 ± 0.083 µM) > phenyl
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(190, EC50 = 0.494 ± 0.083 µM) > ethyl (195, EC50 = 1.00 ± 0.30 µM) > chlorine(192, EC50 = 1.71 ± 0.46 µM) > bromine (188, EC50 = 1.88 ± 0.44 µM) > fluorine(191, EC50 = 4.76 ± 0.32 µM) ≈ methoxy (193, EC50 = 4.71 ± 0.53 µM) > hydrogen(189, EC50 > 10 µM).
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Figure 3.11: Structure-activity relationships of substituents at the 6-position of chromen-4-one derivatives determined for the mouse GPR35. The pEC50 values ± SEM werecalculated from EC50 values that were determined by β-arrestin recruitment assay.
Although the the rank order of potency for the substituents corresponded to thatobserved for the rat GPR35 the potency of the mGPR35 agonists was on aver-age about 10-fold lower compared to the EC50-values determined at the rat GPR35(Figure 3.11). The compounds shown in Table 3.18 were less active and SARs couldhardly be determined. However, like for the rat GPR35, the phenyl-substituted com-pound (205, EC50 = 0.459 ± 0.104 µM), the p-chlorophenyl-substituted compound(208, EC50 = 0.724 ± 0.140 µM) and the ethyl derivative (206, EC50 = 1.83 ± 0.04µM were the most active compounds.A fluoro-substitution at the side-chain further increased potency of the compounds.Compound 280, (EC50 = 0.293 ± 0.042 µM), which contains the ortho-difluoro-substituent was about 2-fold more potent than the non-substituted compound 205(EC50 = 0.459 ± 0.104 µM). An ortho-substitution seemed to be preferred. Themeta-substituted compound 20065 (EC50 = 3.52 ± 0.76 µM) was less active thanthe ortho-substituted 198.65 A second fluorine in the ortho-position did not haveany effect (199,65 EC50 = 2.85 ± 0.41 µM).
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When we looked at the linker we observed again that methylation of the amide (211,EC50 = > 10 µM) resulted in a complete loss of activity. Neither the urea nor thethiourea linker resulted in a change in potency. However what we have to keep inmind is that we do not have a series of compounds that is really comparable.As it was also found for the human and the rat receptor the replacement of theoxygen at the 4-position by sulfur had a positive effect on the potency of the mGPR35agonists. Compound 197 (EC50 = 0.174 ± 0.019 µM) was about 10-fold more potentthan compound 188 (EC50 = 1.88 ± 0.44 µM). The same applied to the compoundsfrom series 2 (Table 3.18. Replacement of oxygen by sulfur in compound MF338,95which was completely inactive, resulted in the mGPR35 agonist 212 (EC50 = 1.31± 0.07 µM) which showed a potency in the micromolar range.One interesting compound is 225 (EC50 = 0.218 ± 0.059 µM) which had an un-expectedly high potency. We already saw this phenomenon at the rat receptor.Compound 225 contains a hydroxyphenyl-group at the 6-position.The dicarboxylic acid derivatives shown in Table 3.17 were the most active com-pounds so far. The ring closure did not have any effect on potency at rat receptoror even resulted in a loss of activity at the human receptor. For the mouse receptorwe observed the opposite. The ring closure (272 EC50 = 0.910 ± 0.120 µM and 273EC50 = 0.955 ± 0.229 µM) resulted in an increase in potency compared to the openform. The position of the oxygen of the amide does not seem to play an importantrole. This would also explain why we do not see any difference when we changethe linker.We also synthesized a derivative of bufrolin (277, EC50 = 0.105 ± 0.015 µM), whichturned out to be the most potent compound (Figure 3.13). Ring closure fixes theconformation of the compound which is no longer flexible. If a sterically fixed con-formation represents the active conformation of a ligand it can be expected to bemore potent than flexible analogues.
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EC50 = 2.38 ± 0.74 µMFigure 3.12: The ring closure at the chromen-4-ones enhances the potency of themouse GPR35 agonists.
The best mouse GPR35 agonist developed so far is 277 (EC50 = 0.105 ± 0.015 µM)which is not based on the chromen-4-one scaffold. The best chromen-4-one basedcompound is 197 (EC50 = 0.174 ± 0.019 µM) (Figure 3.13). All compound which didnot show agonistic activity were also tested for antagonism at the mGPR35 but noneof the compounds showed any antagonistic activity in the β-arrestin recruitmentassays.
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Figure 3.13: Compounds 277 and 197-the most potent agonists for the mouse GPR35
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All in all the compounds are less active at the mouse orthologue than at the rat-orthologue and the human receptor. The fact that many compounds show a lowactivity at the mGPR35 indicates that most of the chromen-4-ones do not perfectlyfit into the binding pocket. The SARs determined for the mouse receptor are shownin Figure 3.14. However, with a potency around 100 nM our mGPR35 agonist arehighly interesting tools for mouse experiments since only few GPR35 agonist for themouse orthologue have been identified so far.
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Figure 3.14: Structure-activity relationships determined for the mouse GPR35.
For further optimization it would be interesting to synthesize compounds containinga sulfur atom at the 4 position of the chromen-4-one with longer alkyl-residues or
96
3.2 Pharmacological evaluation of chromenones at GPR35 Dissertation, Universität Bonn 2016
a phenyl ring at position 6. Additionally ring closure could be beneficial.
3.2.4 GPR35 orthologue selectivityThe comparison of the SARs at the different orthologues shows that there are sub-stantial differences in the potency of the compounds. It is obvious that on averagethe compounds are more potent at the human GPR35 than at the rodent receptors.The most potent compound 210 (hGPR35: EC50 = 0.00108 ± 0.00011 µM; rGPR35:EC50 = 0.157 ± 0.013 µM; mGPR35: EC50 = 0.293 ± 0.042 µM) is about 150-foldmore potent at the human receptor than at the rodent orthologues (Figure 3.15).However, for animal studies we also need potent ligands for the mouse and ratGPR35.Changing the substituents at the side-chain phenyl ring did not increase the po-tency for rodent receptors. A fluorine substituent at the phenyl side chain improvedthe potency at all receptors. What could also be seen in every species was theeffect of the replacement of the oxygen at the 4-position of the chromen-4-one by asulfur. Compounds containing a sulfur were more potent compared to their oxygen-analogues perhaps due to to increased lipophilicity. This indicates that the oxygenatom is not forming hydrogen-bonds since sulfur is a much weaker H-bond acceptor.When we compare the effect of substituents at the 6-position we see differences.Bromine is only tolerated by the human receptor whereas the rodent receptors preferlong aliphatic chains or a phenyl ring. The clearest differences could be observedwhen we changed the side-chain at the 8-position. The introduction of a secondacidic function significantly improved the potency of the compounds at the rodentreceptors whereas the potency at the human receptor was decreased (197 hGPR35:EC50 = 0.00847 ± 0.00072 µM; rGPR35: EC50 = 0.0209 ± 0.0023 µM; mGPR35:EC50 = 0.174 ± 0.019 µM) (Figure 3.15). The ring-closure yielding phenanthrolinederivatives improved only the potency at the mouse receptor but decreased thepotency at the human and the rat orthologue.Compound 225 hGPR35: EC50 = 0.583 ± 0.086 µM; rGPR35: EC50 = 0.140 ±0.022 µM; mGPR35: EC50 = 0.218 ± 0.059 µM) interestingly was about 3 foldsmore potent at the rodent receptors than at the human receptor (Figure 3.15). Itcontains a phenol and a long lipophilic side chain which might not be well toleratedby the human receptor (Figure 3.15).
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Figure 3.15: GPR35 agonists with high species selectivity. The pEC50 values ± SEMwere calculated from the EC50 values that were determined in β-arrestin recruitmentassay.
We also identified one compound which was selective for the rat GPR35. Com-pound 263 (hGPR35: EC50 = 1.87 ± 0.08 µM; rGPR35: EC50 = 0.288 ± 0.034 µM;mGPR35: EC50 = 1.54 ± 0.26 µM) contains an urea linker and a phenol in the
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para-position of the side-chain. It is about 6-fold more potent at the rat orthologuethan at the human or the mouse receptor. The compounds that show a high speciesselectivity are shown in Figure 3.15.We identified also compounds that are almost equipotent at the human and therodent orthologues. These compounds contain two carboxylic acid functions. Ifwe compare the substituents at position 6 of the chromen-4-ones it can clearlybe observed that an introduction of an alkyl side-chain at this position results in adecreased species selectivity between the human and the rat orthologue. Compound277 (hGPR35: EC50 = 0.0214 ± 0.0021 µM; rGPR35: EC50 = 0.0263 ± 0.0023 µM;mGPR35: EC50 = 0.105 ± 0.015 µM) is the most balanced compound. Planaritycould be a feature to design this class of GPR35 agonists (Figure 3.16).
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Figure 3.16: GPR35 agonists with low species selectivity
Physicochemical properties were calculated for the most potent GPR35 agonistsusing Stardrop R© (Figure 3.17). All of the selected chromen-4-ones as well as the
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bufrolin derivative 277 perfectly fit into the criteria of Lipinski’s rule of five, whichis a parameter for predicting the oral bioavailability of drugs.217 Furthermore theTPSA (topological polar surface area), which is a criterion for the drug’s ability topermeate cells, was below or equal to 140 Å which should allow cell permeability.
196 277
210 197
logP =	1.671
MW =	333.3	g/Mol
HBD =	3
HBA =	8
TPSA =	133.9	
logP =	2.987
MW =	454.2	g/Mol
HBD =	2
HBA =	7
TPSA =	105.8	
logP =	0.8675
MW =	314.3	g/Mol
HBD =	4
HBA =	8
TPSA =	140.3	
logP =	1.938
MW =	372.1	g/Mol
HBD =	3
HBA =	7
TPSA =	116.8	
Figure 3.17: Physicochemical properties of selected GPR35 agonists. Analysis of thepolarity of the structure performed with Stardrop R©. Polar groups are shown in bluecolour whereas unpolar parts of the molecule are shown in red colour. The logP, molecularweight (MW), hydrogen-bond donators (HBD), hydrogen-bond acceptors (HBA) and thetopological polar surface area (TPSA) were calculated using Stardrop R©.
In conclusion the second acidic function is the main factor that improves the po-tency at the rodent receptor whereas it is not needed for the potency at the humanreceptor. We designed GPR35 agonists with a high species selectivity as well asbalanced compounds. Both give insight into the receptors’ structures and can beused as pharmacological tools at human cells as well as in animal studies. Thephysicochemical properties indicate that the new GPR35 agonists are suitable leadcompounds for the development of new drugs. Computational methods or mutagen-esis studies could clarify which amino acids in the binding pocket are responsible orthis species differences. It has to be kept in mind that molecular modeling is highlyspeculative since no X-ray structure of GPR35 is available, and only very few classA δ-branch GPCRs have been crystallized so far. In the future a radioligand with
100
3.2 Pharmacological evaluation of chromenones at GPR35 Dissertation, Universität Bonn 2016
high potency at the mouse and the rat orthologue should be developed based onour new agonists. Based on the results from the radioligand binding experimentswith the human GPR35 it is likely that some of the compounds, that were inactivein functional β-arrestin assays, might be identified as biased agonists activating analternative pathway.
3.2.4.1 Strategy for the development of GPR35 radioligands[(3)H]PSB-13253 (6-bromo-8-(4-[(3)H]methoxybenzamido)-4-oxo-4H-chromene-2-car-boxylic acid) is a potent and selective radioligand for the orphan receptor GPR35and was developed in our group. However, the radioligand displays a high orthologeselectivity for the human receptor.65 We developed a series of GPR35 agonists thatshow high potency at the human receptor and at the murine orthologes. In thefollowing a strategy for the development of a radioligand based on the new GPR35agonists will be presented (Figure 3.18).Compounds 277 which is based on bufrolin and the chromenone based compound196 were the most balanced compounds of our series regarding their potency at thedifferent orthologes of GPR35. They showed high potency at the human receptoras well as at the mouse and rat GPR35. Furthermore their structure offers the pos-sibility for the introduction of a radioactive marker. The long aliphatic side-chain,which is present in both compounds, is a suitable structural element for the intro-duction of a tritium marker. Therefore these compounds represent lead structuresfor the development of a orthologe independent radioligand. The first step would bethe optimization of the compounds based on the SARs we determined in our study.Therefore the ketones of the lead structures should be displaced by a thioketonewhich will enhance the potency. For the synthesis of a radioligand a unsaturatedaliphatic chain should be introduced which could then easily be radiolabled usingtritium gas.
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Figure 3.18: Strategy for the development of new radioligands as pharmacological toolsfor the human and the murine orthologes of the orphan receptor GPR35.
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3.3 Pharmacological evaluation at the human GPR84
3.3.1 IntroductionIn contrast to GPR35, which was activated by chromenone derivatives, this class ofcompounds acted as antagonists of the (hydroxy) fatty acid-activated GPR84. Theability of chromen-4-one derivatives to block GPR84 was investigated in a radio-metric cyclic adenosine monophosphate (cAMP) accumulation assay. This assay isbased on the fact that activation of the Gi-coupled receptor GPR84 results in aninhibition of cAMP production. For the assay the cAMP production was stimulatedby the addition of the diterpene forskolin (100 µM), which is a direct activator ofadenylate cyclase. Decanoic was added as a GPR84 agonist and the cAMP accu-mulation was measured radiometrically in the absence and in the presence of testcompounds.
3.3.2 Test resultsThe pharmacological evaluation of the compounds was performed by Dr. MeryemKöse and Katharina Sylvester in our group.The following compounds were originally designed as GPR35 agonists.
Table 3.21: Potency of chromen-4-one-2-carboxylic acidsat GPR84 determined by cAMP accumulation assay inCHO-β-arrestin-GPR84 cells.
O
O
NH
CO2H
O
OHO
O
S
R
NH
CO2H
O
OHO
R
188 - 195 197
compd. R IC50 ± SEMa (µM)(% inhibition)188 Br >> 3 (1%)189 H > 3 (0%)190 phenyl >> 3 (0%)191 F >> 3 (0%)
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compd. R IC50 ± SEMa (µM)(% inhibition)192 Cl >> 3 (0%)193 methoxy >> 3 (0%)194 methyl >> 3 (0%)195 ethyl >> 3 (0%)197 Br >> 3 (5%)a Concentration-inhibition curves were performedin 3 independent experiments.
As expected none of the compounds is able to inhibit GPR84. The compounds inTable 3.22 were also optimized for GPR35.
Table 3.22: Potency of chromen-4-one-2-carboxylic acids at GPR84 determinedby cAMP accumulation assay in CHO-β-arrestin-GPR84 cells.
O
O
NH
CO2H
O
O
S
R1
NH
CO2H
O
R1
R2 R2
O
O
R1
N
CO2H
O
R2
CH3
O
O
NH
CO2H
HN
R1
O
R2
MF374 - 210
211 212
263
substitution pattern GPR84cpd R1 R2 IC50 ± SEM (% inhibition)a
ortho meta para (µM)
19865 Br F H OCH3 > 3 (16%)19965 Br di-F H OCH3 >> 3 (3%)20065 Br H F OCH3 > 3 (11%)20165 methyl H H OCH3 >> 3 (0%)20265 OCH3 H H OCH3 >> 3 (0%)203 Br OCH3 H OCH3 > 3 (33%)204 OCF3 H H OCH3 > 10 (21%)205 phenyl H H OCH3 1.52 ± 0.23206 ethyl H H OCH3 >> 3 (0%)207 Br H H ethyl > 3 (17%)
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substitution pattern GPR84cpd R1 R2 IC50 ± SEMa
ortho meta para (µM)
208 p-chloro-phenyl H H OCH3 0.259 ± 0.109209 Br H H SCH3 > 3 (0%)210 phenyl di-F H OCH3 6.37 ± 0.98MF325 Cl H CH3 H 4.24 ± 0.35172MF133 Br H CH3 H 2.19 ± 1.00172MF298 Br H OCH3 OCH3 1.07 ± 0.44172211 Br H H OCH3 >> 3 (0%)212 Br H H OCH3 9.92 ± 2.27263 H H H OH > 3 (2%)
WA26 H H p-fluo-roben-zyloxy OCH3 0.457 ± 0.103172a Concentration-inhibition curves were performed in 3 independent experiments.
For the development of specific GPR84 antagonists we synthesized chromen-4-oneswith large residues in the 8-position and position 6. The final compounds are shownin Table 3.23.
Table 3.23: Potency and affinity of chromen-4-one-2-carboxylic acids at GPR84 deter-mined by cAMP accumulation assay in CHO-β-arrestin-GPR84 cells.
O
O
CO2H
NH
R1
O
O
R3
R4
R2
O
O
CO2H
NHO
O
R3
R4
R2
R1
O
O
CO2H
NH
R1
O
O
R2
O
O
CO2H
NH
R1
O
O
R2
R3
213 - 215 216 - 226 227 - 233 234substitution pattern GPR84compound R1 R2 R3 R4 IC50 ± SEMa (µM) (% inhibition)213 OCH3 H F H 0.190 ± 0.059
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substitution pattern GPR84compound R1 R2 R3 R4 IC50 ± SEMa (% inhibition) (µM)214 methyl H F H 0.171 ± 0.026215 ethyl H F H 0.514 ± 0.157MF320 H H H H 1.94 ± 0.36172MF201 H H F H 1.33 ± 0.18172MF303 H H Cl H 3.19 ± 1.42172MF302 H H Br H 1.85 ± 0.94172MF282 H H CH3 H 4.43 ± 0.86172MF281 H H H F 1.71 ± 0.37172MF311 F H F H 2.17 ± 0.12172MF304 Cl H F H 0.527 ± 0.055172MF329 Cl H Br H 0.331 ± 0.019172MF299 Br H F H 0.391 ± 0.017172MF321 Br H Br H 0.426 ± 0.053172MF326 Br H H Br 1.29 ± 0.12172216 H H F H 0.165 ± 0.029217 H H F F 0.088 ± 0.018218 Cl H F H 0.00734 ± 0.000168219 H Cl F H 0.122 ± 0.011220 F H F H 0.0592 ± 0.0039221 OCH3 H F H 0.161 ± 0.076222 methyl H F H 0.0404 ± 0.0072223 F H F F 0.126 ± 0.001224 F Cl F F 0.274 ± 0.044225 OH H F H 0.264 ± 0.156226 H F F H 0.257 ± 0.053227 Br F H - 1.99 ± 0.37228 Br Br H - 0.541 ± 0.122229 Br Cl H - 1.46 ± 0.31MF316 H F H - 1.85 ± 0.94172230 H methyl H - 7.27 ± 3.74231 Br methyl H - 4.91 ± 0.30232 H H Br - > 3 (19%)233 Br H Br - 2.50 ± 0.23
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substitution pattern GPR84compound R1 R2 R3 R4 IC50 ± SEMa (% inhibition) (µM)234 Br F - - 3.25 ± 0.78a Concentration-inhibition curves were performed in 3 independent experiments
The following compounds were optimized for GPR17 and GPR55. They contain longalkyl side-chains at position 8 (Table 3.24).
Table 3.24: Potency of chromen-4-one-2-carboxylic acids at GPR84 determinedby cAMP accumulation assay in CHO-β-arrestin-GPR84 cells.
O
O
NH
CO2H
O
R1
O R
2
O
O
NH
CO2H
O
R1
O R2
O
S
NH
CO2H
O
R1
O R
2
O
O
NH
CO2H
HN
S
R1
O R
2
235 - 253
254 - 261
262 264
substitution pattern GPR84
compound R1 R2 IC50 ± SEMa (% inhibition) (µM)
Pranlukast 1.40 ± 0.05218235 H 1-cyclohexylmethyl > 3 (48%)236 H 2-cyclohexylethyl 4.12 ± 0.67237 H 3-cyclohexylpropyl > 3 (29%)238 Cl 3-cyclohexylpropyl > 3 (43%)239 F 3-cyclohexylpropyl 1.68 ± 0.57240 H 4-cyclohexylbutyl 6.36 ± 1.94241 Cl 4-cyclohexylbutyl 0.757 ± 0.05242 F 4-cyclohexylbutyl 1.03 ± 0.04243 H 5-cyclohexylpentyl > 3 (21%)244 Cl 5-cyclohexylpentyl > 3 (33%)245 F 5-cyclohexylpentyl 15.7 ± 3.2246 Cl hexyl 2.09 ± 0.82247 Cl heptyl 1.66 ± 0.61248 Cl octyl 1.04 ± 0.28249 H 1-phenylmethyl >> 3 (4%)250 H 2-phenylethyl >> 3 (4%)
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substitution pattern GPR84compound R1 R2 IC50 ± SEMa (% inhibition) (µM)251 H 3-phenylpropyl > 3 (29%)252 H 4-phenylbutyl 2.00 ± 0.30253 H 5-phenylpentyl 3.16 ± 0.43 (efficacy 58%)MF191 H 2-cyclohexylethoxy 2.21 ± 0.75172254 Br 3-cyclohexylpropyl > 10 (20%)255 OCH3 4-cyclohexylbutyl >> 3 (0%)256 methyl 4-cyclohexylbutyl 3.45 ± 0.60 (65%)257 Cl 4-cyclohexylbutyl >> 3 (0%)258 F 4-cyclohexylbutyl 17.5 ± 2.7 (66%)259 ethyl 4-cyclohexylbutyl > 10 (7 ± 4)260 H 5-cyclohexylpentyl >> 3 (0%)MF192 H 2-phenylethyl 2.00 ± 0.30172MF230 Br 3-phenylpropyl 1.41 ± 0.14172261 Br 5-phenylpentyl262 F 3-cyclohexylpropyl 5.14 ± 0.88264 H 4-cyclohexylbutyl 0.564 ± 0.127a Concentration-inhibition curves were performed in 3 independent experiments
3.3.3 Structure-activity relationshipsGPR84 is a receptor which binds medium-chain free fatty acids.67 So it is no sur-prise that the most polar compounds of our chromen-4-one library, compounds 188- 197, which contain two carboxylic acid functions, were not able to block the re-ceptor (Table 3.21). The compounds shown in Table 3.22, which contain only a smallside-chain with one aromatic ring substituted with small groups, did not show an-tagonistic activity at GPR84 as well, with a few exceptions that will be discussedlater. Previous results showed, that compounds with a halogen in 6-position com-bined with a benzyloxyphenyl side-chain, para-substituted with bromine or fluorine,were able to block the receptor.172We synthesized a series of compounds containing a p-fluorobenzyloxyphenyl residue,the best side chain so far, and modified the 6-position extensively. We alreadyknew from previous results that compounds with chlorine and bromine in this posi-
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tion (MF304 IC50 = 0.527 ± 0.055 µM172 and MF299 IC50 = 0.391 ± 0.017 µM,172respectively) were more potent antagonists than compounds substituted with hy-drogen or fluorine (MF201 IC50 = 1.33 ± 0.18 µM172 and MF311 IC50 = 2.17 ±0.12 µM,172 respectively). We started our series of compounds by inserting smallgroups at the 6-position. Substitution with ethyl (215 IC50 = 0.514 ± 0.157 µM)resulted in a decreased activity whereas substitution with methyl (214 IC50 = 0.171± 0.026 µM) and methoxy (213 IC50 = 0.0.190 ± 0.0.059 µM) resulted in a 2-foldhigher potency compared to the halogen-substituted compounds.
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Figure 3.19: Optimization and structure-activity relationships of the substituent at the6-position of the chromen-4-one. The pIC50 values ± SEM were calculated from IC50values determined by cAMP-accumulation assays. The inhibition of forskolin-activatedGPR84 expressed in CHO cells was measured.
We assumed that bulky substituents are beneficial at the 6-position and as a conse-quence we developed compounds with a phenyl group at that position. Compound216 (IC50 = 0.165 ± 0.029 µM), which contains a phenyl ring, showed compara-ble activity to the methyl- and methoxy-substituted compounds. Substitution of thephenyl ring in the para-position further increased the potency. The best substituent
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was chlorine (218, IC50 = 0.00734 ± 0.000168 µM) followed by methyl (222, IC50= 0.0404 ± 0.0072 µM) and fluorine (220, IC50 = 0.0592 ± 0.0039 µM). Compound221 showed a comparable activity to the unsubstituted derivative 216 with an IC50of 0.161 ± 0.076 µM and the hydroxy-substituted compound 225 showed the lowestpotency of the phenyl derivatives (IC50 = 264 ± 0.156 µM). This results confirmsour hypothesis that large and unpolar substitutents at the 6-position increase theinhibitory potency of our compounds. This is thought to be due to a large lipophilicbinding pocket in that domain of the receptor. This is also supported by the factthat the very few potent compounds with a short side chain (Table 3.22), 205, 208and 210, are substituted with a phenyl ring at the 6-position. The most potentcompound of this series, compound 208, contains a para-chlorophenyl-substituentand displayed an IC50 value of 0.252 ± 0.111 µM. That substituent appears to fillthe binding pocket in this area of the receptor optimally, and thus the nature ofthe side-chain becomes less important. SARs for the 6-position are illustrated inFigure 3.19.Besides the variation of the 6-position many variations of the side-chain were per-formed.
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Figure 3.20: Variation of the position of the p-fluorobenzyloxy-residue. The pIC50 values± SEM were calculated from IC50 values determined by cAMP-accumulation assays. Theinhibition of forskolin-activated GPR84 expressed in CHO cells was measured.
Shifting the p-fluorobenzyl-part of the side-chain from the para- to the meta- or
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the ortho-position resulted in a decrease in potency. The rank order of potency waspara (MF299, IC50 = 0.391 ± 0.017 µM172) > meta (227, IC50 = 1.99 ± 0.37 µM)≈ ortho (234, IC50 = 3.25 ± 0.78 µM) as shown in Figure 3.20.The effects of the introduction of further halogen atoms on the phenyl rings ofthe side chain were diverse. An introduction of chlorine in the meta-position ofthe amide linker at the first phenyl ring of the side-chain (219, IC50 = 0.122 ±0.011 µM) slightly increased the potency compared to the unsubstituted compound216 (IC50 = 0.165 ± 0.029 µM) when there was an unsubstituted phenyl in the 6-position whereas a fluorine substituent was less well tolerated at this position (226,IC50 = 0.257 ± 0.053 µM). However there was almost not difference in inhibitorypotency observed. A slightly increased potency was observed when inserting asecond fluorine atom in the meta-position of the second phenyl ring of the side-chain (139, IC50 = 0.088 ± 0.018 µM) which resulted in a 2-fold higher potencycompared to the mono-fluoro derivative 216. However when there was a p-fluoro-phenyl substituent in the 6-position a second fluorine decreased the potency (223,IC50 = 0.126 ± 0.001 µM) by about 2-fold. A combination of 2 fluoro substituentsand the chloro substitutent resulted in an even lower potency (224 IC50 = 0.274 ±0.044 µM). Ultimately the introduction of further halogen atoms had no major effecton the inhibitory potency.Compounds with larger alkyl side chains (Table 3.24), which were originally designedfor GPR17 and GPR55, did not show high potency at GPR84. Only compoundswhich contained a halogen or a methyl group at the 6-position turned out to beweak antagonists at GPR84 with IC50 values in the micromolar range. Interestinglythe most potent compound of that series was 247 with a heptyl residue in themeta-position (IC50 = 1.03 ± 0.01 µM) which seemed to contradict all previouslydetermined SARs. However the potency was still about 100-fold lower compared tothe most potent antagonist.The SARs determined for GPR84 are illustrated in Figure 3.21.
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Figure 3.21: Structure-activity relationships determined for chromen-4-ones as GPR84antagonists.
We successfully optimized the chromen-4-ones regarding their potency at GPR84.The best GPR84 antagonist of the present series was 218 with a IC50 value in thelow nanomolar range (Figure 3.22). It is at the same time the most potent antagonistknown to date for GPR84.The most potent compounds were further analyzed in β-arrestin recruitment as-says using CHO-β-arrestin-GPR84 cells and in radioligand binding experiments(Table 3.25).
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Table 3.25: Potency and affinity of selected chromen-4-one-2-carboxylic acids at GPR84determined by cAMP accumulation assays in CHO-β-arrestin-GPR84 cells (%inhibitionof Yazh-365 (30nM) response at 10 µM) and β-arrestin assay in CHO-β-arrestin-GPR84cells (% inhibition of the effect of 10 µM Yazh-365) and radioligand binding experimentsin CHO-β-arrestin-GPR84 cells (% inhibition of 5 nM [3H]PSB-1584 at 10 µM).
compd. structure cAMP assay β-arrestinassay
radioligand-bindingexperiments
IC50 ±SEMa [µM] IC50 ±SEMa [µM]
IC50 ±SEMa [µM](% inhibition)
Pranlukast O
O
N N
N
H
N
NHO
O
1.40 ±0.05218 1.23 ± 0.344 40.7 ± 7.4
217 O
O
CO2H
NHO
O
F
F
0.088 ±0.018 0.112 ±0.048 3.61 ± 0.64
218 O
O
CO2H
NHO
O
F
Cl
0.00734 ±0.000168 0.00302 ±0.00095 0.047 ±0.016
220 O
O
CO2H
NHO
O
F
F
0.0592 ±0.0039 0.00708 ±00060 0.241 ±0.043
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222 O
O
CO2H
NHO
O
F
H3C
0.0404 ±0.0072 0.0137 ±0.0025 0.258 ±0.157
a Concentration-inhibition curves were performed in 3 independent experiments.
The selected compounds were able to block GPR84 in all performed pharmacolog-ical assays in a comparable rank order of potency. The IC50-values in β-arrestinassays were slightly lower than the ones determined in the cAMP assay, except forcompound 217 which showed about the same potency in the cAMP-assay. Interest-ingly also in the radioligand binding experiments 217 showed a high IC50-value inthe micromolar range whereas 218, 220 and 222 showed IC50-values in the nanomo-lar range. A large lipophilic group at position 6 seems to be important for a highaffinity.Some selected compounds that were inactive in the cAMP assay were also testedfor agonistic activity at GPR84 (255, 260, 257, 232, 243, 244, 235, 249, 251, 250,238, and 237). None of the tested compounds was able to activate the receptor ata high concentration of 10 µM.
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logP =	5.5
MW =	543.9	g/Mol
HBD =	2
HBA =	7
TPSA =	105.8	
A B
O
O
CO2H
NHO
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O
F
cAMP assay:	 IC50 =	0.00734	± 0.00168 μM
ß-arrestin assay:	IC50 =	0.00302	± 0.00095	μM
Radioligand	binding:	IC50	 =	0.047	± 0.016	μM
Figure 3.22: Structure and physicochemical properties of compound 218, the most potentGPR84 antagonist known to date. A Structure and potency of 218; B Analysis of thepolarity of the structure performed with Stardrop R©. Polar groups are shown in blue colourwhereas unpolar parts of the molecule are shown in red colour. The logP, molecularweight (MW), hydrogen-bond donator (HBD), hydrogen-bond acceptor (HBA) and thetopological polar surface area (TPSA) were calculated using Stardrop R©.
We analyzed the physicochemical properties of the most potent compound of ourseries of chromenones using Stardrop R©. Compound 218 fulfills the criteria of theRule of Five with two exceptions. The logP value, which describes the lipophilicityof the compound and the molecular weight are slightly too high. On the other handthe TPSA is below 140 Å which indicates a potentially good cell permeability. Thecompound represents an important pharmacological tool for further investigationof GPR84. The physicochemical properties can be improved and so the compoundcould also function as a lead structure for the development of future drugs.
3.4 Pharmacological evaluation at the human GPR17
3.4.1 IntroductionSome of the chromenon derivatives were found to block GPR17. None of the in-vestigated compounds appeared to activate the receptor. The inhibitory potency
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of the potential GPR17 antagonists was determined by the calcium ion mobiliza-tion assay. In this assay system the intracellular calcium, which is released viathe signal transduction cascade of the Gq-coupled receptor, is measured fluorimet-rically. A cell-permeable form of the calcium fluorescence indicator Oregon Green R©,Oregon Green R©BAPTA-1/acetoxylmethyl ester (AM), was incubated with 1321N1astocytoma cells, that recombinantly express the receptor. Upon receptor activa-tion by the agonist MDL29,951,40 a calcium-dependend fluorescence signal couldbe measured. When the cells were preincubated with the antagonist the signal wasdecreased in a concentration-depend manner. For screening the compounds wereinitially tested at a concentration of 10 µM. In case the inhibition was higher than50%, concentration-inhibition curves were determined to measure the IC50 values.Concentration-inhibition curves were performed in 3 independent experiments eachin duplicates.
3.4.2 ResultsThe pharmacological evaluation of GPR17 antagonists was performed by Dr. AliaaAbdelrahman.
Table 3.26: Potency of chromen-4-one-2-carboxylic acids at GPR17 determined bycalcium ion mobilization assay in 1321N1 astrocytoma cells.
O
O
NH
CO2H
O
OHO
O
S
R
NH
CO2H
O
OHO
R
188 - 195 197compd. R IC50 ± SEMa (µM) inhibition (%)b188 Br > 10 -5 ± 16189 H > 10 4 ± 2190 phenyl > 10 -19 ± 12191 F > 10 -6 ± 4192 Cl > 10 -9 ± 4193 methoxy > 10 -15 ± 7194 methyl > 10 -4 ± 5
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cpd R IC50 ± SEMa (µM) inhibition (%)b195 ethyl > 10 -9 ± 4197 Br > 10 -5 ± 5a Concentration-inhibition curves were performed in 3 independent experiments.b at 10 µM of the test compound
Small compounds shown in Table 3.26 were not able to block GPR17. They wereoriginally designed as GPR35 agonists.
Table 3.27: Potency of chromen-4-one-2-carboxylic acids at GPR17 determined bycalcium ion mobilization assay in 1321N1 astrocytoma cells.
O
O
NH
CO2H
O
O
S
R1
NH
CO2H
O
R1
R2 R2
O
O
R1
N
CO2H
O
R2
CH3
O
O
NH
CO2H
HN
R1
O
R2
MF374 - 210
211 212
263
substitution pattern GPR17compd. R1 R2 IC50 ± SEMa inhibitionbortho meta para (µM) (%)19865 Br F H OCH3 > 10 10 ± 819965 Br di-F H OCH3 > 10 0 ± 120065 Br H F OCH3 > 10 0 ± 520165 methyl H H OCH3 > 10 -12 ± 1020265 OCH3 H H OCH3 > 10 -3 ± 8203 Br OCH3 H OCH3 > 10 0 ± 2204 OCF3 H H OCH3 > 10 -5 ± 11205 phenyl H H OCH3 > 10 10 ± 12206 ethyl H H OCH3 > 10 5 ± 1207 Br H H ethyl > 10 8 ± 4
208 p-chloro-phenyl H H OCH3 5.44 ± 0.68 95 ± 4c209 Br H H SCH3 > 10 10 ± 3210 phenyl di-F H OCH3 > 10 18 ± 7211 Br H H OCH3 > 10 0 ± 8212 Br H H OCH3 > 10 37 ± 15
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substitution pattern GPR17cpd R1 R2 IC50 ± SEMa inhibitionbortho meta para (µM) (%)263 H H H OH > 10 5 ± 2
MF203 H H H 4-phe-nylbu-toxy 0.748 ± 0.076172 -a Concentration-inhibition curves were performed in 3 independent experiments.b at 10 µM of the test compoundc at 100 µM of the test compound
The compounds shown in Table 3.27 were still too small to interact with GPR17.
Table 3.28: Potency of chromen-4-one-2-carboxylic acids at GPR17 determined bycalcium ion mobilization assay in 1321N1 astrocytoma cells.
O
O
CO2H
NH
R1
O
O
R3
R4
R2
O
O
CO2H
NHO
O
R3
R4
R2
R1
O
O
CO2H
NH
R1
O
O
R2
O
O
CO2H
NH
R1
O
O
R2
R3
213 - 215 216 - 226 227 - 233 234substitution pattern GPR17
compound R1 R2 R3 R4 IC50 ± SEMa(µM)
inhibitionb(%)
213 OCH3 H F H > 10 30 ± 6214 methyl H F H > 10 15 ± 1215 ethyl H F H 2.62 ± 1.05 95 ± 7cMF282 H H methyl H 13.8 ± 0.3172 -MF301 H H CF3 H 7.03 ± 0.75172 -MF299 Br H F H 4.84 ± 0.19172 -MF321 Br H Br H 2.32 ± 0.24172 -216 H H F H ≥ 10 42 ± 3217 H H F F > 10 34 ±2218 Cl H F H > 10 5 ± 5
118
3.4 Pharmacological evaluation at the human GPR17 Dissertation, Universität Bonn 2016
substitution pattern GPR17
compound R1 R2 R3 R4 IC50 ± SEMa(µM)
inhibitionb(%)
219 H Cl F H 10.2 ± 0.8 103 ± 2c220 F H F H > 10 26 ± 8221 OCH3 H F H 16.2 ± 6.1 70 ± 5c222 methyl H F H ≥ 10 39 ± 7223 F H F F > 10 11 ± 5224 F Cl F F > 10 26 ± 4225 OH H F H ≥ 10 33 ± 6226 H F F H ≥ 10 34 ± 5227 Br F - - > 10 10 ± 6228 Br Br - - ≥ 10 40 ± 16229 Br Cl - - > 10 35 ± 16230 H methyl H - > 10 11 ± 7231 Br methyl H - > 10 7 ± 4232 H H Br - > 10 26 ± 4233 Br H Br - > 10 26 ± 4234 Br F - - > 10 11 ± 4a Concentration-inhibition curves were performed in 3 independent experiments.b at 10 µM of the test compoundc at 100 µM of the test compound
Compounds that contain an aromatic side-chain were not able to interact withGPR17 (Table 3.28).
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Table 3.29: Potency of chromen-4-one-2-carboxylic acids at GPR17 determined bycalcium ion mobilization assay in 1321N1 astrocytoma cells.
O
O
NH
CO2H
O
R1
O R
2
O
O
NH
CO2H
O
R1
O R2
O
S
NH
CO2H
O
R1
O R
2
O
O
NH
CO2H
HN
S
R1
O R
2
235 - 253
254 - 261
262 264
substitution pattern GPR17
compound R1 R2 IC50 ± SEMa(µM)
inhibitionb(%)
Pranlukast 2.69 ± 0.12218 -235 H 1-cyclohexylmethyl > 10 30 ± 14236 H 2-cyclohexylethyl ≥ 10 45 ± 3237 H 3-cyclohexylpropyl 4.28 ± 0.49 100 ± 8c238 Cl 3-cyclohexylpropyl 3.05 ± 0.21 93 ± 3c239 F 3-cyclohexylpropyl 4.63 ± 0.60 94 ± 1c240 H 4-cyclohexylbutyl 1.71 ± 0.04 98 ± 1241 Cl 4-cyclohexylbutyl 2.81 ± 0.72 81 ± 7c242 F 4-cyclohexylbutyl 2.67 ± 0.49 82 ± 4c243 H 5-cyclohexylpentyl 3.26 ± 1.04 80± 8244 Cl 5-cyclohexylpentyl 1.58 ± 0.49 96 ± 1245 F 5-cyclohexylpentyl 6.37 ± 0.58 81 ± 9c246 Cl hexyl > 10 27 ± 20247 Cl heptyl 1.58 ± 0.63 95 ± 6248 Cl octyl 2.15 ± 0.66 103 ± 2c249 H 1-phenylmethyl > 10 -4 ± 7250 H 2-phenylethyl > 10 8 ± 10251 H 3-phenylpropyl > 10 0 ± 4252 H 4-phenylbutyl 14.1 ± 3.1 101 ± 5c253 H 5-phenylpentyl 4.97 ± 0.85 74 ± 8cMF191 H 2-cyclohexylethoxy 11.8 ± 0.5172 -MF248 H 3-cyclohexylpropyl 0.945 ± 0.58172 -254 Br 3-cyclohexylpropyl 2.59 ± 0.74 95 ± 2
120
3.4 Pharmacological evaluation at the human GPR17 Dissertation, Universität Bonn 2016
substitution pattern GPR17
compound R1 R2 IC50 ± SEMa(µM) inhibitionb(%)WA24 H 4-cyclohexylbutyl 0.583 ± 0.202172 -WA22 Br 4-cyclohexylbutyl 1.31 ± 0.26172 -255 OCH3 4-cyclohexylbutyl 0.445 ± 0.108 100 ± 1c256 methyl 4-cyclohexylbutyl 0.943 ± 0.277 100 ± 3257 Cl 4-cyclohexylbutyl 1.34 ± 0.24 97 ± 4258 F 4-cyclohexylbutyl 1.15 ± 0.18 90 ± 11259 ethyl 4-cyclohexylbutyl 0.666 ± 0.144 96 ± 5260 H 5-cyclohexylpentyl 1.40 ± 0.40 95 ± 3MF192 H 2-phenylethyl 24.9 ± 3.8172 -MF190 H 3-phenylpropyl 10.9 ± 2.9172 -WA09 F 3-phenylpropyl 4.65 ± 0.46172 -MF300 Cl 3-phenylpropyl 5.94 ± 0.78172 -MF230 Br 3-phenylpropyl 3.30 ± 0.95172 -MF150 H 4-phenylbutyl 7.78 ± 1.72172 -261 Br 5-phenylpentyl 4.30 ± 0.79 88 ± 5cMF259 H n-heptyl 1.63 ± 0.05172 -MF200 H 4-methylpentyl 3.90 ± 0.76172 -262 F 3-cyclohexylpropyl 7.74 ± 0.36 110 ± 3c264 H 4-cyclohexylbutyl 9.45 ± 0.50 93 ± 4cMF208 H 4-phenylbutyl 2.74 ± 0.94172 -a Concentration-inhibition curves were performed in 3 independent experiments.b at 10 µM of the test compoundc at 100 µM of the test compound
Table 3.29 shows compounds that were identified as GPR17 antagonists. The SARswill be further discussed.
3.4.3 Structure-activity relationshipsCompounds 188 - 197 which include two carboxylic acids were completely inactiveat GPR17 (Table 3.26). This also applied to compounds 198 - 212 and 263 whichhave only small side-chains consisting of one aromatic ring with a small substituent.An exception was compound 208 with an IC50 value of 5.44 ± 0.68 µM. In contrast
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to the other compounds it contains a p-chlorophenyl substituent at the 6-positionwhich is very large and lipophilic (Table 3.27).The introduction of an additional phenyl ring at the side-chain further increasedthe lipophilicity and also the size of the compounds. However also in this series ofcompounds (compounds 213 - 234) we identified only few compounds with moderateinhibitory potency at GPR17. The best compounds were 215 (IC50 = 2.62 ± 1.05 µM)and MF321 (IC50 = 2.32 ± 0.24 µM172). Compound 215 has an ethyl substituent atthe 6-position, which increases the lipophilicity, compoundMF321 has a Br at the 6-position and also at the para-position of the second aromatic ring of the side-chain.What both compounds have in common is the position of the second aromatic ring atthe side chain. It appears to be important that the ether linker is in the para-positionto the amide linker. The structurally related compounds MF282,172 MF301172 andMF299,172 which were already published as weak GPR17 antagonists, are alsosubstituted in para-position (Table 3.28).It was previously described that long alkyl side-chains instead of phenyl side-chainsare beneficial for the inhibitory potency at GPR17.172 The best compound so farbased on the chromenone scaffold was compound WA24 (Table 3.29) with an IC50of 0.583 ± 0.202 µM.172 It is about 5-fold more potent than the lead structurePranlukast (IC50 = 2.69 ± 0.12 µM218).A series of compounds which differ only in the number of C-atoms between the etherand the cyclohexyl ring of the side-chain were tested to find the optimal chain-length. Compound WA24 which contains a butyl linker between the ether and thecyclohexyl ring showed the best inhibition. Introduction of the longer pentyl (com-pound 260) or the shorter propyl- or ethyl-chain (compounds MF248 and MF191respectively) resulted in a decreased potency. This effect could be observed whenthe side-chain was in the para- as well as in the meta-position. However the para-substituted compounds were more potent than the corresponding meta-substitutedderivatives (Figure 3.23).
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Figure 3.23: Influence of the chain length of GPR17 antagonists on the inhibitory po-tency. The pIC50 values ± SEM were calculated from IC50 values determined by calciumion mobilization assay in 1321N1 astrocytoma cells.
We could also confirm that a cyclohexyl ring at the end of the side-chain is bet-ter than a phenyl ring and better than n-alkyl-chains. Testing of a series of 3compounds with increasing n-alkyl chain-lengths from hexyl to octyl in the meta-position showed that a number of 7 C-atoms is the optimum. However the bestcompound of this series, compound 247, showed only an IC50 value of 1.58 ± 0.49µM. Interestingly the inhibitory potency of the corresponding para-substituted com-pound MF259 is in the same range.The compound with the optimal chain-length of 4 C-atoms in the para-positionconnected to a cyclohexyl ring was now further modified at the 6-position of thechromen-4-one. The best substituent was methoxy followed by hydrogen, ethyl andmethyl. Halogen substituents resulted in a lower potency regardless of its nature,and chlorine, fluorine or bromine derivatives were in the same range (Figure 3.24).
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Figure 3.24: Different substituents at the 6-position of chromen-4-ones and their effecton the inhibitory potency at human GPR17. The pIC50 values ± SEM were calculatedfrom IC50 values determined by calcium ion mobilization assay in 1321N1 astrocytomacells.
The results show that unpolar substituents are beneficial at the 6-position and thathalogen atoms were already too polar. For the future an introduction of longer alkylchains also at the 6-position connected via an ether linker could be interesting.A further modification was the replacement of the oxygen atom at the 4-position ofthe chromen-4-one by a sulfur atom (compound 262, IC50 = 7.74 ± 0.36 µM). Thismodification resulted in a slightly lower potency compared to the correspondingoxygen compound 239 (IC50 = 4.63 ± 0.60 µM).Previous results indicated that the replacement of the amide linker by a thiourealinker could increase the inhibitory potency.172 This could not be confirmed in thepresent new series of compounds. The replacement of the amide linker by a thiourealinker was not well tolerated. Compound 264 with the thiourea linker had a 20-foldlower potency (IC50 = 9.45 ± 0.50 µM) than WA24 (IC50 = 0.583 ± 0.202 µM) withthe amide linker.A summary of the determined SARs at GPR17 is shown in Figure 3.25.
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X
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O
long lipophilic residues are essential for high inhibitory potency (R2):
substitution pattern (R2): para > meta >> ortho
chain length: C4 > C3 > C5 > C2
cyclohexyl > n-alkyl > phenyl
substituent at 4-position (X): O > S
substituent at 6-position (R1):
methoxy > H > ethyl > methyl > F ~ Cl ~ Br
linker: amide > thiourea
(depends on the further substitution)
R2
Figure 3.25: Structure-activity-relationships determined for GPR17.
Many modifications of the side-chain were performed. The introduction of longerresidues as well as the change of the substitution pattern was not tolerated. Thecyclohexybutyl side-chain in the para-position was still the best substituent. Alsoa modification of the linker by replacing it with thiourea as well as the replacementof the oxygen atom at the 4-position of the chromen-4-one by a sulfur atom was nottolerated and resulted in lower potencies. An improvement of the inhibitory potencycould be achieved by the modification of the substituent at the 6-position. Methoxyand also ethyl are both well tolerated and resulted in potent compounds.The best GPR17 antagonist based on the chromen-4-one scaffold was compound255 with an IC50 value of 0.445 ± 0.108 µM (Figure 3.27).
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Figure 3.26: Structure and physicochemical properties of compound 255, the most potentchromen-4-one antagonist at GPR17. A Structure and potency of 255; B Analysis ofthe polarity of the structure performed with Stardrop R©. Polar groups are shown in bluecolour whereas unpolar parts of the molecule are shown in red colour. The logP, molecularweight (MW), hydrogen-bond donators (HBD), hydrogen-bond acceptors (HBA) and thetopological polar surface area (TPSA) were calculated using Stardrop R©.
Compound 255 fits into the criteria of Lipinski’s rule of five, except for the logPvalue, which is slightly too high.The most potent GPR17 antagonist of the series and Pranlukast were also evaluatedin radioligand binding experiment with the radioligand [3H]PSB12150, which is thetritiated form of the standard agonist MDL29.951. The results are shown in inTable 3.30.
Table 3.30: Potency and affinity of selected chromen-4-one-2-carboxylic acids at GPR17determined in calcium ion mobilization assay using 1321N1 astrocytoma cells (% in-hibition of calcium-dependend fluorimetric signal upon activation by GPR17 agonistMDL29,951) and radioligand binding experiments in CHO-hGPR17 cells (% Inhibitionof 25 nM [3H]PSB-12150 at 10 µM)
compd. structure calcium assay radioligand-bindingexperiments
IC50 ± SEMa [µM] Ki ± SEMa [µM] (%inhibition)
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MDL29.951 Cl
Cl NH
OH
O
OH
O
EC50 = 1.41218 (agonist)
Pranlukast O
O
N N
N
H
N
NHO
O
2.69 ± 0.12218 4.34 ± 0.910 (79% at30 µM)
255 O
O
CO2H
H3CO
NHO
O
0.445 ± 0.108 > 10 (26% at 10 µM)
258 O
O
CO2H
NHO
O
F
1.15 ± 0.18 2.20 ± 0.68 (62% at 30µM)
259 O
O
CO2H
NHO
O
H3C
0.666 ± 0.144 > 10 (37% 6 at 10 µM)
a Concentration-inhibition curves were performed in 3 independent experiments.
Surprisingly the most potent GPR17 antagonists showed only weak or even noaffinity to GPR17 in the radioligand binding experiments. Since the radioligandand the agonists that were used in the calcium ion mobilization assays contain thesame structure we could not explain this result with different binding modes in bothassays. We suspect that our antagonists are weak negative allosteric modulators ofthe receptor. They could bind in a different region and thereby affect a conforma-tional change of the receptor which results in a decreased activity of the agonists
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in the calcium assay and impacts binding of the agonist, but only with some of theantagonists. This is highly speculative and has to be further investigated.
10-9 10-8 10-7 10-6 10-5 10-4 10-3
0
25
50
75
100
125
 [255], M
%
 In
hi
bi
tio
n 
of
 c
al
ci
um
 in
flu
x 
10-9 10-8 10-7 10-6 10-5 10-4 10-3
-25
0
25
50
75
100
125
[258], M
%
 In
hi
bi
tio
n 
of
 c
al
ci
um
 in
flu
x 
10-10 10-8 10-6 10-4 10-2
-25
0
25
50
75
100
125
[259], M
%
 In
hi
bi
tio
n 
of
 c
al
ci
um
 in
flu
x 
Figure 3.27: Dose-response curves of the most potent GPR17 antagonists 255, 258 and259.
Compound 258 and Pranlukast could be confirmed to interact with GPR17 also inthe radioligand binding experiments.
3.5 Pharmacological evaluation at human GPR55
3.5.1 IntroductionL-α-lysophosphatidylinositol (LPI), which was proposed to be the endogenous ligandof GPR55, consists of a long lipophilic tail connected to a polar head. Some of ourcompounds share this structural properties and therefore were tested at GPR55.Additionally, the set of compounds which was active at the closely related GPR35,was tested for selectivity versus GPR55. All compounds were evaluated in theβ-arrestin recruitment assay, which had already been described previously, withCHO-GPR55 cells for agonistic activity and also for antagonistic potency versus 1µM LPI as an agonist.
3.5.2 Test resultsTesting was performed by Clara Schoeder in our group.
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Table 3.31: Potency of chromen-4-one-2-carboxylic acids at GPR55 determined by β-arrestin recruitment assay using GPR55 CHO cells.
O
O
NH
CO2H
O
OHO
O
S
R
NH
CO2H
O
OHO
R
188 - 195 197
cpd R IC50 ± SEM (µM)a EC50 ± SEM (µM)a
188 Br > 10 (1 ± 5) > 10 (3 ± 5)189 H > 10 (-8 ± 17) > 10 (-14 ± 14)190 phenyl >10 (17 ± 8) > 10 (56 ± 8)191 F > 10 (9 ± 11) > 10 (34 ± 10)192 Cl > 10 (6 ± 9) > 10 (27 ± 6)193 methoxy > 10 (-1 ± 7) > 10 (27 ± 6)194 methyl > 10 (11 ± 9) > 10 (29 ± 8)195 ethyl > 10 (27 ± 16) > 10 (19 ± 12)197 Br > 10 (34 ± 9) > 10 (15 ± 5)a Curves were performed in 3 independent experiments.
The GPR35 agonists shown in Table 3.31 and Table 3.32 were not able to interactwith GPR55 although both receptors are closely related.
Table 3.32: Potency of chromen-4-one-2-carboxylic acids at GPR55 determined by β-arrestin recruitment assay using GPR55 CHO cells.
O
O
NH
CO2H
O
O
S
R1
NH
CO2H
O
R1
R2 R2
O
O
R1
N
CO2H
O
R2
CH3
O
O
NH
CO2H
HN
R1
O
R2
MF374 - 210
211 212
263
substitution pattern Antagonist Agonistcpd R1 R2 IC50 ± SEMa EC50 ± SEMaortho meta para (µM) (µM)19865 Br F H OCH3 > 10 (45 ± 11) > 10 (9 ± 9)19965 Br di-F H OCH3 > 10 (14 ± 9) > 10 (8 ± 11)
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substitution pattern Antagonist Agonistcpd R1 R2 IC50 ± SEMa EC50 ± SEMaortho meta para (µM) (µM)20065 Br H F OCH3 > 10 (35 ± 11) > 10 (14 ± 10)20165 methyl H H OCH3 > 10 (18 ± 11) > 10 (7 ± 8)20265 OCH3 H H OCH3 > 10 (4 ± 12) > 10 (12 ± 10)203 Br OCH3 H OCH3 > 10 (44 ± 9) > 10 (-9 ± 11)204 OCF3 H H OCH3 > 10 (17 ± 12) > 10 (-14 ± 5)205 phenyl H H OCH3 > 10 (-16 ± 2) > 10 (7 ± 5)206 ethyl H H OCH3 > 10 (8 ± 11) > 10 (-8 ± 12)207 Br H H ethyl 17.4 ± 6.5 > 10 (10 ± 8)
208 p-chloro-phenyl H H OCH3 > 10 (46 ± 4) > 10 (-5 ± 7)209 Br H H SCH3 12.9 ± 1.7 > 10 (-18 ± 8)210 phenyl di-F H OCH3 > 10 (28 ± 14) > 10 (0 ± 10)211 Br H H OCH3 > 10 (-6 ± 13) > 10 (13 ± 9)212 Br H H OCH3 n.d. n.d.263 H H H OH > 10 (11 ± 8) > 10 (18 ± 14)a Curves were performed in 3 independent experiments.
GPR55 did not tolerate aromatic side-chains. The GPR84-antagonists shown inTable 3.33 though were not able to activate GPR55.
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Table 3.33: Potency of chromen-4-one-2-carboxylic acids at GPR55 determined by β-arrestin recruitment assay using GPR55 CHO cells.
O
O
CO2H
NH
R1
O
O
R3
R4
R2
O
O
CO2H
NHO
O
R3
R4
R2
R1
O
O
CO2H
NH
R1
O
O
R2
O
O
CO2H
NH
R1
O
O
R2
R3
213 - 215 216 - 226 227 - 233 234substitution pattern Antagonist Agonist
compound R1 R2 R3 R4 IC50 ± SEM(µM)a
EC50± SEM(µM)a
213 OCH3 H F H > 10 (5 ± 8) > 10 (-3 ± 6)214 methyl H F H > 10 (6 ± 6) > 10 (11 ± 12)215 ethyl H F H > 10 (29 ± 11) > 10 (0 ± 6)216 H H F H > 10 (1 ± 11) > 10 (-1 ± 10)217 H H F F > 10 (0 ± 7) > 10 (8 ± 12)218 Cl H F H > 10 (-4 ± 5) > 10 (3 ± 4)219 H Cl F H > 10 (21 ± 7) > 10 (10 ± 5)220 F H F H > 10 (35 ± 8) > 10 (-2 ± 12)221 OCH3 H F H > 10 (1 ± 12) > 10 (4 ± 8)222 methyl H F H > 10 (13 ± 14) > 10 (16 ± 13)223 F H F F > 10 (13 ± 8) > 10 (-15 ± 6)224 F Cl F F > 10 (5 ± 11) > 10 (7± 12)225 OH H F H > 10 (31 ± 6) > 10 (4 ± 14)226 H F F H 16.2 ± 6.0 > 10 (-13 ± 13)227 Br F - - 10.6 ± 1.2 > 10 (-2 ± 3)
228 Br Br - - > 10 (-87 ± 34) 0.597 ± 0.137(efficacy 98%)
229 Br Cl - - > 10 (36 ± 13) 0.507 ± 0.033(efficacy 39%)230 H methyl H - > 10 (45 ± 10) > 10 (20 ± 5)
231 Br methyl H - > 10 (-15 ± 5) 0.481 ± 0.85(efficacy 31%)
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substitution pattern Antagonist Agonist
compound R1 R2 R3 R4 IC50 ± SEM(µM)a
EC50± SEM(µM)a
232 H H Br - > 10 (36 ± 13) > 10 (-3 ± 7)233 Br H Br - > 10 (51 ± 11) > 10 (16 ± 7)234 Br F - - 8.54 ± 0.55 > 10 (6 ± 7)a Curves were performed in 3 independent experiments.
Compounds with long alkyl side-chains, shown in Table 3.34 were identified asagonists at GPR55. The SARs will be further discussed in detail.
Table 3.34: Potency of chromen-4-one-2-carboxylic acids at GPR55 determined by β-arrestin recruitment assay using GPR55 CHO cells.
O
O
NH
CO2H
O
R1
O R
2
O
O
NH
CO2H
O
R1
O R2
O
S
NH
CO2H
O
R1
O R
2
O
O
NH
CO2H
HN
S
R1
O R
2
235 - 253
254 - 261
262 264
substitution pattern Antagonist Agonist
compound R1 R2 IC50 ± SEM(µM)a
EC50 ± SEM(µM)a
Pranlukast > 10 (40 ± 7) > 10 (9 ± 2)235 H 1-cyclohexylmethyl > 10 (58 ± 9) > 10 (16 ± 7)236 H 2-cyclohexylethyl > 10 (38 ± 13) > 10 (25 ± 5)
237 H 3-cyclohexylpropyl > 10 (46 ± 11) 0.111 ± 0.042(efficacy 29%)
238 Cl 3-cyclohexylpropyl > 10 (-23 ± 23) 0.323 ± 0.121(efficacy 40%)
239 F 3-cyclohexylpropyl > 10 (8 ± 19) 0.117 ± 0.034(efficacy 29%)
240 H 4-cyclohexylbutyl > 10 (-51 ± 25) 0.474 ± 0.099(efficacy 73%)
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substitution pattern Antagonist Agonist
compound R1 R2 IC50 ± SEM(µM)a
EC50 ± SEM(µM)a
241 Cl 4-cyclohexylbutyl > 19 (-115 ± 57) 0.342 ± 0.039(efficacy 57%)
242 F 4-cyclohexylbutyl > 10 (-93 ± 51) 0.373 ± 0.038(efficacy 71%)
243 H 5-cyclohexylpentyl > 10 (-21 ± 20) 0.202 ± 0.048(efficacy 52%)
244 Cl 5-cyclohexylpentyl > 10 (-39 ± 6) 0.196 ± 0.041(efficacy 86%)
245 F 5-cyclohexylpentyl > 10 (36 ± 7) 0.263 ± 0.074(efficacy 58%)249 H 1-phenylmethyl 6.88 ± 1.70 > 10 (10 ± 6)250 H 2-phenylethyl > 10 (65 ± 5) > 10 (14 ± 14)251 H 3-phenylpropyl > 10 (38 ± 8) > 10 (18 ± 5)252 H 4-phenylbutyl 4.41 ± 0.28 > 10 (2 ± 9)253 H 5-phenylpentyl > 10 (21 ± 14) > 10 (45 ± 6)254 Br 3-cyclohexylpropyl > 10 (18 ± 11) > 10 (6 ± 11)WA24 H 4-cyclohexylbutyl > 10 (2 ± 7) > 10 (-66 ± 27)WA24 Br 4-cyclohexylbutyl > 10 (31 ± 13) > 10 (-27 ± 16)255 OCH3 4-cyclohexylbutyl > 10 (31 ± 9) > 10 (-5 ± 7)256 methyl 4-cyclohexylbutyl 4.54 ± 1.63 > 10 (2 ± 9)257 Cl 4-cyclohexylbutyl 23.6 ± 10.6 > 10 (-2 ± 12)258 F 4-cyclohexylbutyl 3.26 ± 0.14 > 10 (0 ± 13)259 ethyl 4-cyclohexylbutyl > 10 (48 ± 10) > 10 (1 ± 6)260 H 5-cyclohexylpentyl 8.34 ± 1.16 > 10 (7 ± 5)WA09 F 3-phenylpropyl 1.87 ± 0.56 > 10 (1 ± 7)261 Br 5-phenylpentyl 11.7 ± 0.8 > 10 (-1 ± 11)262 F 3-cyclohexylpropyl > 10 (-70 ± 17) > 10 (-9 ± 4)264 H 4-cyclohexylbutyl 8.14 ± 1.88 > 10 (9 ± 11)a Curves were performed in 3 independent experiments.
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3.5.3 Structure-activity relationshipsThe compounds listed in Table 3.31 and Table 3.32 which are agonists of the closestrelative of GPR55, GPR35, were mostly not active at GPR55. However, there weretwo exceptions. Compound 207, which has a bromine atom in the 6-position andan ethyl substituent in the para-position of the phenyl ring of the side-chain, aswell as compound 209, which is also substituted in the 6-position with a bromineatom and in the para-position of the phenyl side-chain with a thiomethyl groupwere weak antagonists at GPR55 (IC50 = 17.4 ± 6.5 µM and IC50 = 12.9 ± 1.7 µM,respectively).The series of compounds that were originally synthesized for GPR84 is much morelipophilic as the compounds contain one more phenyl ring in the side-chain. How-ever also in this series we only identified three weak GPR55 antagonists (226, IC50= 16.2 ± 6.0 µM and 227, IC50 = 10.6 ± 1.2 µM and 234, IC50 = 8.54 ± 0.55 µM).They were structurally diverse and therefore no conclusions about SARs could bedrawn. Interestingly in this series of compounds we also identified three GPR55agonists with EC50-values in the nanomolar range. All of them share a substitutionin the meta-position of the side-chain as well as a bromine substitution in the 6-position of the chromen-4-one. Furthermore they contained a para-substitution atthe second phenyl ring of the side-chain. The most potent compound of this classwas 231, which showed an EC50 value of 0.481 ± 0.85 µM. However the efficacyof the agonist was only 31%. Compound 229, in which the methyl group in the 4-position of the side-chain was replaced by a chlorine atom showed a slightly higherefficacy of 39% but a lower EC50 value of 0.507 ± 0.033 µM. Substitution of the4-position of the side-chain with a bromine atom resulted in the full agonist 228which showed a slightly optimized EC50 of 0.597 ± 0.137 µM. In conclusion theseresults show, that a larger substituent in this position increased the efficacy butdecreased the potency of the agonists.
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Figure 3.28: Agonist-antagonist-switch of chromen-4-one derivatives at GPR55 by arom-atization of the side-chain.
This phenomenon of agonist-antagonist switch within a class of structurally verysimilar compounds could be observed also in the next series of compounds. Thesecompounds were originally designed for GPR17 and contain a longer lipophilic side-chain consisting of long n-alkyl-chains terminated by a cyclohexyl ring or phenylring. Compounds with a terminal cyclohexyl ring mainly showed agonistic activitywhereas compounds with a terminal phenyl ring were antagonists as shown inFigure 3.28Compound 240 is a partial agonist with an efficacy of 73% and an EC50 value of0.474 ± 0.099 µM, in contrast to 252 which is a weak antagonist with an IC50 valueof 4.41 ± 0.28 µM. From these results we conclude that for activation of GPR55 acompletely nonpolar side chain is beneficial. This is also a structural element of thepotential endogenous agonist LPI.
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Figure 3.29: Agonist-antagonist-switch of chromen-4-one derivatives at GPR55 movingthe 4-cyclohexylbenzyloxy side-chain from the meta- to the para position.
We could also observe the antagonist-agonist switch when we changed the positionof the 4-cyclohexylbutyl side-chain.Compounds which were substituted in the meta-position to the amide linker wereagonists whereas compounds which were substituted in the para-position were an-tagonists. Thus the angle of the lipophilic chain is very important for the functionalactivity of the ligand. All compounds that are substituted in the meta-position withan alkyl side-chain were agonists, except for the aromatic compounds as discussedbefore.This interconversion of GPCR agonists and antagonists by only minor structural
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changes is not an individual case. In 2016 Dosa et al. discussed it as a possibilityto switch from a potent GPCR ligand with the undesired functional activity to thedesired one.219 However this phenomenon also shows us that we cannot deducefrom SARs of structurally similar compounds their functional activity. It is alsoproblematic to assume a given functional activity for a published compound if onlybinding data are reported, even if functional data for related ligands are available.The agonists we developed are able to stabilize GPR55 in in its active conformation.The antagonists still have affinity to the receptor but they were not able to inducethe conformational change of the GPCR which is needed to activate the receptor’ssignal cascade.When we analyze the optimal length of the side-chain we need a minimum of threeC-atoms between the ether linker and the cyclohexyl ring to get a potent agonist.The prolongation of the alkyl chain did not result in higher potency. The most potentcompound was compound 237 which contains the 3-cyclohexylpropyl chain. It washighly potent with an EC50 value of 0.111 ± 0.042 µM. However it was only a partialagonist with a low efficacy of only 29%. If we look now on the influence of the lengthof the side-chain on the efficacy we can clearly conclude that an extension resultedin an increase in efficacy. However the optimal length was 4 C-atoms, longer chainsresulted in a decrease in efficacy (Figure 3.30).
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Figure 3.30: Influence of the length of the side chain on the potency and efficacy ofGPR55 agonists.
The substituent at the 6-position of the chromen-4-one did not display remarkableeffects on the potency of the GPR55 agonists. Chlorine, fluorine and hydrogen atomsdid not make a difference. However a chlorine substituent increased the efficacy ofthe compounds.Analyzing the effects of substituents at the 6-position on the potency of GPR55antagonists we also could not observe any preferences.To further identify important structural elements of GPR55 agonists we comparedour chromen-4-one-based agonist 244 with the potential endogenous GPR55 ago-nist LPI. We found that 244 and LPI can be divided into three structural elements.Both compounds consist of a lipophilic tail, which is connected via a linker to anextremely polar head. The linker thereby includes a polar oxygen atom. An analy-sis of the polarity of the compound using Stardrop R© shows that 281 and LPI sharea similar polarity profile (Figure 3.31). We conclude from this analysis that our
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chromen-4-one-based GPR55 agonists bind in the same binding pocket as the po-tential endogenous agonist LPI.
A B
LPI
LPI
244
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OH
OHOHHO
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O OH
O
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Polar headLinkerLipophilic tail
HO
Cl
Figure 3.31: Comparison of the structures of the potential endogenous GPR55 agonistLPI and the potent GPR55 agonist 244 from our series of chromen-4-ones. A Bothagonists share structural elements: the lipophilic tail shown in red, the linker shown inblue, the polar head shown in green. B An analysis of the polarity of the structure wasperformed using Stardrop R©. Polar groups are shown in blue colour whereas unpolarparts of the molecule are shown in red colour.
In conclusion we successfully identified potent GPR55 agonists as well as GPR55antagonists which are based on the chromen-4-one core structure. Minor structuralmodifications completely changed the functionality of our compounds. Compound237 was the most potent GPR55 agonist of our series with an EC50 value of 0.111± 0.042 µM but is behaves as a partial agonist. Compound 244, which was halfas potent compared to 237 showed a much higher efficacy of 86% and is nearly afull agonist. We also developed GPR55 antagonists which showed potencies in themicromolar range. However our compounds were less potent than the previouslypublished WA09.172 The best compounds are shown in Figure 3.32.
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Figure 3.32: Potency and physicochemical properties of the most potent GPR55 ligandsof the series of chromen-4-ones. An analysis of the polarity of the structure and ofphysicochemical parameters was performed using Stardrop R©. Polar groups are shownin blue colour whereas unpolar parts of the molecule are shown in red colour.
All GPR55 agonists are very lipophilic and have logP values around 5. Compound244 does not fit into Lipinki’s rule of five with a logP value of 6.147 and a molec-ular weight of 512 g/mol. However few GPR55 synthetic GPR55 agonists havebeen identified so far and therefore our compound is a promising lead structurefor further development of GPR55 agonists as pharmacological tools. Optimizationof the physicochemical properties could result in a suitable lead structure for thedevelopment of drugs.
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3.6 Selectivity of the compoundsIn this chapter the selectivity of the most potent compounds will be analyzed andfurther discussed. What we can conclude is that the SARs were highly specificfor each receptor. GPR35 agonists have to be small and polar. The most potentcompounds have logP values below 3 (197, logP = 0.34, 210 logP = 2.95). GPR55,GPR84 and GPR17 ligands are more lipophilic and have higher molecular weights.A long lipophilic residue at the 8-position is important for their potency. Althoughthe receptors share this SAR feature, the compounds are highly selective.
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GPR35
- small molecules:	MW	=		300	- 500	g/Mol
- very polar: logP =	0-3
- for the rodent orthologues:	 two acid
functions are needed
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at	position 6	and 8
- very non-polar: logP
5-6
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Figure 3.33: Comparison of the individual structural characteristics of the orphan GPCRligands. An analysis of the polarity of the structure and of physicochemical parameterswas performed using Stardrop R©. Polar groups are shown in blue colour whereas unpolarparts of the molecule are shown in red colour.
GPR84 antagonists need to have a big electron-rich substituent at the 6-position.Phenyl or p-chlorophenyl are the best substituents for this position. In contrastto that GPR17 antagonists only tolerate aliphatic residues. Highly electronegativesubstituents like bromine result in a decreased potency. The same applies to GPR55ligands. GPR55 antagonists as well as agonists prefer small groups like a fluorineor hydrogen atom at the 6-position.When we look at the side-chain in the 8-position of the chromenone core the pref-
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erences of the different receptors are highly diverse. All potent GPR84 antagonistscontain a 4-fluorobenzyloxyphenyl side-chain which is aromatic and rich in elec-trons. GPR17 in contrast to that does not tolerate aromatic side-chains. PotentGPR17 antagonist contain a long alkyl side-chain which has to be in the para-position to the amide linker. The same applies to GPR55 agonists whereby thealkyl side-chain needs to be in the meta-position for potent ligands.The most potent compounds were tested for their selectivity at phylogeneticallyrelated receptors.
3.6.1 Selectivity of the GPR35 agonistsThe most potent GPR35 agonists 210, 197, 196, and 277 were tested at furtherGPCRs of the δ branch of class A with a special focus on GPR55, which representedthe most closely related receptor of the test series.
Table 3.35: Potency and selectivity of GPR35 agonists determined at class A δ-branchorphan GPCRs.Target 210 197 196 277
O CO2H
O
NHO
F F
OCH3
Br
O CO2H
NH
S
O
OHO
NH
O
O
CO2H
O
O OH
N
H
O
H3C
HN
O
CO2H
HO2Chuman GPR35Ki ± SEM (µM)a 0.000426 ±0.000037 0.00271 ±0.00032 0.00897 ±0.0015 0.0062 ±0.00065human GPR35EC50 ± SEM(µM)b
0.00108 ±0.00011 0.00847 ±0.00072 0.0318 ±0.0053 0.0214 ±0.0021
rat GPR35 EC50± SEM (µM)c 0.157 ± 0.013 0.0209 ±0.0023 0.0297 ±0.0040 0.0263 ±0.0023mouse GPR35EC50 ± SEM(µM)d
0.293 ± 0.042 0.174 ± 0.019 0.399 ± 0.083 0.105 ± 0.015
human GPR55EC50 ± SEM(µM)e
> 10 > 10 > 10 > 10
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human GPR55IC50 ± SEM(µM)f
> 10 > 10 > 10 > 10
human GPR84IC50 ± SEM(µM)g
6.37 ± 0.98 > 3 > 3 > 3
human GPR17IC50 ± SEM(µM)h
> 10 > 10 > 10 > 10
human GPR18IC50 ± SEM(µM)i
> 10 > 10 > 10 > 10
aradioligand binding experiments using membrane preparations of CHO cells recombi-nantly expressing the human GPR35, compounds were tested versus the radioligand[3H]PSB13253; bβ-arrestin recruitment assay using human GPR35 CHO-cells (% ac-tivation in comparison to 30 µM zaprinast induced luminescence signal); cβ-arrestinrecruitment assay using rat GPR35 CHO-cells (% activation in comparison to 10 µM za-prinast induced luminescence signal); dβ-arrestin recruitment assay using mouse GPR35CHO-cells (% activation in comparison to 30 µM zaprinast induced luminescence signal);eβ-arrestin recruitment assay using human GPR55 CHO-cells (% activation in compari-son to 1 µM LPI induced luminescence signal) fβ-arrestin recruitment assay using humanGPR55 CHO-cells (% inhibition of 1 µM LPI induced luminescence signal); gcAMP ac-cumulation assay using CHO-β-arrestin-GPR84 cells (% inhibition of Yazh-365 (30 nM)response); hcalcium ion mobilization assay using 1321N1 astrocytoma cells (% inhibitionof calcium-dependend fluorimetric signal upon activation by GPR17 agonist MDL29,951);iβ-arrestin recruitment assay using human GPR18 CHO-cells (% inhibition of 10 µM THCinduced luminescence signal)
All GPR35 agonists were highly selective for GPR35. They were not able to activateor inhibit GPR17, GPR84, GPR18 and GPR55 in our pharmacological test systems(Table 3.35). This result was expected as the SARs, that were determined for GPR35,were unique compared to the other receptors of the test series.
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Figure 3.34: Potency and selectivity of GPR35 agonists at class A δ-branch orphanGPCRs. Potency of the compounds at hGPR35, mGPR35, rGPR35 and hGPR55 wasdetermined in β-arrestin recruitment assays, respectively. Potency of the compoundsat GPR84 was determined by cAMP accumulation assay. Potency of the compounds athGPR17 was determined in the calcium ion mobilization assay.
3.6.2 Selectivity of the GPR84 antagonistsThe most potent GPR84 antagonists 217, 218, 220, and 222 were tested for theirselectivity against other orphan GPCRs of the δ branch of class A and additionallyagainst the free fatty acid receptors FFAR1 and FFAR4. The free fatty acid receptorsFFAR1 (also known as GPR40) and FFAR4 (also known as GPR120) are highlyrelevant regarding the selectivity of GPR84 ligands because they are known to bindmedium-chain fatty acids as GPR84. They also belong to the class A GPCRs.220,221
144
3.6 Selectivity of the compounds Dissertation, Universität Bonn 2016
Table 3.36: Potency and selectivity of GPR84 antagonists determined at class A δ-branchorphan GPCRs and free fatty acid receptors (FFARs).Target 217 218 220 222
O
O
CO2H
NHO
O
F
F
O
O
CO2H
NHO
O
F
Cl
O
O
CO2H
NHO
O
F
F
O
O
CO2H
NHO
O
F
H3C
human GPR35Ki ± SEM (µM)a 0.354 ± 0.049 >10 >10 >10human GPR35EC50 ± SEM(µM)b
> 10 > 10 > 10 > 10
rat GPR35 EC50± SEM (µM)c 0.527 ± 0.055 > 10 > 10 > 10mouse GPR35EC50 ± SEM(µM)d
1.61 ± 0.29 2.77 ± 0.26 1.52 ± 0.28 3.22 ± 0.44
human GPR55EC50 ± SEM(µM)e
> 10 > 10 > 10 > 10
human GPR55IC50 ± SEM(µM)f
> 10 > 10 > 10 > 10
human GPR84IC50 ± SEM(µM)g
0.088 ± 0.018 0.00734 ±0.000168 0.0592 ±0.0039 0.0404 ±0.0072
human GPR84IC50 ± SEM(µM)j
0.112 ± 0.048 0.00302 ±0.00095 0.00708 ±0.00060 0.0137 ±0.0025
human GPR17IC50 ± SEM(µM)h
> 10 > 10 > 10 > 10
human GPR18IC50 ± SEM(µM)i
> 10 > 10 > 10 > 10
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FFAR1 IC50 ±SEM (µM)k > 10 > 10 > 10 > 10 > 10FFAR1 EC50 ±SEM (µM)l > 10 > 10 > 10 > 10FFAR4 IC50 ±SEM (µM)m > 10 > 10 > 10 > 10FFAR4 EC50 ±SEM (µM)n > 10 > 10 > 10 > 10aradioligand binding experiments using membrane preparations of CHO cells recombi-nantly expressing the human GPR35, compounds were tested versus the radioligand[3H]PSB13253; bβ-arrestin recruitment assay using human GPR35 CHO-cells (% ac-tivation in comparison to 30 µM zaprinast induced luminescence signal); cβ-arrestinrecruitment assay using rat GPR35 CHO-cells (% activation in comparison to 10 µM za-prinast induced luminescence signal); dβ-arrestin recruitment assay using mouse GPR35CHO-cells (% activation in comparison to 30 µM zaprinast induced luminescence signal);eβ-arrestin recruitment assay using human GPR55 CHO-cells (% activation in compari-son to 1 µM LPI induced luminescence signal) fβ-arrestin recruitment assay using humanGPR55 CHO-cells (% inhibition of 1 µM LPI induced luminescence signal); gcAMP ac-cumulation assay using CHO-β-arrestin-GPR84 cells (% inhibition of Yazh-365 (30 nM)response); hcalcium ion mobilization assay using 1321N1 astrocytoma cells (% inhibitionof calcium-dependend fluorimetric signal upon activation by GPR17 agonist MDL29,951);iβ-arrestin recruitment assay using human GPR18 CHO-cells (% inhibition of 10 µMTHC induced luminescence signal); j β-arrestin recruitment assay using human GPR84CHO-cells (% inhibition of the effect of 10 µM Yazh-365); k , lcompounds were screenedat a concentration of 10 µM in calcium mobilization assays using 1321N1 astrocytomacells recombinantly expressing human FFAR1 and in m, nβ-arrestin recruitment assaysusing CHO β-arrestin cells recombinantly expressing the prolink-tagged human FFAR4s.Effects were normalized to the signal induced by k10 µM of TUG-424 and m30 µM ofTUG-891 at the hFFAR1 and hFFAR4s, respectively, corresponding to a maximal re-sponse. Antagonist screenings were performed versus l2 µM TUG-424 (hFFAR1) andn4µM TUG-891 (hFFAR4s)
All GPR84 antagonists that were evaluated at the different receptors were highlyselective for GPR84. No potency was observed at the related FFAR receptors. Alsoat the class A receptors GPR18, GPR17 and GPR55 no inhibition or activation couldbe observed in our test assays. The most potent compounds 218, 220, and 222 werecompletely inactive at the human and the rat GPR35. Only compound 217, which is
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substituted with a second fluorine atom at the side chain showed agonistic activityat the human GPR35 and the rat GPR35 in the high nanomolar range. All fourGPR84 antagonists showed agonistic activity in the micromolar range at the mouseGPR35 (Table 3.36).
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Figure 3.35: Potency and selectivity of GPR35 agonists at class A δ-branch orphanGPCRs. Potency of the compounds at hGPR35, mGPR35, rGPR35, hGPR84, FFAR4 andhGPR55 was determined in β-arrestin recruitment assays, respectively. Potency of thecompounds at hGPR17 and FFAR1 was determined in the calcium ion mobilization assay.
3.6.3 Selectivity of the GPR17 antagonistsThe most potent GPR17 antagonists of our series 255 and compoundANM217 weretested for their selectivity against the orphan class A GPCRs GPR35, GPR84, GPR18and GPR55.
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Table 3.37: Potency and selectivity of GPR17 antagonists determined at class A δ-branchorphan GPCRs.Target 255 259
O
O
CO2H
H3CO
NHO
O
O
O
CO2H
NHO
O
H3C
human GPR35 Ki ± SEM (µM)a 0.012 ± 0.005 > 10human GPR35 EC50 ± SEM (µM)b > 10 0.791 ± 0.228rat GPR35 EC50 ± SEM (µM)c > 10 > 10mouse GPR35 EC50 ± SEM (µM)d 2.78 ± 0.27 > 10human GPR55 EC50 ± SEM (µM)e(efficacy) > 10 > 10human GPR55 IC50 ± SEM (µM)f > 10 > 10human GPR84 IC50 ± SEM (µM)g > 3 > 10human GPR17 IC50 ± SEM (µM)h 0.445 ± 0.108 0.666 ± 0.144human GPR18 IC50 ± SEM (µM)i > 10 n.d.aradioligand binding experiments using membrane preparations of CHO cells recombi-nantly expressing the human GPR35, compounds were tested versus the radioligand[3H]PSB13253; bβ-arrestin recruitment assay using human GPR35 CHO-cells (% ac-tivation in comparison to 30 µM zaprinast induced luminescence signal); cβ-arrestinrecruitment assay using rat GPR35 CHO-cells (% activation in comparison to 10 µM za-prinast induced luminescence signal); dβ-arrestin recruitment assay using mouse GPR35CHO-cells (% activation in comparison to 30 µM zaprinast induced luminescence signal);eβ-arrestin recruitment assay using human GPR55 CHO-cells (% activation in compari-son to 1 µM LPI induced luminescence signal) fβ-arrestin recruitment assay using humanGPR55 CHO-cells (% inhibition of 1 µM LPI induced luminescence signal); gcAMP ac-cumulation assay using CHO-β-arrestin-GPR84 cells (% inhibition of Yazh-365 (30 nM)response); hcalcium ion mobilization assay using 1321N1 astrocytoma cells (% inhibitionof calcium-dependend fluorimetric signal upon activation by GPR17 agonist MDL29,951);iβ-arrestin recruitment assay using human GPR18 CHO-cells (% inhibition of 10 µM THCinduced luminescence signal)
The GPR17 antagonist are not selective. Compound 255 binds with high affinity to
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the human GPR35 whereas compound 259 is able to activate the human GPR35 inthe β-arrestin recruitment assay. For the development of drugs the selectivity isimportant. However GPR35 is only poorly investigated yet and its pharmacologicalfunctions remains unclear. It has to be investigated if an activation of GPR35 couldbe tolerated and whether this activation would have a negative side-effect duringthe therapy.
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Figure 3.36: Potency and selectivity of GPR17 antagonists at class A δ-branch orphanGPCRs. Potency of the compounds at hGPR35, mGPR35, rGPR35, GPR18 and hGPR55was determined in β-arrestin recruitment assays, respectively. Potency of the compoundsat GPR84 was determined by cAMP accumulation assay. Potency of the compounds athGPR17 was determined in the calcium ion mobilization assay. Affinity of the compoundsat hGPR35 was determined by radioligand binding experiments.
3.6.4 Selectivity of the GPR55 agonistsTo determine the selectivity of the GPR55 agonists, the most potent compounds ofour series were tested at the G protein-coupled receptors GPR35, GPR18, GPR84and GPR17. GPR35 and GPR84 are phylogenetically related to GPR55. Further-more the GPR55 agonists were also tested for their selectivity against the cannabi-noid receptors CB1 and CB2. This was highly interesting as GPR55 is discussed tobe a third cannabinoid receptor.
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Table 3.38: Potency and selectivity of GPR55 agonists determined at class A δ-branchorphan GPCRs.Target 240 244 237 242
O
O
CO2H
NHO
O
O
O
CO2H
NHO
O
Cl
O
O
CO2H
NH
O
O O
O
CO2H
F
O
NHO
human GPR35Ki ± SEM (µM)a 0.474 ± 0.043 2.67 ± 0.590 0.585 ± 0.070 1.32 ± 0.090human GPR35EC50 ± SEM(µM)b
> 10 > 10 > 10 > 10
rat GPR35 EC50± SEM (µM)c > 10 > 10 > 10 > 10mouse GPR35EC50 ± SEM(µM)d
2.58 ± 0.31 > 10 2.43 ± 0.73 2.90 ± 0.52
human GPR55EC50 ± SEM(µM)e (efficacy)
0.474 ± 0.099(72%) 0.196 ± 0.041(86%) 0.111 ± 0.042(29%) 0.373 ± 0.038(71%)
human GPR55IC50 ± SEM(µM)f
> 10 > 10 > 10 > 10
human GPR84IC50 ± SEM(µM)g
6.36 ± 1.94 > 3 > 3 1.03 ± 0.04
human GPR17IC50 ± SEM(µM)h
1.71 ± 0.04 1.58 ± 0.49 4.28 ± 0.49 2.67 ± 0.49
human GPR18IC50 ± SEM(µM)i
> 10 > 10 > 10 > 10
human CB1 Ki ±SEM (µM)j > 10 > 10 > 10 > 10
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human CB2 Ki ±SEM (µM)k > 10 > 10 > 10 > 10aradioligand binding experiments using membrane preparations of CHO cells recombi-nantly expressing the human GPR35, compounds were tested versus the radioligand[3H]PSB13253; bβ-arrestin recruitment assay using human GPR35 CHO-cells (% ac-tivation in comparison to 30 µM zaprinast induced luminescence signal); cβ-arrestinrecruitment assay using rat GPR35 CHO-cells (% activation in comparison to 10 µM za-prinast induced luminescence signal); dβ-arrestin recruitment assay using mouse GPR35CHO-cells (% activation in comparison to 30 µM zaprinast induced luminescence signal);eβ-arrestin recruitment assay using human GPR55 CHO-cells (% activation in compari-son to 1 µM LPI induced luminescence signal) fβ-arrestin recruitment assay using humanGPR55 CHO-cells (% inhibition of 1 µM LPI induced luminescence signal); gcAMP ac-cumulation assay using CHO-β-arrestin-GPR84 cells (% inhibition of Yazh-365 (30 nM)response); hcalcium ion mobilization assay using 1321N1 astrocytoma cells (% inhibitionof calcium-dependend fluorimetric signal upon activation by GPR17 agonist MDL29,951);iβ-arrestin recruitment assay using human GPR18 CHO-cells (% inhibition of 10 µMTHC induced luminescence signal); j radioligand binding experiments using membranepreparations of CHO cells recombinantly expressing the human CB1 receptor, compoundswere tested versus the radioligand [3H]CP55,940; k radioligand binding experiments usingmembrane preparations of CHO cells recombinantly expressing the human CB2 receptor,compounds were tested versus the radioligand [3H]CP55,940
The results showed that the selectivity of the GPR55 agonists was diverse. First ofall none of the compounds was able to bind to the cannabinoid receptors and noneof the compounds was able to activate or inhibit GPR18. But compound 282 andcompound 242 did not only show effects at GPR55 but also at other GPCRs. Bothcompounds bound with high affinity to the human GPR35 and were able to activatethe mouse orthologue of GPR35 in the micromolar range. They were also weakantagonists at GPR17 in the micromolar range. Compound 242 showed antagonisticactivity at the human GPR84 around 1 µM. It showed the lowest selectivity for thehuman GPR55. However the activity of 282 and 242 still was at least 2-4 timeshigher compared to the other receptors.The selectivity of 244 and 237 for GPR55 was higher. Both showed low affinity atthe human GPR35 and a very low potency at the human GPR17. In contrast to thatthey showed a high agonistic activity at the human GPR55 in the nanomolar range.
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Figure 3.37: Potency and selectivity of GPR35 agonists at class A δ-branch orphanGPCRs. Potency of the compounds at hGPR35, mGPR35, rGPR35 and hGPR55 wasdetermined in β-arrestin recruitment assays, respectively. Potency of the compounds athGPR17 was determined in the calcium ion mobilization assay. Affinity of the compoundsat hGPR35, CB1 and CB2 was determined by radioligand binding experiments.
The compound with the bestover all properties as a GPR55 agonist of our serieswas 244. It is able to activate GPR55 in the nanomolar range with a high efficacyof 86% and it is highly selective to the other GPCRs we tested.
3.7 Biological evaluation of ecto-5’-nucleotidaseinhibitors
3.7.1 Competition studies - Radiometric TLC eN assayIn this study 6 compounds, which were previously identified as potent and selectiveinhibitors at rat ecto-5’-nucleotidase (CD73), were further investigated at the humanenzyme. We performed a radiometric thin-layer chromatography (TLC) assay using
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[3H]AMP as a substrate.222 During the enzyme reaction adenosine 5’-monophos-phate (AMP) is converted by CD73 to adenosine and further to inosine by adenosinedeaminase. This conversion can be monitored by the TLC-assay. To this end thesubstrate AMP was mixted with the enzyme source (recombinant enzyme or humanserum), β-glycerophosphate, the inhibitor and a small amount of the radioactivesubstrate [3H]AMP in RPMI-1640 medium. The mixture was incubated and thereaction was stopped by pipetting aliquots of the reaction mixture on to a TLCplate together with a reference solution. Subsequent separation with a mixture of1-butanol 1.5 vol. eq.; isoamylalcohol 1 vol. eq.; diethyleneglycol monoethylether 3vol. eq.; ammonia solution 1.5 vol. eq.; pure water vol. 2.5 eq.. Then the spots werevisualized by UV light, scraped off and quantified by scintillation β-counting.
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Figure 3.38: Autoradiographic analysis of the eN reaction using purified recombinanthuman enzyme (A) and human serum (B) without inhibitor (control), with inhibitor 283and AOPCP, and without inhibitor and enzyme (Blank).
The TLC assay has got many advantages regarding the analysis of purine-converting
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enzymes since it allows to measure a broad range of enzyme reactions without theneed of modifications in the procedure except for reaction time and eluent. There isalso no limitation to different enzyme sources, so that reactions using pure enzyme,serum or even cells can be measured. Furthermore it does not require expensiveinstruments such as HPLC so that an implementation of the assay is very easyand cheap. A big advantage of radiometric enzyme assays in general is their highsensitivity and stability.All of the 6 compounds and the standard inhibitor α ,β-methylene-ADP (AOPCP)were tested on purified recombinant human enzyme and human blood serum samplesas enzyme source. To visualize the inhibition we prepared an autoradiographicanalysis with AOPCP and inhibitor 283 in different concentrations compared to thecontrol without inhibitor and blank (without enzyme and inhibitor) (Figure 3.38).It was clearly observed that the conversion of AMP to adenosine was reduced inthe presence of inhibitors.
Table 3.39: Ki values of inhibitors at recombinant human eN and at soluble eN in hu-man serum and IC50 values of inhibitors at MDA-MB231 and HUVECs determined byradiometric TLC assay. For structures see Figure 3.39
compound recombinanthuman eNd human serumeN MDA-MB-231 HUVECKi ± SEMa(nM) Ki ±SEMa(nM) IC50 ±SEMb(nM) IC50 ±SEMc (nM)AOPCP 88.4 ± 3.96 487 ± 186 5724 ± 1000 1864 ± 467284 2.21 ± 0.40 18.8 ± 12.5 - -285 4.58 ± 0.23 68.8 ± 23.2 - -286 2.53 ± 0.735 8.61 ± 2.79 - -287 0.757 ± 0.061 13.9 ± 5.74 - -288 1.89 ± 0.061 11.0 ± 1.04 - -283 0.318 ± 0.02 2.51 ± 1.07 103.5 ± 16.9 73.5 ± 11.6a [3H]AMP (40 µM) was used as substrate (Km value 40 µM and 65 µM respectivelyfor recombinant human eN and eN in human serum223)b[3H]AMP (400 µM) was used as substratec [3H]AMP (200 µM) was used as substratedrecombinant human CD73 was purified from transfected CHO cells224
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Compound 283, which was the most potent eN-inhibitor, was also tested in MDA-B-231 breast cancer cells and human umbilical vein endothelial cells (HUVECs), whichare known to express eN. The results of the enzyme competition assays are shownin Table 4.1.
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Figure 3.39: Structures of eN-inhibitors.
All compounds we tested are much more potent inhibitors of CD73 than the standardinhibitor AOPCP. They block the recombinant enzyme in the low nanomolar or evensubnanomolar range. The most potent compound is 283 with a Ki of 0.318 ± 0.02nM which is almost 300 times more potent than AOPCP. The eN inhibitors inhibit
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the recombinant enzyme in the following range order of potency: 283 (about 300folds more potent than AOPCP) > 287 (about 120 folds more potent than AOPCP)> 288 ≈ 284 ≈ 286 (40-50 folds more potent than AOPCP) > 285 (about 20 foldsmore potent than AOPCP). The Ki values are in the same range as the Ki valuesdetermined for recombinant rat CD73 using a different method.171Interestingly the Ki values determined on human serum CD73 are about 10-foldhigher than the ones measured on the recombinant enzyme. We suspect that thiscould be due to plasma protein binding of the compounds, which reduces the freefraction of the drugs. Further explanations could be different conformations ofmembrane- anchored, soluble and purified enzyme, or different viscosities of thesystems. However all compounds were still much more potent than AOPCP.The most potent inhibitor 283 was analysed in more detail using more complexbiological systems. We started with an evaluation of the inhibitor in cancer (MDA-MB-231) and in non-cancer (HUVEC) cells. The IC50 values in both cell lines werecomparable and in the range of 100 nM. It must be kept in mind that IC50 valuescannot be compared to Ki values. We had to use high and different substrate con-centrations for both cell lines because the quantity of the expression of CD73 isdifferent. The substrate concentration in the assay used for both cell lines wasabout 10 times higher than that for recombinant and soluble serum CD73. Com-pared to the standard inhibitor AOPCP our new inhibitor 283 was about 55- and25-fold more potent than AOPCP in MDA-MB-231 cells and HUVECs, respectively(Table 4.1).In conclusion all tested inhibitors were confirmed to inhibit CD73 with Ki valuesin the low nanomolar or subnanomolar range. Inhibitor 283 is significantly morepotent in cancer and also in non-cancer cell lines compared to the standard in-hibitor AOPCP. We also observed that the potency is lower the more complex thebiological system is that we used as an enzyme source. This has to be kept in mindwith regard to animal studies. Inhibitors which show a decent potency in vitro arenot automatically suitable for in vivo studies because their potency could be toolow. With our inhibitor 283 we identified a pharmacological tool which shows anextremely high potency and which can therefore be used for in vivo studies.
156
3.7 Biological evaluation of ecto-5’-nucleotidase inhibitors Dissertation, Universität Bonn 2016
3.7.2 Enzyme histochemistryFor the evaluation of the potent inhibitor 283 in tissues we performed a lead nitratestaining using human tonsil and mouse spleen sections.225 Both tissues are knownto express CD73. The lead nitrate staining is based on the chemical detectionof the phosphate which is formed when AMP is cleaved by CD73. Phosphate isthen reacted with Pb(NO3)2 to Pb3(PO4)2 precipitates in the tissue. The excess ofPb(NO3)2 is washed out and the formed Pb3(PO4)2 is reacted with (NH4)2S to PbSwhich appears as brown staining in the tissue sections (Scheme 3.22).
AMP CD73 Adenosine + PO43-
Pb(NO3)2 + PO43- Pb3(PO4)2
Pb3(PO4)2 + (NH4)2S PbS
Scheme 3.22: Lead-nitrate staining reaction of CD73
Human tonsils and mouse spleen tissue sections were stained with 1 mM AMP inthe absence or the presence of 20 µM AOPCP or 600 nM of 283 and also withhematoxylin/eosin to distinguish between different tissue structures. Especially inthe regions of the central arteries and the capsule intensive brown staining, whichmeans high CD73 activity, is observed in both tissues. This activity was clearlyreduced in the inhibitor treated samples. The inhibitor 283 at a concentration of600 nM blocked CD73 more efficiently than AOPCP at a high concentration of 20µM as shown by reduced brown staining (Figure 3.40).
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Figure 3.40: Enzyme histochemical staining of human tonsil and mouse spleen tis-sue section with 1 mM AMP in absence and presence of inhibitors 283 (600 nM) andAOPCP (20 µM)
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3.7.3 SummaryWe can conclude from our results that the new CD73 inhibitor 283 is not only supe-rior to AOPCP at isolated enzyme and human soluble serum enzyme but also blocksCD73 much more efficiently in human and in mouse tissue sections. It represents themost potent inhibitor for CD73 known to date and is therefore an important phar-macological tool to further characterize the enzyme in vivo and also in functionalstudies.
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4 Summary and outlook
4.1 Development of potent and selective ligands fororphan G protein-coupled receptorsHuman G protein-coupled receptors (GPCRs) are a superfamily of about 800 pro-teins. Nearly 60% of all marketed drugs are targeting GPCRs. However the en-dogenous ligands of more than 100 GPCRs are still unknown or have not beenconfirmed yet. As these so-called orphan receptors might represent future drugtargets these poorly studied receptors bear an enormous potential. Based on se-quence homology and common structural elements G protein-coupled receptors canbe grouped into different branches. In the present study we focused on purine-and cannabinoid-like receptors of the δ-branch of class A (rhodopsin-like) GPCRs.Our aim was to develop and optimize synthetic ligands for several promising or-phan GPCRs of this receptor family. The newly developed ligands can be used aspharmacological tools to further study the structures, functions or effects initiatedby those receptors. Although GPR17, GPR35, GPR55 and GPR84, on which wefocussed, are poorly studied so far, there are indications that these receptors maybe involved in pathological processes. Therefore potent agonists and antagonistsrepresent potential drugs. The results of the study are summarized in the followingparagraphs.
4.1.1 SynthesisFor the development of new potent and selective ligands for orphan GPCRs we syn-thesized a large library of chromen-4-one derivatives that were based on the struc-ture of the cysteinyl-leukotriene receptor 1 antagonist pranlukast. The chromen-4-one core structure was modified extensively as shown in Figure 4.1.
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The preparation of the potential ligands as shown in Scheme 4.1 began with the ni-tration of commercially available 6-substituted 2-hydroxyacetophenones (Scheme 4.1,a). The nitrophenyl derivatives were reacted in a Claisen condensation to obtainethyl chromen-4-one-2-carboxylates (Scheme 4.1, b). Reduction of the nitro groupat the 6-position yielded the corresponding amines (Scheme 4.1, c). The 6-brominoderivative 17 was further modified by several reactions (Scheme 4.1, d-g).It was treated with Lawesson’s reagent (Scheme 4.1, f) and subjected to Suzukicoupling with various phenylboronic acids (Scheme 4.1, d) or with butylboronic acid(Scheme 4.1, e) to give the 4-thio derivative, the 6-phenyl derivatives and the 6-butyl derivative, respectively. No convenient method for Suzuki coupling reactionsat the 6-position of chromen-4-ones has been described in the literature so far.
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Figure 4.1: The lead structure pranlukast was structurally optimized to obtain ligandsfor the orphan receptors GPR17, GPR35, GPR55, and GPR84. Structure-activity rela-tionships of the chromen-4-one derivatives for the individual receptors were analyzed.
Usually the substituent at the 6-position is introduced before the Claisen conden-sation is performed. We developed a more elegant strategy by synthesizing largeamounts of 17 (ethyl 8-amino-6-bromo-4-oxo-4H-chromene-2-carboxylate) followedby variation of the 6-position in a single step. To this end the reaction conditionsfor the Suzuki coupling reaction of the hydrolytically unstable chromen-4-ones hadto be optimized. We developed a Suzuki coupling method which worked under dryconditions to prevent the cleavage of the chromen-4-one ring. The reaction wasperformed in a pressure tube under argon which resulted in short reaction times.The new method worked also with alkyl-boronic acids with slight modifications.Suzuki coupling with aromatic boronic acids gave higher yields than coupling with
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aliphatic boronic acids.Two amines were also reacted in a modified Conrad-Limpach reaction with diethylacetylendicarboxylate followed by ring closure reaction in boiling Dowtherm A R©,a heat transfer fluid consisting of diphenyl (C12H10) and diphenyl oxide (C12H10O)(Scheme 4.1, g-h).The amide coupling with the corresponding acid chlorides/carboxylic acids gavethe desired amides (Scheme 4.1, i). Several linker modifications were performed,including the introduction of an urea and a thiourea linker. One compound was alsomethylated with methyl iodide to obtain a methylated amide as a linker (Scheme 4.1,k).
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The final step was the hydrolysis of the ethyl ester at the 2-position to yield thechromen-4-one-2-carboxylic acid derivatives (Scheme 4.1, j, l).For the synthesis of ligands for GPR17, GPR55, and GPR84 long side-chains inthe 8-position were needed that were not commercially available. We synthesizedthese intermediates starting from the aliphatic carboxylic acid which was reducedto give the corresponding alcohol (Scheme 4.2, a). The alcohol was then brominated(Scheme 4.2, b) and coupled to several methyl hydroxybenzoates via a Williamssonether synthesis (Scheme 4.2, c). Finally the methyl ester was cleaved (Scheme 4.2,d) and the carboxylic acid chlorides were prepared which could be coupled to theamines as previously described.
MeO2C
OH
MeO2C
O
R1 CO2Hn
n = 1-5
R1 OHn
a b
R1 Brn
R1n
HO2C
O R1n
R1 =
H, F, Cl
c
d
CH3
Scheme 4.2: Synthesis of the side-chain. Reagents and conditions: (a) LiAlH4, THF, rt,4 h, 85-83% yield; (b) PBr3, toluene, 0-5 ◦C, 30 min, reflux, 120 min, 86% yield (crudeproduct); (c) K2CO3, DMF, 115 ◦C, 4 h, 37-100% yield; d method 1: microwave, MeOH,KOH, 100 ◦C, 30 min; method 2: pressure tube, MeOH, KOH, 120 ◦C, 4 h, 23-97% yield.For exact structures see Table 3.5 and Table 3.6
Altogether we successfully synthesized 82 chromen-4-one-2-carboxylic acid deriva-tives of which only one was previously described in the literature. These compoundswere evaluated in our group for their potency to activate or block the orphan GPCRsGPR17, GPR35, GPR55 and GPR84.
4.1.2 GPR35One receptor we mainly focused on was GPR35 which has been observed to beexpressed in the gastrointestinal tract, in liver, in the central nervous system, the
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cardiovascular system and the immune system. GPR35 agonists were proposed aspotential drugs for inflammation and pain and for cardiovascular diseases, such ashypertension.The potencies of chromen-4-one-2-carboxylic acids at the human GPR35 were de-termined by β-arrestin recruitment assays and the affinities were measured byradioligand binding studies. Structure-activity relationships are summarized in Fig-ure 4.2. Besides the introduction of substituents at the 6-position, like a phenyl ringor a bromine atom, the replacement of the oxygen atom at the 4-position by a sulfuratom resulted in an increase in potency. Furthermore, fluorine atoms in the ortho-and meta-position and a methoxy group in the para-position of the benzamide atposition 8 were beneficial. The introduction of a second carboxylic acid function aswell as ring closure at position 7 and 8 did not result in an increase in potency.The most potent human GPR35 agonist of this series of compounds was compound210 with an EC50 value of 0.00108 ± 0.00011 µM. It is the most potent GPR35agonist known to date and it is highly selective versus GPR55, which is phyloge-netically the closest relative of GPR35, and it is also selective versus other relatedδ-branch GPCRs including GPR17 and GPR84.
O
X
CO2H
R1 substituent at the 4-position (X): S > O
substituent at the 6-position (R1):
phenyl > 4-chlorophenyl > Br > OCF3 > Cl > methoxy ~ methyl ~ ethyl ~ butyl > F >> H
linker: amide > urea >> N-Me-amide
a ring closure is not tolerated
F > H > OCH3
F > H
OCH3 > SCH3 > ethyl > O-phenyl > O-alkyl
O
X
CO2H
R1
NHO O
X
CO2H
R1
NHO
O OH
O
X
CO2H
R1
N
N N
NH
> >>
O CO2H
O
NHO
F F
OCH3
hGPR35 EC50 = 0.00108 ± 0.00011 µM
hGPR35 Ki =  0.000426 ± 0.000037 µM
rGPR35  EC50 = 0.157 ± 0.013 µM
mGPR35 EC50 = 0.293 ± 0.042 µM
hGPR84 IC50 = 6.37 ± 0.98 µM
hGPR17 IC50 > 10 µM
hGPR55 IC50 > 10 µM; EC50 > 10 µM
hGPR18 IC50 > 10 µM; EC50 > 10 µM
210
Figure 4.2: Structure-activity relationships for chromenones at the human GPR35. Themost potent compound 210 was further evaluated at various related targets.
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The GPR35 agonist 210 showed high orthologue selectivity for the human receptorand only moderate potency at the rodent orthologues. However, for preclinical invivo studies potent ligands at rodent receptors are required. Therefore we optimizedthe chromen-4-one derivatives with regard to their potency at the mouse and therat GPR35.Structure-activity relationships are summarized in Figure 4.3. In contrast to thehuman GPR35 (hGPR35) the introduction of a second carboxylic acid function atposition 8 increased potency at the rodent receptors. At the 6-position large sub-stituents like a bromine atom or a phenyl ring were well tolerated, but in contrastto the human receptor a butyl substituent was preferred. The introduction of athiourea linker instead of an amide linker further increased potency. We observeddifferences not only between the hGPR35 and the rodent orthologues but also be-tween the mouse GPR35 (mGPR35) and the rat GPR35 (rGPR35). Whereas the ringclosure between position 7 and 8 was well tolerated by the mGPR35 it resulted indecreased potency at the rGPR35.
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rGPR35, mGPR35: S > O
substituent at the 6-position (R1):
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mGPR35: butyl > phenyl > ethyl > Cl ~ Br > methyl > methoxy ~ F > H
linker rGPR35, mGPR35: 
thiurea > amide ~ urea >> N-Me-amide
rGPR35: a ring closure 
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mGPR35: a ring closure 
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rGPR35, mGPR35: F > H
rGPR35, mGPR35: F > OCH3 > H
rat GPR35: SCH3 > ethyl > OCH3
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O
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O CO2H
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NHO
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rGPR35 EC50 = 0.0209 ± 0.0023 µM
mGPR35 EC50 = 0.174 ± 0.019 µM
hGPR35 EC50 = 0.00847 ± 0.00072 µM
hGPR35 Ki = 0.00271 ± 0.00032 µM
hGPR84 IC50 > 3 µM
hGPR17 IC50 > 10 µM
hGPR55 IC50 > 10 µM, EC50 > 10 µM
O CO2H
O
NHO
O OH
rGPR35 EC50 = 0.0297 ± 0.0040 µM
mGPR35 EC50 = 0.399 ± 0.083 µM
hGPR35 EC50 = 0.0318 ± 0.0053 µM
hGPR35 Ki = 0.00897 ± 0.0015 µM
hGPR84 IC50 > 3 µM
hGPR17 IC50 > 10 µM
hGPR55 IC50 > 10 µM, 
               EC50 > 10 µM
N
H
HN
O
H3C
O
CO2H
HO2C
rGPR35 EC50 = 0.0263 ± 0.0023 µM
mGPR35 EC50 = 0.105 ± 0.015 µM
hGPR35 EC50 = 0.0214 ± 0.0021 µM
hGPR35 Ki = 0.0062 ± 0.00065 µM
hGPR84 IC50 > 3 µM
hGPR17 IC50 > 10 µM
hGPR55 IC50 > 10 µM, EC50 > 10 µM
277
197
196
Figure 4.3: Structure-activity relationships of chromenones as agonists at the rodentGPR35. The most potent compounds 196, 197, and 277 were further evaluated at variousrelated targets.
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Comparable to the hGPR35, the replacement of the oxygen atom at position 4 bya sulfur atom increased the potency at both rodent orthologues. The most potentchromen-4-one-based agonists at mouse and rat GPR35 were 196 (rGPR35: EC50 =0.0297 ± 0.0040 µM; mGPR35 EC50 = 0.399 ± 0.083 µM) and 197 (rGPR35: EC50= 0.0209 ± 0.0023 µM; mGPR35 EC50 = 0.174 ± 0.019 µM). To further increasethe potency at the mGPR35 we synthesized a derivative of bufrolin (for structuresee chapter 1), which was recently identified as a GPR35 agonist. Compound 277showed high potency at all tested GPR35 orthologues (rGPR35: EC50 = 0.0263 ±0.0023 µM; mGPR35 EC50 = 0.105 ± 0.015 µM; hGPR35 EC50 = 0.0214 ± 0.0021µM).For further optimization an introduction of various alkyl side-chains and bromo-alkyl side-chains at the 6-position would be interesting. Furthermore additionalbufrolin derivatives should be synthesized to develop further GPR35 agonists thatare equally potent at the human and the rodent GPR35.Besides full agonists we also identified potential biased agonists which do notactivate or block the β-arrestin pathway but which showed high affinities in thelow nanomolar range at the human GPR35 (255, EC50 > 10 µM; Ki = 0.012 ± 0.005µM). These compounds should be further investigated regarding their functionalactivity.
4.1.3 GPR84A further receptor that was investigated in this study was the orphan receptorGPR84. It is known to be expressed in immune cells. Therefore GPR84 antago-nist are potential drugs for the treatment of inflammatory diseases. The structure-activity relationships are summarized in Figure 4.4. The potencies of chromen-4-one-2-carboxylic acids at GPR84 were determined by cAMP accumulation assaysin CHO cells recombinantly expressing the human GPR84. The most potent com-pounds were further evaluated in β-arrestin recruitment assays and radioligandbinding experiments.As GPR84 is known to be activated by medium-chain free fatty acids we synthesizeda broad range of chromen-4-one derivatives that contained a long lipophilic side-chain at the 8-position. The introduction of additional halogen atoms, preferablyfluorine atoms, was well tolerated at the second phenyl ring but not at the first
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phenyl ring. The most remarkable increase in potency could be achieved by themodification of the 6-position. The introduction of a larger, para-substituted phenylring strongly increased the inhibitory potency of the GPR84 antagonists. A chlorineatom at the para-position of the phenyl ring was preferred. The modification of thelinker as well as the replacement of the oxygen atom at the 4-position by a sulfuratom had no effect on potency.The most potent compound of our series was 218 (IC50 = 0.00734 ± 0.000168 µM),which is the most potent GPR84 antagonist known to date and displays highselectivity versus GPR17, GPR35 and GPR55 and the free fatty acid receptorsFFAR1 and FFAR2.To improve the potency of GPR84 antagonists a further enlargement of the sub-stituent at the 6-position would be interesting. However this would also result inhigher lipophilicity.
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X
CO2H
R1
Cl H3C F H3CO
HO
Br Cl H F
methyl methoxy
ethyl
> > > ~␣ ~␣ ~␣
> > ~␣ ~␣ > >
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X: O > S
O
R2
H F Cl> ~␣
R2 Halogen substitution in meta 
position is not tolerated R3
F H> >
R3 fluorine is the best substitutent
Br > Cl > methyl
F ~␣ H
R4 fluorine instead of 
hydrogen is well tolerated
R4
linker urea can be better than amide
depending on the other residues
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hGPR84 IC50 = 0.00734 ± 0.00168 µM 
(cAMP assay)
hGPR84 IC50 = 0.00302 ± 0.00095 µM 
(ß-arrestin assay)
hGPR84 IC50 = 0.047 ± 0.016 µM 
(radioligand binding)
hGPR35 EC50 > 10 µM
hGPR35 Ki > 10 µM 
rGPR35 EC50 > 10 µM
mGPR35 EC50 = 2.77 ± 0.26 µM
hGPR17 IC50 > 10 µM
hGPR55 EC50 > 10 µM, IC50 > 10 µM
hGPR18 EC50 > 10 µM, IC50 > 10 µM
FFAR1 EC50 > 10 µM, IC50 > 10 µM
FFAR2 EC50 > 10 µM, IC50 > 10 µM
Cl
O
F
218
Figure 4.4: Structure-activity relationships for chromenones at the human GPR84. Themost potent GPR84 antagonists 218 was evaluated in more detail.
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4.1.4 GPR17The orphan receptor GPR17 is discussed as a novel drug target for multiple sclero-sis as there are indications that GPR17 antagonists could promote the myelination. We optimized chromen-4-one derivatives regarding their inhibitory potency atGPR17. Calcium ion mobilization assays in 1321N1 astrocytoma cells that recombi-nantly expressed the human GPR17 were performed in our group. The most potentcompounds were further evaluated in radioligand-binding experiments. Structure-activity relationships are summarized in Figure 4.5.To increase the inhibitory potency of the compounds at GPR17 the introductionof long alkyl side-chains in the para-position of the phenylamide at position 8was beneficial. The optimal chain-length was 4 C-atoms that were connected toa cyclohexyl ring. At the 6-position halogen atoms were not tolerated. A methoxygroup mostly increased the potency at GPR17. The replacement of the linker atthe 8-position as well as the replacement of the oxygen atom at the 4-position bya sulfur atom only showed minor effects on the potency.The most potent compound of the series was 255, which has an IC50 value of 0.445± 0.108 µM. It is highly selective versus GPR55 and GPR84 but it shows also ahigh affinity for GPR35.
O
X
CO2H
R1
O
long lipophilic residues are essential for high inhibitory potency (R2):
substitution pattern (R2): para > meta >> ortho
chain length: C4 > C3 > C5 > C2
cyclohexyl > n-alkyl > phenyl
substituent at the 4-position (X): 
O > S
substituent at 6-position (R1):
methoxy > H > ethyl > methyl > F ~ Cl ~ Br
linker: amide > thiourea
(depends on the further substitution)
R2
hGPR17 IC50 = 0.445 ± 0.108 µM
hGPR17 Ki > 10 µM 
hGPR35 EC50 > 10 µM
hGPR35 Ki = 0.012 ± 0.005 µM
rGPR35 EC50 > 10 µM
mGPR35 EC50 = 2.78 ± 0.27 µM
hGPR84 IC50 > 3 µM
hGPR55 EC50 > 10 µM, IC50 > 10 µM
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O
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Figure 4.5: Structure-activity relationships for chromenones at the human GPR17. Themost potent GPR17 antagonists 255 was evaluated in more detail.
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4.1.5 GPR55GPR55 is the phylogenetically closest relative of GPR35 and it interacts with cer-tain cannabinoids. It is widely expressed in bone, intestine and brain. GPR55activation was shown to be pro-carcinogenic. GPR55 antagonists my be developedas anticancer drugs. We synthesized a broad range of potent ligands for GPR55,including agonists and partial agonists with potencies in the nanomolar range andantagonists with low micromolar potencies. Structure-activity relationships are dis-played in Figure 4.6. Pharmacological evaluation was performed by the β-arrestinrecruitment assay in our group.The modification of the 6-position, the linker, or of position 4 did not result in anincrease in potency, in contrast to modifications that were performed at the side-chain in position 8. Long and lipophilic residues were essential for high potency atGPR55. Shifting the side-chain from the meta-position to the para-position resultedin a switch from agonistic to antagonistic activity.
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hGPR55 EC50 = 0.111 ± 0.042 µM
                           efficacy = 29%
hGPR35 EC50 > 10 µM
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hGPR17 IC50 = 4.28 ± 0.049 µM
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WA09
244237
hGPR55 EC50 = 0.196 ± 0.041 µM
                           efficacy = 86%
hGPR35 EC50 > 10 µM
hGPR35 Ki = 2.67 ± 0.590 µM
rGPR35 EC50 > 10 µM
mGPR35 EC50 > 10 µM
hGPR84 IC50 = > 3 µM
hGPR17 IC50 = 1.58 ± 0.49 µM
hGPR18 EC50 > 10 µM, IC50 > 10 µM
CB1, CB2 Ki > 10 µM
hGPR55 IC50 = 1.87 ± 0.56 µM
hGPR18 EC50 > 10 µM, IC50 > 10 µM
Figure 4.6: Structure-activity relationships for chromenones at the human GPR55. Themost potent GPR55 agonists 237 and 244 were evaluated in more detail.
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The same switch could be observed when the cyclohexyl ring at the end of the side-chain was replaced by a phenyl ring. The prolongation of the side-chain resultedin an increase in efficacy, but in a slight decrease of potency.6-Chloro-8-(3-((5-cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylicacid, 244 (EC50 ± SEM = 196 ± 41.0 nM, Emax = 86%), is one of the most potentagonists for human GPR55 based on the chromen-4-one scaffold and it is highlyselective versus the closely related GPR35 as well as versus GPR17, GPR84 andthe cannabinoid receptors CB1 and CB2.In conclusion we successfully developed potent and selective agonists and antag-onists respectively, for the orphan receptors GPR17, GPR35, GPR55 and GPR84.Some of the compounds represent the most potent ligands for their receptors knownto date. The new chromen-4-one derivatives are important tools for further inves-tigation of the receptors in vitro and in vivo, and can be used as lead compoundsfor the development of new drugs. The chromen-4-one was confirmed to be a priv-ileged structure for the development of ligands for class A δ-branch GPCRs. Inthe future our comprehensive and structurally diverse library of chromenones canbe pharmacologically evaluated at further receptors of this class of GPCRs andsubsequently be individually optimized.
4.2 Biological evaluation of potent and selectiveecto-5’-nucleotidase inhibitorsEctonucleotidases hydrolyze extracellular nucleotides and are thereby involvedin purinergic signalling. Ecto-5’-nucleotidase (eNT/CD73) mediates hydrolysisof adenosine-5’-monophosphate (AMP) to adenosine and subsequently activatesadenosine receptors. Is is therefore involved in several physiological and patho-logical processes such as immunity, inflammation, neurotransmission and tumori-genesis. The inhibitory potencies of new small molecule inhibitors, which weredeveloped in our group, where measured by using a thin layer chromatographic(TLC) assay with [3H]AMP as a substrate, and compared with the standard CD73inhibitor α ,β-methylene-ADP (AOPCP).
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Table 4.1: Ki values of inhibitors at recombinant human eN and at soluble eN in hu-man serum and IC50 values of inhibitors at MDA-MB231 and HUVECs determined byradiometric TLC assay. For structures see Figure 3.39
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N
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N
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O
OH
P
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HO
283
Cl
compound recombinanthuman eNd human serumeN MDA-MB-231 HUVECKi ± SEMa Ki ± SEMa IC50 ± SEMb IC50 ± SEMcAOPCP 88.4 ± 3.96 487 ± 186 5724 ± 1000 1864 ± 467284 2.21 ± 0.40 18.8 ± 12.5 - -285 4.58 ± 0.23 68.8 ± 23.2 - -286 2.53 ± 0.735 8.61 ± 2.79 - -287 0.757 ± 0.061 13.9 ± 5.74 - -288 1.89 ± 0.061 11.0 ± 1.04 - -283 0.318 ± 0.02 2.51 ± 1.07 103.5 ± 16.9 73.5 ± 11.6a [3H]AMP (40 µM) was used as substrate (Km value 40 µM and 65 µM respectivelyfor recombinant human eN and eN in human serum223)b[3H]AMP (400 µM) was used as substratec [3H]AMP (200 µM) was used as substrated recombinant human CD73 was purified from transfected CHO cells224
The ability of the most potent CD73 inhibitor, 283, to block AMP hydrolysis indifferent cells and tissues was further confirmed in TLC assays with cultured hu-man MDA-MB-231 breast cancer cell lines and human umbilical vein endothelialcells (HUVEC), as well as in lead nitrate-based histochemical analysis of ecto-5’-nucleotidase distribution in human tonsil and mouse spleen sections. The studiesshowed the superiority of our new inhibitors compared to AOPCP in all biologicaltest systems and represent a basis for future in vivo studies.
171
Anne Meyer 5 Experimental part
5 Experimental part
5.1 General remarksAll commercially available reagents were used as purchased (Acros, Alfa Aesar,Sigma-Aldrich, or Fluorochem). Solvents were employed without additional purifica-tion or drying except for dichloromethane, which was distilled over calcium hydride.The reactions were monitored by thin-layer chromatography (TLC) using aluminumsheets with silica gel 60 F254 (Merck). Column chromatography was performedwith silica gel, 0.060-0.200 mm, pore diameter ca. 6 nm. All synthesized compoundswere finally dried in vacuum at 8-12 Pa (0.08-0.12 mbar) using a sliding vane rotaryvacuum pump (Vacuubrand GmbH). 1H and 13C NMR data were collected either ona Bruker Avance 500 MHz NMR spectrometer at 500 MHz (1H) or 126 MHz (13C) oron a Bruker Ascend 600 MHz NMR spectrometer at 600 MHz (1H) or 151 MHz (13C).DMSO-d6 was employed as a solvent at 303 K, unless otherwise noted. Chemicalshifts are reported in parts per million relative to the deuterated solvent, that is,dimethylsulfoxide (DMSO), δ (1H) 2.49 ppm, δ (13C) 39.7 ppm. Coupling constantsJ are given in Hertz, and spin multiplicities are given as s (singlet), d (doublet), t(triplet), q (quartet), m (multiplet). melting points (mps) were determined on a Büchi530 melting point apparatus and are uncorrected. The purities of isolated prod-ucts were determined by electrospray ionization (ESI)-mass spectra obtained onan liquid chromatography-mass spectrometry (LC-MS) instrument (Applied Biosys-tems API 2000 LC-MS/MS, high-performance liquid chromatography (HPLC) Agilent1100) using the following procedure: the compounds that contained a chromen-4-one ring system were dissolved at a concentration of 0.5 mg/mL in acetonitrile/watercontaining 2 mM ammonium acetate. Then 10 µL of the sample was injected intoan HPLC column (Macherey-Nagel Nucleodur 3 µm C18, 50 x 2.00 mm). Elutionwas performed with a gradient of water/acetonitrile (containing 2 mM ammoniumacetate) from 90:10 to 0:100 for 20 min at a flow rate of 300 µL/min, starting the
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gradient after 10 min. ultraviolet (UV) absorption was detected from 200 to 950 nmusing a diode array detector. For all other compounds the same method was used,but acetonitrile was replaced by methanol. Purity of all compounds was determinedat 254 nm.
5.2 Synthesis and characterization
5.2.1 4-Bromo-2-cyanophenyl acetate5.2.1.1 4-Bromo-2-cyanophenyl acetate 269 (ANM380)226
Br
CN
O CH3
O 5-Bromo-2-hydroxybenzonitrile (9.1 g, 46 mmol) was stirred withacetic anhydride (20 mL) and three drops of concd. H2SO4 wereadded. After 1 hour the reaction mixture was poured on ice andthe obtained solid was filtered, washed with water, and dried in vacuum at rt. Theproduct was isolated as white crystals (9.3 g, 84% yield). 1H NMR: δ 2.36 (s, 3H,CH3), 7.42 (d, J = 8.8 Hz, 1H, 6-H), 7.98 (ddd, J = 8.8, 2.4, 0.6 Hz, 1H, 5-H), 8.24 (d, J= 2.4 Hz, 1H, 3-H). 13C NMR: δ 20.6 (OCOCH3), 108.4 (C-2), 114.0 (CN), 118.7 (C-4),125.7 (C-6), 135.8 (C-3), 138.0 (C-5), 151.5 (C-1), 168.3 (C=O). LC-MS (m/z): positivemode 198 [M-COCH3]-. Purity by HPLC-UV (254 nm)-ESI-MS: 90.0%. lit. mp 60-61◦C.
5.2.2 3-Acetyl-5-bromo-2-hydroxybenzonitrile5.2.2.1 3-Acetyl-5-bromo-2-hydroxybenzonitrile 265 (ANM381)226
Br
CN
OH
CH3
O Compound 269 (9.12 g, 38 mmol) and AlCl3 (16 g, 120 mmol) wereheated to 160 ◦C under stirring. After 3 hours the reaction mixturewas cooled down to rt and poured on 200 g of ice containing 20 mLof concd. HCl. The slurry was extracted three times with 50 mL of EtOAc, acidifiedwith 1 N HCl, washed with brine and dried over MgSO4. After removing the solventunder reduced pressure the crude product was recrystallized in DCM. The productwas isolated as a pale brown solid (2.48 g, 27% yield). 1H NMR: δ 2.69 (s, 3H,COCH3), 8.22 (d, J = 2.5 Hz, 1H, 4-H), 8.35 (d, J = 2.5 Hz, 1H, 6-H), 12.74 (s, 1H,OH). 13C NMR: δ 27.5 (COCH3), 103.4 (C-1), 110.1 (CN), 114.2 (C-6), 122.2 (C-3),138.9 (C-4), 141.5 (C-6), 161.6 (C-2), 204.3 (C=O). LC-MS (m/z): positive mode 239
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[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 92.8%. lit. mp 151-152 ◦C.
5.2.3 1-(5-((Tert-butyldimethylsilyl)oxy)-2-hydroxyphenyl)etha-none5.2.3.1 1-(5-((Tert-butyldimethylsilyl)oxy)-2-hydroxyphenyl)ethanone 289(ANM208)227
OH
O
SitBu CH3
O Dihydroxyacetophenon (5.00 g, 33 mmol), TBDMSCl (5.90 g, 39mmol), and imidazole (1.97 g, 29 mmol) were dissolved in 80mL of dry DMF under an argon atmosphere and stirred for 12h at rt. After addition of 60 mL of H2O the product was extracted with 3x15 mLEtOAc, dried over MgSO4 and the solvent was removed under reduced pressure.The product was purified on a column of silica gel (10% EtOAc in cyclohexane) andwas isolated as a yellow oil (4.21 g, 48% yield). 1H NMR: δ 0.17 (s, 6H, Si(CH3)2),0.94 (s, 9H, SiC(CH3)3), 2.59 (s, 3H, COCH3), 6.85 (d, 1H, J = 8.9 Hz, 5-H), 7.05(dd, 1H, J = 3.0, 8.9 Hz, 6-H), 7.21 (d, 1H, J = 3.0 Hz, 3-H), 11.40 (s, 1H, OH). 13CNMR: δ 4.5 (Si(CH3)2), 18.0 (SiC), 25.7 (SiC(CH3)3), 28.1 (COCH3), 118.6 (C-6), 120.5(C-3), 120.7 (C-6), 128.5 (C-5), 147.0 (C-4), 155.3 (C-1), 203.6 (COCH3). LC-MS (m/z):positive mode 267 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 93.0%.
5.2.4 1-(2-Hydroxy-3-nitrophenyl)ethanones5.2.4.1 General procedure for the synthesis of 1-(2-hydroxy-3-nitrophenyl)etha-nones (GP-1)
The appropriate 2-hydroxyacetophenone (10 mmol) was dissolved in 6.74 mL ofglacial acetic acid. Then a mixture of fumic nitric acid (0.46 mL, 11.1 mmol) andglacial acetic acid (0.85 mL, 13.5 mmol) was added dropwise and the reaction mixturewas stirred for 120 min at rt. The product was precipitated by pouring it on ice andthe solid was subsequently filtered off, washed with water (30 mL), and dried invacuum at 50 ◦C.
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5.2.4.2 1-(2-Hydroxy-5-methoxy-3-nitrophenyl)ethanone 1 (ANM29)175
OH
CH3
OCH3
O2N
O The compound was synthesized according to GP-1 using 2-hydroxy-5-methoxyacetophenone (1.66 g, 10 mmol). The product was iso-lated as an orange solid (1.31 g, 62%). 1H NMR: δ 2.70 (s, 3H,COCH3), 3.84 (s, 3H, O-CH3), 7.74 (d, J = 3.2 Hz, 1H, 3-H), 7.79 (d, J= 3.2 Hz, 1H, 5-H), 12.20 (s, 1H, OH). 13C NMR: δ 28.5 (COCH3), 56.6 (O-CH3), 115.8(C-5), 122.5 (C-3), 124.1 (C-2), 138.3 (C-6), 147.3 (C-1), 150.5 (C-4), 204 (COCH3).LC-MS (m/z): positive mode 209 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100%. lit. mp 112-114 ◦C.
5.2.4.3 1-(2-Hydroxy-3-nitro-5-(trifluoromethoxy)phenyl)ethanone 2 (ANM50)
OH
CH3
OCF3
O2N
O The compound was synthesized according to GP-1 using 2-hydro-xy-5-(trifluoromethoxy)acetophenone (1.76 g, 8 mmol). The productwas isolated as a yellow solid (881 mg, 42%). 1H NMR: δ 2.63 (s,3H, COCH3), 7.89-7.93 (m, 1H, 3-H), 8.05 (s, 1H, 5-H). 13C NMR: δ40.1 (COCH3), 117.3 (C-2), 119.4 (OCF3), 123.9 (C-5), 128.1 (C-6), 129.0 (C-3), 134.1(C-1), 158.3 (C-4), 201.0 (COCH3). LC-MS (m/z): positive mode 264 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 87-88 ◦C.
5.2.4.4 1-(5-Ethyl-2-hydroxy-3-nitrophenyl)ethanone 3 (ANM83)176
OH
CH3
O2N
O
CH3
The compound was synthesized according to GP-1 using 5-ethyl-2-hydroxyacetophenone (3.3 g, 20 mmol). The product was isolatedas a yellow solid (3.83 g, 92%). 1H NMR: δ 1.20 (t, J = 7.6, 3H,CH2CH3), 2.64-2.68 (m, 2H, CH2CH3), 2.71 (s, 3H, COCH3), 8.04-8.09(m, 1H, 3-H), 8.09-8.11 (m, 1H, 5-H), 12.77 (s, 1H, OH). 13C NMR: δ 15.4 (CH2CH3),26.8 (CH2CH3), 28.2 (COCH3), 122.9 (C-2), 130.1 (C-5), 134.7 (C-4), 136.2 (C-3), 138.1(C-6), 152.4 (C-1), 204.9 (COCH3). LC-MS (m/z): positive mode 208 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 92.7%. lit. mp 125-126 ◦C.
5.2.4.5 1-(5-Fluoro-2-hydroxy-3-nitrophenyl)ethanone 4 (THB30)176
OH
CH3
F
O2N
O The compound was synthesized according to GP-1 using 5-fluoro-2-hydroxyacetophenone (2.1 g, 13.4 mmol). The product was isolatedas a white solid (1.34 g, 50%). 1H NMR: δ 2.69 (s, 3H, COCH3), 8.16
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(dd, J = 3.2, 8.6 Hz, 1H, 2-H), 8.21 (dd, J = 3.2, 8.0 Hz, 1H, 6-H). 13C NMR: δ 28.5(COCH3), 118.1-118.3 (C-2), 123.1-123.3 (C-6), 124.1-124.2 (C-5), 150.5-151.7 (C-1),153.6 (C-3, C-4), 203.5 (COCH3). LC-MS (m/z): negative mode 198 [M-H]-. Purity byHPLC-UV (254 nm)-ESI-MS: 99.4%. lit. mp 93-94 ◦C.
5.2.4.6 1-(3-Bromo-6-hydroxy-2-methyl-5-nitrophenyl)ethanone 5 (ANM85)
OH
CH3
Br
O2N
O
CH3
The compound was synthesized according to GP-1 using 1-(3-bromo-6-hydroxy-2-methylphenyl)ethanone (2.18 g, 9.5 mmol). Theproduct was isolated as a pale yellow solid (2.5 g, 95%). 1H NMR:δ 2.40 (d, J = 0.7 Hz, 3H, CH3), 2.57 (s, 3H, COCH3), 8.15 (d, J = 0.7 Hz, 1H, 3-H).13C NMR: δ 21.6 (CH3), 27.6 (COCH3), 121.1 (C-4), 121.3 (C-2), 129.5 (C-6), 133.8(C-3), 150.1 (C-1), 204.3 (COCH3). LC-MS (m/z): negative mode 271 [M-H]-. Purityby HPLC-UV (254 nm)-ESI-MS: 80.0%. mp 163-164 ◦C.
5.2.4.7 1-(3-Bromo-6-hydroxy-2-methyl-5-nitrophenyl)ethanone 6 (ANM207)177
OH
CH3
CH3
O2N
O
H3C
The compound was synthesized according to GP-X using 1-(2-hydroxy-4,5-dimethylphenyl)ethanone (1.97 g, 12 mmol). The prod-uct was isolated as a yellow solid (2.12 g, 84%). 1H NMR: δ 2.17 (s,3H, C5-CH3), 2.28 (s, 3H, C4-CH3), 2.66 (s, 3H, COCH3), 7.95 (d, J =0.9 Hz, 1H, 3-H), 12.42 (s, 1H, OH). 13C NMR: δ 14.7 (C4-CH3), 18.7 (C5-CH3), 27.2(COCH3), 118.7 (C-2), 128.3 (C-4), 133.2 (C-3), 136.4 (C-5), 141.4 (C-6), 150.1 (C-1),204.8 (COCH3). LC-MS (m/z): positive mode 210 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 87.0%. lit. mp 143-144 ◦C.
5.2.4.8 1-(5-((Tert-butyldimethylsilyl)oxy)-2-hydroxy-3-nitrophenyl)ethanone 7(ANM213)
OH
O
SitBu CH3
O
NO2
The compound was synthesized according to GP-1 using com-pound 289 (8.8 g, 33 mmol). The product was isolated as abrown solid (6.3 g, 62%). 1H NMR: δ 0.22 (s, 6H, Si(CH3)2), 0.96(s, 9H, SiC(CH3)3), 2.68 (s, 3H, COCH3), 7.61 (d, J = 3.1 Hz, 1H,3-H), 7.66 (d, J = 3.0 Hz, 1H, 5-H), 12.26 (s, 1H, OH). 13C NMR: δ 4.7 (Si(CH3)2),18.0 (Si-C), 25.6 (SiC(CH3)3), 28.5 (COCH3), 121.7 (C-5), 124.2 (C-2), 127.6 (C-3),138.3 (C-4), 146.3 (C-6), 148.5 (C-1), 203.7 (COCH3). LC-MS (m/z): positive mode312 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 74.0%. mp 87-89 ◦C.
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5.2.5 8-Nitro-4-oxo-4H-chromene-3-carbaldehyde5.2.5.1 8-Nitro-4-oxo-4H-chromene-3-carbaldehyde 40 (ANM185)228
NO2
O
O
CHO
1-(2-Hydroxy-3-nitrophenyl)ethanone (1.36 g, 7.5 mmol) was dis-solved in 6 mL of DMF cooled down to 0-5 ◦C. Then POCl3 (2.80mL, 30 mmol) was added dropwise and the reaction mixture stirredat rt overnight. After the reaction mixture was poured on water theobtained solid was filtered, washed with 2x10 mL of water and dried in vaccum at50 ◦C The product was isolated as a white solid (1.12 g, 68%). 1H NMR: δ 7.74 (t, J= 8.0 Hz, 1H, 6-H), 8.45 (dd, J = 1.7, 8.0 Hz, 1H, 5-H), 8.54 (dd, J = 1.7, 8.0 Hz, 1H,7-H), 10.09 (s, 1H, CHO). 13C NMR: δ 120.8 (C-3), 126.3 (C-6), 126.6 (C-4a), 130.8(C-7), 131.1 (C-5), 139.1 (C-8), 147.8 (C-8a), 163.4 (C-2), 173.5 (C-4), 187.9 (CHO).LC-MS (m/z): positive mode 220 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:not detectable. lit. mp 133-134 ◦C.
5.2.6 Ethyl 4-oxo-4H-chromene-2-carboxylates5.2.6.1 General procedure for the synthesis of the ethyl 4-oxo-4H-chromene-2-carboxylates (GP-2)
The appropriate 5’-substituted 1-(2-hydroxyphenyl)ethanone (4.0 mmol) and diethyloxalate (1.3 mL, 9.8 mmol) were dissolved in 27 mL of anhydrous DMF under anargon atmosphere and were cooled to 0-5 ◦C. Potassium tert-butoxide (1.79 g, 15.6mmol) was added, and the reaction mixture was stirred under an argon atmospherefor 2-3 h at 0-5 ◦C. Then a cooled solution of concd. (12 M) aq HCl solution (2.6mL, 31.2 mmol) in 27 mL of water was added, and the mixture was extracted withEtOAc (3 x 20 mL). The combined organic layers were dried over anhydrous MgSO4and concentrated under reduced pressure. The residue was dissolved in 20 mL ofEtOH, and concd. (12 M) aq HCl (1.3 mL, 15.6 mmol) was subsequently added. Thereaction mixture was refluxed overnight under an argon atmosphere. The mixturewas concentrated under reduced pressure until the product started to crystallize andwas subsequently cooled to 0-5 ◦C for completion of crystallization. The productwas filtered off, washed with ice-cold EtOH in small portions, and dried in vacuumat 50 ◦C.
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5.2.6.2 Ethyl 6-bromo-8-nitro-4-oxo-4H-chromene-2-carboxylate 8 (ANM1)179
NO2
O
O
CO2Et
Br
The compound was synthesized according to GP-2 using 1-(5-bromo-2-hydroxy-3-nitrophenyl)-ethanone (3.12 g, 12 mmol).The product was isolated as a pale-white solid (3.8 g, 93%). 1HNMR: δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 4.40 (q, J = 7.1 Hz,2H, CH2CH3), 7.00 (s, 1H, 3-H), 8.42 (d, J = 2.5 Hz, 1H, 5-H), 8.77 (d, J = 2.5 Hz,1H, 7-H). 13C NMR: δ 13.9 (CH2CH3), 63.1 (CH2CH3), 114.62 (C-3), 117.3 (C-6), 126.8(C-4a), 132.58 (C-7), 133.1 (C-5), 140.0 (C-8), 146.7 (C-8a), 152.4 (C-2), 159.3 (CO2Et),175.0 (C-4). LC-MS (m/z): positive mode 358 [M+NH4]+. Purity by HPLC-UV (254nm)-ESI-MS: 95.3%. lit. mp 141-142 ◦C.
5.2.6.3 Ethyl 8-nitro-4-oxo-4H-chromene-2-carboxylate 10 (ANM44)32
NO2
O
O
CO2Et
The compound was synthesized acording to GP-2 using 1-(2-hy-droxy-3-nitrophenyl)ethanone (2.17 g, 12 mmol). The product wasisolated as a white solid (2.8 g, 89%). 1H NMR: δ 1.34 (t, J = 7.1, 3H,CH2CH3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 7.07 (s, 1H, 3-H), 7.70(t, J = 8.0 Hz, 1H, 6-H), 8.36 (dd, J = 1.7, 8.0 Hz, 1H, 5-H), 8.54 (dd, J = 1.7, 7.9 Hz,1H, 7-H). 13C NMR: δ 13.9 (CH2CH3), 63.0 (CH2CH3), 114.6 (C-3), 125.5 (C-8), 125.8(C-6), 130.8 (C-7), 131.0 (C-5), 139.2 (C-8a), 147.6 (C-4a), 152.3 (C-2), 159.5 (CO2Et),176.10 (C-4). LC-MS (m/z): positive mode 264 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 99.0%. lit. mp 122-123 ◦C.
5.2.6.4 Ethyl 8-nitro-4-oxo-6-(trifluoromethoxy)-4H-chromene-2-carboxylate 9(ANM52)
NO2
O
O
CO2Et
F3CO
The compound was synthesized according to GP-2 using 2 (795mg, 3 mmol). The product was isolated as a white solid (550mg, 53%). 1H NMR: δ 1.34 (t, J = 7.1, 3H, CH2CH3), 4.40 (q, J= 7.1 Hz, 2H, CH2CH3), 7.12 (s, 1H, 3-H), 8.23 (d, J = 3.1 Hz,1H, 5-H), 8.70 (d, J = 3.0 Hz, 1H, 7-H). 13C NMR: δ 13.0 (CH2CH3), 34.4 (O-CF3),63.2 (CH2CH3), 114.3 (C-3), 122.1 (C-7), 124.6 (C-5), 126.7 (C-4a), 140.2 (C-8), 143.9(C-8a), 146.3 (C-2), 152.6 (C-6), 159.3 (CO2Et), 175.4 (C-4). LC-MS (m/z): positivemode 365 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 91.3%. mp 120-121 ◦C.
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5.2.6.5 Ethyl 6-ethyl-8-nitro-4-oxo-4H-chromene-2-carboxylate 11 (ANM84)
NO2
O
O
CO2Et
H3C
The compound was synthesized according to GP-2 using 3(2.51 g, 12 mmol). The product was isolated as a white solid(2.27 g, 65%). 1H NMR: δ 1.24 (t, 3H, J = 7.6 Hz, C6-CH2CH3),1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 2.83 (q, 2H, J = 7.6 Hz, C6-CH2CH3), 4.39 (q, J = 7.1, 2H, CH2CH3), 7.04 (s, 1H, 3-H), 8.18 (dd, J = 0.8, 2.3Hz, 1H, 5-H), 8.43 (dd, J = 0.6, 2.3 Hz, 1H, 7-H). 13C NMR: δ 13.9 (CH2CH3), 15.1(C6-CH2CH3), 27.2 (C6-CH2CH3), 63.0 (CH2CH3), 114.4 (C-3), 125.3 (C-8), 128.9 (C-7), 130.5 (C-5), 139.0 (C-8a), 142.1 (C-6), 145.9 (C-4a), 152.2 (C-2), 159.5 (CO2Et),176.1 (C-4). LC-MS (m/z): positive mode 292 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 90.1%. mp 116-117 ◦C.
5.2.6.6 Ethyl 6-methoxy-8-nitro-4-oxo-4H-chromene-2-carboxylate 15(ANM36)65
NO2
O
O
CO2Et
H3CO
The compound was synthesized according to GP-2 using 1 (844mg, 4 mmol). The product was isolated as a white solid (917mg, 78%). 1H NMR: δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 3.95(s, 3H, O-CH3), 4.39 (q, J = 7.1 Hz, 2H, CH2CH3), 7.02 (s, 1H,3-H), 7.72 (d, J = 3.2 Hz, 1H, 5-H), 8.16 (d, J = 3.2 Hz, 1H, 7-H). 13C NMR: δ 14.0(CH2CH3), 56.8 (O-CH3), 63.0 (CH2CH3), 111.5 (C-7), 114.5 (C-3), 119.2 (C-5), 126.3(C4a), 140.0 (C-8), 141.9 (C-8a), 152.2 (C-2), 155.8 (C-6), 159.5 (CO2Et), 175.7 (C-4).LC-MS (m/z): positive mode 294 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:98.4%. lit. mp 175-176 ◦C.
5.2.6.7 Ethyl-6-methyl-8-nitro-4-oxo-4H-chromene-2-carboxylate 14(ANM31)183
NO2
O
O
CO2Et
H3C
The compound was synthesized according to GP-2 using 2-hydroxy-5-methyl-3-nitroacetophenone (781 mg, 4 mmol). Theproduct was isolated as a white solid (763 mg, 69%). 1H NMR:δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 2.50 (s, 3H, C6-CH3), 4.39(q, J = 7.1 Hz, 2H, CH2CH3), 7.03 (s, 1H, 3-H), 8.16 (dd, J = 0.9, 2.2 Hz, 1H, 5-H),8.40 (dd, J = 0.6, 2.2 Hz, 1H, 7-H). 13C NMR: δ 14.0 (CH2CH3), 20.2 (C6-CH3) 63.0(CH2CH3), 114.4 (C-3), 125.2 (C-8), 130.2 (C-7), 131.5 (C-5), 136.2 (C-6), 138.8 (C-8),145.8 (C-4a), 152.2 (C-2), 159.5 (CO2Et), 176.0 (C-4). LC-MS (m/z): positive mode
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278 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 95.4%. lit. mp 148-151 ◦C.
5.2.6.8 Ethyl 6-fluoro-8-nitro-4-oxo-4H-chromene-2-carboxylate 12 (THB37)95
F
O
O
NO2
CO2Et
The compound was synthesized according to GP-2 using 4 (1.3 g,6.5 mmol). The product was isolated as a white solid (1.25 g, 68%).1H NMR: δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 4.40 (q, J = 7.1 Hz,2H, CH2CH3), 7.07 (s, 1H, 3-H), 8.14 (dd, J = 3.2, 7.6 Hz, 1H, 5-H),8.62 (dd, J = 3.2, 7.8 Hz, 1H, 7-H). 13C NMR: δ 13.9 (CH2CH3), 63.1 (CH2CH3), 113.8(C-3), 116.0-116.1 (C-7), 119.5-119.7 (C-5), 126.7-126.8 (C-4a), 139.9 (C-8), 144.4 (C-8a), 152.5 (C-2), 156.4 (C-6), 159.4 (CO2Et), 175.46 (C-4). LC-MS (m/z): positivemode 282 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 90.2%. lit. mp 112-113◦C.
5.2.6.9 Ethyl 6-chloro-8-nitro-4-oxo-4H-chromene-2-carboxylate 13 (THB38)182
Cl
O
O
NO2
CO2Et
The compound was synthesized according to GP-2 using 1-(5-chloro-2-hydroxy-3-nitrophenyl)ethanone (2.6 g, 12 mmol). Theproduct was isolated as a white solid (3.5 g, 98%). 1H NMR: δ1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3),7.10 (s, 1H, 3-H), 8.30 (d, J = 2.6 Hz, 1H, 5-H), 8.69 (d, J = 2.6 Hz, C-7). 13C NMR:δ 13.9 (CH2CH3), 63.1 (CH2CH3), 114.5 (C-3), 126.6 (C-4a), 129.6 (C-7), 129.9 (C-8),130.6 (C-5), 140.0 (C-8a), 146.4 (C-2), 152.4 (C-6), 159.3 (CO2Et), 175.1 (C-4). LC-MS(m/z): positive mode 298 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 85.8%. lit.mp 126-127 ◦C.
5.2.6.10 Ethyl 6-bromo-8-cyano-4-oxo-4H-chromene-2-carboxylate 266(ANM382)
Br
CN
O
O
CO2Et
The compound was synthesized according to GP-2 using 265(2.16 g, 9 mmol). The product was isolated as a pale-white solid(2.29 g, 79%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 4.41(q, J = 7.1 Hz, 2H, CH2CH3), 7.08 (s, 1H, 3-H), 8.37 (d, J = 2.4 Hz, 1H, 5-H), 8.72 (d,J = 2.5 Hz, 1H, 7-H). 13C NMR: δ 13.9 (CH2CH3), 63.1 (CH2CH3), 105.2 (C-8), 112.9(CN), 114.7 (C-3), 118.0 (C-6), 125.7 (C-4a), 132.6 (C-5), 141.7 (C-7), 152.4 (C-8a),154.9 (C-2), 159.3 (CO2H), 175.4 (C-4). LC-MS (m/z): positive mode 324 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 94.3%. mp 172-173 ◦C.
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5.2.6.11 Ethyl 6-bromo-7-methyl-8-nitro-4-oxo-4H-chromene-2-carboxylate 16(ANM89)
NO2
O
O
CO2Et
Br
H3C
The compound was synthesized according to GP-2 using 5 (2.40g, 9 mmol). The product was isolated as a white solid (2.03 g,63%). 1H NMR: δ 1.31 (t, J = 7.1 Hz, 3H, CH2CH3), 2.55 (d, J= 0.8 Hz, 3H, CH3), 4.41 (q, J = 7.1 Hz, 2H, CH2CH3), 7.03 (s,1H, 3-H), 8.20 (d, J = 1 Hz, 1H, 5-H). 13C NMR: δ 13.9 (CH2CH3), 22.3 (CH3), 63.1(CH2CH3), 114.8 (C-3), 121.9 (C-6), 123.7 (C-4a), 127.5 (C-5), 137.2 (C-8, C-7), 144.9(C-8a), 151.8 (C-2), 159.2 (CO2Et), 175.7 (C-4). LC-MS (m/z): positive mode 356[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 91.5%. mp 204-205 ◦C.
5.2.7 Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylates5.2.7.1 General procedure for the synthesis of the ethyl 8-amino-4-oxo-4H-chro-mene-2-carboxylates (GP-3)
The appropriate nitro derivative (2.5 mmol) was suspended in a mixture of EtOH (7mL) and diluted aq HCl (2 N, 7 mL). Tin(II)chloride dihydrate (2.26 g, 10.0 mmol)was subsequently added, and the reaction mixture was heated at 65 ◦C until thesolid was completely dissolved. The mixture was stirred for an additional 20 minat the same temperature. The EtOH was removed under reduced pressure, and theresulting suspension was added to 50 mL of EtOAc containing sodium carbonate (7g). The precipitated tin complex was filtered off and washed with 30 mL of EtOAc.The filtrate was washed with brine (30 mL), dried over anhydrous MgSO4, andconcentrated under reduced pressure. The resulting solid was dried in vacuum at50 ◦C.
5.2.7.2 Ethyl 8-amino-6-bromo-4-oxo-4H-chromene-2-carboxylate 17(ANM2)180
NH2
O
O
CO2Et
Br
The compound was synthesized according to GP-3 using 8 (3.36g, 9.8 mmol). The product was isolated as a yellow solid (2.89 g,95%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 4.39 (q, J =7.1 Hz, 2H, CH2CH3), 5.86 (s, 2H, NH), 6.90 (s, 1H, 3-H), 7.19 (d,J = 2.4 Hz, 1H, 7-H), 7.22 (d, J = 2.4 Hz, 1H, 5-H). 13C NMR: δ 14.0 (CH2CH3), 62.8
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(CH2CH3), 112.0 (C-3), 113.4 (C-5), 119.2 (C-7), 119.2 (C-6), 125.5 (C-4a), 140.9 (C-8),143.0 (C-8a), 151.9 (C-2), 160.0 (CO2Et), 176.7 (C-4). LC-MS (m/z): negative mode310 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 99.4%. lit. mp 161-162 ◦C.
5.2.7.3 Ethyl 8-amino-4-oxo-6-(trifluoromethoxy)-4H-chromene-2-carboxylate18 (ANM61)
NH2
O
O
CO2Et
F3CO
The compound was synthesized according to GP-3 using 9 (486mg, 1.4 mmol). The product was isolated as a yellow solid (253mg, 57%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 4.39(q, J = 7.1 Hz, 2H, CH2CH3), 6.01 (s, 2H, NH), 6.91 (s, 1H, 3-H), 6.94 (d, J = 2.5 Hz, 1H, 7-H), 7.01 (d, J = 2.8 Hz, 1H, 5-H). 13C NMR: δ 13.9(CH2CH3), 62.9 (CH2CH3), 100.4 (C-7), 109.1 (C-5), 113.1 (C-3), 119.2 (OCF3), 125.0(C-4a), 141.3 (C-8), 142.4 (C-8a), 146.4 (C-6), 152.0 (C-2), 160.0 (CO2Et), 177.1 (C-4).LC-MS (m/z): positive mode 318 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:90.0%. mp 100-102 ◦C.
5.2.7.4 Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate 19 (ANM75)181
NH2
O
O
CO2Et
The compound was synthesized according to GP-3 using 10 (2.63g, 10 mmol). The product was isolated as a yellow solid (2.12 g,91%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 4.39 (q, J = 7.1Hz, 2H, CH2CH3), 5.50 (s, 2H, NH), 6.86 (s, 1H, 3-H), 7.11 (d, J =1.9, 7.4 Hz, 1H, 7-H), 7.18-7.20 (m, 2H, 5-H, 6-H). 13C NMR: δ 14.0 (CH2CH3), 62.8(CH2CH3), 110.6 (C-3), 113.2 (C-5), 117.9 (C-7), 124.4 (C-4a), 126.3 (C-6), 138.8 (C-8),143.8 (C-8a), 151.7 (C-2), 160.2 (CO2Et), 177.9 (C-4). LC-MS (m/z): positive mode233 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. lit. mp 153-154 ◦C.
5.2.7.5 Ethyl 8-amino-6-ethyl-4-oxo-4H-chromene-2-carboxylate 20 (ANM87)
NH2
O
O
CO2Et
H3C
The compound was synthesized according to GP-3 using 11(2.11 g, 7.3 mmol). The product was isolated as a yellow solid(1.45 g, 76%). 1H NMR: δ 1.17 (t, 3H, J = 7.6 Hz, Ar-CH2CH3),1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 2.59 (q, 2H, J = 7.6 Hz, Ar-CH2CH3), 4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 5.43 (s, 2H, NH), 6.84 (s, 1H, 3-H), 6.98(d, J = 2.1 Hz, 1H, 7-H), 7.0 (d, J = 2.0 Hz, 1H, 5-H). 13C NMR: δ 14.0 (CH2CH3);15.4 (Ar-CH2CH3), 28.1 (Ar-CH2CH3), 62.7 (CH2CH3), 109.2 (C-3), 113.1 (C-5), 117.8
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(C-7), 124.2 (C-4a), 138.6 (C-8), 142.1 (C-6), 142.5 (C-8a), 151.5 (C-2), 160.3 (CO2Et),177.8 (C-4). LC-MS (m/z): positive mode 262 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 98.2%. mp 132-133 ◦C.
5.2.7.6 Ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate 21 (THB39)95
F
O
O
NH2
CO2Et
The compound was synthesized according to GP-3 using 12 (1.2g, 4.2 mmol). The product was isolated as a yellow solid (644 mg,60%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 4.39 (q, J = 7.1Hz, 2H, CH2CH3), 5.91 (s, 2H, NH), 6.78 (dd, J= 3.0, 8.5 Hz, 1H, 3-H), 6.81?6.93 (m, 2H, 5-H, 7-H). 13C NMR: δ 14.0 (CH2CH3), 62.8 (CH2CH3), 94.4-94.6(C-5), 104.3-104.6 (C-7), 112.6 (C-3), 125.2-125.3 (C-4a), 140.8 (C-8a), 141.4-141.5 (C-8), 151.8 (C-2), 159.2- 161.2 (C-6), 160.0 (CO2Et), 177.2 (C-4). LC-MS (m/z): positivemode 252 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.8%. lit. mp 164-165◦C.
5.2.7.7 Ethyl 8-amino-6-chloro-4-oxo-4H-chromene-2-carboxylate 22(THB40)95
Cl
O
O
NH2
CO2Et
The compound was synthesized according to GP-3 using 13 (2.7g, 9.1 mmol). The product was isolated as a yellow solid (1.7 g,62%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 4.39 (q, J = 7.1Hz, 2H, CH2CH3), 5.87 (s, 2H, NH), 6.89 (s, 1H, 3-H), 7.01?7.10 (m,2H, 5-H, 7-H). 13C NMR: δ 14.0 (CH2CH3), 62.8 (CH2CH3), 108.8 (C-3), 113.3 (C-7),116.3 (C-5), 125.2 (C-4a), 131.0 (C-8), 140.8 (C-8a), 142.7 (C-6), 151.9 (C-2), 160.0(CO2Et), 176.8 (C-4). LC-MS (m/z): positive mode 268 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.2%. lit. mp 150-151 ◦C.
5.2.7.8 Ethyl-8-amino-6-methyl-4-oxo-4H-chromene-2-carboxylate 23(ANM32)183
NH2
O
O
CO2Et
H3C
The compound was synthesized according to GP-3 using 14 (693mg, 2.5 mmol). The product was isolated as a yellow solid (561mg, 91%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 2.28 (s,3H, Ar-CH3), 4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 5.45 (s, 2H, NH),6.83 (s, 1H, 3-H), 6.94 (dd, J = 0.5, 2.1 Hz, 1H, 7-H), 6.97 (dd, J = 0.9, 2.2 Hz, 0.8Hz, 1H, 5-H). 13C NMR: δ 14.0 (CH2CH3), 21.1 (Ar-CH3), 62.7 (CH2CH3), 110.4 (C-5),
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113.1 (C-3), 118.8 (C-7), 124.5 (C-4a), 135.9 (C-6), 138.5 (C-8), 142.3 (C-8a), 151.5(C-2), 160.3 (CO2Et), 177.8 (C-4). LC-MS (m/z): positive mode 248 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 98.0%. lit. mp 127-132 ◦C.
5.2.7.9 Ethyl-8-amino-6-methoxy-4-oxo-4H-chromene-2-carboxylate 24(ANM37)184
NH2
O
O
CO2Et
H3CO
The compound was synthesized according to GP-3 using 15(733 mg, 2.5 mmol). The product was isolated as a yellow solid(623 mg, 95%). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3),3.76 (s, 3H, O-CH3), 4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 5.56 (s,2H, NH), 6.61 (d, J = 2.9 Hz, 1H, 5-H), 6.70 (d, J = 2.9 Hz, 1H, 7-H), 6.84 (s, 1H, 3-H).13C NMR: δ 14.0 (CH2CH3), 55.5 (O-CH3), 63.0 (CH2CH3), 91.6 (C-7), 105.8 (C-5),112.5 (C-3), 125.1 (C4a), 139.8 (C-8), 140.2 (C-8a), 151.3 (C-2), 157.7 (C-6), 160.2(CO2Et), 177.5 (C-4). LC-MS (m/z): positive mode 264 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 98.5%. lit. mp 144-145 ◦C.
5.2.7.10 Ethyl 8-amino-6-bromo-7-methyl-4-oxo-4H-chromene-2-carboxylate25 (ANM99)
NH2
O
O
CO2Et
Br
H3C
The compound was synthesized according to GP-3 using 16(1.90 g, 5.3 mmol). The product was isolated as a yellow solid(1.6 g, 92%). 1H NMR: δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 2.39(d, J = 0.8 Hz, 3H, CH3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 5.46 (s,2H, NH), 6.88 (s, 1H, 3-H), 7.19 (d, J = 0.9 Hz, 1H, 5-H). 13C NMR: δ 14.0 (CH2CH3),23.2 (CH, CH3), 62.8 (CH2CH3), 111.3 (C-3), 113.52 (C-5), 114.2 (C-6), 122.6 (C-4a),135.5 (C-8), 136.4 (C-7), 142.0 (C-8a), 151.7 (C-2), 160.00 (CO2Et), 177.3 (C-4). LC-MS (m/z): positive mode 328 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.5%.mp 164-166 ◦C.
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5.2.8 Ethyl 8-amino-5,7-dibromo-6-chloro-4-oxo-4H-chromene-2-carboxylate5.2.8.1 Ethyl 8-amino-5,7-dibromo-6-chloro-4-oxo-4H-chromene-2-carboxylate38 (ANM310)
O CO2Et
Cl
NH2
OBr
Br
Compound 22 (267 mg, 1.0 mmol), NBS (214 mg, 1.2 mmol), andthree drops of AIBN were dissolved in 10 mL of benzene and threedrops of DMF and heated to reflux for 6 h. Then the reaction mix-ture was poured into ice containing water and the precipitatedsolid filtered, washed three times with 5 mL water and dried in the oven at 60 ◦C.The product was isolated as a yellow solid (86 mg, 20%). 1H NMR: δ 1.39 (t, J =7.7 Hz, 3H, CH2CH3), 4.44 (q, J = 7.1 Hz, 2H, CH2CH3), 5.74 (s, 2H, NH), 6.91 (s, 1H,3-H). 13C NMR: δ 13.6 (CH2CH3), 62.6 (CH2CH3), 102.5 (C-5), 110.4 (C-7), 114.4 (C-3),121.4 (C-4a), 133.0 (C-6), 137.7 (C-8), 142.9 (C-8a), 150.0 (C-2), 159.3 (CO2Et), 175.2(C-4). LC-MS (m/z): positive mode 412 [M+H]+ measured in MeOH –> ester at2-position changed to methylester. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%.mp 251-253 ◦C.
5.2.9 Ethyl 4-thioxo-4H-chromene-2-carboxylates5.2.9.1 General procedure for the synthesis of the ethyl4-thioxo-4H-chromene-2-carboxylates (GP-4)To a solution of the appropriate ethyl 8-amino-4-oxo-4H-chromene-2-carboxylate(3 mmol) in toluene (20 mL) was added Lawesson’s reagent (606 mg, 1.5 mmol) andthe reaction mixture heated to 100 ◦C for 16 hours. After addition of aq. NaHCO3solution (80 mL) the product was extracted with DCM (3 x 20 mL) and separated bycolumn chromatography on a column of silica gel (50% cyclohexane in EtOAc).
5.2.9.2 Ethyl 8-amino-6-bromo-4-thioxo-4H-chromene-2-carboxylate 34(ANM274)
Br
NH2
O
S
CO2Et
The compound was synthesized according to GP-4 using 17 (936mg, 3 mmol) and was isolated as a red-browne solid (619 mg,63% yield). 1H NMR: δ 1.36 (t, 3H, J = 7.1 Hz, CH2CH3), 4.39 (q,2H, J = 7.1 Hz, CH2CH3), 5.95 (s, 2H, NH), 7.25 (d, 1H, J = 2.3
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Hz, 5-H), 7.51 (d, 1H, J = 2.3 Hz, 7-H), 7.60 (s, 1H, 3-H). 13C NMR: δ 14.0 (CH2CH3),62.9 (CH2CH3), 114.5 (C-7), 119.3 (C-5), 121.0 (C-6), 124.6 (C-3), 132.0 (C-4a), 138.5(C-8a), 141.4 (C-8), 142.4 (C-2), 160.4 (CO2Et), 201.6 (C-4). LC-MS (m/z): positivemode 329 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 84.9%. mp 176-177 ◦C.
5.2.9.3 Ethyl 8-amino-6-chloro-4-thioxo-4H-chromene-2-carboxylate 35(ANM272)
O CO2Et
Cl
NH2
S The compound was synthesized according to GP-4 using 22 (267mg, 1 mmol) and was isolated as a red-browne solid (112 mg,40% yield). 1H NMR: δ 1.36 (t, 3H, J = 7.1 Hz, CH2CH3), 4.30 (q,2H, J = 7.1 Hz, CH2CH3), 5.96 (s, 2H, NH), 7.11 (d, 1H, J = 2.5Hz, 5-H), 7.38 (d, 1H, J = 2.5 Hz, 7-H), 7.60 (s, 1H, 3-H). 13C NMR: δ 14.0 (CH2CH3),62.9 (CH2CH3), 111.4 (C-7), 116.4 (C-5), 124.5 (C-3), 131.7 (C-6), 132.7 (C-4a), 138.2(C-8a), 141.3 (C-8), 142.4 (C-2), 160.4 (CO2Et), 201.8 (C-4). LC-MS (m/z): positivemode 284 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.1%. mp 190-192 ◦C.
5.2.9.4 Ethyl 8-amino-6-fluoro-4-thioxo-4H-chromene-2-carboxylate 36(ANM314)
O CO2Et
F
NH2
S The compound was synthesized according to GP-4 using 21 (689mg, 2.6 mmol) and was isolated as a green solid (224 mg, 68%yield). 1H NMR: δ 1.36 (t, J = 7.1 Hz, 3H, CH2CH3), 4.40 (q, J =7.1 Hz, 2H, CH2CH3), 6.02 (s, 2H, NH), 6.93 (d, J = 3.0 Hz, 1H,5-H), 7.11 (d, J = 3.0 Hz, 1H, 7-H), 7.61 (s, 1H, 3-H). 13C NMR: δ 14.0 (CH2CH3),62.9 (CH2CH3), 97.0-97.1 (C-7), 104.6-104.8 (C-5), 124.0 (C-3), 131.9 (C-4a), 136.3 (C-8a), 142.0 (C-2), 142.4 (C-8), 160.5 (CO2Et), 162.2 (C-6), 202.0-202.1 (C-4). LC-MS(m/z): positive mode 268 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 84.0%. mp175-177 ◦C.
5.2.10 8-Amino-6-bromo-4-oxo-4H-chromene-2-carboxamide5.2.10.1 8-Amino-6-bromo-4-oxo-4H-chromene-2-carboxamide 39 (ANM46)
O
O
Br
NH2
NH2
O
Compound 17 (255 mg, 0.9 mmol) was dissolved in 1 mL of MeOH.After addition of 2 mL of a solution of NH3 in MeOH (7N) thereaction mixture was stirred over night at rt under an argonatmosphere. The product was obtained by filtration and washed
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twice with 3 mL of MeOH and was dried in vacuum at 50 ◦C. The product wasisolated as a pale white solid (243 mg, 95% yield). 1H NMR: δ 6.43 (s, 2H, C8-NH2),6.81 (s, 1H, 3-H), 7.13 (d, J = 2.4 Hz, 1H, 7-H), 7.15 (d, J = 2.4 Hz, 1H, 5-H), 8.18-8.68(s, 2H, CONH2). 13C NMR: δ 110.7 (C-3), 111.4 (C-5), 118.6 (C-7), 119.1 (C-6), 125.6(C-4a), 141.0 (C-8), 142.6 (C-8a), 155.6 (C-2), 160.4 (CONH), 176.7 (C-4). LC-MS(m/z): positive mode 284 [M+H]+, negative mode 281 [M-2H]2-. Purity by HPLC-UV(254 nm)-ESI-MS: 97.4%. mp > 350 ◦C.
5.2.11 Ethyl 4-oxo-6-phenyl-4H-chromene-2-carboxylates5.2.11.1 General procedure for the synthesis of the ethyl4-oxo-6-phenyl-4H-chromene-2-carboxylates (GP-5)Compound 17 (1.0 mmol) and the appropriate phenylboronic acid (1.2 mmol) weresuspended in 16 mL of toluene and 1 mL DMF in a 30 mL pressure flask (ACE R©-glass). After addition of K2CO3 (2 mmol) the suspension was degased in an ultrasonicbath for 5 min. Then tetrakis(triphenylphosphine)palladium(0) (0.025 mmol) wasadded under an argon atmosphere and the mixture was heated to 120 ◦C overnight.The reaction mixture was dissolved in 30 mL of EtOAc, filtrated, washed twice withsaturated NaCl in water solution and separated by column chromatography on acolumn of silica gel (1:4 cyclohexane/EtOAc).
5.2.11.2 Ethyl-8-amino-4-oxo-6-phenyl-4H-chromene-2-carboxylate 26(ANM38)
O
O
NH2
CO2Et
The compound was synthesized according to GP-5 using 17(312 mg, 1 mmol) and phenylboronic acid (146 mg, 1.2 mmol).The product was isolated as a yellow solid (275 mg, 89% yield).1H NMR: δ 1.37 (t, J = 7.1 Hz, 3H, CH2CH3), 4.40 (q, J = 7.1Hz, 2H, CH2CH3), 5.64 (s, 2H, NH), 6.90 (s, 1H, 3-H), 7.36-7.40 (m, 2H, 4’-H, 7-H),7.41 (d, J = 2.2 Hz, 1H, 5-H), 7.45-7.51 (m, 2H, 3’-H, 5’-H), 7.60-7.65 (m, 2H, 2’-H, 6’-H). 13C NMR: δ 14.0 (CH2CH3), 62.8 (CH2CH3), 108.3 (C-5), 113.3 (C-3), 116.1 (C-7),124.6 (C-4a), 126.8 (C-2’, C-6’), 128.0 (C-4’), 129.2 (C-3’, C-5’), 138.3 (C-6), 139.3 (C-8), 139.2 (C-1’), 143.5 (C-8a), 151.7 (C-2), 160.2 (CO2Et), 177.8 (C-4). LC-MS (m/z):negative mode 308 [M-H]-, positive mode 310 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 99.1%. mp 138-139 ◦C.
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5.2.11.3 Ethyl-8-amino-6-(4-chlorophenyl)-4-oxo-4H-chromene-2-carboxylate27 (ANM118)
O COOEt
NH2
O
Cl The compound was synthesized according to GP-5 using17 (312 mg, 1 mmol) and 4-chlorophenylboronic acid (164mg, 1.05 mmol). The product was isolated as a yellow solid(158 mg, 46% yield). 1H NMR: δ 1.36 (t, J = 7.1 Hz, 3H,CH2CH3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 5.66 (s, 2H, NH), 6.90 (s, 1H, 3-H), 7.37(d, J = 2.2 Hz, 3’-H, 5’-H), 7.39 (d, J = 2.2 Hz, 1H, 5-H), 7.49-7.54 (m, 2H, 3’-H,5’-H), 7.62-7.67 (m, 2H, 2’-H, 6’-H). 13C NMR: δ 14.0 (CH2CH3), 62.8 (CH2CH3), 108.3(C-5), 113.3 (C-3), 115.8 (C-7), 124.7 (C-4a), 128.6 (C-2’, C-6’), 129.1 (C-3’, C-5’), 132.8(C-6), 137.0 (C-4’), 138.3 (C-1’), 139.4 (C-8), 143.7 (C-8a), 151.7 (C-2), 160.2 (CO2Et),177.8 (C-4). LC-MS (m/z): positive mode 344 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 94.8%. mp 183-184 ◦C.
5.2.11.4 Ethyl 8-amino-4-oxo-6-(p-tolyl)-4H-chromene-2-carboxylate 28(ANM119)
O COOEt
NH2
O
H3C The compound was synthesized according to GP-5 using17 (312 mg, 1 mmol) and 4-tolylboronic acid (143 mg,1.05 mmol). The product was isolated as a yellow solid(191 mg, 59% yield). 1H NMR: δ 1.36 (t, J = 7.1 Hz, 3H,CH2CH3), 2.34 (s, 3H, Ar-CH3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 5.61 (s, 2H, NH),6.89 (s, 1H, 3-H), 7.28 (m, 2H, 3’-H, 5’-H), 7.36 (d, J = 2.2 Hz, 1H, 7-H), 7.40 (d, J =2.2 Hz, 1H, 5-H), 7.52 (m, 2H, 2’-H, 6’-H). 13C NMR: δ 14.0 (CH2CH3), 20.8 (Ar-CH3),62.8 (CH2CH3), 108.0 (C-5), 113.2 (C-3), 115.9 (C-7), 124.6 (C-4a), 126.6 (C-2’, C-6’),129.8 (C-3’, C-5’), 136.6 (C-4’), 137.3 (C-6), 138.2 (C-1’), 139.3 (C-8), 143.4 (C-8a),151.6 (C-2), 160.2 (CO2Et), 177.9 (C-4). LC-MS (m/z): positive mode 324 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 97.1%. mp 127-128 ◦C.
5.2.11.5 ethyl 8-amino-6-(4-methoxyphenyl)-4-oxo-4H-chromene-2-carboxylate29 (ANM127)
O CO2Et
NH2
O
H3CO The compound was synthesized according to GP-5 using17 (312 mg, 1 mmol) and 4-methoxyphenylboronic acid(160 mg, 1.05 mmol). The product was isolated as a yel-low solid (255 mg, 75% yield). 1H NMR: δ 1.36 (t, J =
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7.1 Hz, 3H, CH2CH3), 3.79 (s, 3H, O-CH3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 5.59 (s,2H, NH), 6.89 (s, 1H, 3-H), 7.03 (m, 2H, 3’-H, 5’-H), 7.33 (d, J = 2.2 Hz, 1H, 7-H),7.37 (d, J = 2.2 Hz, 1H, 5-H), 7.56 (m, 2H, 2’-H, 6’-H). 13C NMR: δ 14.0 (CH2CH3),55.3 (O-CH3), 62.8 (CH2CH3), 107.66 (C-5), 113.2 (C-3), 114.6 (C-3’, C-5’), 114.8 (C-7),124.6 (C-4a), 127.9 (C-2’, C-6’), 131.8 (C-6), 138.0 (C-1’), 139.2 (C-8), 143.2 (C-8a),151.6 (C-2), 159.3 (C-4’), 160.2 (CO2Et), 177.9 (C-4). LC-MS (m/z): positive mode 340[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 95.3%. mp 162-163 ◦C.
5.2.11.6 Ethyl 8-amino-6-(4-fluorophenyl)-4-oxo-4H-chromene-2-carboxylate30 (ANM128)
O CO2Et
NH2
O
F The compound was synthesized according to GP-5 using 17(312 mg, 1 mmol) and 4-fluorophenylboronic acid (147 mg,1.05 mmol). The product was isolated as a yellow solid (243mg, 74% yield). 1H NMR: δ 1.36 (t, J = 7.1 Hz, 3H, CH2CH3),4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 5.64 (s, 2H, NH), 6.90 (s, 1H, 3-H), 7.30 (m, 2H,3’-H, 5’-H), 7.35 (d, ( J) = 2.2 Hz, 1H, 7-H), 7.37 (d, J = 2.2 Hz, 1H, 5-H), 7.66 (m,2H, 2’-H, 6’-H). 13C NMR: δ 14.0 (CH2CH3), 62.8 (CH2CH3), 108.2 (C-5), 113.3 (C-3),116.1 (C-3’, C-5’, C-7), 124.6 (C-4a), 128.9 (C-2’, C-6’), 136.0 (C-6), 137.3 (C-1’), 139.3(C-8), 143.5 (C-8a), 151.7 (C-2), 160.2 (CO2Et), 161.2-163.1 (C-4’), 177.8 (C-4). LC-MS (m/z): positive mode 328 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.3%.mp 176-177 ◦C.
5.2.11.7 Ethyl 8-amino-6-(4-((tert-butyldimethylsilyl)oxy)phenyl)-4-oxo-4H-chromene-2-carboxylate 31 (ANM191)
O CO2Et
NH2
O
O
SitBu The compound was synthesized according to GP-5 us-ing 17 (312 mg, 1 mmol) and (4-(tert-butyldimethylsi-lyl)phenyl)boronic acid (248 mg, 1.05 mmol). The prod-uct was isolated as a yellow solid (281 mg, 64% yield).1H NMR: δ 0.21 (s, 6H, Si-(CH3)2), 0.96 (s, 9H, SiC(CH3)3), 1.36 (t, J = 7.1 Hz, 3H,CH2CH3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 5.59 (s, 2H, NH), 6.89 (s, 1H, 3-H), 6.90-6.98 (m, 2H, 3’-H, 5’-H), 7.33 (d, J = 2.2 Hz, 1H, 7-H), 7.36 (d, J = 2.2 Hz, 1H, 5-H),7.50-7.54 (m, 2H, 2’-H, 6’-H). 13C NMR: δ 4.4 (Si(CH3)2), 14.0 (CH2CH3), 18.1 (SiC),25.7 (SiC(CH3)3), 62.8 (CH2CH3), 107.7 (C-5), 113.2 (C-3), 115.8 (C-7), 120.5 (C-3’,C-5’), 124.6 (C-4a), 128.0 (C-2’, C-6’), 132.6 (C-6), 127.9 (C-1’), 139.2 (C-8), 143.2
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(C-8a), 151.6 (C-2), 155.2 (C-4’), 160.2 (CO2Et), 177.8 (C-4). LC-MS (m/z): positivemode 440 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.7%. mp 155-157 ◦C.
5.2.11.8 Ethyl 8-amino-6-(4-((tert-butoxycarbonyl)amino)phenyl)-4-oxo-4H-chromene-2-carboxylate 32 (ANM192)
O CO2Et
NH2
O
H
N
Boc
The compound was synthesized according to GP-5 using17 (614 mg, 2 mmol) and 4-(N-Boc-amino)phenylboronicacid (498 mg, 2.1 mmol). The product was isolated as ayellow solid (506 mg, 60% yield). 1H NMR: δ 1.36 (t, J= 7.1 Hz, 3H, CH2CH3), 1.48 (s, 9H, C(CH3)3), 4.40 (q, J = 7.1 Hz, 2H, CH2CH3), 5.60(s, 2H, NH), 6.89 (s, 1H, 3-H), 7.34 (d, J = 2.2 Hz, 1H, 5-H), 7.52-7.56 (m, 4H, 2’-H,3’-H, 5’-H, 6’-H), 9.45 (s, 1H, CONH). 13C NMR: δ 14.0 (CH2CH3), 28.3 (C(CH3)3), 62.8(CH2CH3), 79.3 (C(CH3)3), 107.7 (C-5), 113.2 (C-3), 115.7 (C-7), 118.6 (C-3’, C-5’), 124.6(C-4a), 127.0 (C-2’, C-6’), 133.0 (C-6), 138.0 (C-1’). 139.2 (C-8), 139.5 (CONH), 143.3(C-8a), 151.6 (C-2), 152.9 (C-4’), 160.2 (CO2Et), 177.9 (C-4). LC-MS (m/z): positivemode 425 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.5%. mp 222-223 ◦C.
5.2.12 Ethyl 8-amino-6-butyl-4-oxo-4H-chromene-2-carboxylate5.2.12.1 Ethyl 8-amino-6-butyl-4-oxo-4H-chromene-2-carboxylate 33 (ANM80)
O CO2Et
NH2
O
H3C
Compound 17 (156 mg, 0.5 mmol) and butylboronic acid(56 mg, 0.55 mmol) were suspended in 8 mL of toluene and0.5 mL DMF in a 30 mL pressure flask (ACE R©-glass). Afteraddition of K2CO3 (1 mmol) the suspension was degasedin an ultrasonic bath for 5 min. Then bis(triphenylphosphine)palladium(II)dichlo-ride (0.025 mmol) and triphenylphosphine (0.5 mmol) were added under an argonatmosphere and the mixture was heated to 120 ◦C overnight. The reaction mixturewas dissolved in 30 mL of EtOAc, filtrated, washed twice with saturated NaCl inwater solution and separated by column chromatography on a column of silica gel(1:4 cyclohexane/EtOAc). The product was isolated as a yellow solid (25 mg, 17%yield). 1H NMR: δ 0.89 (t, J = 7.2 Hz, 3H, 4’-H), 1.26-1.28 (m, 2H, 3’-H), 1.35 (t, J =7.1 Hz, 3H, CH2CH3), 1.53-1.55 (m, 2H, 2’-H), 2.55-2.57 (m, 2H, 1’-H), 4.38 (q, J = 7.1Hz, 2H, CH2CH3), 5.43 (s, 2H, NH), 6.84 (s, 1H, 3-H), 6.96 (d, J = 2.1 Hz, 1H, 7-H),6.99 (d, J = 1.9 Hz, 1H, 5-H). 13C NMR: δ 13.3 (C-4’), 14.0 (CH2CH3), 21.8 (C-3’), 33.0(C-2’), 34.7 (C-1’), 62.7 (CH2CH3), 109.8 (C-3), 113.1 (C-5), 118.2 (C-7), 124.2 (C-4a),
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138.5 (C-6), 140.7 (C-8), 142.5 (C-8a), 151.5 (C-2), 160.3 (CO2Et), 177.8 (C-4). LC-MS(m/z): positive mode 290 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 95.4%. mp119-121 ◦C.
5.2.13 Ethyl 8-isothiocyanato-4-oxo-4H-chromene-2-carboxylate5.2.13.1 Ethyl 8-isothiocyanato-4-oxo-4H-chromene-2-carboxylate 184(ANM162)
O
O
CO2Et
NCS
Thiophosgene (150 mg, 1.3 mmol) was dissolved in EtOAc (5.5 mL)cooled down to -78 ◦C (acetone/dry ice mixture) under an argonatmosphere. Then triethylamine (0.37 mL, 2.7 mmol) in 4 mL EtOAcwas added dropwise over a period of 30 min and the reaction mixture stirred for 15min. After that 19 (280 mg, 1.2 mmol) in THF (6.6 mL) was added dropwise over aperiod of 30 min and the reaction mixture was stirred overnight at rt. After additionof 26 mL EtOAc the organic layer was washed two times with 10 mL H2O each andtwo times with 20 mL brine each and dried over MgSO4. After removing the solventunder reduced pressure the product was isolated as a pink-white solid (310 mg, 94%yield). 1H NMR: δ 1.38 (t, J = 7.1 Hz, 3H, CH2CH3), 4.41 (q, J = 7.1 Hz, 2H, CH2CH3),7.00 (s, 1H, 3-H), 7.51 (t, J = 7.9 Hz, 1H, 6-H), 7.85 (dd, J = 1.6, 7.8 Hz, 1H, 7-H),7.94 (dd, J = 1.6, 8.0 Hz, 1H, 5-H). 13C NMR: δ 14.1 (CH2CH3), 63.0 (CH2CH3), 114.3(C-3), 121.3 (C-8), 123.9 (C-5), 124.9 (C-4a), 126.2 (C-7), 130.6 (C-6), 140.7 (NCS),151.5 (C-8a), 152.1 (C-2), 159.7 (CO2Et), 176.9 (C-4). LC-MS (m/z): positive mode276 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.7%. mp 108-109 ◦C.
5.2.14 4-(Ethoxycarbonyl)benzoic acid5.2.14.1 4-(Ethoxycarbonyl)benzoic acid 290 (ANM219)229
CO2H
CO2Et
Diethyl terephthalate (2.22 g, 10 mmol) was dissolved in 30 mL EtOH andstirred for 15 min at 40-50 ◦C. Then KOH (560 mg, 10 mmol) was addedand the reaction mixture refluxed for 4 h. After removing the solvent underreduced pressure the product was suspended in 60 mL of water and ex-tracted with 3 x 15 mL of DCM. The water-phase was then acidified with 10 % HCland extracted with 3 x 10 mL diethyl ether. The diethyl ether phase was dried overMgSO4 and the solvent removed under reduced pressure. The product was isolatedas a white solid (950 mg, 49% yield). 1H NMR: δ 1.32 (t, J = 7.1 Hz, 3H, CH2CH3),
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4.33 (q, J = 7.1 Hz, 2H, CH2CH3), 8.04 (s, 4H, 2-H, 3-H, 5-H, 6-H), 13.29 (s, 1H,OH). 13C NMR: δ 14.2 (CH2CH3), 61.3 (CH2CH3), 129.4 (C-3, C-5), 129.7 (C-2, C-6),133.6 (C-1), 134.9 (C-4), 165.2 (CO2Et), 166.7 (O2H). LC-MS (m/z): positive mode 195[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. lit. mp 167-171 ◦C.
5.2.15 Alkylalcohols5.2.15.1 General procedure for the synthesis of alkylalcohols (GP-6)To a solution of 16 mL of LiAlH4 in THF (1 M), 10 mmol of the appropriate alkyl-carboxylic acid dissolved in 8 mL of dry THF was dropped slowly over 30 min. Anincrease of temperature was observed. After that the reaction mixture was stirredfor 4 h at rt and then quenched with water at 0-5 ◦C. Carefully H2SO4 (10 M) wasadded until the precipitated solid was dissolved. The product was extracted with3 x 30 mL EtOAc and the combined organic layers were washed with Brine, driedover MgSO4 and filtered. After removing the solvent under reduced pressure theproduct was used without further characterization.
5.2.15.2 5-Cyclohexylpentan-1-ol 41 (ANM86)193
OH The product was synthesized according to GP-6 using 5-cyclo-hexylpentanoic acid (921 mg, 5 mmol) and was isolated as acolourless oil (793 mg, 93% yield). The product was used without further purificationand characterization.
5.2.15.3 4-Cyclohexylbutan-1-ol 42 (ANM159)193
OH The product was synthesized according to GP-6 using 5-cyclohex-ylbutanoic acid (1.70 g, 10 mmol) and was isolated as a colourlessoil (1.32 g, 85% yield). The product was used without further purification and char-acterization.
5.2.16 Alkylbromides5.2.16.1 General procedure for the synthesis of alkylbromides (GP-7)10.9 mmol of the aliphatic alcohol were dissolved in 2 mL of toluene under argonatmosphere and cooled down to 0-5 ◦C. Then very slowly 12.1 mmol of PBr3 were
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added and the reaction mixture was stirred for 30 min at rt and then heated for2 h at 100 ◦C. After cooling the reaction mixture to 0-5 ◦C it was poured on ice,washed with Brine and the water phase extracted with 2 x 10 mL of diethyl ether.The combined organic layers were dried over MgSO4, the solvent removed underreduced pressure and the product was finally dried in vacuum at 45 ◦C.
5.2.16.2 (5-Bromopentyl)cyclohexane 43 (ANM144)193
Br The product was synthesized according to GP-7 using 41 (766mg, 4.5 mmol) and was isolated as a colourless oil (899 mg, 86%yield). The product was used without further purification and characterization.
5.2.16.3 (5-Bromobutyl)cyclohexane 44 (ANM160)193
Br The product was synthesized according to GP-7 using 42 (1.25 g,8.0 mmol) and was isolated as a colourless oil (1.50 g, 86% yield).The product was used without further purification and characterization.
5.2.17 Methyl alkyloxybenzoates5.2.17.1 General procedure for the synthesis of methyl alkyloxybenzoates(GP-8)
The appropriate alkyl bromide (7.0 mmol), methyl 4-hydroxybenzoate (1.07 g, 7.0mmol), and potassium carbonate (1.10 g, 8.0 mmol) were suspended in 15 mL ofanhydrous DMF. The reaction mixture was heated at 110-115 ◦C under an argonatmosphere overnight. DMF was removed under reduced pressure. After addition of60 mL water, the resulting suspension was extracted with ethyl acetate (3 x 25 mL).The combined organic layers were dried over anhydrous MgSO4 and concentratedunder reduced pressure. If purification by column chromatography was necessary,see individual compounds. The product was dried in vacuum at 50 ◦C.
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5.2.17.2 Methyl-3-(4-fluorobenzyloxy)benzoate 60 (ANM8)202
O
F
CO2Me The compound was synthesized according to GP-8 using 4-fluorobenzyl bromide (0.87 mL, 7.0 mmol) and methyl 3-hydro-xybenzoate (1.06 g, 7.0 mmol), and was isolated as white solid(1.56 g, 86% yield). LC-MS (m/z): positive mode 261 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 100%.
5.2.17.3 Methyl-3-(4-bromobenzyloxy)benzoate 62 (ANM9)203
O
Br
CO2Me The compound was synthesized according to GP-8 using 4-bromobenzyl bromide (1.75 mL, 7.0 mmol) and methyl 3-hy-droxybenzoate (1.06 g, 7.0 mmol), and was isolated as whitesolid (1.95 g, 87% yield). LC-MS (m/z): positive mode 323[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.5%.
5.2.17.4 Methyl-3-(4-chlorobenzyloxy)benzoate 64 (ANM10)204
O
Cl
CO2Me The compound was synthesized according to GP-8 using 4-chlorobenzyl bromide (1.44 g, 7.0 mmol) and methyl 3-hydro-xybenzoate (1.06 g, 7.0 mmol), and was isolated as white solid(1.59 g, 82% yield). LC-MS (m/z): positive mode 277 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 94.7%.
5.2.17.5 Methyl-2-(fluorobenzyloxy)benzoate 72 (ANM11)207
O
F
MeO2C The compound was synthesized according to GP-8 using 4-fluo-robenzyl bromide (0.87 mL, 7.0 mmol) and methyl 2-hydroxyben-zoate (1.06 g, 7.0 mmol), and was isolated as yellow oil (1.54 g,85% yield). LC-MS (m/z): positive mode 278 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 89.6%.
5.2.17.6 Methyl-4-(fluorobenzyloxy)benzoate 46 (ANM54)195
CO2Me
O
F
The compound was synthesized according to GP-8 using4-fluorobenzyl bromide (0.87 mL, 7.0 mmol) and methyl 4-hydroxybenzoate (1.06 g, 7.0 mmol), and was isolated aswhite solid (1.60 g, 88% yield). LC-MS (m/z): positive mode 261 [M+H]+. Purity by
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HPLC-UV (254 nm)-ESI-MS: 99.2%.
5.2.17.7 Methyl-4-(3,4-difluorobenzyloxy)benzoate 48 (ANM114)197
CO2Me
O
F
F
The compound was synthesized according to GP-8 using3,4-difluorobenzyl bromide (0.90 mL, 7.0 mmol) and methyl4-hydroxybenzoate (1.06 g, 7.0 mmol), and was isolated aswhite solid (1.73 g, 89% yield). LC-MS (m/z): positive mode 279 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 96.0%.
5.2.17.8 Methyl-3-chloro-4-(4-fluorobenzyloxy)benzoate 50 (ANM115)
CO2Me
O
F
Cl The compound was synthesized according to GP-8 using 4-fluorobenzyl bromide (0.87 mL, 7.0 mmol) and methyl 3-chlo-ro-4-hydroxybenzoate (1.3 g, 7.0 mmol), and was isolatedas white solid (1.77 g, 86% yield). LC-MS (m/z): positive mode 295 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 97.0%.
5.2.17.9 Methyl-3-chloro-4-(3,4-difluorobenzyloxy)benzoate 52 (ANM146)198
CO2Me
O
F
F
Cl The compound was synthesized according to GP-8 using3,4-difluorobenzyl bromide (1.31 g, 7.0 mmol) and methyl3-chloro-4-hydroxybenzoate (1.3 g, 7.0 mmol), and was iso-lated as white solid (1.92 g, 88% yield). LC-MS (m/z): positive mode 313 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 92.4%.
5.2.17.10 Methyl-3-fluoro-4-(4-fluorobenzyloxy)benzoate 54 (THB7)
CO2Me
O
F
F The compound was synthesized according to GP-8 using 4-fluorobenzyl bromide (1.00 g, 5.88 mmol) and methyl 3-fluo-ro-4-hydroxybenzoate (1.00 g, 5.88 mmol), and was isolatedas white solid (1.51 g, 92% yield). ). 1H NMR: δ 3.82 (s, 3H, CO2CH3), 5.25 (s, 2H,CH2), 7.17-7.29 (m, 2H, 3’-H, 5’-H), 7.38 (t, J = 8.5 Hz, 1H, 5-H), 7.46-7.57 (m, 2H,2’-H, 6’-H), 7.70 (dd, J = 2.1 Hz, 11.8 Hz, 1H, 6-H), 7.77 (ddd, J = 1.1, 2.1, 8.6 Hz, 1H,2-H). 13C NMR: δ 52.3 (CO2CH3), 69.8 (CH2), 115.0 (C-5), 115.4-115.6 (C-3’, C-5’),116.6-116.7 (C-3), 122.6 (C-1), 126.7 (C-2’, C-6’), 130.4 (C-6), 130.5 (C-2), 132.3 (C-1’),150.3-152.2 (C-4), 161.2-163.1 (C-4’), 165.2 (CO2Me). LC-MS (m/z): positive mode279 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.0%. mp 89-90 ◦C.
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5.2.17.11 Methyl 4-((5-phenylpentyl)oxy)benzoate 74 (THB18)208
CO2Me
O
The compound was synthesized according to GP-8 us-ing (5-bromopentyl)benzene (1.00 g, 4.4 mmol) andmethyl 4-hydroxybenzoate (748 mg, 4.4 mmol), andwas isolated as white solid (1.51 g, 92% yield). ). LC-MS (m/z): positive mode 299[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.7%.
5.2.17.12 Methyl 3-(4-phenylbutoxy)benzoate 84 (THB32)
O
CO2Me The compound was synthesized according to GP-8 using(5-bromobutyl)benzene (1.00 g, 4.69 mmol) and methyl 3-hydroxybenzoate (797 mg, 4.69 mmol), and was isolated asa colourless oil (1.14 g, 90% yield). 1H NMR: δ 1.71 (tt, J = 3.4, 7.0 Hz, 4H, 2’-H,3’-H), 2.63 (t, J = 7.1 Hz, 2H, 4’-H), 3.83 (s, 3H, CO2CH3), 3.98-4.05 (m, 2H, 1’-H),7.13-7.31 (m, 5H, 2”-H, 3”-H, 4”-H, 5”-H, 6”-H), 7.36-7.44 (m, 2H, 2-H, 6-H), 7.52(dt, J = 1.2, 7.6 Hz, 2H, 5-H, 6-H). 13C NMR: δ 27.4 (C-3’), 28.3 (C-2’), 34.9 (C-4’),52.3 (CO2CH3), 67.7 (C-1’), 114.5 (C-2), 119.9 (C-4), 121.4 (C-6), 125.8 (C-4’), 128.4(C-3”, C-5”), 128.4 (C-2”, C-6”), 130.0 (C-5’), 131.1 (C-1), 142.1 (C-1”), 158.8 (C-3),166.2 (CO2Me). LC-MS (m/z): positive mode 285 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 78.5%.
5.2.17.13 Methyl 4-(4-fluorobenzyloxy)-3-methoxybenzoate 56 (ANM112)201
CO2Me
O
H3CO
F
The compound was synthesized according to GP-8 using4-fluorobenzyl bromide (0.87 mL, 7.00 mmol) and methyl 4-hydroxy-3-methoxybenzoate (1.28 g, 7.00 mmol), and wasisolated as a white solid (1.83 g, 90% yield). LC-MS (m/z): positive mode 291[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.2%.
5.2.17.14 Methyl 3-bromo-4-((4-fluorobenzyl)oxy)benzoate 58 (ANM113)
CO2Me
O
Br
F
The compound was synthesized according to GP-8 using4-fluorobenzyl bromide (0.87 mL, 7.00 mmol) and methyl 3-bromo-4-hydroxybenzoate (1.62 g, 7.00 mmol), and was iso-
196
5.2 Synthesis and characterization Dissertation, Universität Bonn 2016
lated as a white solid (2.16 g, 91% yield). LC-MS (m/z): positive mode 337 [M-H]-.Purity by HPLC-UV (254 nm)-ESI-MS: 93.2%.
5.2.17.15 Methyl 4-((5-cyclohexylpentyl)oxy)benzoate 78 (ANM145)
CO2Me
O
The compound was synthesized according to GP-8 us-ing 43 (931 mg, 4.00 mmol) and methyl 4-hydroxyben-zoate (609 mg, 4.00 mmol), and was isolated as a whitesolid (570 g, 47% yield). 1H NMR: δ 0.81-0.86 (m, 2H, Cyclohexyl), 1.12-1.19 (m, 6H,5’-H, Cyclohexyl), 1.30-1.38 (m, 4H, 3’-H, 4’-H), 1.61-1.70 (m, 7H, 2’-H, Cyclohexyl),3.80 (s, 3H, CO2CH3), 4.02 (t, J = 6.5 Hz, 2H, 1’-H), 7.01 (d, J = 8.9 Hz, 2H, 3-H,5-H), 7.84-7.90 (m, 2H, 2-H, 6-H). 13C NMR: δ 25.9-26.1 (C-4’, C-5’), 26.0 (C-3”, C-5”),26.3 (C-4”), 28.7 (C-3’), 33.0 (C-2”, C-6”), 37.0 (C-2’), 37.1 (C-1”), 51.9 (CO2CH3), 68.0(C-1’), 114.6 (C-3, C-5), 121.8 (C-1), 131.3 (C-2, C-6), 162.7 (C-4), 166.0 (CO2Me).LC-MS (m/z): positive mode 305 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100%. mp 59-60 ◦C.
5.2.17.16 Methyl 4-(4-cyclohexylbutoxy)benzoate 76 (ANM163)
CO2Me
O
The compound was synthesized according to GP-8 using44 (1.50 g, 7.00 mmol) and methyl 4-hydroxybenzoate(1.06 g, 7.00 mmol), and was isolated as a white solid (1.57 g, 77% yield). 1H NMR: δ0.81-0.86 (m, 2H, Cyclohexyl), 1.11-1.22 (m, 6H, 4’-H, Cyclohexyl), 1.37-1.45 (m, 2H,3’-H), 1.60-1.69 (m, 7H, 2’-H, Cyclohexyl), 3.80 (s, 3H, CO2CH3), 4.02 (t, J = 6.5 Hz,2H, 1’-H), 7.01 (d, J = 8.9 Hz, 2H, 3-H, 5-H), 7.85-7.91 (m, 2H, 2-H, 6-H). 13C NMR:δ 22.8 (C-4’), 26.0 (C-3”, C-5”), 26.3 (C-4”), 28.9 (C-3’), 32.9 (C-2”, C-6”), 36.7 (C-2’),37.1 (C-1”), 51.9 (CO2CH3), 68.0 (C-1’), 114.5 (C-3, C-5), 121.8 (C-1), 131.3 (C-2, C-6),162.7 (C-4), 166.0 (CO2Me). LC-MS (m/z): positive mode 291 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 99.1%. mp < 50 ◦C.
5.2.17.17 Methyl 3-(4-cyclohexylbutoxy)benzoate 100 (ANM164)
O
CO2Me The compound was synthesized according to GP-8 using 44(857 g, 4.00 mmol) and methyl 3-hydroxybenzoate (609 mg,4.00 mmol), and was isolated as a white solid (673 g, 58%yield). 1H NMR: δ 0.81-0.86 (m, 2H, Cyclohexyl), 1.11-1.22 (m, 6H, 4’-H, Cyclohexyl),
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1.37-1.45 (m, 2H, 3’-H), 1.60-1.69 (m, 7H, 2’-H, Cyclohexyl), 3.83 (s, 3H, CO2CH3),3.94-4.03 (m, 2H, 1’-H), 7.14-7.24 (m, 1H, 4-H), 7.39-7.48 (m, 2H, 2-H, 5-H), 7.51 (dq,J = 1.3, 7.5 Hz, 1H, 6-H). 13C NMR: δ 22.8 (C-4’), 25.9 (C-3”, C-5”), 26.3 (C-4”), 29.0(C-3’), 32.9 (C-2”, C-6”), 36.7 (C-2’), 37.1 (C-1”), 52.3 (CO2CH3), 67.8 (C-1’), 114.5(C-2), 119.9 (C-4), 121.3 (C-6), 130.0 (C-5), 131.1 (C-1), 158.8 (C-4), 166.3 (CO2Me).LC-MS (m/z): positive mode 291 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:94.9%. mp < 50 ◦C.
5.2.17.18 Methyl 3-((3-bromobenzyl)oxy)benzoate 66 (ANM225)
O
CO2Me
Br
The compound was synthesized according to GP-8 using 4-bromobenzyl bromide (1.75 g, 7.00 mmol) and methyl 3-hydro-xybenzoate (1.07 g, 7.00 mmol), and was isolated as a whitesolid (2.20 g, 97% yield). LC-MS (m/z): positive mode 321[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 78.8%.
5.2.17.19 Methyl 3-((4-methylbenzyl)oxy)benzoate 68 (ANM227)
O
CO2Me
H3C
The compound was synthesized according to GP-8 using 4-methylbenzyl bromide (1.30 g, 7.00 mmol) and methyl 3-hy-droxybenzoate (1.07 g, 7.00 mmol), and was isolated as awhite solid (1.56 g, 88% yield). LC-MS (m/z): positive mode257 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 74.5%.
5.2.17.20 Methyl 3-((5-cyclohexylpentyl)oxy)benzoate 45 (ANM239)
O
CO2Me The compound was synthesized according to GP-8 us-ing 43 (1.94 g, 8.30 mmol) and methyl 3-hydroxybenzoate(1.26 g, 8.30 mmol), and was isolated as a colourless oil(940 mg, 37% yield). 1H NMR: δ 0.74-0.91 (m, 2H, Cyclo-hexyl), 1.02-1.25 (m, 6H, 5’-H, Cyclohexyl), 1.25-1.46 (m, 4H, 3’-H, 4’-H), 1.52-1.76(m, 7H, 2’-H, Cyclohexyl), 3.83 (s, 3H, CO2CH3), 4.00 (t, J = 6.5 Hz, 2H, 1’-H), 7.20(ddd, J = 8.2, 2.6, 1H, 1.0 Hz, 4-H), 7.35-7.48 (m, 2H, 2-H, 5-H), 7.47-7.56 (m, 1H,6-H). 13C NMR: δ 25.9 (C-4’, C-5’), 26.0 (C-3”, C-5”), 26.3 (C-4”), 28.7 (C-3’), 33.0(C-2”, C-6”), 37.0 (C-2’), 37.1 (C-1”), 52.3 (CO2CH3), 67.9 (C-1’), 114.5 (C-2), 119.9(C-4), 121.4 (C-6), 130.0 (C-5), 131.1 (C-1), 158.9 (C-4), 166.2 (CO2Me). LC-MS (m/z):
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positive mode 305 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 95.4%.
5.2.17.21 Methyl 3-(cyclohexylmethoxy)benzoate 94 (ANM244)211
CO2Me
O
The compound was synthesized according to GP-8 using (bromo-methyl)cyclohexane (1.42 g, 8.00 mmol) and methyl 3-hydroxy-benzoate (1.22 g, 8.00 mmol), and was isolated as a colourlessoil (911 mg, 46% yield). LC-MS (m/z): positive mode 249 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 98.8%.
5.2.17.22 Methyl 3-(2-cyclohexylethoxy)benzoate 96 (ANM245)
CO2Me
O
The compound was synthesized according to GP-8 using (bro-moethyl)cyclohexane (1.53 g, 8.00 mmol) and methyl 3-hydroxy-benzoate (1.22 g, 8.00 mmol), and was isolated as a colourlessoil (1.89 g, 90% yield). 1H NMR: δ 0.88-1.02 (m, 2H, Cyclohexyl), 1.07-1.27 (m, 2H,Cyclohexyl), 1.44-1.48 (m, 2H, Cyclohexyl), 1.55-1.78 (m, 7H, 2’-H, Cyclohexyl), 3.83(s, 3H, CO2CH3), 4.04 (t, J = 6.6 Hz, 2H, 1’-H), 7.20 (ddd, J = 8.2, 2.7, 1.1 Hz, 1H, 4-H),7.38-7.44 (m, 2H, 2-H, 5-H), 7.49-7.54 (m, 1H, 6-H). 13C NMR: δ 25.9 (C-3”, C-5”),26.2 (C-4”), 34.2 (C-1”), 32.8 (C-2”, C-6”), 36.1 (C-2’), 52.3 (CO2CH3), 65.9 (C-1’), 114.5(C-2), 119.9 (C-4), 121.4 (C-6), 130.0 (C-5), 131.1 (C-1), 158.8 (C-4), 166.2 (CO2Me).LC-MS (m/z): positive mode 263 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:95.9%.
5.2.17.23 Methyl 3-(benzyloxy)benzoate 70 (ANM246)206
CO2Me
O
The compound was synthesized according to GP-8 using (bromo-methyl)benzene (1.73 g, 8.00 mmol) and methyl 3-hydroxybenzo-ate (1.22 g, 8.00 mmol), and was isolated as a white solid (1.77 g,91% yield). LC-MS (m/z): positive mode 243 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 94.2%.
5.2.17.24 Methyl 3-phenethoxybenzoate 80 (ANM247)
CO2Me
O
The compound was synthesized according to GP-8 using (2-bromoethyl)benzene (1.48 g, 8.00 mmol) and methyl 3-hydroxy-benzoate (1.22 g, 8.00 mmol), and was isolated as a colourless
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oil (1.32 g, 64% yield). 1H NMR: δ 3.04 (t, J = 6.8 Hz, 2H, 2’-H), 3.83 (s, 3H, CO2CH3),4.24 (t, J = 6.8 Hz, 2H, 1’-H), 7.19-7.24 (m, 2H, 4-H, 4”-H), 7.28-7.34 (m, 4H, 2”-H,3”-H, 5”-H, 6”-H), 7.39-7.44 (m, 2H, 2-H, 5-H), 7.51-7.54 (m, 1H, 6-H). 13C NMR: δ35.0 (C-2’), 52.3 (CO2CH3), 68.5 (C-1’), 114.6 (C-2), 119.8 (C-4), 121.5 (C-6), 126.4(C-4”), 128.4 (C-2”, C-6”), 129.1 (C-3”, C-5”), 130.1 (C-5), 131.1 (C-1), 138.4 (C-1”),158.6 (C-4), 166.1 (CO2Me). LC-MS (m/z): positive mode 257 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 97.0%.
5.2.17.25 Methyl 3-(3-phenylpropoxy)benzoate 82 (ANM248)
CO2Me
O
The compound was synthesized according to GP-8 using (3-bromopropyl)benzene (1.59 g, 8.00 mmol) and methyl 3-hy-droxybenzoate (1.22 g, 8.00 mmol), and was isolated as acolourless oil (1.70 g, 79% yield). 1H NMR: δ 1.96-2.07 (m,2H, 2’-H), 2.69-2.76 (m, 2H, 3’-H), 3.83 (s, 3H, CO2CH3), 4.00 (t, J = 6.3 Hz, 2H, 1’-H), 7.14-7.30 (m, 6H, 2”-H, 3”-H, 4”-H, 5”-H, 6”-H, 4-H), 7.38-7.45 (m, 2H, 2-H, 5-H),7.50-7.55 (m, 1H, 6-H). 13C NMR: δ 30.4 (C-2’), 31.5 (C-3’), 52.3 (CO2CH3), 67.1 (C-1’),114.6 (C-2), 119.8 (C-4), 121.5 (C-6), 126.0 (C-4”), 128.4 (C-2”, C-3”, C-5”, C-6”), 130.0(C-5), 131.1 (C-1), 141.4 (C-1”), 158.8 (C-4), 166.2 (CO2Me). LC-MS (m/z): positivemode 271 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 92.0%.
5.2.17.26 Methyl 3-((5-phenylpentyl)oxy)benzoate 86 (ANM271)
CO2Me
O
The compound was synthesized according to GP-8 using(5-bromopentyl)benzene (1.82 g, 8.00 mmol) and methyl3-hydroxybenzoate (1.22 g, 8.00 mmol), and was isolatedas a colourless oil (2.1 g, 88% yield). 1H NMR: δ 1.39-1.48 (m, 2H, 3’-H), 1.57-1.67 (m, 2H, 4’-H), 1.70-1.78 (m, 2H, 2’-H), 2.56-2.60 (m,2H, 5’-H), 3.83 (s, 2H, CO2CH3), 3.99 (t, J = 6.45 Hz, 2H, 1’-H), 7.13-7.20 (m, 4H,2”-H, 4”-H, 6”-H, 4-H), 7.25 (t, J = 7.58 Hz, 2H, 3”-H, 5”-H), 7.39-7.43 (m, 2H, 2-H,5-H), 7.50-7.53 (m, 1H, 6-H). 13C NMR: δ 25.2 (C-3’), 28.5 (C-2’), 30.8 (C-5’), 35.2(C-4’), 52.3 (CO2CH3), 67.8 (C-1’), 114.5 (C-2), 119.9 (C-4), 121.4 (C-4), 125.7 (C-4”),128.3-128.4 (C-2”, C-3”, C-5”, C-6”), 130.0 (C-5), 131.1 (C-1), 142.3 (C-1”), 158.8 (C-4),166.2 (CO2Me). LC-MS (m/z): positive mode 299 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 90.5%.
200
5.2 Synthesis and characterization Dissertation, Universität Bonn 2016
5.2.17.27 Methyl 3-(hexyloxy)benzoate 88 (ANM321)210
OH3C
CO2Me The compound was synthesized according to GP-8 using 1-bromohexane (0.986 mL, 7.00 mmol) and methyl 3-hydroxy-benzoate (1.07 g, 7.00 mmol), and was isolated as a yellowoil (1.10 g, 67% yield). 1H NMR: δ 0.82-0.91 (m, 3H, 6’-H), 1.16-1.34 (m, 4H, 4’-H,5’-H), 1.36-1.46 (m, 2H, 3’-H), 1.64-1.76 (m, 2H, 2’-H), 3.83 (s, 3H, CO2CH3), 3.99 (t,J = 6.5 Hz, 2H, 1’-H), 7.13-7.18 (m, 1H, 4-H), 7.38-7.44 (m, 2H, 2-H, 6-H), 7.49-7.54(m, 1H, 5-H). 13C NMR: δ 14.0 (C-6’), 22.2 (C-5’), 25.2 (C-4’), 28.7 (C-3’), 31.1 (C-2’),52.3 (CO2CH3), 67.9 (C-1’), 114.5 (C-2), 119.9 (C-4), 121.4 (C-6), 130.0 (C-5), 131.1(C-1), 158.9 (C-3), 166.2 (CO2Me). LC-MS (m/z): positive mode 237 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 98.2%.
5.2.17.28 Methyl 3-(heptyloxy)benzoate 90 (ANM322)
O
CO2Me
H3C
The compound was synthesized according to GP-8 using1-bromoheptane (1.10 mL, 7.00 mmol) and methyl 3-hy-droxybenzoate (1.07 g, 7.00 mmol), and was isolated as ayellow oil (1.12 g, 64% yield). 1H NMR: δ 0.80-0.90 (m, 3H, 7’-H), 1.20-1.45 (m, 8H,6’-H, 5’-H, 4’-H, 3’-H), 1.65-1.85 (m, 2H, 2’-H), 3.80-3.90 (m, 3H, CO2CH3), 3.98-4.09(m, 2H, 1’-H), 7.18-7.22 (m, 1H, 4-H), 7.39-7.44 (m, 2H, 2-H, 6-H), 7.50-7.53 (m, 1H,5-H). 13C NMR: δ 14.0 (C-7’), 22.1 (C-5’), 28.7 (C-4’), 32.3 (C-3’), 35.2 (C-2’), 52.3(CO2CH3), 67.8 (C-1’), 114.4 (C-2), 119.9 (C-4), 121.3 (C-6), 130.0 (C-5), 131.1 (C-1),158.8 (C-3), 166.2 (CO2Me). LC-MS (m/z): positive mode 251 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 63.4%.
5.2.17.29 Methyl 3-(octyloxy)benzoate 92 (ANM323)
O
CO2Me
H3C
The compound was synthesized according to GP-8 using1-bromooctane (1.22 mL, 7.00 mmol) and methyl 3-hy-droxybenzoate (1.07 g, 7.00 mmol), and was isolated asa yellow oil (1.61 g, 87% yield). 1H NMR: δ 0.80-0.88 (m, 3H, 8’-H), 1.20-1.45 (m,10H, 7’-H, 6’-H, 5’-H, 4’-H, 3’-H), 1.60-1.80 (m, 2H, 2’-H), 3.80-3.85 (m, 3H, CO2CH3),3.98-4.05 (m, 2H, 1’-H), 7.18-7.21 (m, 1H, 4-H), 7.38- 7.44 (m, 2H, 2-H, 6-H), 7.50-7.54(m, 1H, 5-H). 13C NMR: δ 14.1 (C-8’), 22.2 (C-7’), 25.6 (C-6’), 28.7 (C-5’), 28.8 (C-4’),28.8 (C-3’), 31.3 (C-2’), 52.3 (CO2CH3), 67.9 (C-1’), 114.5 (C-2), 119.9 (C-4), 121.4(C-6), 130.1 (C-5), 131.1 (C-1), 158.9 (C-3), 166.2 (CO2Me). LC-MS (m/z): positive
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mode 265 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 93.3%.
5.2.17.30 Methyl 3-(3-cyclohexylpropoxy)benzoate 98 (THB58)
O
CO2Me The compound was synthesized according to GP-8 using (3-bromopropyl)cyclohexane (1.4 g, 7.00 mmol) and methyl 3-hydroxybenzoate (1.07 g, 7.00 mmol), and was isolated as acolourless oil (1.02 g, 53% yield). 1H NMR: δ 0.81-0.92 (m,2H, 3’-H), 1.05-1.33 (m, 8H, 2”-H, 3”-H, 5”-H, 6”-H), 1.57-1.76 (m, 5H, 2’-H, 1”-H,4”-H), 3.28 (s, 3H, CO2CH3), 3.98 (t, J = 6.5 Hz, 2H, 1’-H), 7.19 (ddd, J = 1.0, 2.7,8.2 Hz, 1H, 4-H), 7.36-7.44 (m, 2H, 5-H, 6-H), 7.48-7.54 (m, 1H, 2-H). 13C NMR: δ25.9 (C-3”, C-5”), 26.1 (C-4”), 26.3 (C-2’), 32.9 (C-2”, C-6”), 33.3 (C-3’), 36.9 (C-1”),52.3 (CO2CH3), 68.2 (C-1’), 114.5 (C-5), 119.9 (C-6), 121.4 (C-4), 130.0 (C-2), 131.1(C-1), 158.8 (C-3), 166.2 (CO2Me). LC-MS (m/z): positive mode 277 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 98.0%.
5.2.18 1-(4-Cyclohexylbutoxy)-4-nitrobenzene5.2.18.1 1-(4-Cyclohexylbutoxy)-4-nitrobenzene 186 (ANM161)230
NO2
O
The product was synthesized according to GP-8 using 44(877 mg, 4 mmol) and 4-nitrophenol (556 mg, 4 mmol) andwas isolated as a white solid (720 mg, 65% yield). 1H NMR: δ 0.83-0.87 (m, 2H,Cyclohexyl), 1.12-1.19 (m, 6H, 4’-H, Cyclohexyl), 1.38-1.42 (m, 2H, 3’-H), 1.61-1.70(m, 7H, 2’-H, Cyclohexyl), .10 (t, J = 4.1 Hz, 2H, 1’-H), 7.09-7.15 (m, 2H, 3-H, 5-H),8.16-8.20 (m, 2H, 2-H, 6-H). 13C NMR: δ 22.7 (C-4’), 25.9 (C-3”, C-5”), 26.3 (C-4’),28.8 (C-3’), 32.9 (C-2”, C-6”), 36.6 (C-2’), 37.1 (C-1”), 68.8 (C-1’), 115.1 (C-3, C-5),126.0 (C-2, C-6), 140.8 (C-1), 164.2 (C-4). LC-MS (m/z): positive mode 278 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 99.1%. lit. mp 51-52 ◦C.
5.2.19 Benzoic acids5.2.19.1 General procedure for the synthesis of the alkyloxybenzoic acids (GP-9)5.2.19.2 Method 1 (GP-9a)In a 10 mL microwave-reaction vessel equipped with a magnetic stirring bar, theappropriate ester (2 mmol) was suspended in MeOH (1 mL) and aq. KOH solution(1 N, 3 mL). The vessel was sealed, and the mixture was irradiated in a microwave
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oven at 100 ◦C for 60 min (3-10 bar, 40-65 W). The reaction mixture was cooled to rt,and 20 mL of water were added. The product was precipitated by dropwise additionof diluted aq. HCl (2 N) until a pH ≤ 2 was reached. The solid was subsequentlyfiltered off, washed with water (15 mL), and dried in vacuum at 50 ◦C.
5.2.19.3 Method 2 (GP-9b)In a 30 mL pressure tube (ACE R©-glass), the appropriate ester (3 mmol) was sus-pended in MeOH (5 mL) and KOH (1N, 7 mL) and heated to 120 ◦C for 4 h. Afteraddition of 80 mL of water the product was precipitated by dropwise addition ofdiluted aq. HCl (2 N) until a pH ≤ 2 was reached. The solid was subsequentlyfiltered off, washed with water (15 mL), and dried in vacuum at 50 ◦C.
5.2.19.4 3-(4-Fluorobenzyloxy)benzoic acid 61 (ANM12)196
O
F
CO2H The compound was synthesized according to GP-9a using 60(521 mg, 2.0 mmol), and was isolated as a white solid (422 mg,86% yield). 1H NMR: δ 5.13 (s, 2H, CH2), 7.18-7.23 (m, 2H, 3’-H,5’-H), 7.25 (ddd, J = 8.2, 2.7 Hz, 1H, 4-H), 7.40 (t, J = 7.9 Hz,1H, 5-H), 7.48-7.52 (m, 3H, 2-H, 2’-H, 6’-H), 7.52-7.55 (m, 1H, 6-H). 13C NMR: δ 68.8(CH2), 115.1 (C-2), 115.4 (C-3’, C-5’), 119.9 (C-6), 122.0 (C-4), 129.9 (C-2’, C-6’), 130.1(C-5), 132.4 (C-1’), 133.2 (C-1), 158.4 (C-3), 162.9 (C-4’), 167.2 (CO2H). LC-MS (m/z):negative mode 245 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. lit. mp150-152 ◦C.
5.2.19.5 3-(4-Bromobenzyloxy)benzoic acid 63 (ANM13)196
O
Br
CO2H The compound was synthesized according to GP-9a using 62(642 mg, 2.0 mmol), and was isolated as a white solid (548 mg,89% yield). 1H NMR: δ 5.13 (s, 2H, CH2), 7.29 (ddd, J = 8.2,2.7 Hz, 1H, 4-H), 7.37 (t, J = 7.9 Hz, 1H, 5-H), 7.40-7.43 (m, 2H,2’-H, 6’-H), 7.51 (dd, J = 2.6 Hz, 1H, 2-H), 7.51-7.54 (m, 2H, 3’-H, 5’-H). 13C NMR: δ68.7 (CH2), 115.1 (C-2), 119.3 (C-6), 121.1 (C-4’), 122.0 (C-4), 129.7 (C-5), 129.9 (C-2’,C-6’), 131.5 (C-3’, C-5’), 133.9 (C-3), 136.6 (C-1’), 158.2 (C-3), 167.4 (CO2H). LC-MS(m/z): negative mode 306 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. lit.
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mp 180-183 ◦C.
5.2.19.6 3-(4-Chlorobenzyloxy)benzoic acid 65 (ANM14)196
O
Cl
CO2H The compound was synthesized according to GP-9a using 64(553 mg, 2.0 mmol), and was isolated as a white solid (494 mg,94% yield). 1H NMR: δ 5.16 (s, 2H, CH2), 7.25 (ddd, J = 8.2, 2.7Hz, 1H, 4-H), 7.41 (t, J = 7.9 Hz, 1H, 5-H), 7.43-7.50 (m, 4H, 2’-H,3’-H, 5’-H, 6’-H), 7.51 (dd, J = 2.6 Hz, 1H, 2-H), 7.52-7.55 (m, 1H, 6-H). 13C NMR: δ68.7 (CH2), 115.1 (C-2), 119.9 (C-6), 122.1 (C-4), 128.6 (C-3’, C-5’), 129.6 (C-2’, C-6’),129.9 (C-5), 132.5 (C-4’), 132.6 (C-1), 136.0 (C-1’), 158.3 (C-3), 167.2 (CO2H). LC-MS(m/z): negative mode 261 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 99.6%. lit.mp 95-96 ◦C.
5.2.19.7 2-(4-Fluorobenzyloxy)benzoic acid 73 (ANM15)196
O
F
HO2C The compound was synthesized according to GP-9a using 72 (521mg, 2.0 mmol), and was isolated as a white solid (479 mg, 97%yield). 1H NMR: δ 5.17 (s, 2H, CH2), 7.00 (td, J = 0.9, 7.5 Hz, 1H,5-H), 7.16-7.23 (m, 3H, 3-H, 3’-H, 5’-H), 7.47 (ddd, J = 1.8, 7.4 Hz, 1H, 5-H), 7.51-7.56(m, 2H, 2’-H, 6’-H), 7.64 (dd, J = 1.8, 7.6 Hz, 1H, 6-H), 12.59 (s, 1H, OH). 13C NMR: δ69.1 (CH2), 114.1 (C-3), 115.3 (C-3’, C-5’), 120.2 (C-5), 122.2 (C-1), 129.4 (C-2’, C-6’),130.8 (C-6), 133.0 (C-4), 133.4 (C-1’), 157.0 (C-2), 162.5 (C-4’), 167.5 (CO2H). LC-MS(m/z): negative mode 245 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 96.8%. lit.mp 82-83 ◦C.
5.2.19.8 4-(3,4-Difluorobenzyloxy)benzoic acid 49 (ANM122)
CO2H
O
F
F
The compound was synthesized according to GP-9a using 48(557 mg, 2.0 mmol), and was isolated as a white solid (507mg, 96% yield). 1H NMR: δ 5.16 (s, 2H, CH2), 7.07-7.11 (m,2H, 3-H, 5-H), 7.30-7.34 (m, 1H, 6’-H), 7.45 (dt, J = 8.4 Hz, 1H, 5’-H), 7.53 (ddd, J =7.8, 2.1 Hz, 1H, 2’-H), 7.87-7.91 (m, 2H, 2-H, 6-H), 12.6 (s, 1H, OH). 13C NMR: δ 68.3(CH2), 114.8 (C-3, C-5), 117.0 (C-2’), 117.8 (C-5’), 123.6 (C-1), 123.9 (C-6’), 131.5 (C-2,C-6), 134.5 (C-1’), 148.2-148.6 (C-4’), 150.3-150.5 (C-3’), 161.7 (C-4), 167.2 (CO2H).LC-MS (m/z): negative mode 263 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS:99.7%. mp 212-213 ◦C.
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5.2.19.9 3-Chloro-4-(4-fluorobenzyloxy)benzoic acid 51 (ANM126)
CO2H
O
F
Cl The compound was synthesized according to GP-9a using 50(589 mg, 2.0 mmol), and was isolated as a white solid (538mg, 96% yield). 1H NMR: δ 5.27 (s, 2H, CH2), 7.21-7.27 (m,2H, 3’-H, 5’-H), 7.33 (d, J = 8.7 Hz, 1H, 5-H), 7.50-7.55 (m, 2H, 2’-H, 6’-H), 7.88 (dd, J= 8.6, 2.1 Hz, 1H, 6-H), 7.91 (d, J = 2.1 Hz, 1H, 2-H), 12.93 (s, 1H, OH). 13C NMR: δ69.8 (CH2), 114.0 (C-5), 115.6 (C-3’, C-5’), 121.6 (C-3), 124.4 (C-1), 130.0 (C-6), 130.1(C-2’, C-6’), 130.9 (C-2), 132.4 (C-1’), 157.1 (C-4), 161.1-163.0 (C-4’), 166.1 (CO2H).LC-MS (m/z): negative mode 279 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS:99.4%. mp 209-210 ◦C.
5.2.19.10 3-Chloro-4-(3,4-difluorobenzyloxy)benzoic acid 53 (ANM148)199
CO2H
O
F
F
Cl The compound was synthesized according to GP-9a using 52(625 mg, 2.0 mmol), and was isolated as a white solid (549mg, 92% yield). 1H NMR: δ 5.27 (s, 2H, CH2), 7.32 (d, J = 8.7Hz, 1H, 6’-H), 7.34 (dt, J = 1.9, 4.8 Hz, 1H, 5-H), 7.47 (dt, J = 8.4 Hz, 1H, 5’-H), 7.54(ddd, J = 7.8, 2.1 Hz, 1H, 2’-H), 7.88 (dd, J = 2.1, 8.6 Hz, 1H, 6-H), 7.92 (d, J = 2.1Hz, 1H, 2-H), 13.0 (s, 1H, OH). 13C NMR: δ 69.2 (CH2), 113.9 (C-5), 116.8-116.9 (C-2’), 117.7-117.9 (C-5’), 121.6 (C-3), 124.5 (C-1), 124.6-124.7 (C-6’), 130.1 (C-6), 130.9(C-2), 133.9 (C-1’), 148.3 (C-4’), 150.3-150.5 (C-3’), 156.9 (C-4), 166.0 (CO2H). LC-MS(m/z): negative mode XXXXXXXX [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS:99.5%. lit. mp 213-215 ◦C.
5.2.19.11 3-Fluor-4-(4-fluorobenzyloxy)benzoic acid 55 (THB13)200
CO2H
O
F
F The compound was synthesized according to GP-9a by heat-ing 54 (556 mg, 2.0 mmol), 5 mL MeOH and 7 mL KOH (1N)for 4 h at 120 ◦C in a pressure tube (ACE-glass), and wasisolated as a white solid (457 mg, 86% yield). 1H NMR: δ 5.24 (s, 2H, CH2), 7.35(t, J = 8.5 Hz, 1H, 5-H), 7.52 (ddd, J = 2.6, 5.34 Hz, 8.5 Hz, 2H, 2’-H, 6’-H), 7.67(dd, J = 2.1, 11.8 Hz, 1H, 6-H), 7.74 (ddd, J = 1.0, 2.0, 8.6 Hz, 1H, 2-H). 13C NMR: δ69.8 (CH2), 114.9 (C-5), 115.6 (C-3’, C-5’), 116.8 (C-6), 123.88 (C-1), 126.8 (C-2), 130.4(C-2’, C-6’), 132.4 (C-1’), 150.2-152.2 (C-3), 161.2 (C-4), 163.1 (C-4’), 166.2 (CO2H).LC-MS (m/z): negative mode 263 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS:99.0%. lit. mp 89-90 ◦C.
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5.2.19.12 4-(3-Cyclohexylpropoxy)benzoic acid 291 (ANM24)231
CO2H
O
The compound was synthesized according to GP-9a us-ing methyl 4-(3-cyclohexylpropoxy)benzoate (553 mg, 2.0mmol), and was isolated as a white solid (488 mg, 97%yield). 1H NMR: δ 0.83-0.91 (q, J = 9.9 Hz, 2H, 3’-H), 1.16-1.25 (m, 6H, Cyclohexyl),1.61-1.72 (m, 7H, Cyclohexyl, 2’-H), 4.00 (t, J = 6.6 Hz, 2H, 1’-H), 6.98 (d, J = 9.0Hz, 2H, 3-H, 5-H), 7.86 (d, J = 8.9 Hz, 2H, 2-H, 6-H), 12.53 (s, 1H, OH). 13C NMR:δ 26.0 (C-3”, C-5”), 26.1 (C-4”), 26.3 (C-2’), 32.9 (C-1”, C-6”), 33.3 (C-3’), 36.9 (C-1”),68.3 (C-1’), 114.4 (C-3, C-5), 122.9 (C-1), 131.5 (C-2, C-6), 162.4 (C-4), 167.1 (CO2H).LC-MS (m/z): positive mode 263 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100.0%. lit. mp 182-183 ◦C.
5.2.19.13 4-((4-Fluorobenzyl)oxy)benzoic acid 47 (ANM55)196
CO2H
O
F
The compound was synthesized according to GP-9a using 46(520 mg, 2.0 mmol), and was isolated as a white solid (418mg, 85% yield). 1H NMR: δ 5.15 (s, 2H, CH2), 7.02-7.09 (m,2H, 3-H, 5-H), 7.17-7.27 (m, 2H, 3’-H, 5’-H), 7.45-7.55 (m, 2H, 2’-H, 6’-H), 7.88 (m, 2H,2-H, 6-H), 12.59 (s, 1H, OH). 13C NMR: δ 68.9 (CH2), 114.7 (C-2, C-6), 115.5-115.3(C-3’, C-5’), 123.4 (C-1), 130.3 (C-2’, C-6’), 131.5 (C-3, C-5), 132.9 (C-1’), 161.9 (C-1,C-4), 167.1 (CO2H). LC-MS (m/z): positive mode 245 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 100.0%. lit. mp 212-213 ◦C.
5.2.19.14 4-(4-Cyclohexylbutoxy)benzoic acid 77 (ANM109)
CO2H
O
The compound was synthesized according to GP-9a us-ing 76 (439 mg, 1.5 mmol), and was isolated as a whitesolid (377 mg, 91% yield). 1H NMR: δ 1.29-1.55 (m, 17H, 2’-H, 3’-H, 4’-H, 1”-H, 2”-H,3’-H, 4”-H, 5”-H, 6”-H), 4.01 (t, J = 6.5 Hz, 2H, 1’-H), 6.94-7.02 (m, 2H, 3-H, 5-H),7.82-7.90 (m, 2H, 2-H, 6-H), 12.69 (s, 1H, OH). 13C NMR: δ 22.8 (C-3’), 26.0 (C-3”,C-5”), 26.3 (C-4”), 29.0 (C-2’), 33.0 (C-2”, C-6”), 36.7 (C-4’), 37.1 (C-1”), 67.9 (C-1’),114.3 (C-3, C-5), 122.9 (C-1), 131.4 (C-2, C-6), 162.4 (C-4), 167.1 (CO2H). LC-MS(m/z): positive mode 277 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%.mp 141-142 ◦C.
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5.2.19.15 4-((4-Fluorobenzyl)oxy)-3-methoxybenzoic acid 57 (ANM120)232
CO2H
O
F
H3CO The compound was synthesized according to GP-9a using56 (581 mg, 2.0 mmol), and was isolated as a white solid(514 mg, 93% yield). 1H NMR: δ 3.80 (s, 3H, OCH3), 5.14 (s,2H, CH2), 7.12 (d, J = 8.5 Hz, 1H, 5-H), 7.22 (m, 2H, 3’-H, 5’-H), 7.46 (d, J = 2.0 Hz,1H, 2-H), 7.48-7.52 (m, 2H, 2’-H, 6’-H), 7.53 (dd, J = 8.4, 2.0 Hz, 1H, 6-H), 12.64 (s,1H, OH). 13C NMR: δ 55.7 (OCH3), 69.3 (CH2), 112.4 (C-5), 112.7 (C-3’, C-5’), 123.1(C-6), 123.5 (C-1), 130.2 (C-2’, C-6’), 133.0 (C-1’), 148.8 (C-3), 151.6 (C-4), 161.0-163.0(C-4’), 167.2 (CO2H). LC-MS (m/z): positive mode 277 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.5%. lit. mp 208-209 ◦C.
5.2.19.16 3-Bromo-4-((4-fluorobenzyl)oxy)benzoic acid 59 (ANM121)
CO2H
O
F
Br The compound was synthesized according to GP-9a using58 (678 mg, 2.0 mmol), and was isolated as a white solid(585 mg, 90% yield). 1H NMR: δ 5.27 (s, 2H, CH2), 7.21-7.27(m, 2H, 3’-H, 5’-H), 7.29 (d, J = 8.7 Hz, 1H, 5-H), 7.49-7.55 (m, 2H, 2’-H, 6’-H), 7.92(dd, J = 8.6, 2.10 Hz, 1H, 6-H), 8.07 (d, J = 2.1 Hz, 1H, 2-H), 12.92 (s, 1H, OH).13C NMR: δ 69.9 (CH2), 111.1 (C-3), 113.8 (C-5), 115.4-115.6 (C-3’, C-5’), 124.8 (C-1),129.9 (C-2’, C-6’), 130.7 (C-6), 132.5 (C-1’), 134.0 (C-2), 158.0 (C-4), 161.1-163.0 (C-4’), 165.94 (CO2H). LC-MS (m/z): positive mode 326 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 97.5%. mp 218-219 ◦C.
5.2.19.17 4-((4-Methoxybenzyl)oxy)benzoic acid 292 (ANM131)232
CO2H
O
H3CO
The compound was synthesized according to GP-9a using293 (545 mg, 2.0 mmol), and was isolated as a white solid(495 mg, 95% yield). 1H NMR: δ 3.75 (s, 3H, OCH3), 5.08(s, 2H, CH2), 6.90-6.99 (m, 2H, 3’-H, 5’-H), 7.04-7.09 (m, 2H, 3-H, 5-H), 7.30-7.40(m, 2H, 2’-H, 6’-H), 7.82-7.90 (m, 2H, 2-H, 6-H), 12.55 (s, 1H, OH). 13C NMR: δ 55.3(OCH3), 69.4 (CH2), 114.0 (C-3’, C-5’), 114.8 (C-2, C-6), 123.2 (C-1), 128.5 (C-1’), 129.8(C-2’, C-6’), 131.4 (C-3, C-5), 159.3 (C-4’), 162.1 (C-4), 167.1 (CO2H). LC-MS (m/z):positive mode 259 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 95.9%. lit. mp189-191 ◦C.
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5.2.19.18 4-((5-Cyclohexylpentyl)oxy)benzoic acid 79 (ANM154)
CO2H
O
The compound was synthesized according to GP-9a us-ing 78 (517 mg, 1.7 mmol), and was isolated as a whitesolid (297 mg, 60% yield). 1H NMR: δ 0.81-0.86 (m,2H, Cyclohexyl), 1.12-1.19 (m, 6H, 5’-H, Cyclohexyl), 1.30-1.38 (m, 4H, 3’-H, 4’-H),1.61-1.70 (m, 7H, 2’-H, Cyclohexyl), 4.01 (t, J = 6.5 Hz, 2H, 1’-H), 6.94-7.01 (m, 2H,3-H, 5-H), 7.84-7.90 (m, 2H, 2-H, 6-H). 13C NMR: δ 25.9-26.1 (C-4’, C-5’), 26.0 (C-3”,C-5”), 26.3 (C-4”), 28.7 (C-3’), 33.0 (C-2”, C-6”), 37.0 (C-2’), 37.1 (C-1”), 67.9 (C-1’),114.3 (C-3, C-5), 121.9 (C-1), 131.4 (C-2, C-6), 162.4 (C-4), 167.1 (CO2H). LC-MS(m/z): positive mode 292 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.7%. mp180-181 ◦C.
5.2.19.19 3-(4-Cyclohexylbutoxy)benzoic acid 101 (ANM174)
O
CO2H The compound was synthesized according to GP-9a using100 (522 mg, 1.8 mmol), and was isolated as a white solid(312 mg, 63% yield). 1H NMR: δ 0.81-0.86 (m, 2H, Cyclo-hexyl), 1.11-1.22 (m, 6H, 4’-H, Cyclohexyl), 1.37-1.45 (m, 2H, 3’-H), 1.60-1.69 (m, 7H,2’-H, Cyclohexyl), 3.94-4.03 (m, 2H, 1’-H), 7.15 (ddd, J = 1.0, 2.7, 8.2 Hz, 1H, 4-H),7.39-7.48 (m, 2H, 2-H, 5-H), 7.50 (dq, J = 1.3, 7.5 Hz, 1H, 6-H). 13C NMR: δ 22.8 (C-4’), 26.0 (C-3”, C-5”), 26.3 (C-4”), 29.0 (C-3’), 32.9 (C-2”, C-6”), 36.7 (C-2’), 37.1 (C-1”),67.8 (C-1’), 114.6 (C-2), 119.5 (C-4), 121.5 (C-6), 129.8 (C-5), 132.3 (C-1), 158.8 (C-4),167.2 (CO2H). LC-MS (m/z): positive mode 294 [M+NH4]+. Purity by HPLC-UV (254nm)-ESI-MS: 100.0%. mp 93-94 ◦C.
5.2.19.20 3-((3-Bromobenzyl)oxy)benzoic acid 67 (ANM226)
O
CO2H
Br
The compound was synthesized according to GP-9b using 66(964 mg, 3.0 mmol), and was isolated as a white solid (660 mg,72% yield). 1H NMR: δ 5.17 (s, 2H, CH2), 7.26 (ddd, J = 1.0, 2.7,8.2 Hz, 1H, 4-H), 7.36 (t, J = 7.8 Hz, 1H, 5’-H), 7.41 (t, J = 7.9Hz, 1H, 5-H), 7.42-7.48 (m, 1H, 6’-H), 7.51-7.55 (m, 3H, 2-H, 6-H, 2’-H), 7.62-7.68(m, 1H, 4’-H), 12.96 (s, 1H, OH). 13C NMR: δ 68.5 (CH2), 115.1 (C-2), 119.9 (C-6),121.8 (C-3’), 122.1 (C-4), 126.7 (C-6’), 129.9 (C-5’), 130.3 (C-5), 130.8 (C-4’), 132.4 (C-1), 139.8 (C-1’), 158.2 (C-3), 167.1 (CO2H). LC-MS (m/z): positive mode 305 [M-H]-.Purity by HPLC-UV (254 nm)-ESI-MS: 98.5%. mp 144-145 ◦C.
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5.2.19.21 3-((4-Methylbenzyl)oxy)benzoic acid 69 (ANM221)205
O
CO2H
H3C
The compound was synthesized according to GP-9b using 68(768 mg, 3.0 mmol), and was isolated as a white solid (687 mg,95% yield). 1H NMR: δ 2.29 (s, 3H, CH3), 5.10 (s, 2H, CH2),7.18 (d, J = 7.9 Hz, 2H, 2’-H, 6’-H), 7.23 (ddd, J = 1.4, 2.7, 8.3Hz, 1H, 4-H), 7.31-7.35 (m, 2H, 5’-H, 3’-H), 7.39 (t, J = 7.9 Hz, 1H, 5-H), 7.48-7.53(m, 2H, 2-H, 6-H), 12.93 (s, 1H, OH). 13C NMR: δ 20.9 (CH3), 69.4 (CH2), 115.1 (C-2),119.8 (C-6), 121.8 (C-4), 127.8 (C-2’, C-6’), 129.1 (C-3’, C-5’), 129.8 (C-5), 132.3 (C-1’),133.9 (C-1), 137.2 (C-4’), 158.4 (C-3), 167.2 (CO2H). LC-MS (m/z): positive mode 243[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. lit. mp 149-150 ◦C.
5.2.19.22 3-((5-Cyclohexylpentyl)oxy)benzoic acid 102 (ANM240)
O
CO2H The compound was synthesized according to GP-9b using45 (912 mg, 3.0 mmol), and was isolated as a white solid(843 mg, 97% yield). 1H NMR: δ 0.80-0.86 (m, 2H, Cyclo-hexyl), 1.03-1.25 (m, 6H, 5’-H, Cyclohexyl), 1.25-1.44 (m,4H, 3’-H, 4’-H), 1.47-1.82 (m, 7H, 2’-H, Cyclohexyl), 3.99 (t, J = 6.5 Hz, 2H, 1’-H),7.15 (ddd, J = 8.2, 2.6, 1H, 1.0 Hz, 4-H), 7.35-7.42 (m, 2H, 2-H, 5-H), 7.47-7.56 (m, 1H,6-H), 12.92 (s, 1H, OH). 13C NMR: δ 25.9 (C-4’, C-5’), 26.0 (C-3”, C-5”), 26.4 (C-4”),28.7 (C-3’), 33.0 (C-2”, C-6”), 37.0 (C-2’), 37.0 (C-1”), 67.8 (C-1’), 114.6 (C-2), 119.5(C-4), 121.5 (C-6), 129.8 (C-5), 132.3 (C-1), 158.8 (C-4), 167.2 (CO2Me). LC-MS (m/z):positive mode 291 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.1%. mp 93-94◦C.
5.2.19.23 3-(Cyclohexylmethoxy)benzoic acid 95 (ANM253)212
O
CO2H The compound was synthesized according to GP-9b using 94 (911mg, 3.7 mmol), and was isolated as a white solid (788 mg, 91%yield). 1H NMR: δ 1.00-1.08 (m, 2H, Cyclohexyl), 1.11-1.29 (m, 3H,Cyclohexyl), 1.60-1.84 (m, 7H, Cyclohexyl), 3.80 (d, J = 6.3 Hz, 2H,C1?H), 7.16 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H, 4-H), 7.34-7.42 (m, 2H, 2-H, 5-H), 7.50(dt, J = 7.7, 1.2 Hz, 1H, 6-H), 12.92 (s, 1H, OH).13C NMR: δ 25.3 (C-3”, C-5”), 26.1(C-4”), 29.3 (C-2”, C-6”), 37.1 (C-1”), 73.0 (C-1’), 114.5 (C-2), 119.4 (C-4), 121.5 (C-6),129.7 (C-5), 132.2 (C-1), 158.9 (C-4), 167.2 (CO2H). LC-MS (m/z): positive mode 235[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. lit. mp 123-124 ◦C.
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5.2.19.24 3-(2-Cyclohexylethoxy)benzoic acid 97 (ANM254)196
O
CO2H The compound was synthesized according to GP-9b using 96(1.80 g, 7.0 mmol), and was isolated as a white solid (1.42 g, 82%yield). 1H NMR: δ 0.89-1.00 (m, 2H, Cyclohexyl), 1.07-1.25 (m,2H, Cyclohexyl), 1.44-1.48 (m, 2H, Cyclohexyl), 1.55-1.75 (m, 7H, 2’-H, Cyclohexyl),4.03 (t, J = 6.6 Hz, 2H, 1’-H), 7.16 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H, 4-H), 7.35-7.43(m, 2H, 2-H, 5-H), 7.49-7.54 (m, 1H, 6-H), 12.92 (s, 1H, OH). 13C NMR: δ 25.8 (C-3”,C-5”), 26.1 (C-4”), 32.8 (C-2”, C-6”), 34.1 (C-1”), 36.0 (C-2’), 65.9 (C-1’), 114.6 (C-2),119.4 (C-4), 121.5 (C-6), 129.7 (C-5), 132.2 (C-1), 158.7 (C-4), 167.18 (CO2H). LC-MS(m/z): positive mode 249 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.6%. lit.mp 119-121 ◦C.
5.2.19.25 3-(Benzyloxy)benzoic acid 71 (ANM255)196
O
CO2H The compound was synthesized according to GP-9b using 70 (1.70g, 7.0 mmol), and was isolated as a white solid (1.95 g, 82% yield).1H NMR: δ 5.16 (s, 2H, 1’-H), 7.25 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H,4-H), 7.30-7.35 (m, 1H, 4”-H), 7.36-7.43 (m, 3H, 2-H, 3”-H, 5”-H),7.43-7.47 (m, 2H, 2”-H, 6”-H), 7.50-7.55 (m, 2H, 5-H, 6-H), 12.95 (s, 1H, OH). 13C NMR:δ 69.5 (C-1’), 115.0 (C-2), 119.8 (C-4), 121.9 (C-6), 127.7 (C-2”, C-6”), 128.0 (C-4”),128.5 (C-3”, C-5”), 129.8 (C-5), 132.3 (C-1), 136.9 (C-1”), 158.4 (C-4), 167.15 (CO2H).LC-MS (m/z): positive mode 229 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100.0%. lit. mp 136-138 ◦C.
5.2.19.26 3-(3-Phenylpropoxy)benzoic acid 83 (ANM257)196
O
CO2H The compound was synthesized according to GP-9b using 82(1.62 g, 6.0 mmol), and was isolated as a white solid (1.29 g,84% yield). 1H NMR: δ 1.81-2.21 (m, 2H, 2’-H), 2.72-2.76 (m,2H, 3’-H), 4.00 (t, J = 6.3 Hz, 2H, 1’-H), 7.15-7.19 (m, 2H, 4-H,4”-H), 7.20-7.24 (m, 2H, 2”-H, 6”-H), 7.27 (t, J = 7.5 Hz, 2H, 3”-H, 5”-H), 7.39 (t,J = 7.9 Hz, 1H, 5-H), 7.42 (dd, J = 2.7, 1.2 Hz, 1H, 2-H), 7.49-7.53 (m, 1H, 6-H).13C NMR: δ 30.4 (C-2’), 31.5 (C-3’), 67.0 (C-1’), 114.6 (C-2), 119.4 (C-4), 121.6 (C-6),125.9 (C-4”), 128.4 (C-2”, C-3”, C-5”, C-6”), 129.8 (C-5), 132.3 (C-1), 141.4 (C-1”), 158.7(C-4), 167.2 (CO2H). LC-MS (m/z): positive mode 257 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 98.5%. lit. mp 118-120 ◦C.
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5.2.19.27 3-Phenethoxybenzoic acid 81 (ANM258)196
CO2H
O
The compound was synthesized according to GP-9b using 80(1.28 g, 5.0 mmol), and was isolated as a white solid (1.10 g,90% yield). 1H NMR: δ 3.04 (t, J = 6.8 Hz, 2H, 2’-H), 4.23 (t, J= 6.8 Hz, 2H, 1’-H), 7.15-7.19 (m, 1H, 4-H), 7.19-7.24 (m, 1H, 4’-H), 7.27-7.34 (m,4H, 2”-H, 3”-H, 5”-H, 6”-H), 7.38 (t, J = 7.9 Hz, 1H, 5-H), 7.42 (dd, J = 1.5, 2.7 Hz,2-H), 7.49-7.54 (m, 1H, 6-H). 13C NMR: δ 35.0 (C-2’), 68.5 (C-1’), 114.8 (C-2), 119.4(C-4), 121.7 (C-6), 126.4 (C-4”), 128.4 (C-2”, C-6”), 129.1 (C-3”, C-5”), 129.9 (C-5),132.3 (C-1), 138.4 (C-1”), 158.5 (C-4), 167.2 (CO2H). LC-MS (m/z): positive mode 243[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.8%. lit. mp 112-113 ◦C.
5.2.19.28 3-((5-Phenylpentyl)oxy)benzoic acid 87 (ANM273)
CO2H
O
The compound was synthesized according to GP-9b using86 (2.10 g, 7.0 mmol), and was isolated as a white solid(1.70 g, 86% yield). 1H NMR: δ 1.40-1.46 (m, 2H, 3’-H),1.60-1.64 (m, 2H, 4’-H), 1.70-1.76 (m, 2H, 2’-H), 2.54-2.62(m, 2H, 5’-H), 3.99 (t, J = 6.4 Hz, 2H, 1’-H), 7.17-7.20 (m, 4H, 2”-H, 4”-H, 6”-H, 4-H),7.25 (t, J = 7.6 Hz, 2H, 3”-H, 5”-H), 7.35-7.42 (m, 2H, 2-H, 5-H), 7.50 (d, J = 7.5 Hz,1H, 6-H), 12.93 (s, 1H, OH). 13C NMR: δ 25.2 (C-3’), 28.6 (C-2’), 30.8 (C-5’), 35.2 (C-4’), 67.7 (C-1’), 114.6 (C-2), 119.5 (C-4), 121.5 (C-4), 125.7 (C-4”), 128.3-128.4 (C-2”,C-3”, C-5”, C-6”), 129.8 (C-5), 132.3 (C-1), 142.3 (C-1”), 158.8 (C-4), 167.2 (CO2H).LC-MS (m/z): positive mode 285 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100.0%. mp 89-92 ◦C.
5.2.19.29 3-(Hexyloxy)benzoic acid 89 (ANM325)196
OH3C
CO2H The compound was synthesized according to GP-9b using 88(1.06 g, 4.05 mmol), and was isolated as a white solid (725mg, 73% yield). 1H NMR: δ 0.81-0.91 (m, 2H, 6’-H), 1.25-1.32(m, 4H, 4’-H, 5’-H), 1.38-1.45 (m, 2H, 3’-H), 1.64-1.76 (m, 2H, 2’-H), 3.99 (t, J = 6.5 Hz,2H, 1’-H), 7.13-7.18 (m, 1H, 4-H), 7.35-7.42 (m, 2H, 2-H, 6-H), 7.47-7.53 (m, 1H, 5-H),12.92 (s, 1H, OH). 13C NMR: δ 14.0 (C-6’), 22.2 (C-5’), 25.3 (C-4’), 28.7 (C-3’), 31.1(C-2’), 67.8 (C-1’), 114.6 (C-2), 119.5 (C-4), 121.6 (C-6), 129.8 (C-5), 132.3 (C-1), 158.8(C-3), 167.2 (CO2H). LC-MS (m/z): positive mode 223 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 100.0%. lit. mp 74-75 ◦C.
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5.2.19.30 3-(Octyloxy)benzoic acid 93 (ANM326)196
O
CO2H
H3C
The compound was synthesized according to GP-9b us-ing 92 (1.06 g, 4.00 mmol), and was isolated as a whitesolid (1.09 g, 72% yield). 1H NMR: δ 0.85-0.90 (m, 3H,6’-H), 1.28-1.40 (m, 6H, 5’-H, 4’-H, 3’-H), 1.68-1.72 (m, 2H, C2?H); 3.98-4.05 (m, 2H,C1?H); 7.15-7.16 (m, 1H, C4H); 7.36-7.51 (m, 3H, C2H, C5H, C6H); 12.92 (s, 1H, OH).13C NMR: δ 14.1 (CH, C-8’), 22.2 (C-7’), 25.6 (C-6’), 28.7 (C-3’), 28.8 (C-4’), 28.8 (C-3’), 31.3 (C-2’), 67.8 (C-1’), 114.6 (C-2), 119.5 (C-4), 121.5 (C-6), 129.8 (C-5), 132.3(C-1), 158.8 (C-3), 167.2 (CO2H). LC-MS (m/z): positive mode 251 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 99.0%. lit. mp 76-79 ◦C.
5.2.19.31 3-(Heptyloxy)benzoic acid 91 (ANM328)196
O
CO2H
H3C
The compound was synthesized according to GP-9b using90 (751 mg, 3.00 mmol), and was isolated as a white solid(879 mg, 84% yield). 1H NMR: δ 0.80-0.90 (m, 3H, 7’-H),1.20-1.45 (m, 8H, 6’-H, 5’-H, 4’-H, 3’-H), 1.65-1.75 (m, 2H, 2’-H), 3.95-4.05 (m, 2H,1’-H), 7.10-7.20 (m, 1H, 4-H), 7.30-7.55 (m, 2H, 2-H, 6-H), 7.50-7.53 (m, 1H, 5-H),12.7 (s, 1H, OH). 13C NMR: δ 14.1 (C-7’), 22.2 (C-6’), 25.6 (C-5’), 28.5 (C-4’), 28.7(C-3’), 31.4 (C-2’), 67.8 (C-1’), 114.6 (C-2), 119.5 (C-4), 121.5 (C-6), 129.8 (C-5), 132.3(C-1), 158.8 (C-3), 167.3 (CO2H). LC-MS (m/z): positive mode 237 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 99.5%. lit. mp 81-82 ◦C.
5.2.19.32 4-((5-Phenylpentyl)oxy)benzoic acid 75 (THB20)32
CO2H
O
The compound was synthesized according to GP-9b us-ing 74 (706 mg, 2.35 mmol), and was isolated as a whitesolid (649 mg, 97% yield). 1H NMR: δ 1.42 (p, J = 7.6Hz, 2H, 3’-H), 1.62 (p, J = 7.6 Hz, 2H, 4’-H), 1.74 (dt, J = 6.6, 14.3 Hz, 2H, 2’-H),2.41-2.66 (m, 2H, 5’-H), 4.02 (t, J = 6.5 Hz, 2H, 1’-H), 6.89-7.03 (m, 2H, 3-H, 5-H),7.07-7.32 (m, 5H, 2”-H, 3”-H, 4”-H, 5”-H, 6”-H), 7.77-7.95 (m, 2H, 2-H, 6-H). 13CNMR: δ 25.3 (C-2’), 28.5 (C-3’), 30.8 (C-4’), 35.2 (C-5’), 67.9 (C-1’), 114.3 (C-3, C-5),123.1 (C-1), 125.7 (C-4’), 128.3 (C-3”, C-5”), 128.4 (C-2”, C-6”), 131.4 (C-2, C-6), 142.3(C-1”), 162.4 (C-4), 167.1 (CO2H). LC-MS (m/z): positive mode 285 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 99.0%. lit. mp 151-152 ◦C.
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5.2.19.33 3-(4-Phenylbutoxy)benzoic acid 85 (THB33)209
O
CO2H The compound was synthesized according to GP-9b using 84(816 mg, 2.86 mmol), and was isolated as a white solid (185mg, 23% yield). 1H NMR: δ 1.68-1.75 (m, 4H, 2’-H, 3’-H), 2.49(p, J = 1.8 Hz, 2H, 4’-H), 3.99-4.05 (m, 2H, 1’-H), 7.12-7.30 (m, 5H, 2”-H, 3”-H, 4”-H,5”-H, 6”-H), 7.34-7.44 (m, 2H, 2-H, 6-H), 7.50 (dt, J = 1.1, 7.6 Hz, 2H, 5-H, 6-H), 12.91(s, 1H, OH). 13C NMR: δ 27.5 (C-3’), 28.3 (C-2’), 34.9 (C-4’), 67.6 (C-1’), 114.6 (C-2),119.5 (C-4), 121.6 (C-6), 125.8 (C-4’), 128.4 (3”-H, 5”-H), 128.4 (2”-H, 6”-H), 129.8(5’-H), 132.3 (C-1), 142.1 (C-1”), 158.8 (C-3), 167.2 (CO2H). LC-MS (m/z): positivemode 271 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.0%. lit. mp 78-79 ◦C.
5.2.19.34 3-(3-Cyclohexylpropoxy)benzoic acid 99 (THB60)
O
CO2H The compound was synthesized according to GP-9b using 98(723 mg, 2.60 mmol), and was isolated as a white solid (641mg, 94% yield). 1H NMR: δ 0.81-0.92 (m, 2H, 3’-H), 1.05-1.33(m, 8H, 2”-H, 3”-H, 5”-H, 6”-H), 1.57-1.76 (m, 5H, 2’-H, 1”-H,4”-H), 3.97 (t, J = 6.5 Hz, 2H, 1’-H), 7.15 (ddd, J = 1.0, 2.7, 8.2 Hz, 1H, 4-H), 7.34-7.43(m, 2H, 5-H, 6-H), 7.50 (dt, J = 1.2, 7.6 Hz, 1H, 2-H). 13C NMR: δ 25.9 (C-3”, C-5”),26.1 (C-4”), 26.3 (C-2’), 32.9 (C-2”, C-6”), 33.3 (C-3’), 36.9 (C-1”), 68.1 (C-1’), 114.6(C-5), 119.4 (C-6), 121.5 (C-4), 129.8 (C-2), 132.3 (C-1), 158.8 (C-3), 167.2 (CO2H).LC-MS (m/z): positive mode 263 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:97.0%. mp 113-114 ◦C.
5.2.20 4-(4-Cyclohexylbutoxy)aniline5.2.20.1 4-(4-Cyclohexylbutoxy)aniline 187 (ANM180)
NH2
O
Compound 186 (555 mg, 2.00 mmol) was hydrogenated (45psi) with Pd/C 5% (150 mg) in 10 mL of MeOH for 1 h atrt, filtrated over Celite R© and isolated as a colourless oil (403 mg, 82% yield). Thecompound is unstable and therefore was further reacted without further purificationand characterization.
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5.2.21 Ethyl 8-benzamido-4-oxo-4H-chromene-2-carboxylates5.2.21.1 General procedure for the synthesis of the ethyl 8-benzamido-4-oxo-4H-chromene-2-carboxylates (GP-10)
To form the acid chloride, the appropriate acid (1.2 mmol) and three drops of an-hydrous DMF were dissolved in DCM (5 mL). Then 1 mL of freshly distilled thionylchloride was added and the reaction mixture was stirred under an argon atmo-sphere at rt for 30 min. The DCM and excess of thionyl chloride were distilled offunder reduced pressure using a glass filter pump. Cooling by an ice-bath inducedthe crystallization of the desired acid chloride. In the meantime, the appropriateethyl 8-amino-4-oxo-4H-chromene-2-carboxylate (0.9 mmol) and DIPEA (0.20 mL,1.2 mmol) were dissolved in DCM (4.5 mL) and anhydrous THF (1.5 mL). This so-lution was added to the formed acid chloride, which had been dissolved in 4 mL ofDCM. The reaction mixture was then stirred at rt from 1 to 2 days under an argonatmosphere. For work-up conditions, see individual compounds.
5.2.21.2 Ethyl 6-bromo-8-(2-fluoro-4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylate 104 (ANM3)65
O
O
CO2Et
Br
NHO
OCH3
F
The compound was synthesized according to GP-10 using 2-fluo-ro-4-methoxybenzoic acid (204 mg, 1.2 mmol) and 17 (281 mg, 0.9mmol). The precipitate was filtered off, washed three times with1 mL of DCM each, and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (267 mg, 64% yield). 1H NMR: δ1.35 (t, J = 7.1 Hz, 3H, CH2CH3), 3.88 (s, 3H, OCH3), 4.41 (q, J =7.1 Hz, 2H, CH2CH3), 7.00 (dd, J = 8.9, 2.4 Hz, 1H, 5’-H), 7.04 (s, 1H, 3-H), 7.07 (dd,J = 13.8, 2.3 Hz, 1H, 3’-H), 7.89 (d, J = 2.4 Hz, 1H, 5-H), 7.94 (dd, J = 8.9 Hz, 1H,6’-H), 8.68 (d, J = 2.4 Hz, 1H, 7-H), 9.82 (s, 1H, CONH). 13C NMR: δ 14.2 (CH2CH3)56.7 (OCH3), 63.4 (CH2CH3),102.5 (d, J = 28.6 Hz, C-3’), 111.9 (C-5’), 113.6 (d, J =13.2 Hz, C-1’), 114.4 (C-3), 118.6 (C-6), 122.3 (C-5), 125.7 (C-4a), 129.3 (C-7), 130.5(C-8), 133.0 (d, J = 3.3 Hz, C-6’), 146.6 (C-8a), 152.3 (C-2), 160.0 (CO2Et), 161.7 (d,J = 248.7 Hz, C-2’), 162.0 (C-4’), 164.1 (d, J = 12.1 Hz, CONH), 176.4 (C4). LC-MS(m/z): negative mode 464 [M-H]-, positive mode 464 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 100.0%. mp 216 ◦C.
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5.2.21.3 Ethyl 6-bromo-8-(2,6-difluoro-4-methoxybenzamido)-4-oxo-4H-chro-mene-2-carboxylate 105 (ANM4)65
O
O
CO2Et
Br
NHO
OCH3
FF
The compound was synthesized according to GP-10 using 2,6-difluoro-4-methoxybenzoic acid (226 mg, 1.2 mmol) and 17 (281mg, 0.9 mmol). The precipitate was filtered off, washed threetimes with 1 mL of DCM each, and dried in vacuum at 50 ◦C. Thefiltrate was concentrated under reduced pressure and separatedby column chromatography on a column of silica gel (5% EtOAcin DCM), yielding further product. The amide was isolated as a white powder (221mg, 51% yield). 1H NMR: δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 3.87 (s, 3H, OCH3), 4.39(q, J = 7.1 Hz, 2H, CH2CH3), 6.85 (d, J = 10.0 Hz, 2H, 3’-H, 5’-H), 7.00 (s, 1H, 3-H),7.97 (d, J = 2.4 Hz, 1H, 5-H), 8.33 (d, J = 2.4 Hz, 1H, 7-H), 10.27 (s, 1H, CONH).13C NMR: δ 14.2 (CH2CH3), 57.0 (OCH3), 63.3 (CH2CH3), 99.1 (d, J = 28.6 Hz, C-3’,C-5’), 106.8-107.1 (m, C-1’), 114.4 (C-3), 118.3 (C- 6), 124.0 (C-5), 126.1 (C-4a), 129.7(C-8), 132.1 (C-7), 148.1 (C-8a), 152.6 (C-2), 159.3 (C-4’), 160.1 (CO2Et), 160.0-161.7(m, C-2’, C- 6’), 162.6 (t, J = 14.3 Hz, CONH), 176.4 (C4). LC-MS (m/z): negativemode 482 [M-H]-, positive mode 484 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:98.6%. mp 263 ◦C.
5.2.21.4 Ethyl 6-bromo-8-(3-fluoro-4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylate 106(ANM5)65
O
O
CO2Et
Br
NHO
OCH3
F
The compound was synthesized according to GP-10 using 3-fluo-ro-4-methoxybenzoic acid (204 mg, 1.2 mmol) and 17 (281 mg, 0.9mmol). The precipitate was filtered off, washed three times with1 mL of DCM each, and dried in vacuum at 50 ◦C. The filtrate wasconcentrated under reduced pressure and separated by columnchromatography on a column of silica gel (2 % EtOAc in DCM),yielding further product. The amide was isolated as a white solid (309 mg, 74%yield). 1H NMR: δ 1.29 (t, J = 7.1 Hz, 3H, CH2CH3), 3.96 (s, 3H, OCH3), 4.37 (q, J =7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H), 7.34 (dd, J = 8.5 Hz, 1H, 5’-H), 7.83-7.89 (m,2H, 2’-H, 6’-H), 7.97 (d, J = 2.4 Hz, 1H, 5-H), 8.32 (d, J = 2.4 Hz, 1H, 7-H), 10.05 (s,1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 56.4 (OCH3), 62.6 (CH2CH3), 113.6 (C-3 orC-6’), 113.7 (C-3 or C-6’), 115.1 (d, J = 19.2 Hz, C-2’), 117.6 (C-6), 123.0 (C-5), 124.8
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(d, J = 2.7 Hz, C-5’), 125.3 (C-4a), 126.0 (d, J = 5.5 Hz, C-1’), 130.0 (C-8), 131.8 (C-7),147.9 (C-8a), 150.5 (d, J = 10.1 Hz, C-4’), 151.0 (d, J = 245.6 Hz, C-3’), 151.8 (C- 2),159.4 (CO2Et), 163.7 (CONH), 175.7 (C4). LC-MS (m/z): negative mode 461 [M-H]-,positive mode 466 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.2%. mp 251◦C.
5.2.21.5 Ethyl6-bromo-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylate103 (ANM28)95
O
O
CO2Et
Br
NHO
OCH3
The compound was synthesized according to GP-10 using 4-me-thoxybenzoic acid (409 mg, 2.4 mmol) and 17 (562 mg, 1.8 mmol).The precipitate was filtered off, washed three times with 1 mLof DCM each, and dried in vacuum at 50 ◦C. The filtrate wasconcentrated under reduced pressure and separated by columnchromatography on a column of silica gel (2 % EtOAc in DCM),yielding further product. The amide was isolated as a white solid (832 mg, 78%yield). 1H NMR: δ 1.26 (t, J = 7.1 Hz, 3H, CH2CH3), 3.86 (s, 3H, OCH3), 4.34 (q, J= 7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H), 7.09-7.13 (m, 2H, 3’-H, 5’-H), 7.95 (d, J =2.4 Hz, 1H, 5-H), 7.98-8.03 (m, 2H, 2’-H, 6’-H), 8.33 (d, J = 2.4 Hz, 1H, 7-H), 10.18(s, 1H, CONH). 13C NMR: δ 13.8 (CH2CH3), 55.7 (OCH3), 63.0 (CH2CH3), 114.0 (C-3’,C-5’), 118.1 (C-6), 123.0 (C-5), 125.6 (C-4a), 125.8 (C-1’), 129.9 (C-2’, C-6’), 130.5 (C-8), 132.2 (C-7), 148.2 (C-8a), 152.0 (C-2), 159.8 (CO2Et), 162.6 (C-4’), 164.9 (CONH),176.2 (C4). LC-MS (m/z): negative mode 446 [M-H]-, positive mode 448 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 251-252 ◦C.
5.2.21.6 Ethyl8-(4-methoxybenzamido)-6-methyl-4-oxo-4H-chromene-2-carboxylate107 (ANM33)65
O
O
CO2Et
H3C
NHO
OCH3
The compound was synthesized according to GP-10 using 23(226 mg, 0.9 mmol) and 4-methoxybenzoylchloride (204 mg, 1.2mmol). The precipitate was filtered off, washed three times with1 mL of DCM each, and dried in vacuum at 50 ◦C. The productwas isolated as a white powder (278 mg, 81% yield). 1H NMR:δ 1.27 (t, J = 7.1 Hz, 3H, CH2CH3), 2.46 (s, 3H, Ar-CH3), 3.87 (s,
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3H, OCH3), 4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 6.93 (s, 1H, 3-H), 7.07-7.10 (m, 2H, 3’-H,5’-H), 7.68-7.69 (m, 1H, 5-H), 7.98 (d, J = 2.1 Hz, 1H, 7-H), 8.00-8.03 (m, 2H, 2’-H,6’-H), 9.85 (s, 1H, CONH). 13C NMR: δ 13.5 (CH2CH3), 20.5 (Ar-CH3), 55.4 (OCH3),62.4 (CH2CH3), 113.3 (C-3), 113.7 (C-3’, C-5’), 120.2 (C-5), 123.9 (C-4a), 126.1 (C-1’),128.2 (C-8), 129.4 (C-2’, C-6’), 130.9 (C-7), 135.3 (C-6), 147.2 (C-8a), 151.5 (C-2), 159.7(CO2Et), 162.1 (C-4’), 164.7 (CONH), 176.9 (C4). LC-MS (m/z): negative mode 380[M-H]-, positive mode 382 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.2%.mp 219 ◦C.
5.2.21.7 Ethyl6-methoxy-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylate108 (ANM39)65
O
O
CO2Et
H3CO
NHO
OCH3
The compound was synthesized according to GP-10 using 24(237 mg, 0.9 mmol) and 4-methoxybenzoylchloride (204 mg, 1.2mmol). The precipitate was filtered off, washed three times with1 mL of DCM each, and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (304 mg, 85% yield). 1H NMR:δ 1.30 (t, J = 7.1 Hz, 3H, CH2CH3), 3.87 (s, 3H, C6-OCH3 or4’-OCH3), 3.90 (s, 3H, C6-OCH3 or 4’-OCH3), 4.36 (q, J = 7.1 Hz, 2H, CH2CH3), 6.93(s, 1H, 3-H), 7.09 (d, J = 8.8 Hz, 2H, 3’-H, 5’-H), 7.27 (d, J = 3.1 Hz, 1H, 5-H), 7.85 (d, J= 3.0 Hz, 1H, 7-H), 8.00 (d, J = 9.1 Hz, 2H, 2’-H, 6’-H), 9.76 (s, 1H, CONH). 13C NMR:δ 13.5 (CH2CH3), 55.4 (C6-OCH3 or C4’-OCH3), 55.8 (C6-OCH3 or C4’-OCH3), 62.4(CH2CH3), 101.1 (C-5), 112.5 (C-3), 113.8 (C-3’, C-5’), 118.0 (C-7), 124.7 (C-4a), 126.0(C-1’), 129.3 (C-2’, C-6’), 129.7 (C-8), 143.5 (C-8a), 151.3 (C-2), 156.6 (C-6), 159.7(CO2Et), 162.3 (C-4’), 164.6 (CONH), 176.5 (C4). LC-MS (m/z): negative mode 396[M-H]-, positive mode 398 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.9%.mp 217-218 ◦C.
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5.2.21.8 Ethyl 6-bromo-8-(2,4-dimethoxybenzamido)-4-oxo-4H-chromene-2-car-boxylate 109(ANM43)
O
O
CO2Et
Br
NHO
OCH3
OCH3
The compound was synthesized according to GP-10 using 17(281 mg, 0.9 mmol) and 2,4-dimethoxybenzoyl chloride (240 mg,1.2 mmol). The precipitate was filtered off, washed three timeswith 1 mL of DCM each, and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (257 mg, 69% yield). 1H NMR: δ1.37 (t, J = 7.1 Hz, 3H, CH2CH3), 3.90 (s, 3H, C4’-OCH3), 4.18 (s,3H, C2’OCH3), 4.46 (q, J = 7.1 Hz, 2H, CH2CH3), 5.68 (s, 1H, CONH), 6.77 (dd, J= 8.8, 2.3 Hz, 1H, 5’-H), 6.82 (d, J = 2.2 Hz, 1H, 3’-H), 7.03 (s, 1H, 3-H), 7.82 (d,J = 2.5 Hz, 1H, 5-H), 8.08 (d, J = 8.8 Hz, 1H, 6’-H), 9.08 (d, J = 2.4 Hz, 1H, 7-H),10.56 (s, 1H, OH). 13C NMR: δ 13.6 (CH2CH3), 55.6 (C2’-OCH3), 56.9 (C4’-OCH3), 62.7(CH2CH3), 99.3 (C-3’), 107.0 (C-5’), 112.8 (C-6), 113.9 (C-3), 118.2 (C-1’), 120.2 (C-7),125.0 (C-4a), 126.4 (C-5), 130.4 (C-8), 133.3 (C-6’), 144.7 (C-8a), 152.9 (C-2), 159.2(C-2’), 160.7 (CO2Et), 162.9 (C-4’), 164.3 (CONH), 175.8 (C-4). LC-MS (m/z): positivemode 450 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.5%. mp 284-285 ◦C.
5.2.21.9 Ethyl 8-(4-methoxybenzamido)-4-oxo-6-(trifluoromethoxy)-4H-chro-mene-2-carboxylate 110(ANM62)
O
O
CO2Et
F3CO
NHO
OCH3
The compound was synthesized according to GP-10 using 18(206 mg, 0.65 mmol) and 4-methoxybenzoyl chloride (205 mg,1.2 mmol) and was isolated as a white solid (50 mg, 17 % yield).1H NMR: δ 1.27 (t, J = 7.1 Hz, 3H, CH2CH3), 3.86 (s, 3H, OCH3),4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 6.98-7.02 (m, 2H, 3’-H, 5’-H),7.04 (s, 1H, 3-H), 7.70-7.74 (m, 1H, 5-H), 7.86-7.90 (m, 2H, 2’-H, 6’-H), 8.21-9.25 (m, 1H, 7-H), 10.20 (s, 1H, CONH). 13C NMR: δ 13.8 (CH2CH3),55.6 (OCH3), 63.0 (CH2CH3), 111.8 (C-5), 113.9 (C-3’, C-5’), 114.1 (C-3), 119.2-121.2(OCF3), 122.3 (C-7), 124.9 (C-4a), 125.6 (C-1’), 131.0 (C-8), 131.5 (C-2’, C-6’), 145.1(C-8a), 147.3 (C-6), 152.1 (C-2), 159.7 (CO2Et), 164.9 (C-4’), 167.1 (CONH), 176.6 (C-4). LC-MS (m/z): positive mode 452 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100%. mp 176-177 ◦C.
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5.2.21.10 Ethyl8-(4-methoxybenzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylate111 (ANM74)
O
O
CO2Et
NHO
OCH3
The compound was synthesized according to GP-10 using 26(185 mg, 0.60 mmol) and 4-methoxybenzoyl chloride (135 mg,0.8 mmol) and was isolated as a white solid (252 mg, 95%yield). 1H NMR: δ 1.31 (t, J = 7.1 Hz, 3H, CH2CH3), 3.88 (s,3H, OCH3), 4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H),7.09-7.13 (m, 2H, 3’-H, 5’-H), 7.43-7.48 (m, 1H, 4”-H), 7.51-7.55(m, 2H, 3”-H, 5”-H), 7.72-7.76 (m, 2H, 2”-H, 6”-H), 8.01-8.05 (m,2H, 2’-H, 6’-H), 8.07 (d, J = 2.3 Hz, 1H, 5-H), 8.48 (d, J = 2.3 Hz, 1H, 7-H), 9.89 (s, 1H,CONH). 13C NMR: δ 13.5 (CH2CH3), 55.4 (OCH3), 62.5 (CH2CH3), 113.4 (C-3), 113.8(C-3’, C-5’), 117.9 (C-5), 124.4 (C-4a), 126.0 (C-1’), 126.7 (C-2”, C-6”), 127.9 (C-4”),128.0 (C-7), 128.1 (C-8), 128.1 (C-3”, C-5”), 129.4 (C-2’, C-6’), 137.7 (C-6), 138.2 (C-1”), 148.1 (C-8a), 151.6 (C-2), 159.6 (C-4’), 162.3 (CO2Et), 164.7 (CONH), 176.9 (C-4).LC-MS (m/z): positive mode 444 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100%. mp 237-238 ◦C.
5.2.21.11 Ethyl6-ethyl-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylate112 (ANM92)
O
O
CO2Et
NHO
OCH3
H3C
The compound was synthesized according to GP-10 using 20(234 mg, 0.9 mmol) and 4-methoxybenzoyl chloride (205 mg,1.2 mmol) and was isolated as a white solid (321 mg, 90%yield). 1H NMR: δ 1.22-1.26 (m, 6H, CO2CH2CH3, C6-CH2CH3),2.76 (q, J = 7.6 Hz, 2H, C6-CH2CH3), 3.85 (s, 3H, OCH3), 4.32(q, J = 7.1 Hz, 2H, CO2-CH2CH3), 6.95 (s, 1H, 3-H), 7.07-7.11(m, 2H, 3’-H, 5’-H), 7.71 (d, J = 2.0 Hz, 1H, 5-H), 7.97 (d, J = 2.2 Hz, 1H, 7-H),7.98-8.02 (m, 2H, 2’-H, 6’-H), 10.03 (s, 1H, CONH). 13C NMR: δ 13.8 (CO2-CH2CH3),15.4 (C6-CH2CH3), 27.8 (C6-CH2CH3), 55.6 (OCH3), 62.8 (CO2-CH2CH3), 113.6 (C-3),113.9 (C-3’, C-5’), 119.5 (C-5), 124.2 (C-4a), 126.1 (C-1’), 128.5 (C-8), 129.7 (C-2’, C-6’),130.8 (C-7), 141.8 (C-6), 147.8 (C-8a), 151.7 (C-2), 160.0 (CO2Et), 162.4 (C-4’), 164.9(CONH), 177.3 (C-4). LC-MS (m/z): positive mode 369 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 97.9%. mp 168-170 ◦C.
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5.2.21.12 Ethyl 6-bromo-8-(2-ethoxy-2-oxoacetamido)-4-oxo-4H-chromene-2-carboxylate 120(ANM181)
O
O
CO2Et
Br
NHO
O OEt
The compound was synthesized according to GP-10 using 17 (280mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2 mmol)and was isolated as a white solid (271 mg, 73% yield). 1H NMR:δ 1.35 (t, J = 7.1 Hz, 6H, CH2CH3), 4.38 (dq, J = 7.1 Hz, 2H,CH2CH3), 7.02 (s, 1H, 3-H), 7.94 (d, J = 2.4 Hz, 1H, 5-H), 8.38 (d,J = 2.5 Hz, 1H, 7-H), 10.39 (s, 1H, CONH). 13C NMR: δ 13.9 (CH2CH3), 63.0-63.2(CH2CH3), 114.04 (C-3), 118.1 (C-6), 123.6 (C-7), 125.5 (C-4a), 128.6 (C-8), 129.9 (C-5), 146.8 (C-8a), 151.8 (C2), 155.3 (CONH), 159.6-159.7 (CO2Et), 174.9 (C-4). LC-MS(m/z): positive mode 415 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.7%. mp172-173 ◦C.
5.2.21.13 Ethyl6-bromo-8-(4-ethylbenzamido)-4-oxo-4H-chromene-2-carboxylate113 (ANM186)
O
O
CO2Et
Br
NHO
CH3
The compound was synthesized according to GP-10 using 17 (280mg, 0.9 mmol) and 4-ethylbenzoyl chloride (0.18 mL, 1.2 mmol)and was isolated as a white solid (363 mg, 91% yield). 1H NMR:δ 1.26 (t, J = 7.1 Hz, 3H, C4’-CH2CH3), 1.31 (t, J = 7.1 Hz, 3H,CO2-CH2CH3), 2.75 (q, emphJ = 7.6 Hz, 2H, C4’-CH2CH3), 4.39 (q,J = 7.1 Hz, 2H, CO2-CH2CH3), 7.02 (s, 1H, 3-H), 7.41-7.45 (m, 2H,3’-H, 5’-H), 7.95-7.99 (m, 3H, 5-H, 2’-H, 6’-H), 8.40 (dd, J = 2.4 Hz,1H, 7-H), 9.99 (s, 1H, CONH). 13C NMR: δ 13.4 (CO2-CH2CH3), 14.8 (C4’-CH2CH3),27.9 (C4’-CH2CH3), 62.6 (CO2-CH2CH3), 113.5 (C-3), 117.7 (C-6), 122.6 (C-5), 125.2(C-4a), 127.6-127.7 (C-2’, C-3’, C-5’, C-6’), 130.2 (C-8), 130.9 (C-1’), 131.1 (C-7), 147.6(C-4’), 148.5 (C-8a), 151.8 (C-2), 159.4 (CO2Et), 165.1 (CONH), 175.7 (C-4). LC-MS(m/z): positive mode 430 [M+H]+ (methylester). Purity by HPLC-UV (254 nm)-ESI-MS: 95.9%. mp 208-210 ◦C.
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5.2.21.14 Ethyl 6-(4-chlorophenyl)-8-(4-methoxybenzamido)-4-oxo-4H-chro-mene-2-carboxylate 114(ANM195)
O
O
CO2Et
NHO
OCH3
Cl The compound was synthesized according to GP-10 using27 (152 mg, 0.44 mmol) and 4-methoxybenzoyl chloride (100mg, 0.59 mmol) and was isolated as a white solid (181 mg,86% yield). 1H NMR: δ 1.30 (t, J = 7.1 Hz, 3H, CH2CH3),3.88 (s, 3H, OCH3), 4.39 (q, J = 7.1 Hz, 2H, CH2CH3), 7.01(s, 2H, 3-H), 7.09-7.13 (m, 2H, 3’-H, 5’-H), 7.56 (d, J = 8.6Hz, 2H, 3”-H, 5”-H), 7.78 (d, J = 8.6 Hz, 2H, 2”-H, 6”-H),8.01-8.05 (m, 2H, 2’-H, 6’-H), 8.08 (d, J = 2.3 Hz, 1H, 5-H), 8.47 (d, J = 2.3 Hz, 1H,7-H), 9.92 (s, 1H, CONH). 13C NMR: δ 13.5 (CH2CH3), 55.4 (OCH3), 62.5 (CH2CH3),113.4 (C-3), 113.7 (C-3’, C-5’), 118.0 (C-5), 124.4 (C-4a), 126.0 (C-1”), 127.8 (C-7),128.5 (C-2’, C-6’), 128.9 (C-3”, C-5”), 129.2 (C-8), 129.4 (C-2”, C-6”), 136.2 (C-6), 137.0(C-1’), 148.3 (C-8a), 151.6 (C-2), 159.6 (CO2Et), 162.3 (C-4”), 164.7 (CONH), 176.8 (C-4). LC-MS (m/z): positive mode 478 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:96.4%. mp 250-251 ◦C.
5.2.21.15 Ethyl 6-bromo-8-(4-(methylthio)benzamido)-4-oxo-4H-chromene-2-carboxylate 115(THB8)
Br
O
O CO2Et
NHO
SCH3
The compound was synthesized according to GP-10 using 17(280 mg, 0.9 mmol) and 4-(methylthio)benzoyl chloride (224 mg,1.2 mmol) and was isolated as a white solid (209 mg, 50% yield).1H NMR: δ 1.25 (t, J = 7.1 Hz, 3H, CH2CH3), 2.55 (s, 3H, S-CH3),4.34 (q, J = 7.1 Hz, 2H, CH2CH3), 7.02 (s, 1H, 3-H), 7.43 (d, J =8.1 Hz, 2H, 3’-H, 5’-H), 7.96 (d, J = 8.1 Hz, 3H, 5-H, 2’-H, 6’-H),8.31 (s, 1H, 7-H), 10.29 (s, 1H, CONH). 13C NMR: δ 13.9 (CH2CH3), 14.3 (S-CH3),63.0 (CH2CH3), 113.9 (CH, C-3’, C-5’), 118.1 (C-6), 123.4 (C-5), 125.2 (C-4a), 125.6(C-1’), 128.4 (C-2’, C-6’), 129.5 (C-8), 130.4 (C-7), 132.5 (C-8a), 144.4 (C-2), 148.4(C-4’), 152.07 (CO2Et), 159.78 (CONH), 176.21 (C-4). LC-MS (m/z): positive mode464 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.9%. mp 231-232 ◦C.
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5.2.21.16 Ethyl8-(2-ethoxy-2-oxoacetamido)-4-oxo-4H-chromene-2-carboxylate 121(THB11)
O
O CO2Et
NHO
OEtO
The compound was synthesized according to GP-10 using 19 (209mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2 mmol) andwas isolated as a white solid (299 mg, 99% yield). 1H NMR: δ1.30 (dt, J = 7.1, 11.1 Hz, 6H, CH2CH3), 4.37 (dq, J = 7.1, 11.9Hz, 4H, CH2CH3), 6.98 (s, 1H, 3-H), 7.55 (t, J = 7.9 Hz, 1H, 6-H),7.89 (dd, J = 1.6, 8.0 Hz, 1H, 5-H), 8.20 (dd, J = 1.5, 7.8 Hz, 1H, 7-H), 10.40 (s, 1H,CONH). 13C NMR: δ 13.8-13.9 (CH2CH3), 62.9-63.0 (CH2CH3), 113.9 (C-3), 121.8 (C-5), 124.3 (C-4a), 126.0 (C-7), 126.7 (C-8), 128.5 (C-6), 147.9 (C-8a), 151.7 (C-2), 155.3(C-1’), 159.8 (CONH), 160.0 (CO2Et). 177.09 (C-4). LC-MS (m/z): positive mode 334[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.6%. mp 174-175 ◦C.
5.2.21.17 Ethyl 8-(2,6-difluoro-4-methoxybenzamido)-4-oxo-6-phenyl-4H-chro-mene-2-carboxylate 116(THB25)
O CO2Et
O
NHO
F F
OCH3
The compound was synthesized according to GP-10 using 26(278 mg, 0.9 mmol) and 2,6-difluoro-4-methoxybenzoic acid(226 mg, 1.2 mmol) and was isolated as a white solid (236mg, 55% yield). 1H NMR: δ 1.35 (t, J = 7.1 Hz, 3H, CH2CH3),3.87 (s, 3H, O-CH3), 4.41 (q, J = 7.1 Hz, 2H, CH2CH3), 6.85 (d,J = 10.0 Hz, 2H, 3”-H, 5”-H), 7.00 (s, 1H, 3-H), 7.41?7.48 (m,1H, 4’-H), 7.53 (t, J = 7.6 Hz, 2H, 3’-H, 5’-H), 7.7 (d, J = 7.9Hz, 2H, 2’-H, 6’-H), 8.10 (d, J = 2.1 Hz, 1H, 7-H), 8.39 (s, 1H, 5-H), 10.26 (s, 1H,CONH). 13C NMR: δ 13.5 (CH2CH3), 56.3 (O-CH3), 62.5 (CH2CH3), 98.5-98.7 (C-3’, C-5’), 106.8 (C-1’), 113.6 (C-3), 118.6 (C-5), 124.6 (C-4a), 126.7 (C-2”, C-6”), 127.8 (C-7),128.0 (C-8), 128.1 (C-4”), 129.0 (C-3”, C-5”), 137.7 (C-6), 138.0 (C-1”), 147.9 (C-8a),151.9 (C-2), 158.7 (C-4’), 159.6 (C-2’, C-6’), 161.4 (CO2Et), 162.3 (CONH), 177.8 (C-4).LC-MS (m/z): positive mode 480 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.0%. mp 210-211 ◦C.
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5.2.21.18 Ethyl 6-bromo-8-(4-methoxybenzamido)-4-thioxo-4H-chromene-2-carboxylate 119(ANM278)
O
S
CO2Et
Br
NHO
OCH3
The compound was synthesized according to GP-10 using 34(295 mg, 0.9 mmol) and 4-methoxybenzoyl chloride (205 mg, 1.2mmol)and was isolated as a green solid (195 mg, 47% yield). 1HNMR: δ 1.27 (t, J = 7.1 Hz, 3H, CH2CH3), 3.86 (s, 3H, OCH3),4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 7.11 (d, J = 8.8 Hz, 2H, 3’-H,5’-H),7.69 (s, 1H, 3-H), 7.95-8.05 (m, 2H, 2’-H, 6’-H), 8.24 (d, J =2.4 Hz, 1H, 5-H), 8.38 (d, J = 2.4 Hz, 1H, 7-H), 10.21 (s, 1H, CONH). 13C NMR:δ 13.8 (CH2CH3), 55.7 (OCH3), 63.0 (CH2CH3), 114.0 (C-3’, C-5’), 119.7 (C-6), 125.6(C-5, C-3), 126.6 (C-1’), 129.9 (C-2’, C-6’), 132.0 (C-8), 132.0 (C-4a), 132.4 (C-7), 142.5(C-8a), 143.8 (C-2), 160.2 (CO2Et), 162.6 (C-4’), 164.9 (CONH), 201.4 (C-4). LC-MS(m/z): positive mode 463 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 85.9%. mp231-232 ◦C.
5.2.21.19 Ethyl 8-(2-ethoxy-2-oxoacetamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylate 122(ANM282)
O CO2Et
NH
O
O
OEtO
The compound was synthesized according to GP-10 using 26(278 mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2mmol) and was isolated as a white solid (282 mg, 77% yield).1H NMR: δ 1.35 (td,J = 7.2, 1.1 Hz, 6H, CH2CH3), 4.38 (dq,J = 7.1 Hz, 4H, CH2CH3), 7.02 (s, 1H, 3-H), 7.41-7.48 (m, 1H,4’-H), 7.52 (dd, J = 8.0, 7.0 Hz, 2H, 3’-H, 5’-H), 7.69-7.75 (m, 2H, 2’-H, 6’-H), 8.08(d, J = 2.3 Hz, 1H, 5-H), 8.48 (d, J = 2.3 Hz, 1H, 7-H), 10.52 (s, 1H, CONH). 13CNMR: δ 13.9 (CH2CH3), 62.95 (CH2CH3), 113.9 (C-3), 119.1 (C-5), 124.6 (C-4a), 127.0(C-7, C-2’, C-6’), 127.4 (C-8), 128.6 (C-4’), 129.4 (C-3’, C-5’), 137.8 (C-6), 138.1 (C-1’),147.6 (C-8a), 151.7 (CONH), 155.5 (C-2), 159.8-160.0 (CO2Et), 177.1 (C-4). LC-MS(m/z): positive mode 410 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.8%. mp158-159 ◦C.
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5.2.21.20 Ethyl 8-(2-ethoxy-2-oxoacetamido)-6-fluoro-4-oxo-4H-chromene-2-carboxylate 123(ANM289)
F
O CO2Et
NH
O
O
OEtO
The compound was synthesized according to GP-10 using 21 (226mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2 mmol) andwas isolated as a white solid (234 mg, 74% yield). 1H NMR: δ1.35 (td, J = 7.1, 3.6 Hz, 6H, CH2CH3), 4.38 (dq, J = 7.1 Hz, 4H,CH2CH3), 7.01 (s, 1H, 3-H), 7.59 (dd, J = 3.1, 7.9 Hz, 1H, 5-H), 8.16(dd, J = 9.6, 3.1 Hz, 1H, 7-H), 10.43 (s, 1H, CONH). 13C NMR: δ 13.8-13.9 (CH2CH3),63.0-63.2 (CH2CH3), 106.1- 106.2 (C-5), 113.2 (C-3), 115.6-115.8 (C-7), 125.1 (C-4a),128.8-128.9 (C-8), 143.3 (C-8a), 151.8 (C-2), 155.3-157.8 (C-6), 159.6 (CONH), 159.7(CO2Et), 176.4 (C-4). LC-MS (m/z): positive mode 352 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.3%. mp 164-166 ◦C.
5.2.21.21 Ethyl 6-chloro-8-(2-ethoxy-2-oxoacetamido)-4-oxo-4H-chromene-2-carboxylate 124(ANM290)
Cl
O CO2Et
NH
O
O
OEtO
The compound was synthesized according to GP-10 using 22 (241mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2 mmol) andwas isolated as a white solid (77 mg, 23% yield). 1H NMR: δ 1.30-1.33 (m, 6H, CH2CH3), 4.38 (dq, J = 7.1 Hz, 4H, CH2CH3), 7.03 (s,1H, 3-H), 7.84 (d, J = 2.6 Hz, 1H, 5-H), 8.27 (d, J = 2.6 Hz, 1H,7-H), 10.45 (s, 1H, CONH). 13C NMR: δ 13.9-14.0 (CH2CH3), 63.0 (CH2CH3), 114.0(C-3), 120.6 (C-5), 125.2 (C-4a), 127.4 (C-7), 128.6 (C-8), 130.3 (C-6), 146.6 (C-8a),151.9 (C-2), 155.3 (CONH), 159.6 (CO2Et), 176.1 (C-4). LC-MS (m/z): positive mode368 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.4%. mp 148-150 ◦C.
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5.2.21.22 Ethyl 8-(2-ethoxy-2-oxoacetamido)-6-methoxy-4-oxo-4H-chromene-2-carboxylate 125(ANM291)
H3CO
O CO2Et
NH
O
O
OEtO
The compound was synthesized according to GP-10 using 24(237 mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2mmol) and was isolated as a white solid (74 mg, 23% yield).1H NMR: δ 1.34 (td, J = 7.1, 1.8 Hz, 6H, CH2CH3), 3.87 (s, 3H,OCH3), 4.37 (dq, J = 7.1, 1.8 Hz, 4H, CH2CH3), 6.95 (s, 1H, 3-H),7.26 (d, J = 3.0 Hz, 1H, 5-H), 7.86 (d, J = 3.0 Hz, 1H, 7-H), 10.31 (s, 1H, CONH).13C NMR: δ 13.9 (CH2CH3), 56.1 (OCH3), 62.9 (CH2CH3), 101.5 (C-5), 113.0 (C-3),117.0 (C-7), 124.9 (C-4a), 128.0 (C-8), 142.6 (C-8a), 151.4 (C-2), 155.2 (CONH), 156.7(C-6), 159.8 (CO2Et), 176.7 (C-4). LC-MS (m/z): positive mode 364 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 99.8%. mp 147-149 ◦C.
5.2.21.23 Ethyl 8-(2-ethoxy-2-oxoacetamido)-6-methyl-4-oxo-4H-chromene-2-carboxylate 126(ANM292)
H3C
O CO2Et
NH
O
O
OEtO
The compound was synthesized according to GP-10 using 23(222 mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2mmol) and was isolated as a white solid (121 mg, 39% yield).1H NMR: δ 1.31 (m, 6H, CH2CH3), 2.43 (s, 3H, CH3), 4.36 (dq, J= 7.1 Hz, 4H, CH2CH3), 6.95 (s, 1H, 3-H), 7.68 (t, J = 1.5 Hz, 1H,5-H), 8.02 (d, J = 2.0 Hz, 1H, 7-H), 10.36 (s, 1H, CONH). 13C NMR: δ 13.9 (CH2CH3),20.9 (CH3), 62.9 (CH2CH3), 113.8 (C-3), 121.8 (C-5), 124.0 (C-4a), 126.4 (C-8), 129.5(C-7), 135.9 (C-6), 146.3 (C-8a), 151.6 (C-2), 155.6 (CONH), 159.9 (CO2Et), 177.0 (C-4). LC-MS (m/z): positive mode 348 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:97.6%. mp 133-135 ◦C.
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5.2.21.24 Ethyl 8-(2-ethoxy-2-oxoacetamido)-6-ethyl-4-oxo-4H-chromene-2-carboxylate 127(ANM293)
O CO2Et
NH
O
O
OEtO
H3C
The compound was synthesized according to GP-10 using 23(222 mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2mmol) and was isolated as a white solid (121 mg, 39% yield).1HNMR: δ 1.22 (t, J = 7.6 Hz, 3H, C6-CH2CH3), 1.34 (td, J =7.1,1.8 Hz, 6H, CH2CH3), 2.75 (q, J = 7.6 Hz, 2H, C6-CH2CH3), 4.37(dq, J = 7.1 Hz, 4H, CH2CH3), 6.96 (s, 1H, 3-H), 7.71 (d, J = 2.1 Hz, 1H, 5-H), 8.05(d, J = 2.1 Hz, 1H, 7-H), 10.39 (s, 1H, CONH). 13C NMR: δ 13.9 (CH2CH3), 15.3 (C6-CH2CH3), 27.8 (C6-CH2CH3), 62.9 (CH2CH3), 113.8 (C-3), 120.1 (C-5), 124.1 (C-4a),126.6 (C-8), 128.7 (C-7), 141.9 (C-6), 146.5 (C-8a), 151.6 (C-2), 155.4 (CONH), 159.8(CO2Et), 177.1 (C-4). LC-MS (m/z): positive mode 362 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.4%. mp 133-135 ◦C.
5.2.21.25 Ethyl 6-bromo-8-(2-ethoxy-2-oxoacetamido)-4-thioxo-4H-chromene-2-carboxylate 128(ANM294)
Br
O CO2Et
NH
S
O
OEtO
The compound was synthesized according to GP-10 using 34 (295mg, 0.9 mmol) and ethyl chlorooxoacetate (0.13 mL, 1.2 mmol) andwas isolated as a green solid (113 mg, 29% yield). 1H NMR: δ1.35 (td, J = 7.1, 3.1 Hz, 6H, CH2CH3), 4.38 (dq, J = 7.1 Hz, 4H,CH2CH3), 7.66 (s, 1H, 3-H), 8.22 (d, J = 2.4 Hz, 1H, 5-H), 8.43 (d, J= 2.4 Hz, 1H, 7-H), 10.44 (s, 1H, CONH). 13C NMR: δ 13.9 (CH2CH3), 63.1 (CH2CH3),119.7 (C-6), 125.0 (C-7), 125.7 (C-5), 129.2 (C-8), 130.2 (C-3), 131.8 (C-4a), 142.3(C-8a), 155.3 (CONH), 159.6 (C-2), 160.1 (CO2Et), 201.3 (C-4). LC-MS (m/z): positivemode 428 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 91.6%. mp 171-173 ◦C.
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5.2.21.26 Ethyl-6-bromo-8-(3-(4-fluorobenzyloxy)benzamido)oxo-4H-chromene-2-carboxylate 146(ANM16)
O
O
CO2Et
Br
NHO
O
F
The compound was synthesized according to GP-10 using 61(295 mg, 1.2 mmol) and 17 (281 mg, 0.9 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM each anddried in vacuum at 50 ◦C. The product was isolated as a whitesolid (229 mg, 35% yield). 1H NMR: δ 1.26 (t, J = 7.1 Hz, 3H,CH2CH3), 4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 5.20 (s, 2H, CH2-O),7.00 (s, 1H, 3-H), 7.17-7.24 (m, 2H, 3”-H, 5”-H), 7.30 (ddd, J =8.2, 2.6, 0.9 Hz, 1H, 4’-H), 7.50 (t, J = 7.9 Hz, 1H, 5’-H), 7.51-7.55 (m, 2H, 2”-H,6”-H), 7.60-7.64 (m, 1H, 6’-H), 7.96 (d, J = 2.4 Hz, 1H, 5-H), 8.36 (d, J = 2.4 Hz, 1H,7-H), 10.06 (s, 1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 62.6 (CH2CH3), 69.0 (CH2-O),113.6 (C-3), 114.3 (C-2’), 114.9 (C-3”, C-5”), 117.6 (C-6), 118.6 (C-6’), 120.0 (C-4’),122.8 (C-5), 125.3 (C-4a), 129.6 (C-2”, C-6”), 129.6 (C-5’), 130.1 (C-8), 131.5 (C-7),132.9 (C-1”), 135.0 (C-1’), 147.5 (C-8a), 151.8 (C-2), 158.4 (C-3’), 159.4 (CO2Et), 164.9(CONH), 175.7 (C-4). LC-MS (m/z): negative mode 538 [M-H]-, positive mode 542[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 186-187 ◦C.
5.2.21.27 Ethyl-6-bromo-8-(3-(4-bromobenzyloxy)benzamido)oxo-4H-chromene-2-carboxylate 147(ANM17)
O
O
CO2Et
Br
NHO
O
Br
The compound was synthesized according to GP-10 using 63(369 mg, 1.2 mmol) and 17 (281 mg, 0.9 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM each anddried in vacuum at 50 ◦C. The product was isolated as a whitesolid (331 mg, 46% yield). 1H NMR: δ 1.28 (t, J = 7.1 Hz, 3H,CH2CH3), 4.37 (q, J = 7.1 Hz, 2H, CH2CH3), 5.22 (s, 2H, CH2-O),7.02 (s, 1H, 3-H), 7.31 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H, 4’-H), 7.43-7.48 (m, 2H, 3’-H, 5’-H), 7.51 (t, J = 7.9 Hz, 1H, 5’-H), 7.59-7.63 (m, 2H, 2”-H, 6”-H),7.63-7.66 (m, 1H, 2’-H), 7.67-7.69 (m, 1H, 6’-H), 7.99 (dd, J = 2.4 Hz, 1H, 5-H), 8.37 (d,J = 2.4 Hz, 1H, 7-H), 10.10 (s, 1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 62.6 (CH2CH3),68.9 (CH2-O), 113.6 (C-3), 114.3 (C-2’), 117.6 (C-6), 118.7 (C-6’), 120.1 (C-4’), 120.8(C-4”), 122.9 (C-5), 125.3 (C-4a), 129.5 (C-2”, C-6”), 129.6 (C-5’), 130.0 (C-8), 131.2
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(C-3”, C-5”), 131.5 (C-7), 135.0 (C-1’), 136.2 (C-1”), 147.8 (C-8a), 151.8 (C-2), 158.3(C-3’), 159.4 (CO2Et), 164.9 (CONH), 175.6 (C-4). LC-MS (m/z): negative mode 600[M-H]-, positive mode 602 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.3%.mp 195-196 ◦C.
5.2.21.28 Ethyl-6-bromo-8-(3-(4-chlorobenzyloxy)benzamido)oxo-4H-chromene-2-carboxylate 148(ANM18)
O
O
CO2Et
Br
NHO
O
Cl
The compound was synthesized according to GP-10 using 65(315 mg, 1.2 mmol) and 17 (281 mg, 0.9 mmol). The product wasdissolved in 1 mL of DCM, separated by column chromatographyon a column of silica gel (2% EtOAc in DCM) and dried in vacuumat 50 ◦C. The product was isolated as a white solid (185 mg, 33%yield). 1H NMR: δ 1.26 (t, J = 7.0 Hz, 3H, CH2CH3), 4.36 (q, J= 7.1 Hz, 2H, CH2CH3), 5.22 (s, 2H, CH2-O), 7.00 (s, 1H, 3-H),7.30 (dd, J = 8.3, 2.6 Hz, 1H, 4’-H), 7.44-7.52 (m, 5H, 5’-H, 2”-H, 3”-H, 5”-H, 6”-H),7.61-7.67 (m, 2H, 2’-H, 6’-H), 7.97 (d, J = 2.5 Hz, 1H, 5-H), 8.35 (d, J = 2.4 Hz, 1H,7-H), 10.06 (s, 1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 62.6 (CH2CH3), 68.9 (CH2-O),113.6 (C-3), 114.3 (C-2’), 117.7 (C-6), 118.7 (C-6’), 118.6 (C-4”), 120.1 (C-4’), 122.9(C-5), 125.3 (C-4a), 128.3 (C-3”, C-5”), 129.2 (C-2”, C-6”), 129.6 (C-5’), 130.1 (C-8),131.5 (C-7), 132.4 (C-1’), 135.0 (C-4”), 135.7 (C-1”), 147.8 (C-8a), 151.8 (C-2), 158.3(C-3’), 159.4 (CO2Et), 164.9 (CONH), 175.7 (C-4). LC-MS (m/z): positive mode 558[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100%. mp 186-187 ◦C.
5.2.21.29 Ethyl-6-bromo-8-(2-(4-fluorobenzyloxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 153(ANM19)
O
O
CO2Et
Br
NHO
O
F
The compound was synthesized according to GP-10 using 73(297 mg, 1.2 mmol) and 17 (281 mg, 0.9 mmol). The precipitatewas filtered off and the filtrate was concentrated under reducedpressure und separated by column chromatography on a columnof silica gel (2% EtOAc in DCM) yielding further product. Theproduct was isolated as a white solid (364 mg, 56% yield). 1HNMR: δ 1.27 (t, J = 7.1 Hz, 3H, CH2CH3), 4.30 (q, J = 7.1 Hz,
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2H, CH2CH3), 5.54 (s, 2H, CH2-O), 6.98 (s, 1H, 3-H), 7.02-7.08 (m, 2H, 3”-H, 5”-H),7.18 (t, J = 7.5 Hz, 1H, 5’-H), 7.38 (d, J = 8.3 Hz, 1H, 3’-H), 7.45-7.49 (m, 2H, 2”-H,6”-H), 7.57-7.62 (m, 1H, 4”-H), 7.86 (d, J = 2.4 Hz, 1H, 5-H), 8.04 (dd, J = 7.8, 1.7Hz, 1H, 6’-H), 8.93 (s, 1H, 7-H), 10.68 (s, 1H, CONH). 13C NMR: δ 13.8 (CH2CH3),63.0 (CH2CH3), 70.4 (CH2-O), 113.9 (C-3), 115.2 (C-3’), 115.3 (C-2”, C-5”), 118.5 (C-6),121.2 (C-5’), 121.8 (C-1’), 122.0 (C-5), 125.3 (C-4a), 127.4 (C-7), 130.0 (C-2”, C-6”),130.1 (C-8), 131.6 (C-6’), 132.6 (C-1”), 134.3 (C-4’), 145.2 (C-8a), 151.7 (C-2), 156.3(C-2’), 159.4 (CO2Et), 160.9 (C-4”), 163.6 (CONH), 176.0 (C-4). LC-MS (m/z): negativemode 538 [M-H]-, positive mode 542 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100%. mp 190-191 ◦C.
5.2.21.30 Ethyl-8-(4-(4-fluorobenzyloxy)benzamido)-6-methoxy-4-oxo-4H-chro-mene-2-carboxylate 133(ANM56)
O
O
CO2Et
H3CO
NHO
O
F
The compound was synthesized according to GP-10 using 47(297 mg, 1.2 mmol) and 24 (237 mg, 0.9 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (175 mg, 79% yield). 1H NMR: δ 1.29 (t, J = 7.1Hz, 3H, CH2CH3), 3.89 (s, 3H, O-CH3), 4.36 (q, J = 7.1 Hz, 2H,CH2CH3), 5.22 (s, 2H, CH2-O), 6.93 (s, 1H, 3-H), 7.15-7.23 (m, 4H, 3’-H, 5’-H, 3”-H,5”-H), 7.27 (d, J = 3.1 Hz, 1H, 5-H), 7.50-7.55 (m, 2H, 2”-H, 6”-H), 7.84 (d, J = 3.1Hz, 1H, 7-H), 7.97-8.02 (m, 2H, 2’-H, 6’-H), 9.78 (s, 1H, CONH). 13C NMR: δ 13.5(CH2CH3), 55.8 (OCH3), 62.4 (CH2CH3), 68.9 (CH2-O), 101.1 (C-5), 112.5 (C-3), 114.7(C-3’, C-5’), 115.1 (C-3”, C5”), 118.1 (C-7), 124.7 (C-4a), 126.3 (C-1’), 129.3 (C-2’, C-6’),129.7 (C-2”, C-6”), 129.7 (C-8), 132.8 (C-1”), 143.5 (C-8a), 151.3 (C-2), 156.6 (C-6),159.7 (CO2Et), 161.2 (C-4), 162.7 (C-4’), 164.6 (CONH), 176.5 (C-4). LC-MS (m/z):negative mode 490 [M-H]-, positive mode 492 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 100%. mp 253-254 ◦C.
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5.2.21.31 Ethyl-8-(4-(4-fluorobenzyloxy)benzamido)-6-methyl-4-oxo-4H-chro-mene-2-carboxylate 134(ANM57)
O
O
CO2Et
H3C
NHO
O
F
The compound was synthesized according to GP-10 using 47(297 mg, 1.2 mmol) and 23 (223 mg, 0.9 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM each anddried in vacuum at 50 ◦C. The product was isolated as a whitesolid (166 mg, 78% yield). 1H NMR: δ 1.22 (t, J = 7.1 Hz, 3H,CH2CH3), 2.45 (s, 3H, CH3), 4.32 (q, J = 7.1 Hz, 2H, CH2CH3),5.20 (s, 2H, CH2-O), 6.95 (s, 1H, 3-H), 7.15-7.19 (m, 2H, 3’-H, 5’-H), 7.20-7.26 (m, 2H,3”-H, 5”-H), 7.51-7.56 (m, 2H, 2”-H, 6”-H), 7.69 (dd, J = 2.2 Hz, 1H, 5-H), 7.92 (d, J =2.1 Hz, 1H, 7-H), 7.98-8.03 (m, 2H, 2’-H, 6’-H), 10.10 (s, 1H, CONH). 13C NMR: δ 13.8(CH2CH3), 20.8 (OCH3), 62.8 (CH2CH3), 68.9 (CH2-O), 113.6 (C-3), 114.8 (C-3’, C-5’),115.4-115.5 (C-3”, C-5”), 120.8 (C-5), 124.1 (C-4a), 126.4 (C-1’), 128.3 (C-8), 128.3(C-2’, C-6’), 129.8-130.2 (C-2”, C-6”), 131.9 (C-7), 133.0 (C-1”), 135.7 (C-6), 147.7 (C-8a), 151.7 (C-2), 160.0 (CO2Et), 161.0 (C-4’), 162.9 (C-4”), 162.9 (C-4’), 164.9 (CONH),177.3 (C-4). LC-MS (m/z): negative mode 474 [M-H]-, positive mode 476 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 63.0%. mp 234-235 ◦C.
5.2.21.32 Ethyl-6-ethyl-8-(4-(4-fluorobenzyloxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 135(ANM90)
O
O
CO2Et
NHO
O
F
H3C
The compound was synthesized according to GP-10 using 47(297 mg, 1.2 mmol) and 20 (235 mg, 0.9 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated asa white solid (321 mg, 73% yield). 1H NMR: δ 1.24-1.30 (m,6H, CO2-CH2CH3, C6-CH2CH3), 2.78 (q, J = 7.6 Hz, 2H, C6-CH2CH3), 4.35 (q, J = 7.1 Hz, 2H, CO2-CH2CH3), 5.22 (s, 2H, CH2-O), 6.94 (s, 1H, 3-H),7.14-7.24 (m, 4H, 3’-H, 5’-H, 3”-H, 5”-H), 7.50-7.55 (m, 2H, 2”-H, 6”-H), 7.71 (d, J =2.2 Hz, 1H, 5-H), 7.96-8.02 (m, 2H, 2’-H, 6’-H), 8.03 (d, J = 2.2 Hz, 1H, 7-H), 9.78 (s,1H, CONH). 13C NMR: δ 13.4 (CO2-CH2CH3), 14.8 (C6-CH2CH3), 27.5 (C6-CH2CH3),62.4 (CO2-CH2CH3), 68.8 (CH2-O), 113.2 (C-3), 114.6 (C-3’, C-5’), 114.9-115.1 (C-3”,C-5”), 118.9 (C-5), 123.9 (C-4a), 126.4 (C-1’), 128.2 (C-8), 129.3 (C-2’, C-6’), 129.7
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(C-2”, C-6”, C-7), 132.8 (C-1”), 141.4 (C-8), 147.2 (C-6), 147.2 (C-8a), 151.5 (C-2),159.7 (CO2Et), 161.1 (C-4’), 162.7 (C-4”), 164.1 (CONH), 176.9 (C-4). LC-MS (m/z):negative mode 488 [M-H]-, positive mode 490 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 97.4%. mp 210-211 ◦C.
5.2.21.33 Ethyl-8-(4-(4-fluorobenzyloxy)benzamivdo)-4-oxo-6-phenyl-4H-chro-mene-2-carboxylate 136(ANM91)
O
O
CO2Et
NHO
O
F
The compound was synthesized according to GP-10 using 47(148 mg, 0.6 mmol) and 26 (139 mg, 0.45 mmol). The precip-itate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a white solid (220 mg, 91% yield). 1H NMR: δ 1.30 (t, J =7.1 Hz, 3H, CH2CH3), 4.38 (q, J = 7.0 Hz, 2H, CH2CH3), 5.22(s, 2H, CH2-O), 7.00 (s, 1H, 3-H), 7.16-7.24 (m, 4H, 3’-H, 5’-H, 3”-H, 5”-H), 7.42-7.47 (m, 1H, 4”’-H), 7.50-7.56 (m, 4H, 2”-H, 6”-H, 3”’-H, 5”’-H),7.72-7.77 (m, 2H, 2”’-H, 6”’-H), 8.01-8.05 (m, 2H, 2’-H, 6’-H), 8.08 (d, J = 2.3 Hz, 1H,5-H), 8.48 (d, J = 2.3 Hz, 1H, 7-H), 9.90 (s. 1H, CONH). 13C NMR: δ 13.5 (CH2CH3),62.5 (CH2CH3), 68.8 (CH2-O), 113.4 (C-3), 114.7 (C-3’, C-5’), 114.9-115.1 (C-3”, C-5”),117.9 (C-5), 124.4 (C-4a), 126.4 (C-1”’), 126.6 (C-2”’, C-6”’), 127.9 (C-7), 128.0 (C-4”’),129.0 (C-2”’, C-6”’), 129.0 (C-8), 129.4 (C-2’, C-6’), 129.6-129.7 (C-2”, C-6”), 132.7 (C-1”), 137.6 (C-6), 138.2 (C-1’), 148.1 (C-8a), 151.6 (C-2), 159.6 (CO2Et), 160.8-162.7(C-4”), 161.2 (C-4’), 164.7 (CONH), 176.9 (C-4). LC-MS (m/z): negative mode 536[M-H]-, positive mode 538 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 86.3%.mp 246-247 ◦C.
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5.2.21.34 Ethyl-8-(4-(3,4-difluorobenzyloxy)benzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylate 137(ANM125)
O
O
CO2Et
NHO
O
F
F
The compound was synthesized according to GP-10 using 49(159 mg, 0.6 mmol) and 26 (139 mg, 0.45 mmol). The precip-itate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a white solid (173 mg, 69% yield). 1H NMR: δ 1.25 (t, J =7.1 Hz, 3H, CH2CH3), 4.37 (q, J = 7.1 Hz, 2H, CH2CH3), 5.22(s, 2H, CH2-O), 7.01 (s, 1H, 3-H), 7.17-7.21 (m, 2H, 3’-H, 5’-H), 7.32-7.65 (m, 6H, 6”-H, 4”’-H, 5”-H, 5”’-H, 3”’-H, 2”-H), 7.73-7.78 (m, 2H, 2”’-H,6”’-H), 8.01-8.06 (m, 2H, 2?-H, 6?-H), 8.08 (d, J = 2.3 Hz, 1H, 5-H), 8.41 (d, J =2.3 Hz, 1H, 7-H), 10.20 (s, 1H, CONH). 13C NMR: δ 13.8 (CH2CH3), 62.9 (CH2CH3),68.3 (CH2-O), 113.7 (C-3), 114.8 (C-3’, C-5’), 117.0-117.1 (C-2”), 117.7-117.8 (C-5”),118.5 (C-5), 124.7 (C-4a), 124.9 (C-6”), 126.5 (C-1”’), 127.0 (C-2”’, C-6”’), 128.4 (C-7),129.2 (C-4”’), 129.3 (C-8), 129.4 (C-3”’, C-5”’), 129.9 (C-2’, C-6’), 134.6 (C-1”), 137.7 (C-6),138.3 (C-1’), 148.2-148.5 (C-4”), 148.8 (C-8a), 150.3-150.5 (C-3”), 151.9 (C-2), 160.0(CO2Et), 161.2 (C-4’), 165.0 (CONH), 177.3 (C-4). LC-MS (m/z): negative mode 554[M-H]-, positive mode 556 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 63.9%.mp 215-218 ◦C.
5.2.21.35 Ethyl-6-(4-chlorophenyl)-8-(4-(4-fluorobenzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 138(ANM132)
O
O
CO2Et
NHO
O
F
Cl The compound was synthesized according to GP-10 using47 (134 mg, 0.51 mmol) and 27 (130 mg, 0.38 mmol). Theprecipitate was filtered off, washed three times with 1 mL ofDCM each and dried in vacuum at 50 ◦C. The product wasisolated as a white solid (185 mg, 85% yield). 1H NMR: δ1.29 (t, J = 7.2 Hz, 3H, CH2CH3), 4.37 (q, J = 7.1 Hz, 2H,CH2CH3), 5.23 (s, 2H, CH2-O), 7.01 (s, 1H, 3-H), 7.17-7.24 (m,4H, 3’-H, 5’-H, 3”-H,5’-H), 7.50-7.59 (m, 4H, 2”-H, 6”-H, 5”’-H, 3”’-H), 7.75-7.80 (m,2H, 2”’-H, 6”’-H), 8.01-8.05 (m, 2H, 2’-H, 6’-H), 8.08 (d, J = 2.3 Hz, 1H, 5-H), 9.47 (d,J = 2.5 Hz, 1H, 7-H), 9.93 (s, 2H, CONH). 13C NMR: δ 13.5 (CH2CH3), 62.5 (CH2CH3),
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68.8 (CH2-O), 113.4 (C-3), 114.7 (C-3’, C-4’), 115.0-115.1 (C-3”, C-5”), 118.0 (C-5),124.4 (C-4a), 126.3 (C-1”’), 127.8 (C-7), 128.5 (C-2’, C-6’), 129.0 (C-3”’, C-5”’), 129.1(C-8),129.4 (C-2”’, C-6”’), 129.6-129.7 (C-2”, C-6”), 133.1 (C-1”), 136.2 (C-6), 137.0 (C-1’), 148.3 (C-8a), 151.7 (C-2), 159.6 (CO2Et), 161.2 (C-4”’), 162.7 (C-4’), 164.7 (CONH),176.8 (C-4). LC-MS (m/z): negative mode 570 [M-H]-, positive mode 572 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 93.6%. mp 247-248 ◦C.
5.2.21.36 Ethyl-8-(3-chloro-4-(4-fluorobenzyloxy)benzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylate 139(ANM133)
O
O
CO2Et
NHO
O
F
Cl
The compound was synthesized according to GP-10 using 51(168 mg, 0.6 mmol) and 26 (139 mg, 0.45 mmol). The precip-itate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a white solid (115 mg, 45% yield). 1H NMR: δ 1.28 (t, J =7.1 Hz, 3H, CH2CH3), 4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 5.33(s, 2H, CH2-O), 7.01 (s, 1H, 3-H), 7.20-7.26 (m, 2H, 3”-H, 5”-H),7.40-7.47 (m, 2H, 4”’-H, 5’-H), 7.50-7.58 (m, 4H, 2”-H, 6”-H, 3”’-H, 5”’-H), 7.73-7.77(m, 2H, 2”’-H, 6”’-H), 8.03 (dd, J = 2.3, 8.6 Hz, 1H, 5-H), 8.15 (d, J = 2.2 Hz, 1H,2’-H), 8.39 (d, J = 2.3 Hz, 1H, 7-H), 10.15 (s, 1H, CONH). 13C NMR: δ 13.5 (CH2CH3),62.5 (CH2CH3), 69.8 (CH2-O), 113.4 (C-3), 114.1 (C-5’), 115.0-115.2 (C-3”, C-5”), 118.5(C-5), 121.8 (C-3’), 124.5 (C-4a), 126.7 (C-2”’, C-6”’), 127.3 (C-1”’), 128.1 (C-7), 128.7(C-8), 128.8 (C-4”’), 129.0 (C-3”’, C-5”’), 129.3 (C-2’, C-6’), 129.5-129.6 (C-2”, C-6”),132.3 (C-1”), 137.6 (C-6), 138.0 (C-1’), 148.6 (C-8a), 151.7 (C-2), 156.3 (C-4’), 159.6(CO2Et), 160.9-162.8 (C-4”), 163.7 (CONH), 176.8 (C-4). LC-MS (m/z): negative mode570 [M-H]-, positive mode 572 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.3%.mp 242-243 ◦C.
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5.2.21.37 Ethyl-8-(4-(4-fluorobenzyloxy)benzamido)-6-(4-fluorophenyl)-4-oxo-4H-chromene-2-carboxylate 140(ANM135)
O
O
CO2Et
NHO
O
F
F The compound was synthesized according to GP-10 using47 (214 mg, 0.87 mmol) and 30 (213 mg, 0.65 mmol). Theprecipitate was filtered off, washed three times with 1 mLof DCM each and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (225 mg, 62% yield). 1H NMR:δ 1.29 (t, J = 7.1 Hz, 3H, CH2CH3), 4.38 (q, J = 7.1 Hz, 2H,CH2CH3), 5.22 (s, 2H, CH2-O), 7.00 (s, 1H, 3-H), 7.16-7.24 (m,4H, 3’-H, 5’-H, 3”-H, 5”-H), 7.30-7.35 (m, 2H, 3”’-H, 5”’-H), 7.51-7.55 (m, 2H, 2”-H,6”-H), 7.77-7.81 (m, 2H, 2”’-H, 6”’-H), 8.01-8.04 (m, 2H, 2’-H, 6’-H), 8.05 (d, J = 2.3Hz, 1H, 5-H), 8.45 (d, J = 2.3 Hz, 1H, 7-H), 9.92 (s, 1H, CONH). 13C NMR: δ 13.5(CH2CH3), 62.5 (CH2CH3), 68.9 (CH2-O), 113.4 (C-3), 114.7 (C-3’, C-5’), 115.0-115.1(C-3”’, C-5”’), 115.7-115.9 (C-3”, C-5”), 117.9 (C-5), 124.4 (C-4a), 126.3 (C-1”’), 127.9(C-7), 128.8 (C-2”’, C-6”’), 129.1 (C-8), 129.4 (C-2’, C-6’), 129.6-129.7 (C-2”, C-6”),132.8 (C-1”), 134.7 (C-6), 136.5 (C-8), 148.1 (C-8a), 151.6 (C-2), 159.6 (CO2Et), 160.8-161.2 (C-4”), 162.7-163.2 (C-4’), 164.7 (CONH), 176.8 (C-4). LC-MS (m/z): negativemode 554 [M-H]-, positive mode 556 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:93.3%. mp 219-220 ◦C.
5.2.21.38 Ethyl-8-(4-(4-fluorobenzyloxy)benzamido)-6-(4-methoxyphenyl)-4-oxo-4H-chromene-2-carboxylate 141(ANM136)
O
O
CO2Et
NHO
O
F
H3CO The compound was synthesized according to GP-10 using47 (214 mg, 0.87 mmol) and 29 (221 mg, 0.65 mmol). Theprecipitate was filtered off, washed three times with 1 mLof DCM each and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (280 mg, 75% yield). 1HNMR: δ 1.29 (t, J = 7.1 Hz, 3H, CH2CH3), 3.83 (sm, 3H,OCH3), 4.37 (q, J = 7.1 Hz, 2H, CH2CH3), 5.22 (s, 2H, CH2-O), 6.98 (s, 1H, 3-H), 7.05-7.12 (m, 2H, 3”’-H,5”’-H), 7.15-7.25 (m, 4H, 3’-H, 5’-H, 3”-H,5”-H), 7.48-7.56 (m, 2H, 2”-H, 6”-H), 7.64-7.72 (m, 2H, 2”’-H, 6”’-H), 7.98-8.07 (m, 3H,5-H, 2’-H, 6’-H), 8.42 (d, J = 2.2 Hz, 1H, 7-H), 9.89 (s, 1H, CONH). 13C NMR: δ 13.5
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(CH2CH3), 55.2 (OCH3), 62.5 (CH2CH3), 68.9 (CH2-O), 113.3 (C-3), 114.7 (C-3”’, C-5”’,C-3’, C-5’), 115.0-115.1 (C-3”, C-5”), 117.2 (C-5), 124.4 (C-4a), 126.4 (C-1”’), 127.6 (C-7), 127.9 (C-2”’, C-6”’), 128.9 (C-8), 129.1 (C-2’, C-6’), 129.6-129.8 (C-2”, C-6”), 130.5(C-6’) 132.8 (C-1”) 137.3 (C-4”’), 147.8 (C-8a), 151.6 (C-2), 159.5 (CO2Et), 160.8-162.8(C-4”), 161.2 (C-4’), 164.7 (CONH), 176.9 (C-4). LC-MS (m/z): negative mode 566[M-H]-, positive mode 568 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.5%.mp 225-226 ◦C.
5.2.21.39 Ethyl-8-(4-(4-fluorobenzyloxy)benzamido)-4-oxo-6-p-tolyl-4H-chro-mene-2-carboxylate 142(ANM137)
O
O
CO2Et
NHO
O
F
H3C The compound was synthesized according to GP-10 using47 (165 mg, 0.67 mmol) and 28 (160 mg, 0.5 mmol). Theprecipitate was filtered off, washed three times with 1 mLof DCM each and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (226 mg, 82% yield). 1HNMR: δ 1.29 (t, J = 7.1 Hz, 3H, CH2CH3), 4.38 (q, J = 7.1Hz, 2H, CH2CH3), 5.23 (s, 2H, CH2-O), 7.00 (s, 1H, 3-H),7.11-7.27 (m, 4H, 3’-H, 5’-H, 3”-H, 5”-H), 7.44-7.62 (m, 4H, 3”’-H, 5”’-H, 2”-H, 6”-H),7.73-7.82 (m, 2H, 2”’-H, 6”’-H), 8.00-8.06 (m, 2H, 2’-H, 6’-H), 8.08 (d, J = 2.3 Hz, 1H,5-H), 8.47 (d, J = 2.3 Hz, 1H, 7-H), 9.93 (s, 1H, CONH). 13C NMR: δ 13.8 (CH2CH3),55.1 (C4”’-CH3), 62.9 (CH2CH3), 68.9 (CH2-O), 113.3 (C-3), 115.8 (C-3’, C-5’), 115.6(C-3”, C-5”), 124.7 (C-5), 124.7 (C-4a), 126.4 (C-1”’), 126.6 (C-2”’, C.6””), 126.9 (C-7),129.3 (C-8), 129.8 (C-2’, C-6’), 130.0 (C-3”’, C-5”’), 130.2 (C-2”, C-6”), 133.0 (C-1”),135.4 (C-6), 137.4 (C-1’), 138.0 (C-8), 148.7 (C-8a), 151.7 (C-2), 160.0 (C-4’), 160.3(CO2Et), 161.4 (C-4”), 165.0 (CONH), 177.4 (C-4). LC-MS (m/z): negative mode 550[M-H]-, positive mode 552 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 87.4%.mp 223-224 ◦C.
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5.2.21.40 Ethyl-8-(4-(3,4-difluorobenzyloxy)benzamido)-6-(4-fluorophenyl)-4-oxo-4H-chromene-2-carboxylate 143(ANM147)
O
O
CO2Et
NHO
O
F
F
F The compound was synthesized according to GP-10 using49 (282 mg, 1.07 mmol) and 30 (262 mg, 0.8 mmol). Theprecipitate was filtered off, washed three times with 1 mLof DCM each and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (252 mg, 55% yield). 1H NMR:δ 1.29 (t, J = 7.1 Hz, 3H, CH2CH3), 4.38 (q, J = 7.1 Hz, 2H,CH2CH3), 5.23 (s, 2H, CH2-O), 6.99 (s, 1H, 3-H), 7.16-7.22 (m,2H, 3’-H, 5’-H), 7.28-7.37 (m, 3H, 5”’-H, 3”’-H, 6”-H), 7.43 (dt, J = 8.3 Hz, 1H, 5”-H),7.52 (ddd, J = 2.1, 7.9 Hz, 1H, 2”-H), 7.75-7.82 (m, 2H, 2”’-H, 6”’-H), 8.00-8.07 (m, 3H,5-H, 2’-H, 6’-H), 8.45 (d, J = 2.3 Hz, 1H, 7-H), 9.92 (s, 1H, CONH). 13C NMR: δ 13.5(CH2CH3), 62.5 (CH2CH3), 68.2 (CH2-O), 113.4 (C-3), 114.7 (C-3’, C-5’), 115.7-115.9(C-3”, C-5”), 116.4-116.6 (C-2”), 117.3-117.4 (C-5”), 117.9 (C-7), 124.2 (C-6”), 124.4(C-4a), 126.5 (C-1’), 127.9 (C-5), 128.8 (C-2”’, C-6”’), 129.0 (C-8), 129.4 (C-2’, C-6’),134.3 (C-1”), 134.6 (C-6), 136.5 (C-1”’), 146.9-147.3 (C-4”), 148.1 (C-8a), 149.5-150.2(C-3”), 151.6 (C-2), 159.6 (CO2Et), 161.0 (C-4”’), 161.2 (C-4’), 164.7 (CONH), 176.8 (C-4). LC-MS (m/z): positive mode 574 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:98.1%. mp 223-224 ◦C.
5.2.21.41 Ethyl-8-(3-chloro-4-(3,4-difluorobenzyloxy)benzamido)-6-(4-fluoro-phenyl)-4-oxo-4H-chromene-2-carboxylate 144(ANM149)
O
O
CO2Et
NHO
O
F
F
F
Cl
The compound was synthesized according to GP-10 using53 (358 mg, 1.2 mmol) and 30 (294 mg, 0.9 mmol). Theprecipitate was filtered off, washed three times with 1 mL ofDCM each and dried in vacuum at 50 ◦C. The product wasisolated as a white solid (407 mg, 75% yield). 1H NMR: δ1.27 (t, J = 7.1 Hz, 3H, CH2CH3), 4.37 (q, J = 7.1 Hz, 2H,CH2CH3), 5.34 (s, 2H, CH2-O), 7.00 (s, 1H, 3-H), 7.27-7.39(m, 3H, 3”’-H, 5”’-H, 6”-H), 7.39-7.50 (m, 2H, 5’-H, 5”-H), 7.53 (ddd, J = 2.1, 7.8 Hz,1H, 2”-H), 7.71-7.86 (m, 2H, 2”’-H, 6”’-H), 8.02 (dd, J = 2.2, 8.6 Hz, 1H, 6’-H), 8.08(d, J = 2.4 Hz, 1H, 5-H), 8.16 (d, J = 2.2 Hz, 1H, 2’-H), 8.36 (d, J = 2.4 Hz, 1H, 7-H),
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10.17 (s, 1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 62.5 (CH2CH3), 69.2 (CH2-O), 113.4(C-3), 114.1 (C-5’), 115.7-115.9 (C-3”’, C-5”’), 116.3-116.5 (C-2”), 117.4-117.5 (C-5”),118.5 (C-7), 121.8 (C-3’), 124.1-124.2 (C-6”), 124.5 (C-4a), 127.4 (C-1’), 128.1-129.4(C-2’, C-6’, C-5), 128.8 (C-2”’, C-6”’, C-8), 132.8 (C-1”), 134.5 (C-6), 136.5 (C-1”’), 148.1(C-4”), 148.5 (C-8a), 150.0 (C-3”), 151.7 (C-2), 159.6 (C-4”), 161.2 (CO2Et), 163.2 (C-4’), 163.7 (CONH), 176.8 (C-4). LC-MS (m/z): positive mode 608 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 88.6%. mp 210-212 ◦C.
5.2.21.42 Ethyl-6-(4-((tert-butoxycarbonyl)amino)phenyl)-8-(4-((4-fluorobenzyl)-oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 129(ANM197)
O CO2Et
NH
O
O
SitBu
O
O
F
The compound was synthesized according to GP-10using 47 (194 mg, 0.79 mmol) and 31 (264 mg, 0.6mmol). The precipitate was filtered off, washed threetimes with 1 mL of DCM each and dried in vacuum at50 ◦C. The product was isolated as a white solid (330mg, 82% yield). 1H NMR: δ 0.23 (s, 6H, Si(CH3)2), 0.97(s, 9H, Si(C-H3)3), 1.26 (t, J = 7.1 Hz, 3H, CH2CH3),4.34 (q, J = 7.1 Hz, 2H, CH2CH3), 5.21 (s, 2H, CH2-O), 6.95-7.01 (m, 3H, 3”’-H, 5”’-H,3-H), 7.15-7.26 (m, 4H, 3”-H, 5”-H, 3’-H, 5’-H), 7.50-7.56 (m, 2H, 2H, 2”’-H, 6”’-H),7.63-7.68 (m, 2H, 2”-H, 6”-H), 7.99-8.05 (m, 3H, 5-H, 2’-H, 6’-H), 8.37 (d, J = 2.3Hz, 1H, 7-H), 10.14 (s, 1H, CONH). 13C NMR: δ 4.4 (Si(CH3)2), 13.8 (CH2CH3), 18.1(SiC), 25.7 (SiC(CH3)3), 62.8 (CH2CH3), 68.9 (CH2-O), 113.6 (C-3), 114.7 (C-3’, C-5’),115.4-115.5 (C-3”, C-5”), 117.7 (C-5), 120.7 (C-3”’, C-5”’), 124.6 (C-4a), 126.4 (C-1’),128.8 (C-2”’, C-6”’), 128.5 (C-7), 129.1 (C-8), 129.8 (C-2’, C-6’), 130.2 (C-2”, C-6”),131.5 (C-1”), 133.0 (C-6, C-1”’), 148.3 (C-8a), 151.8 (C-2), 155.7 (C-4”’), 160.0 (C-4’),161.0-162.9 (C-4”), 161.4 (CO2Et), 164.9 (CONH), 177.3 (C-4). LC-MS (m/z): positivemode 668 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 83.7%. mp 172-173 ◦C.
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5.2.21.43 Ethyl-8-(3-fluor-4-(4-fluorobenzyloxy)benzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylate 145(THB24)
O CO2Et
O
NHO
F
O
F
The compound was synthesized according to GP-10 using 26(278 mg, 1.2 mmol) and 55 (317 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (363 mg, 72% yield). 1H NMR: δ 1.28 (t, J = 7.1Hz, 3H, CH2CH3), 4.37 (q, J = 7.1 Hz, 2H, CH2CH3), 5.30 (s,2H, CH2-O), 7.00 (s, 1H, 3-H), 7.22 (t, J = 8.9 Hz, 2H, 3”’-H,5”’-H), 7.41-7.47 (m, 2H, 2”’-H, 6”’-H), 7.49-7.57 (m, 5H, 2’-H, 3’-H, 4’-H, 5’-H, 6’-H),7.70-7.77 (m, 2H, 5”-H, 6”-H), 7.86-7.92 (m, 1H, 2”-H), 8.10 (d, J = 2.3 Hz, 1H, 7-H),8.41 (d, J = 2.3 Hz, 1H, 5-H), 10.09 (s, 1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 62.5(CH2CH3), 69.9 (CH2-O), 113.4 (C-3), 115.0 (C-5”), 115.2-115.3 (C-3”’, C-5”’), 118.4(C-5), 124.5 (C-3”), 124.6 (C-7), 126.7 (C-2’, C-6’), 127.9 (C-4a), 128.0 (C-4’), 128.7(C-1’, C-8), 129.0 (C-3’, C-5’), 129.8 (C-2”, C-6”), 129.9 (C-2”’, C-6”’), 137.6 (C-1”’),138.1 (C-6), 151.7 (C-1”), 152.3 (C-8a), 153.0 (C-2), 154.2 (C-4”), 159.6 (CO2Et), 163.8(C-4”’), 166.1 (CONH), 176.9 (C-4). LC-MS (m/z): positive mode 556 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 89.0%. mp 249-250 ◦C.
5.2.21.44 Ethyl 6-bromo-8-(4-(3-cyclohexylpropoxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 172(ANM25)
O
O
CO2Et
Br
NHO
O
The compound was synthesized according to GP-10 using 17 (281mg, 0.9 mmol) and 291 (314 mg, 1.2 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid(249 mg, 37% yield). 1H NMR: δ 0.91-1.79 (m, 18H, Cyclohexyl-H,2”-H, 3”-H, CH2CH3), 4.08 (t, J = 6.5 Hz, 2H, 1”-H), 4.38 (q, J =7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H), 7.05-7.10 (m, 2H, 3’-H,5’-H), 7.94 (d, J = 2.4 Hz, 1H, 5-H), 7.96-8.01 (m, 2H, 2’-H, 6’-H), 8.38 (d, J = 2.4Hz, 1H, 7-H), 9.87 (s, 1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 25.5-26.0 (C-2”, C-3”’,C-4”’, C-5”’), 32.6 (C-2”’, C-6”’), 32.8 (C-3”), 62.6 (CH2CH3), 68.3 (C-1”), 113.5 (C-3),114.3 (C-3’, C-5’), 117.7 (C-6), 122.4 (C-5), 125.2 (C-1’), 126.0 (C-4a), 129.4 (C-2’,
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C-6’), 130.3 (C-8), 131.0 (C-7), 148.3 (C-8a), 151.8 (C-2), 159.4 (C-4’), 162.0 (CO2Et),169.3 (CONH), 177.5 (Cq, C-4). LC-MS (m/z): positive mode 557 [M+H]+, negativemode 554 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 98.4%. mp 268-271 ◦C.
5.2.21.45 Ethyl 8-(4-(4-cyclohexylbutoxy)benzamido)-6-methoxy-4-oxo-4H-chromene-2-carboxylate 173(ANM111)
O
O
CO2Et
H3CO
NHO
O
The compound was synthesized according to GP-10 using 24(177 mg, 0.68 mmol) and 77 (250 mg, 0.91 mmol). The precip-itate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a white solid (142 mg, 40% yield). 1H NMR: δ 0.84-0.89 (m,2H, cyclohexyl), 1.07-1.27 (m, 6H, 4”-H, cyclohexyl), 1.30 (t, J= 7.7 Hz, 3H, CH2CH3), 1.40-1.51 (m, 2H, 3”-H), 1.55-1.80 (m,7H, 2”-H, cyclohexyl), 3.90 (s, 3H, OCH3), 4.09 (t, J = 6.5 Hz, 2H, 1”-H), 4.37 (q, J =7.1 Hz, 2H, CH2CH3), 6.93 (s, 1H, 3-H), 7.06-7.08 (m, 2H, 3’-H, 5’-H), 7.27 (d, J = 3.1Hz, 1H, 5-H), 7.85 (d, J = 3.0 Hz, 1H, 7-H), 7.96-8.00 (m, 2H, 2’-H, 6’-H), 9.75 (s, 1H,CONH). 13C NMR: δ 13.5 (CH2CH3), 22.5 (C-3”), 25.6 (C-3”’, C-5”’), 26.0 (C-4”’), 28.7(C-2”’, C-6”’), 36.2 (C-4”), 36.8 (C-1”’), 55.8 (OCH3), 62.4 (CH2CH3), 67.9 (C-1”), 101.0(C-5), 112.5 (C-3), 114.3 (C-3’, C-5’), 118.0 (C-7), 124.6 (C-4a), 125.8 (C-1’), 129.3(C-2’, C-6’), 129.7 (C-8), 143.5 (C-8a), 151.6 (C-6), 156.6 (C-2), 159.7 (CO2Et), 161.8(C-4’), 164.6 (CONH), 176.5 (C-4). LC-MS (m/z): positive mode 522 [M+H]+, negativemode 520 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 100%. mp 174-175 ◦C.
5.2.21.46 Ethyl 8-(4-(4-cyclohexylbutoxy)benzamido)-6-methyl-4-oxo-4H-chro-mene-2-carboxylate 174(ANM110)
O
O
CO2Et
H3C
NHO
O
The compound was synthesized according to GP-10 using 23(167 mg, 0.68 mmol) and 77 (250 mg, 0.91 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (291 mg, 64% yield). 1H NMR: δ 0.84-0.89 (m, 2H,cyclohexyl), 1.20-1.35 (m, 9H, 4”-H, cyclohexyl, CH2CH3), 1.42-1.46 (m, 2-H, 3”-H), 1.65-1.75 (m, 7H, 2”-H, cyclohexyl), 2.46 (s,
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3H, CH3), 4.09 (t, J = 6.5 Hz, 2H, 1”-H), 4.36 (q, J = 7.1 Hz, 2H, CH2CH3), 6.93 (s,1H, 3-H), 7.04-7.08 (m, 2H, 3’-H, 5’-H), 7.68 (dd, J = 2.1 Hz, 1H, 5-H), 7.96-8.00 (m,2H, 2’-H, 6’-H), 8.00 (d, J = 2.2 Hz, 1H, 7-H), 9.75 (s, 1H, CONH). 13C NMR: δ 13.5(CH2CH3), 20.5 (CH3), 22.5 (C-4”), 25.6 (C-3”’, C-5”’), 26.0 (C-3”), 28.7 (C-2”’, C-6”’),32.6 (C-2”’, C-6”’), 36.2 (C-2”), 36.8 (C-1”’), 62.4 (CH2CH3), 67.9 (C-1”), 113.3 (C-3),114.2 (C-3’, C-5’), 120.1 (C-5), 123.8 (C-4a), 125.9 (C-1’), 128.1 (C-8), 129.3 (C-2’, C-6’),130.7 (C-7), 135.3 (C-6), 147.0 (C-8a), 151.5 (C-2), 159.7 (CO2Et), 161.6 (C-4’), 164.6(CONH), 176.8 (C-4). LC-MS (m/z): positive mode 506 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 92.0%. mp 165-166 ◦C.
5.2.21.47 Ethyl 8-(4-((5-cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 178(ANM155)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19(179 mg, 0.68 mmol) and 79 (250 mg, 0.91 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (207 mg, 60% yield). 1H NMR: δ 0.86-0.95 (m, 2H,Cyclohexyl), 1.08-1.27 (m, 6H, Cyclohexyl, 5”-H), 1.28 (t, J = 7.1Hz, 3H, CH2CH3), 1.32-1.50 (m, 4H, 4”-H, 3”-H), 1.60-1.78 (m,7H, 2”-H, Cyclohexyl), 4.00-4.22 (m, 2H, 1”-H), 4.37 (q, J = 7.1 Hz, 2H, CH2CH3),6.96 (s, 1H, 3-H), 7.04-7.14 (m, 2H, 3’-H, 5’-H), 7.54 (t, J = 7.9 Hz, 1H, 6-H), 7.88(dd, J = 1.6, 8.0 Hz, 1H, 5-H), 7.95-8.01 (m, 2H, 2’-H, 6’-H), 8.16 (dd, J = 1.58, 7.8Hz, 1H, 7-H), 9.79 (s, 1H, CONH). 13C NMR: δ 13.4 (CH2CH3), 25.6 (C-3”’, C-5”’),25.8-26.0 (C-5”, C-4”), 28.4 (C-3”), 32.7 (C-2”’, C-6”’), 36.5 (C-2”), 36.8 (C-1”’), 62.4(CH2CH3), 67.9 (C-1”), 113.1 (C-3), 114.2 (C-3’, C-5’), 120.6 (C-5), 124.1 (C-4a), 125.2(C-7), 126.0 (C-1’), 128.4 (C-8), 129.3 (C-2’, C-6’), 129.5 (C-6), 148.7 (C-8a), 152.8(C-2), 160.9 (CO2H), 161.6 (C-4’), 164.7 (CONH), 177.2 (C-4). LC-MS (m/z): positivemode 507 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 186-188 ◦C.
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5.2.21.48 Ethyl 6-chloro-8-(4-(4-cyclohexylbutoxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 175(ANM166)
O
O
CO2Et
NHO
O
Cl The compound was synthesized according to GP-10 using 22 (203mg, 0.76 mmol) and 79 (270 mg, 1.01 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid(263 mg, 50% yield). 1H NMR: δ 0.86-0.95 (m, 2H, Cyclohexyl),1.08-1.30 (m, 9H, Cyclohexyl, 4”-H, CH2CH3), 1.32-1.50 (m, 2H,3”-H), 1.60-1.78 (m, 7H, 2”-H, Cyclohexyl), 4.09 (t, J = 6.5 Hz,2H, 1”-H), 4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H), 7.04-7.14 (m, 2H,3’-H, 5’-H), 7.80 (d, J = 2.5 Hz, 1H, 5-H), 7.95-8.01 (m, 2H, 2’-H, 6’-H), 8.27 (d, J= 2.6 Hz, 1H, 7-H), 9.87 (s, 1H, CONH). 13C NMR: δ 13.6 (CH2CH3), 22.5 (C-4”),25.6 (C-3”’, C-5”’), 26.2 (C-3”), 28.7 (C-3”), 32.7 (C-2”’, C-6”’), 36.2 (C-2”), 36.8 (C-1”’),62.6 (CH2CH3), 67.9 (C-1”), 113.4 (C-3), 114.3 (C-3’, C-5’), 119.2 (C-7), 124.9 (C-4a),125.2 (C-7), 125.5 (C-1’), 128.2 (C-5), 129.4 (C-2’, C-6’), 130.0-130.3 (C-6, C-8), 147.1(C-8a), 151.8 (C-2), 159.4 (CO2H), 161.9 (C-4’), 164.6 (CONH), 175.8 (C-4). LC-MS(m/z): positive mode 526 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.6%. mp162-163 ◦C.
5.2.21.49 Ethyl 8-(4-(4-cyclohexylbutoxy)benzamido)-6-fluoro-4-oxo-4H-chro-mene-2-carboxylate 176(ANM175)
O
O
CO2Et
NHO
O
F The compound was synthesized according to GP-10 using 21 (176mg, 0.70 mmol) and 79 (258 mg, 1.01 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid (214mg, 60% yield). 1H NMR: δ 0.86-0.95 (m, 2H, Cyclohexyl), 1.08-1.30 (m, 9H, Cyclohexyl, 4”-H, CH2CH3), 1.32-1.50 (m, 2H, 3”-H),1.60-1.78 (m, 7H, 2”-H, Cyclohexyl), 4.09 (t, J = 6.5 Hz, 2H, 1”-H),4.39 (q, J = 7.1 Hz, 2H, CH2CH3), 6.98 (s, 1H, 3-H), 7.04-7.14 (m, 2H, 3’-H, 5’-H),7.53 (dd, J = 3.1, 8.1 Hz, 1H, 5-H), 7.95-8.01 (m, 2H, 2’-H, 6’-H), 8.15 (dd, J = 3.1,9.8 Hz, 1H, 7-H), 9.86 (s, 1H, CONH). 13C NMR: δ 13.5 (CH2CH3), 22.5 (C-4”), 25.6(C-3”’, C-5”’), 26.0 (C-3”), 28.7 (C-3”), 32.6 (C-2”’, C-6”’), 36.2 (C-2”), 36.8 (C-1”’), 62.5
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(CH2CH3), 67.9 (C-1”), 104.5-104.7 (C-5), 112.7 (C-3), 114.3 (C-3’, C-5’), 116.3-116.5(C-7), 124.7-124.8 (C-4a), 125.4 (C-1’), 129.4 (C-2’, C-6’), 130.6-130.7 (C-8), 144.8 (C-8a), 151.7 (C-2), 157.5 (C-6), 159.5 (CO2H), 161.9 (C-4’), 164.5 (CONH), 176.2 (C-4).LC-MS (m/z): positive mode 510 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.1%. mp 151-152 ◦C.
5.2.21.50 Ethyl 8-(3-(4-cyclohexylbutoxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 159(ANM176)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19(142 mg, 0.61 mmol) and 101 (225 mg, 0.81 mmol). The pre-cipitate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a yellow-white solid (183 mg, 61% yield). 1H NMR: δ 0.83-0.89 (m, 2H, Cyclohexyl), 1.08-1.29 (m, 9H, Cyclohexyl, 4”-H,CH2CH3), 1.32-1.50 (m, 2H, 3”-H), 1.60-1.78 (m, 7H, 2”-H, Cyclohexyl), 4.02-4.08 (m,2H, 1”-H), 4.33 (q, J = 7.9 Hz, 2H, CH2CH3), 6.98 (s, 1H, 3-H), 7.19 (ddd, J = 2.5,8.2 Hz, 1H, 2’-H), 7.46 (t, J = 7.9 Hz, 1H, 6-H), 7.50-7.60 (m, 3H, 4’-H, 5’-H, 6’-H),7.91 (dd, J = 1.6, 8.0 Hz, 1H, 5-H), 8.09 (dd, J = 1.6, 7.7 Hz, 1H, 7-H), 10.20 (s,1H, CONH). 13C NMR: δ 13.7 (CH2CH3), 22.9 (C-4”), 25.6 (C-3”’, C-5”’), 26.3 (C-4”’),29.1 (C-3”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.1 (C-1”’), 62.5 (CH2CH3), 67.9 (C-1”),113.7 (C-3, C-2’), 118.2-119.9 (C-4’, C-6’), 121.6 (C-5), 124.4 (C-8), 125.8 (C-7), 128.3(C-4a), 129.8 (C-5’), 130.9 (C-6), 135.3 (C-1’), 149.4 (C-8a), 151.8 (C-2), 158.9 (C-3’),159.9 (CO2Et), 165.3 (CONH), 177.3 (C-4). LC-MS (m/z): positive mode 492 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 98.1%. mp 148-149 ◦C.
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5.2.21.51 Ethyl 6-(4-((tert-butoxycarbonyl)amino)phenyl)-8-(4-((4-fluorobenzyl)-oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 130(ANM193)
O
O
CO2Et
NHO
O
H
N
Boc
F
The compound was synthesized according to GP-10 us-ing 32 (467 mg, 1.1 mmol) and 47 (361 mg, 1.47 mmol).The precipitate was filtered off, washed three timeswith 1 mL of DCM each and dried in vacuum at 50◦C. The product was isolated as a yellow solid (515mg, 72% yield). 1H NMR: δ 1.24 (td, J = 7.12 Hz, 3H,CO2CH2CH3), 1.49 (s, 9H, C(CH3)3), 4.33 (q, J = 7.1 Hz,2H, CO2CH2CH3), 5.21 (s, 2H, CH2), 7.00 (s, 1H, 3-H), 7.15-7.20 (m, 2H, 3’-H, 5’-H),7.23 (td, J = 8.8 Hz, 2H, 3”-H, 5”-H), 7.51-7.58 (m, 2H, 2”-H, 6”-H), 7.62-7.67 (m,4H, 2”’-H, 3”’-H, 5”’-H, 6”’-H), 8.01-8.85 (m, 3H, 5-H, 2’-H, 6’-H), 8.36 (d, J = 2.2Hz, 1H, 7-H), 9.50 (s, 1H, CONH), 10.15 (C-4”’NH). 13C NMR: δ 13.8 (CO2CH2CH3),28.3 (C(CH3)3), 62.8 (CO2CH2CH3), 68.9 (CH2), 79.4 (C(CH3)3), 113.6 (C-3), 114.8 (C-3’,C-5’), 115.3-115.5 (C-3”, C-5”), 117.6 (C-7), 118.7 (C-3”’, C-5”’), 124.7 (C-4a), 126.3(C-1’), 127.3 (C-2”’, C-6”’), 128.5 (C-5), 129.2 (C-8), 129.8 (C-2’, C-6’), 130.2 (C-2”,C-6”), 131.7 (C-1”), 133.0 (C-6), 137.4 (C-1”’), 140.0 (CO2NH), 148.4 (C-8a), 151.8 (C-4”’), 152.8 (C-2), 159.9 (CO2Et), 161.0 (C-4”), 162.9 (C-4’), 164.9 (CONH), 177.3 (C-4).LC-MS (m/z): positive mode 653 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:96.9%. mp 232-233 ◦C.
5.2.21.52 Ethyl 8-(4-(4-cyclohexylbutoxy)benzamido)-6-ethyl-4-oxo-4H-chro-mene-2-carboxylate 177(ANM216)
O
O
CO2Et
NHO
O
H3C
The compound was synthesized according to GP-10 using 20(235 mg, 0.9 mmol) and 77 (331 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (403 g, 86% yield). 1H NMR: δ 0.88-0.92 (m, 2H,cyclohexyl), 1.24-1.29 (m, 12H, cyclohexyl, 4”-H, C6-CH2CH3,CO2CH2CH3), 1.42-1.46 (m, 2H, 3”-H), 1.69-1.73 (m, 7H, 2”-H,cyclohexyl), 2.75-2.81 (m, 2H, C6-CH2CH3), 4.07-4.10 (m, 2H, 1”-H), 4.34-4.38 (m,2H, CO2CH2CH3), 6.94 (s, 1H, 3-H), 7.06 (dd, J = 1.7, 8.75 Hz, 2H, 3’-H, 5’-H), 7.68-
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7.02 (m, 1H, 5-H), 7.96-8.00 (m, 2H, 2’-H, 6’-H), 8.01-8.04 (m, 1H, 7-H), 9.76 (s, 1H,CONH). 13C NMR: δ 13.5 (CO2CH2CH3), 14.8 (C6-CH2CH3), 22.6 (C-4”), 25.6 (C-3”’,C-5”’), 26.0 (C-4”’), 27.6 (C6-CH2CH3), 28.7 (C-3”), 32.7 (C-2”’, C-6”’), 36.2 (C-2”), 36.8(C-1”’), 62.4 (CO2CH2CH3), 67.9 (C-1”), 113.3 (C-3), 114.2 (C-3’, C-5’), 118.9 (C-5),123.9 (C-4a), 126.0 (C-1’), 128.3 (C-8), 129.3 (C-2’, C-6’), 129.7 (C-7), 141.5 (C-6),147.2 (C-8a), 151.5 (C-2), 159.7 (CO2Et), 161.6 (C-4’), 164.7 (CONH), 176.9 (C-4).LC-MS (m/z): positive mode 520 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.3%. mp 147-148 ◦C.
5.2.21.53 Ethyl8-(4-(ethoxycarbonyl)benzamido)-4-oxo-4H-chromene-2-carboxylate117 (ANM220)
O
O
CO2Et
NHO
CO2Et
The compound was synthesized according to GP-10 using 19 (209mg, 0.9 mmol) and 290 (232 mg, 1.2 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid(297 mg, 80% yield). 1H NMR: δ 1.21 (t, J = 7.2 Hz, 3H, C4’-CO2CH2CH3), 1.36 (t, J = 7.1 Hz, 3H, C2-CO2CH2CH3), 4.34-4-36(m, 4H, CH2CH3), 6.99 (s, 1H, 3-H), 7.58 (t, J = 7.9 Hz, 1H, 6-H), 7.97-8.01 (m, 2H,5-H, 7-H), 8.12-8.16 (m, 4H, 2’-H, 3’-H, 5’-H, 6’-H), 10.50 (s, 1H, CONH). 13C NMR: δ13.7 (CH, C2-CO2CH2CH3), 14.3 (C4’-CO2CH2CH3), 61.3 (C4’-CO2CH2CH3), 62.8 (C2-CO2CH2CH3), 113.8 (C-3), 122.2 (C-5), 124.5 (C-8), 125.9 (C-7), 128.0 (C-4a), 128.2(C-2’, C-6’), 129.4 (C-3’, C-5’), 131.6 (C-6), 132.9 (C-4’), 138.0 (C-1’), 149.7 (C-8a),151.9 (C-2), 159.9 (C2-CO2Et), 164.9 (CONH), 165.3 (C4’-CO2Et), 177.3 (C-4). LC-MS (m/z): positive mode 410 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.0%.mp 201-202 ◦C.
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5.2.21.54 Ethyl 6-bromo-8-(4-(ethoxycarbonyl)benzamido)-4-oxo-4H-chromene-2-carboxylate 118(ANM223)
O
O
CO2Et
NHO
CO2Et
Br The compound was synthesized according to GP-10 using 17 (280mg, 0.9 mmol) and 290 (232 mg, 1.2 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid(387 mg, 88% yield). 1H NMR: δ 1.27 (t, J = 7.1 Hz, 3H, C4’-CO2CH2CH3), 1.37 (t, J = 7.1 Hz, 3H, C2-CO2CH2CH3), 4.34-4-36(m, 4H, CH2CH3), 7.00 (s, 1H, 3-H), 7.99 (d, J = 2.5 Hz, 1H, 5-H), 8.12-8.16 (m, 4H,2’-H, 3’-H, 5’-H, 6’-H), 8.30-8.33 (m, 1H, 7-H), 10.32 (s, 1H, CONH). 13C NMR: δ13.4 (CH, C2-CO2CH2CH3), 13.9 (C4’-CO2CH2CH3), 60.9 (C4’-CO2CH2CH3), 62.6 (C2-CO2CH2CH3), 113.6 (C-3), 117.6 (C-6), 123.4 (C-5), 125.3 (C-8), 127.8 (C-2’, C-6’),129.0 (C-3’, C-5’), 129.8 (C-4a), 132.2 (C-7), 133.0 (C-4’), 137.4 (C-1’), 148.1 (C-8a),151.8 (C-2), 159.4 (C2-CO2Et), 164.6 (CONH), 164.9 (C4’-CO2Et), 175.6 (C-4). LC-MS(m/z): positive mode 490 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 96.0%. mp207-208 ◦C.
5.2.21.55 Ethyl 8-(3-((5-cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 162(ANM241)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using19 (209 mg, 0.9 mmol) and 102 (348 mg, 1.2 mmol). Theprecipitate was filtered off, washed three times with 1 mL ofDCM each and dried in vacuum at 50 ◦C. The product wasisolated as a white solid (388 mg, 85% yield). 1H NMR: δ0.78-0.90 (m, 2H, cyclohexyl), 1.04-1.21 (m, 6H, 5”-H, cyclo-hexyl), 1.24 (t, J = 8.1 Hz, 3H, CH2CH3), 1.32-1.48 (m, 4H, 3”-H, 4”-H), 1.54-1.79 (m,7H, 2”-H, cyclohexyl), 4.05 (t, J = 6.5 Hz, 2H, 1”-H), 4.33 (q, J = 7.1 Hz, 2H, CH2CH3),6.99 (s, 1H, 3-H), 7.19 (ddd, J = 8.3, 2.4, 1.0 Hz, 1H, 4’-H), 7.46 (t, J = 7.9 Hz, 1H,2’-H), 7.54-7.60 (m, 3H, 5’-H, 6’-H, 6-H), 7.91 (dd, J = 8.0, 1.6 Hz, 1H, 5-H), 8.08 (dd,J = 7.8, 1.6 Hz, 1H, 7-H), 10.21 (s, 1H, CONH). 13C NMR: δ 13.8 (CO2CH2CH3), 26.0(C-5”, C-4”, C-3”’, C-5”’), 26.3 (C-4”’), 28.8 (C-3”), 33.0 (C-2”’, C-6”’), 37.0 (C-2”), 37.1(C-1”’), 62.8 (CO2CH2CH3), 67.9 (C-1”’), 113.7 (C-3, C-2’), 118.3 (C-4’), 119.9 (C-5),
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121.7 (C-6’), 124.5 (C-4a), 125.9 (C-7), 128.3 (C-8), 129.8 (C-6), 131.0 (C-5’), 135.4 (C-1’), 149.4 (C-8a), 151.9 (C-2), 158.9 (C-3’), 160.0 (CO2Et), 165.3 (CONH), 177.3 (C4).LC-MS (m/z): positive mode 506 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.4%. mp 144-145 ◦C.
5.2.21.56 Ethyl 6-chloro-8-(3-((5-cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 163(ANM242)
O
O
CO2Et
NHO
O
Cl The compound was synthesized according to GP-10 using22 (160 mg, 0.6 mmol) and 102 (232 mg, 0.8 mmol). Theprecipitate was filtered off, washed three times with 1 mL ofDCM each and dried in vacuum at 50 ◦C. The product wasisolated as a white solid (234 mg, 72% yield). 1H NMR: δ0.83-0.94 (m, 2H, cyclohexyl), 1.14-1.22 (m, 6H, cyclohexyl,5”-H), 1.29 (t, 3H, J = 7.1 Hz, CH2CH3), 1.32-1.48 (m, 4H, 3”-H, 4”-H), 1.56-1.80(m, 7H, 2”-H, cycylohexyl), 4.08 (t, J = 6.5 Hz, 2H, 1”-H), 4.37 (q, J = 7.1 Hz, 2H,CH2CH3), 7.00 (s, 1H, 3-H), 7.20 (dd, J = 8.3 Hz, 1H, 4’-H), 7.47 (t, J = 7.9 Hz,1H, 2’-H), 7.53-7.60 (m, 2H, 5’-H, 6’-H), 7.80-7.84 (m, 1H, 5-H), 8.25 (d, J = 2.6 Hz,1H, 7-H), 10.02 (s, 1H, CONH). 13C NMR: δ 13.4 (CO2CH2CH3), 25.6 (C-4”, C-5”,C-3”’, C-5”’), 26.0 (C-4”’), 28.5 (C-3”), 32.7 (C-2”’, C-6”’), 36.5 (C-2”), 36.8 (C-1”’), 62.6(CO2CH2CH3), 67.9 (C-1”), 113.5 (C-2’, C-3), 118.3 (C-4’), 119.6 (C-5, C-6’), 124.9(C-4a), 128.6 (C-7), 129.6 (C-5’), 130.0 (C-8), 134.9 (C-1’), 147.3 (C-8a), 151.8 (C-2),158.8 (C-3’), 159.4 (CO2Et), 165.0 (CONH), 175.8 (C-4). LC-MS (m/z): positive mode541 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 148-149 ◦C.
5.2.21.57 Ethyl 8-(3-((5-cyclohexylpentyl)oxy)benzamido)-6-fluoro-4-oxo-4H-chromene-2-carboxylate 164(ANM243)
O
O
CO2Et
NHO
O
F The compound was synthesized according to GP-10 using21 (160 mg, 0.6 mmol) and 102 (232 mg, 0.8 mmol). Theprecipitate was filtered off, washed three times with 1 mL ofDCM each and dried in vacuum at 50 ◦C. The product wasisolated as a white solid (198 mg, 63% yield). 1H NMR: δ0.83-0.93 (m, 2H, cyclohexyl), 1.08-1.27 (m, 6H, cyclohexyl,
246
5.2 Synthesis and characterization Dissertation, Universität Bonn 2016
5”-H), 1.30 (t, J = 7.1 Hz, 3H, CH2CH3), 1.32-1.48 (m, 4H, 3”-H, 4”-H), 1.57-1.81(m, 7H, 2”-H, cycylohexyl), 4.08 (t, J = 6.5 Hz, 2H, 1”-H), 4.38 (q, J = 7.1 Hz, 2H,CH2CH3), 6.98 (s, 1H, 3-H), 7.20 (dd, J = 8.3 Hz, 1H, 4’-H), 7.47 (t, J = 7.9 Hz, 1H,2’-H), 7.52-7.61 (m, 3H, 5’-H, 6’-H, 5-H), 8.13 (d, J = 3.1 Hz, 1H, 7-H), 10.02 (s, 1H,CONH). 13C NMR: δ 13.5 (CO2CH2CH3), 25.6 C-4”, C-5”, C-3”’, C-5”’), 26.0 (C-4”’),28.5 (C-3”), 32.7 (C-2”’, C-6”’), 36.5 (C-2”), 36.8 (C-1”’), 62.5 (CO2CH2CH3), 67.9 (C-1”), 105.1-105.3 (C-7), 112.8 (C-2’), 113.7 (C-3), 116.8 (C-5), 118.4 (C-4’), 119.5 (C-6’),124.8 (C-4a), 129.6 (C-5’), 130.3 (C-8), 134.9 (C-1’), 145.1 (C-8a), 151.7 (C-2), 157.5(C-6), 158.8 (C-3’), 159.5 (CO2Et), 165.0 (CONH), 176.2 (C-4). LC-MS (m/z): positivemode 524 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.6%. mp 148-149 ◦C.
5.2.21.58 Ethyl 8-(3-(cyclohexylmethoxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 154(ANM259)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19 (209mg, 0.9 mmol) and 95 (281 mg, 1.2 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid (348mg, 86% yield). 1H NMR: δ 1.04-1.12 (m, 2H, cyclohexyl), 1.13-1.32 (m, 6H, cyclohexyl, CH2CH3), 1.62-1.87 (m, 7H, cyclohexyl),3.88 (d, J = 6.3 Hz, 2H, 1”-H), 4.33 (q, J = 7.1 Hz, 2H, CH2CH3), 6.99 (s, 1H, 3-H),7.19 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H, 4’-H), 7.46 (t, J = 7.9 Hz, 1H, 2’-H), 7.53-7.60 (m,3H, 5’-H, 6’-H, 6-H), 7.91 (dd, J = 8.0, 1.6 Hz, 1H, 5-H), 8.07 (dd, J = 7.7, 1.5 Hz, 1H,7-H), 10.22 (s, 1H, CONH). 13C NMR: δ 13.8 (CO2CH2CH3), 25.4 (C-3”’, C-5”’), 26.2(C-4”’), 29.4 (C-2”’, C-6”’), 37.3 (C-1”’), 62.8 (CO2CH2CH3), 73.1 (C-1”), 113.6 (C-3,C-2’), 118.3 (C-4’), 119.9 (C-5), 121.7 (C-6’), 124.5 (C-4a), 125.9 (C-8), 129.8 (C-6),131.1 (C-5’), 135.4 (C-1’), 149.5 (C-8a), 151.9 (C-2), 159.0 (C-3’), 160.0 (CO2Et), 165.3(CONH), 177.3 (C-4). LC-MS (m/z): positive mode 450 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.2%. mp 199-201 ◦C.
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5.2.21.59 Ethyl 8-(3-(benzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylate167 (ANM260)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19 (209mg, 0.9 mmol) and 71 (274 mg, 1.2 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid(268 mg, 67% yield). 1H NMR: δ 1.25 (t, J = 7.1 Hz, 3H, CH2CH3),4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 5.22 (s, 2H, 1”-H), 6.97 (s, 1H,3-H), 7.26-7.31 (m, 1H, 4’-H), 7.31-7.36 (m, 1H, 4”’-H), 7.38-7.43 (m, 2H, 3”’-H, 5”’-H),7.44-7.52 (m, 3H, 2”’-H, 6”’-H, 2’-H), 7.52-7.59 (m, 1H, 6-H), 7.58-7.64 (m, 1H, 5’-H),7.66-7.69 (m, 1H, 6’-H), 7.91 (dd, J = 8.0, 1.6Hz, 1H, 5-H), 8.14 (dd, J = 7.7, 1.6 Hz,1H, 7-H), 9.97 (s, 1H, CONH). 13C NMR: δ 13.4 (CO2CH2CH3), 62.5 (CO2CH2CH3),69.7 (C-1”), 113.46 (C-3), 114.2 (C-2’), 118.4 (C-4’), 119.9 (C-5), 121.2 (C-6’), 124.2(C-4a), 125.5 (C-7), 127.4 (C-2”’, C-6”’), 127.7 (C-5”’), 128.1 (C-8), 128.2 (C-3”’, C-5”’),129.5 (C-6), 130.1 (C-5’), 135.4 (C-1’), 136.7 (C-1”’), 148.9 (C-8a), 151.7 (C-2), 158.5(C-3’), 159.7 (CO2Et), 165.0 (CONH), 176.9 (C-4). LC-MS (m/z): positive mode 444[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.7%. mp 195-197 ◦C.
5.2.21.60 Ethyl4-oxo-8-(3-(3-phenylpropoxy)benzamido)-4H-chromene-2-carboxylate169 (ANM261)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19(209 mg, 0.9 mmol) and 83 (308 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM each anddried in vacuum at 50 ◦C. The product was isolated as a whitesolid (172 mg, 41% yield). 1H NMR: δ 1.24 (t, J = 7.1 Hz, 3H,CH2CH3), 1.94-2.20 (m, 2H, 2”-H), 4.08 (t, J = 6.3 Hz, 2H, 1”-H),4.34 (q, J = 7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H), 7.17-7.24 (m, 2H, 4’-H, 4”’-H),7.24-7.28 (m, 2H, 3”’-H, 5”’-H), 7.28-7.34 (m, 2H, 2”’-H, 6”’-H), 7.49 (t, J = 7.9 Hz, 1H,6-H), 7.56-7.64 (m, 2H, 5’-H, 6’-H), 7.93 (dd, J = 8.0, 1.6 Hz, 1H, 5-H), 8.09 (dd, J =7.7, 1.6 Hz, 1H, 7-H), 10.25 (s, 1H, CONH). 13C NMR: δ 14.1 (CO2CH2CH3), 30.8 (C-2”), 31.9 (C-3”), 63.1 (CO2CH2CH3), 67.5 (C-1”), 114.1 (C-2’, C-3), 118.6 (C-4’), 120.4(C-5), 122.1 (C-6’), 124.8 (C-7), 128.8 (C-8), 128.8 (C-2”’, C-3”’, C-4”’, C-5”’, C-6”’),130.2 (C-6), 131.4 (C-5’), 135.7 (C-1”’), 141.8 (C-1’), 149.8 (C-8a), 152.2 (C-2), 159.2
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(C-3’), 160.3 (CO2Et), 165.6 (CONH), 177.7 (C-4). LC-MS (m/z): positive mode 472[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.9%. mp 157-159 ◦C.
5.2.21.61 Ethyl 4-oxo-8-(3-phenethoxybenzamido)-4H-chromene-2-carboxylate168 (ANM262)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19 (209mg, 0.9 mmol) and 81 (291 mg, 1.2 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid (203mg, 49% yield). 1H NMR: δ 1.21 (t, J = 7.1 Hz, 3H, CH2CH3), 3.08(t, J = 6.8 Hz, 2H, 2”-H), 4.12-4.46 (m, 3H, 1”-H, CH2CH3), 6.98 (s,1H, 3-H), 7.17-7.25 (m, 2H, 4’-H, 4”’-H), 7.27-7.39 (m, 4H, 2”’-H, 3”’-H, 5”’-H, 6”’-H),7.46 (t, J = 7.9 Hz, 1H, 6-H), 7.52-7.62 (m, 3H, 2’-H, 5’-H, 6’-H), 7.91 (dd, J = 8.1,1.6 Hz, 1H, 5-H), 8.06 (dd, J =7.7, 1.6Hz, 1H, 7-H), 10.22 (s, 1H, CONH). 13C NMR:δ 13.8 (CO2CH2CH3), 35.1 (C-2”), 62.8 (CO2CH2CH3), 68.6 (C-1”), 113.7 (C-2’, C-3),118.3 (C-4’), 120.1 (C-5), 121.8 (C-6’), 124.5 (C-4a), 125.9 (C-7), 126.5 (C-4”’), 128.3(C-8), 128.5 (C-2”’, C-6”’), 129.1 (C-3”’, C-5”’), 129.9 (C-6), 131.2 (C-5’), 135.4 (C-1’),138.4 (C-1”’), 149.5 (C-8a), 151.9 (C-2), 158.6 (C-3’), 159.9 (CO2Et), 165.9 (CONH),177.3 (C-4). LC-MS (m/z): positive mode 458 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 99.5%. mp 168-169 ◦C.
5.2.21.62 Ethyl 8-(3-(2-cyclohexylethoxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 155(ANM266)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19 (209mg, 0.9 mmol) and 97 (298 mg, 1.2 mmol). The precipitate wasfiltered off, washed three times with 1 mL of DCM each and driedin vacuum at 50 ◦C. The product was isolated as a white solid (232mg, 78% yield). 1H NMR: δ 0.97-1.10 (m, 2H, cyclohexyl), 1.14-1.27 (m, 2H, cyclohexyl), 1.27-1.33 (m, 3H, CH2CH3), 1.50-1.60 (m,2H, cyclohexyl), 1.60-1.84 (m, 7H, cyclohexyl, 2”-H), 4.14 (t, J = 6.6 Hz, 2H, 1”-H),4.38 (t, J = 7.1 Hz, 2H, CH2CH3), 6.99 (s, 1H, 3-H), 7.21 (ddd, J = 8.1, 2.6, 1.0 Hz,1H, 4’-H), 7.48 (t, J = 7.9 Hz, 1H, 2’-H), 7.54-7.64 (m, 3H, 6-H, 5’-H, 6’-H), 7.93 (dd,J = 8.0, 1.6 Hz, 1H, 5-H), 8.16 (dd, J = 7.7, 1.6 Hz, 1H, 7-H), 9.97 (s, 1H, CONH).
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13C NMR: δ 13.4 (CO2CH2CH3), 25.5 (C-3”’, C-5”’), 25.8 (C-4”’), 32.5 (C-2”’, C-6”’),34.0 (C-1”’), 35.8 (C-2”), 62.4 (CO2CH2CH3), 66.0 (C-1”), 113.4-113.6 (C-2’, C-3), 118.0(C-4’), 119.5 (C-5), 121.1 (C-6’), 124.2 (C-4a), 125.4 (C-7), 128.1 (C-8), 129.4 (C-6),130.0 (C-5’), 135.3 (C-1’), 148.9 (C-8a), 151.6 (C-2), 158.7 (C-3’), 159.6 (CO2Et), 165.0(CONH), 176.9 (C-4). LC-MS (m/z): positive mode 464 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 100.0%. mp 150-151 ◦C.
5.2.21.63 Ethyl 4-oxo-8-(3-((5-phenylpentyl)oxy)benzamido)-4H-chromene-2-carboxylate 171(ANM276)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using19 (209 mg, 0.9 mmol) and 87 (340 mg, 1.2 mmol). Theprecipitate was filtered off, washed three times with 1 mL ofDCM each and dried in vacuum at 50 ◦C. The product wasisolated as a white solid (168 mg, 37% yield). 1H NMR: δ1.22 (t, J = 7.1 Hz, 3H, CH2CH3), 1.40-1.53 (m, 2H, 2”-H),1.60-1.67 (m, 2H, 3”-H), 1.73-1.82 (m, 2H, 5”-H), 2.54-2.63 (m, 2H, 4”-H), 4.05 (t, J =6.5 Hz, 2H, 1”-H), 4.31 (q, J = 7.1 Hz, 2H, CH2CH3), 6.98 (s, 1H, 3-H), 7.12-7.22 (m,4H, 4’-H, 3”’-H, 4”’-H, 5”’-H), 7.25 (t, J = 7.6 Hz, 2H, 2”’-H, 6”’-H), 7.46 (t, J = 7.9 Hz,1H, 6-H), 7.52-7.61 (m, 3H, 5’-H, 6’-H, 2’-H), 7.91 (dd, J = 8.0, 1.6 Hz, 1H, 5-H), 8.08(dd, J = 7.7, 1.5 Hz, 1H, 7-H), 10.21 (s, 1H, CONH). 13C NMR: δ 13.7 (CO2CH2CH3),25.3 (C-2”), 28.6 (C-3”), 30.8 (C-5”), 35.2 (C-4”), 62.8 (CO2CH2CH3), 67.8 (C-1”), 113.6(C-3, C-2’), 118.2 (C-4’), 119.9 (C-5), 121.7 (C-6’), 124.4 (C-4a), 125.7 (C-7), 128.3(C-8), 128.3 (C-2”’, C-3”’, C-4”’, C-5”’, C-6”’), 129.8 (C-6), 131.0 (C-5’), 135.3 (C-1’),142.2 (C-1”’), 149.4 (C-8a), 151.8 (C-2), 158.8 (C-3’), 159.9 (CO2Et), 165.3 (CONH),177.3 (C-4). LC-MS (m/z): positive mode 500 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 100.0%. mp 137-138 ◦C.
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5.2.21.64 Ethyl 8-(3-((4-methylbenzyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 149(ANM229)
O
O
CO2Et
NHO
O
CH3
The compound was synthesized according to GP-10 using 19(209 mg, 0.9 mmol) and 69 (291 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (152 mg, 36% yield). 1H NMR: δ 1.24 (t, J = 7.1Hz, 3H, CH2CH3), 2.31 (s, 3H, CH3), 4.34 (q, J = 7.1 Hz, 2H,CH2CH3), 5.16 (s, 2H, CH2), 6.96 (s, 1H, 2’-H), 7.20 (d, J = 7.7Hz, 2H, 3”-H, 5”-H), 7.26 (dd, J = 2.6, 8.2 Hz, 1H, 4’-H), 7.36 (d, J = 7.7 Hz, 2H, 2”-H,6”-H), 7.47 (t, J = 7.9 Hz, 1H, 6’-H), 7.55 (t, J = 7.9 Hz, 1H, 5’-H), 7.61 (d, J = 7.6Hz, 1H, 6-H), 7.65 (s, 1H, 3-H), 7.90 (dd, J = 1.5, 8.2 Hz, 1H, 5-H), 8.13 (d, J = 7.7Hz, 1H, 7H), 9.97 (s, 1H, CONH). 13C NMR: δ 13.5 (CO2CH2CH3), 20.5 (CH3), 62.5(CO2CH2CH3), 69.6 (CH2), 113.5 (C-2’), 114.2 (C-4’), 118.4 (C-6’), 119.9 (C-3), 121.2(C-5), 124.2 (C-4a), 125.5 (C-7), 127.5 (C-2”, C-6”), 128.2 (C-8), 128.8 (C-3”, C-5”),129.6 (C-6), 130.1 (C-5’), 133.7 (C-1”), 135.4 (C-1’), 137.0 (C-4”), 149.0 (C-8a), 151.7(C-3’), 158.5 (C-2), 159.7 (CO2Et), 165.1 (CONH), 177.0 (C-4). LC-MS (m/z): positivemode 558 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.5%. mp 196-198 ◦C.
5.2.21.65 Ethyl 6-bromo-8-(3-((4-methylbenzyl)oxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 150(ANM232)
O
O
CO2Et
NHO
O
Br
CH3
The compound was synthesized according to GP-10 using 17(281 mg, 0.9 mmol) and 69 (291 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as apale white solid (65 mg, 14% yield). 1H NMR: δ 1.26 (t, J = 7.1Hz, 3H, CH2CH3), 2.31 (s, 3H, CH3), 2.32 (s, 3H, CH3), 4.35 (q,J = 7.1 Hz, 2H, CH2CH3), 5.16 (s, 2H, CH2), 7.00 (s, 1H, 2’-H),7.21 (dt, J = 0.9, 7.7 Hz, 2H, 3”-H, 5”-H), 7.29 (ddd, J = 1.0, 2.6, 8.2 Hz, 1H, 4’-H),7.36 (m, 2H, 2”-H, 6”-H) 7.48 (t, J = 7.9 Hz, 1H, 3-H), 7.60 (ddd, J = 1.0, 1.7, 7.6Hz, 1H, 6’-H), 7.7 (dd, J = 1.6, 2.6 Hz, 1H, 5’-H), 7.96 (d, J = 2.4 Hz, 1H, 5-H), 8.36(d, J = 2.4 Hz, 1H, 7-H), 10.04 (m, 1H, CONH). 13C NMR: δ 13.5 (CO2CH2CH3), 20.5
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(CH3), 62.7 (CO2CH2CH3), 69.7 (CH2), 113.6 (C-2’), 114.3 (C-4’), 117.7 (C-6), 118.7(C-6’), 119,9 (C-3), 122.9 (C-7), 125.3 (C-4a), 127.5 (C-2”, C-6”), 128.8 (C-3”, C-5”),129.6 (C-5), 130.4 (C-8), 131.2 (C-5’), 133.7 (C-1”), 135.0 (C-1’), 137.0 (C-4”), 147.8(C-8a), 151.9 (C-3’), 158.6 (C-2), 159.5 (CO2Et), 165.0 (CONH), 175.7 (C-4). LC-MS(m/z): positive mode 538 [M+H]+, negative mode 534 [M-H]-. Purity by HPLC-UV(254 nm)-ESI-MS: 95.8%. mp 194-196 ◦C.
5.2.21.66 Ethyl 8-(3-((3-bromobenzyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 151(ANM233)
O
O
CO2Et
NHO
O
Br
The compound was synthesized according to GP-10 using 19(140 mg, 0.6 mmol) and 67 (249 mg, 0.8 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM each anddried in vacuum at 50 ◦C. The product was isolated as a palewhite solid (197 mg, 63% yield). 1H NMR: δ 1.21 (t, J = 7.1 Hz,3H, CH2CH3), 4.32 (q, J = 7.1 Hz, 2H, CH2CH3), 5.22 (s, 2H, CH2),6.99 (s, 1H, 2’-H), 7.30 (ddd, J = 0.9, 2.5, 8.3 Hz, 1H, 4’-H), 7.38(t, J = 7.8 Hz, 1H, 5”-H), 7.53 (m, 4H, 3-H, 6-H, 2”-H, 6”-H), 7.66 (m, 3H, 5’-H, 6’-H, 4”-H), 7.92 (dd, J = 1.56, 8.0 Hz, 1H, 5-H), 8.08 (dd, J = 1.6, 7.7 Hz, 1H, 7-H),10.25 (s, 1H, CONH). 13C NMR: δ 14.1 (CO2CH2CH3), 63.2 (CO2CH2CH3), 69.0 (CH2),114.1 (C-2’), 114.7 (C-4’), 118.8 (C-6’), 120.8 (C-3), 122.1 (C-5), 122.2 (C-3”), 124.8(C-4a), 126.3 (C-7), 127.0 (C-6”), 128.7 (C-8), 130.3 (C-6), 130.7 (C-5”), 131.2 (C-5’),131.2 (C-4”), 131.4 (C-2”), 135.8 (C-1’), 140.1 (C-1”), 149.1 (C-8a), 152.2 (C-3’), 158.7(C-2), 160.3 (CO2Et), 165.5 (CONH), 177.7 (C-4). LC-MS (m/z): positive mode 522[M+H]+, negative mode 520 [M-H]-. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%.mp 175-176 ◦C.
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5.2.21.67 Ethyl 6-bromo-8-(3-((3-bromobenzyl)oxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 152(ANM230)
O
O
CO2Et
NHO
O
Br
Br
The compound was synthesized according to GP-10 using 17(281 mg, 0.9 mmol) and 67 (368 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM each anddried in vacuum at 50 ◦C. The product was isolated as a palewhite solid (402 mg, 74% yield). 1H NMR: δ 1.22 (t, J = 7.1 Hz,3H, CH2CH3), 4.33 (q, J = 7.1 Hz, 2H, CH2CH3), 5.22 (s, 2H, CH2),7.03 (s, 1H, 2’-H), 7.31 (ddd, J = 1.0, 2.6, 8.2 Hz, 1H, 4’-H), 7.38(t, J = 7.8 Hz, 1H, 5”-H), 7.52 (m, 3H, 3-H, 2”-H, 6”-H), 7.65 (m, 3H, 5’-H, 6’-H, 4”-H),7.98 (d, J = 2.4 Hz, 1H, 5-H), 8.31 (d, J = 2.4 Hz, 1H, 7-H), 10.34 (s, 1H, CONH). 13CNMR: δ 13.7 (CO2CH2CH3), 62.9 (CO2CH2CH3), 68.7 (CH2), 113.9 (C-2’), 114.4 (C-4’),118.0 (C-6), 118.7 (C-6’), 120.5 (C-3), 121.9 (C-3”), 123.5 (C-6”), 125.6 (C-4a), 126.7(C-7), 130.0 (C-5”), 130.2 (C-8), 130.3 (C-5), 130.8 (C-5’), 130.9 (C-4”), 132.5 (C-2”),135.1 (C-1’), 139.7 (C-1”), 148.3 (C-8a), 152.0 (C-3’), 158.3 (C-2), 159.7 (CO2Et), 165.2(CONH), 176.1 (C-24). LC-MS (m/z): negative mode 597 [M-H]-. Purity by HPLC-UV(254 nm)-ESI-MS: 96.5%. mp 198-200 ◦C.
5.2.21.68 Ethyl 6-chloro-8-(3-(hexyloxy)benzamido)-4-oxo-4H-chromene-2-car-boxylate 165(ANM331)
O
O
CO2Et
NHO
O CH3
Cl
The compound was synthesized according to GP-10 using 22(240 mg, 0.9 mmol) and 89 (268 mg, 1.2 mmol). The precip-itate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a white solid (40 mg, 9% yield). 1H NMR: δ 0.84-0.92 (m,2H, 6”-H), 1.24 (td, J = 7.1, 1.1 Hz, 3H, CH2CH3), 1.32 (m, 4H,4”-H, 5”-H), 1.38-1.49 (m, 2H, 3”-H), 1.72-1.76 (m, 2H, 2”-H), 4.06 (t, J = 6.5 Hz, 2H,1”-H), 4.21-4.50 (m, 2H, CH2CH3), 7.02 (s, 1H, 3-H), 7.15-7.24 (m, 1H, 4’-H), 7.47 (t, J= 7.9 Hz, 1H, 5’-H), 7.54-7.63 (m, 2H, 2’-H, 6’-H), 7.84 (dd, J = 2.6 Hz, 1H, 5-H), 8.19(dd, J = 2.5, 1.0 Hz, 1H, 7-H), 10.41 (s, 1H, CONH). 13C NMR: δ 13.75 (CO2CH2CH3),22.2 (C-5”), 25.3 (C-4”), 28.7 (C-3”), 31.1 (C-2”), 62.9 (CO2CH2CH3), 67.9 (C-1”), 113.7(C-3, C-2’), 118.5 (C-4’), 120.0 (C-6’), 120.3 (C-5), 125.2 (C-4a), 129.9 (C-7, C-5’), 130.1
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(C-6, C-1’), 134.9 (C-8), 148.0 (C-8a), 152.0 (C-2), 158.9 (C-3’), 159.7 (CO2Et), 165.3(CONH), 176.3 (C-4). LC-MS (m/z): positive mode 472 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 93.9%. mp 149-150 ◦C.
5.2.21.69 Ethyl 6-chloro-8-(3-(octyloxy)benzamido)-4-oxo-4H-chromene-2-car-boxylate 294(ANM333)
O
O
CO2Et
NHO
O
Cl
CH3
The compound was synthesized according to GP-10 using22 (240 mg, 0.9 mmol) and 93 (301 mg, 1.2 mmol). Theprecipitate was filtered off, washed three times with 1mL of DCM each and dried in vacuum at 50 ◦C. The prod-uct was isolated as a white solid (312 mg, 70% yield).1H NMR: δ 0.84-0.90 (m, 2H, 8”-H), 1.23-1.40 (m, 13H,CH2CH3, 4”-H, 5”-H, 6”-H, 7”-H), 1.38-1.49 (m, 2H, 3”-H), 1.72-1.76 (m, 2H, 2”-H),4.08 (t, J = 6.5 Hz, 2H, 1”-H), 4.37 (q, J = 7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H),7.20 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H, 4’-H), 7.47 (t, J = 7.9 Hz, 1H, 5’-H), 7.52-7.61 (m,2H, 2’-H, 6’-H), 7.82 (d, J = 2.6 Hz, 1H, 5-H), 8.25 (d, J = 2.6 Hz, 1H, 7-H), 10.01(s, 1H, CONH). 13C NMR: δ 13.4-13.5 (CO2CH2CH3, C-8”), 21.8 (C-7”), 25.3 (C-6”),28.5 (C-3”, C-4”, C-5”), 30.0 (C-2”), 62.6 (CO2CH2CH3), 67.9 (C-1”), 113.5-113.7 (C-3,C-2’), 118.3 (C-4’), 119.6 (C-6’, C-5’), 124.9 (C-4a), 128.7 (C-7), 129.6 (C-5’), 130.0(C-6, C-1’), 134.9 (C-8), 147.3 (C-8a), 151.8 (C-2), 158.8 (C-3’), 159.4 (CO2Et), 165.0(CONH), 176.8 (C-4). LC-MS (m/z): positive mode 501 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 97.5%. mp 151-153 ◦C.
5.2.21.70 Ethyl 6-chloro-8-(3-(heptyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 166(ANM336)
O
O
CO2Et
NHO
O
Cl
CH3
The compound was synthesized according to GP-10 using22 (240 mg, 0.9 mmol) and 91 (283 mg, 1.2 mmol). Theprecipitate was filtered off, washed three times with 1 mLof DCM each and dried in vacuum at 50 ◦C. The productwas isolated as a white solid (234 mg, 54% yield). 1H NMR:δ 0.84-0.91 (m, 2H, 7”-H), 1.24-1.41 (m, 11H, CH2CH3, 4”-H,5”-H, 6”-H), 1.42-1.51 (m, 2H, 3”-H), 1.71-1.81 (m, 2H, 2”-H), 4.08 (t, J = 7.9 Hz,
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2H, 1”-H), 4.38 (q, J = 7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H), 7.20 (ddd, J = 8.2,2.6, 1.0 Hz, 1H, 4’-H), 7.47 (t, J = 7.9 Hz, 1H, 5’-H), 7.54-7.61 (m, 2H, 2’-H, 6’-H),7.83 (d, J = 2.6 Hz, 1H, 5-H), 8.25 (d, J = 2.6 Hz, 1H, 7-H), 10.02 (s, 1H, CONH).13C NMR: δ 13.8 (CO2CH2CH3, C-7”), 22.0 (C-6”), 25.6 (C-5”), 28.5 (C-3”, C-4”), 31.3(C-2”), 62.9 (CO2CH2CH3), 68.2 (C-1”), 113.8-114.0 (C-3, C-2’), 118.7 (C-4’), 119.9 (C-6’, C-5’), 125.2 (C-4a), 129.9 (C-7), 130.3 (C-5’), 130.3 (C-6, C-1’), 135.2 (C-8), 147.7(C-8a), 152.1 (C-2), 159.1 (C-3’), 159.7 (CO2Et), 165.4 (CONH), 176.1 (C-4). LC-MS(m/z): positive mode 486 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.0%. mp153-155 ◦C.
5.2.21.71 Ethyl 6-bromo-4-oxo-8-(4-((5-phenylpentyl)oxy)benzamido)-4H-chro-mene-2-carboxylate 179(THB31)
Br
O
O
CO2Et
NH
O
O
The compound was synthesized according to GP-10 using 17(280 mg, 0.9 mmol) and 75 (341 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (229 mg, 44% yield). 1H NMR: δ 1.29 (t, J = 7.1 Hz,3H, CH2CH3), 1.48 (ddd, J = 6.5, 8.6, 15.1 Hz, 2H, 3”-H), 1.67(p, J = 7.5 Hz, 2H, 4”-H), 1.76-1.83 (m, 2H, 2”-H), 2.60-2.64 (m,2H, 5”-H), 4.09 (t, J = 6.5 Hz, 2H, 1”-H), 4.37 (q, J = 7.1 Hz, 2H, CH2CH3), 7.00 (s,1H, 3-H), 7.05-7.08 (m, 2H, 3’-H, 5’-H), 7.14-7.21 (m, 4H, 2”’-H, 3”’-H, 5”’-H, 6”’-H),7.25-7.28 (m, 1H, 4”’-H), 7.89-8.01 (m, 3H, 2’-H, 6’-H, 5-H), 8.38 (d, J = 2.5 Hz, 1H,5-H), 9.89 (s, 1H, CONH). 13C NMR: δ 13.4 (CO2CH2CH3), 24.9 (C-2”), 28.2 (C-3”),30.2 (C-5”), 34.9 (C-4”), 62.6 (CO2CH2CH3), 67.8 (C-1”), 113.5 (C-3), 114.3 (C-3’, C-5’),117.7 (C-6), 122.4 (C-5), 125.2-125.4 (C-4a, C-1’), 125.4 (C-4”’), 128.0 (C-2’, C-6’, C-2”’,C-6”’), 129.4 (C-3”’, C-5”’), 130.0 (C-8), 131.0 (C-7), 142.0 (C-1”’), 147.5 (C-8a), 151.8(C-2), 159.4 (C-4’), 161.8 (CO2Et), 164.6 (CONH), 175.7 (C-4). LC-MS (m/z): positivemode 580 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 94.7%. mp 176-177 ◦C.
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5.2.21.72 Ethyl4-oxo-8-(3-(4-phenylbutoxy)benzamido)-4H-chromene-2-carboxylate170 (THB41)
O
O
CO2Et
NHO
O
The compound was synthesized according to GP-10 using 19(105 mg, 0.45 mmol) and 85 (162 mg, 0.6 mmol). The precip-itate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a white solid (206 mg, 94% yield). 1H NMR: δ 1.21 (t, J= 7.1 Hz, 3H, CH2CH3), 1.74 (ddd, J = 3.2, 7.1 Hz, 2H, 2”-H),2.49 (p, J = 1.8 Hz, 2H, 3”-H), 2.61-2.69 (m, 2H, 4”-H), 4.09 (t, J = 5.9 Hz, 2H, 1”-H),4.31 (q, J = 7.1 Hz, 2H, CH2CH3), 6.98 (s, 1H, 3-H), 7.13-7.34 (m, 6H, 2’-H, 2”’-H,3”’-H, 4”’-H, 5”’-H, 6”’-H), 7.34-7.51 (m, 1H, 6-H), 7.53-7.61 (ddd, J = 3.2, 7.1 Hz, 3H,4’-H, 5’-H, 6’-H), 7.91 (dd, J = 1.6, 8.0 Hz, 1H, 5-H), 8.09 (dd, J = 1.6, 7.7 Hz, 1H,7-H), 10.19 (s, 1H, CONH). 13C NMR: δ 13.7 (CO2CH2CH3), 27.6 (C-2”), 28.4 (C-3”),34.9 (C-4”), 62.8 (CO2CH2CH3), 67.7 (C-1”), 113.7 (C-3), 118.2-119.9 (C-4’, C-6’), 121.7(C-5), 124.4 (C-8), 125.8 (C-4”’), 125.9 (C-2”’, C-6”’), 128.3 (C-4a), 128.4 (C-7, C-3”’,C-5”’), 129.8 (C-5’), 131.0 (C-6), 135.4 (C-1’), 142.1 (C-1”’), 149.4 (C-8a), 151.8 (C-2),158.8 (C-3’), 159.9 (CO2Et), 165.3 (CONH), 177.3 (C-4). LC-MS (m/z): positive mode486 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 92.0%. mp 136-137 ◦C.
5.2.21.73 Ethyl 8-(3-(4-cyclohexylbutoxy)benzamido)-6-fluoro-4-oxo-4H-chro-mene-2-carboxylate 161(THB64)
O
O
CO2Et
F
O
NHO
The compound was synthesized according to GP-10 using 21(113 mg, 0.45 mmol) and 101 (176 mg, 0.6 mmol). The precip-itate was filtered off, washed three times with 1 mL of DCMeach and dried in vacuum at 50 ◦C. The product was isolatedas a white solid (109 mg, 48% yield). 1H NMR: δ 0.80-0.90 (m,2H, Cyclohexyl), 1.05-1.35 (m, 6H, Cyclohexyl, 4”-H), 1.27 (t, J= 7.1 Hz, 3H, CH2CH3), 1.39-1.48 (m, 2H, 3”-H), 1.57-1.77 (m, 7H, 2”-H, Cyclohexyl),4.06 (t, J = 6.4 Hz, 2H, 1”-H), 4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 7.00 (s, 1H, 3-H), 7.18-7.24 (m, 1H, 2’-H), 7.34-7.43 (m, 1H, 5’-H), 7.44-7.63 (m, 3H, 5-H, 4’-H, 6’-H), 8.10 (dd,J = 3.1, 9.7 Hz, 1H, 7-H), 10.30 (s, 1H, CONH). 13C NMR: δ 13.7 (CO2CH2CH3), 22.9(C-4”), 26.0 (C-3”’, C-5”’), 26.3 (C-4”’), 29.1 (C-3”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.2
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(C-1”’), 62.9 (CO2CH2CH3), 67.9 (C-1”), 105.8 (C-5), 113.1 (C-2’), 113.7 (C-3), 118.2(C-7), 118.5-119.9 (C-4’, C-6’), 125.2 (C-4a), 129.9 (C-5’), 130.5 (C-8), 135.0 (C-1’),145.7 (C-8a), 152.0 (C-2), 153.2 (C-2), 157.7 (C-6), 158.9 (C-3’), 158.9 (CO2Et), 165.3(CONH), 176.9 (C-4). LC-MS (m/z): positive mode 510 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 93.1%. mp 147-148 ◦C.
5.2.21.74 Ethyl 6-chloro-8-(3-(4-cyclohexylbutoxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 160(THB65)
O
O
CO2Et
Cl
O
NHO
The compound was synthesized according to GP-10 using22 (240 mg, 0.9 mmol) and 101 (352 mg, 1.2 mmol). Theprecipitate was filtered off, washed three times with 1 mL ofDCM each and dried in vacuum at 50 ◦C. The product wasisolated as a yellow solid (259 mg, 48% yield). 1H NMR:δ 0.78-0.93 (m, 2H, cyclohexyl), 1.02-1.27 (m, 9H, CH2CH3,cyclohexyl, 4”-H), 1.38-1.49 (m, 2H, 3”-H), 1.54-1.77 (m, 7H, 2”-H, cyclohexyl), 4.05(t, J = 6.4 Hz, 2H, 1”-H), 4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 6.68-7.76 (m, 5H, 2’-H, 3-H,4’-H, 5’-H, 6’-H), 7.84 (d, J = 2.6 Hz, 1H, 5-H), 8.21 (d, J = 2.6 Hz, 1H, 7-H), 10.31(s, 1H, CONH). 13C NMR: δ 13.8 (CO2CH2CH3), 22.9 (C-4”), 26.0 (C-3”’, C-5”’), 26.3(C-4”’), 29.1 (C-3”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.2 (C-1”’), 62.9 (CO2CH2CH3),67.9 (C-1”), 105.9 (C-6), 113.1-113.7 (C-3, C-2’), 118.2 (C-7), 118.6-118.5 (C-4’, C-6’),125.2 (C-4a), 129.9 (C-5), 130.5 (C-8), 130.1 (C-5’), 135.0 (C-1’), 145.7 (C-8a), 152.0(C-2), 157.7 (C-3’), 158.9 (CO2Et), 165.3 (CONH), 176.5 (C-4). LC-MS (m/z): positivemode 526 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 94.2%. mp 147-148 ◦C.
5.2.21.75 Ethyl 8-(3-(3-cyclohexylpropoxy)benzamido)-6-fluoro-4-oxo-4H-chro-mene-2-carboxylate 158(THB66)
O
O
CO2Et
F
O
NHO
The compound was synthesized according to GP-10 using 21(226 mg, 0.9 mmol) and 99 (314 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (256 mg, 53% yield).1H NMR: δ 0.79-0.98 (m, 2H,Cyclohexyl), 1.05-1.37 (m, 9H, CH2CH3, Cyclohexyl, 3”-H), 1.56-
257
Anne Meyer 5 Experimental part
1.80 (m, 7H, 2”-H, Cyclohexyl), 4.04 (t, J = 6.5 Hz, 2H, 1”-H), 4.35 (q, J = 7.1 Hz, 2H,CH2CH3), 7.01 (s, 1H, 3-H), 7.18-7.24 (m, 1H, 2’-H), 7.37-7.53 (m, 1H, 5’-H), 7.54-7.63(m, 3H, 5-H, 4’-H, 6’-H), 8.10 (dd, J = 3.1, 9.6 Hz, 1H, 7-H), 10.31 (s, 1H, CONH). 13CNMR: δ 13.7 (CO2CH2CH3), 25.8-26.2 (C-3”’, C-5”’, C-4”’. C-3”), 32.9 (C-2”’, C-6”’),33.2 (C-2”), 36.8 (C-1”’), 62.8 (CO2CH2CH3), 68.2 (C-1”), 105.6 (C-5), 113.0 (C-2’),113.7 (C-3), 117.9 (C-7), 118.4-119.8 (C-4’, C-6’), 125.0 (C-4a), 129.9 (C-5’), 130.5(C-8), 134.9 (C-1’), 145.6 (C-8a), 151.9 (C-2), 156.8 (C-6), 158.8 (C-3’), 159.7 (CO2Et),165.4 (CONH), 176.9 (C-4). LC-MS (m/z): positive mode 496 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 98.7%. mp 147-148 ◦C.
5.2.21.76 Ethyl 6-chloro-8-(3-(3-cyclohexylpropoxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylate 157(THB67)
O
O
CO2Et
Cl
O
NHO
The compound was synthesized according to GP-10 using 22(240 mg, 0.9 mmol) and 99 (314 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (259 mg, 58% yield). 1H NMR: δ 0.84-0.94 (m, 2H,Cyclohexyl), 1.04-1.23 (m, 6H, Cyclohexyl, 3”-H), 1.26 (t, J = 7.1Hz, 3H, CH2CH3), 1.28-1.80 (m, 8H, 2”’-H, 6”’-H, 3”-H, 2”-H, Cyclohexyl), 4.04 (t, J= 6.4 Hz, 2H, 1”-H), 4.34 (q, J = 7.1 Hz, 2H, CH2CH3), 7.02 (s, 1H, 3-H), 7.20 (ddd,J = 2.5, 7.5 Hz, 1H, 2’-H), 7.49 (dt, J = 7.9 Hz, 3H, 5’-H, 4’-H, 6’-H), 7.84 (d, J = 2.6Hz, 1H, 5-H), 8.21 (d, J = 2.6 Hz, 1H, 7-H), 10.30 (s, 1H, CONH). 13C NMR: δ 13.8(CO2CH2CH3), 25.9 (C-3”’, C-5”’, C-4”’. C-3”), 33.0 (C-2”’, C-6”’), 33.3 (C-2”), 36.9 (C-1”’), 62.9 (CO2CH2CH3), 68.3 (C-1”), 113.8-114.6 (C-3, C-2’), 118.5 (C-7), 120.0-120.4(C-4’, C-6’), 125.2 (C-4a), 129.7 (C-5), 129.9 (C-8, C-6), 130.2 (C-5’), 135.0 (C-1’), 147.9(C-8a), 152.0 (C-2), 158.9 (C-3’), 159.7 (CO2H), 165.3 (CONH), 176.3 (C-4). LC-MS(m/z): positive mode 512 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 95.2%. mp129-130 ◦C.
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5.2.21.77 Ethyl 8-(3-(3-cyclohexylpropoxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 156(THB68)
O
O
CO2Et
O
NHO
The compound was synthesized according to GP-10 using 19(210 mg, 0.9 mmol) and 99 (314 mg, 1.2 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM eachand dried in vacuum at 50 ◦C. The product was isolated as awhite solid (207 mg, 48% yield). 1H NMR: δ 0.83-0.94 (m, 2H,cyclohexyl), 1.08-1.24 (m, 6H, Cyclohexyl, 3”-H), 1.24 (t, J = 7.1Hz, 3H, CH2CH3), 1.26-1.80 (m, 7H, 2”-H, Cyclo- hexyl), 4.04 (t, J = 6.4 Hz, 2H, 1”-H),4.33 (q, J = 7.1 Hz, 2H, CH2CH3), 6.99 (s, 1H, 3-H), 7.19 (dd, J = 1.7, 8.3 Hz, 1H, 2’-H),7.46 (t, J = 7.9 Hz, 1H, 6-H), 7.54-7.61 (m, 3H, 4’-H, 5’-H, 6’-H), 7.91 (dd, J = 1.6, 8.0Hz, 1H, 5-H), 8.08 (dd, J = 1.7, 7.8 Hz, 1H, 7-H), 10.20 (s, 1H, CONH). 13C NMR: δ13.8 (CO2CH2CH3), 25.9-26.3 (C-3”’, C-5”’, C-4”’. C-3”), 33.0 (C-2”’, C-6”’), 33.3 (C-2”),36.9 (C-1”’), 62.9 (CO2CH2CH3), 68.2 (C-1”), 113.7-114.6 (C-3, C-2’), 118.2-119.9 (C-4’, C-6’), 121.7 (C-5), 124.5 (C-8), 125.9 (C-7), 128.3 (C-4a), 129.8 (C-5’), 131.0 (C-6),135.4 (C-1’), 149.4 (C-8a), 151.9 (C-2), 158.9 (C-3’), 159.9 (CO2H), 165.3 (CONH),177.3 (C-4). LC-MS (m/z): positive mode 478 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 85.1%. mp 129-130 ◦C.
5.2.21.78 Ethyl 8-(3-(3-cyclohexylpropoxy)benzamido)-6-fluoro-4-thioxo-4H-chromene-2-carboxylate 180(ANM319)
O
S
CO2Et
NHO
O
F The compound was synthesized according to GP-10 using 36(200 mg, 0.76 mmol) and 99 (280 mg, 1.01 mmol). The precipitatewas filtered off, washed three times with 1 mL of DCM each anddried in vacuum at 50 ◦C. The product was isolated as a greensolid (115 mg, 30% yield). 1H NMR: δ 0.88-0.99 (m, 2H, 4”’-H),1.12-1.40 (m, 11H, CH2CH3, 2”’-H, 3”’-H, 5”’-H, 6”’-H), 1.57-1.82(m, 5H, 1”’-H, 3”-H, 2”-H), 4.07 (t, J = 6.5 Hz, 2H, 1”-H), 4.39 (q, J = 7.1 Hz, 2H,CH2CH3), 7.21 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H, 4’-H), 7.48 (t, J = 7.9 Hz, 1H, 5’-H), 7.53-7.62 (m, 2H, 2’-H, 6’-H), 7.69 (s, 1H, 3-H), 7.85 (dd, J = 9.1, 3.1 Hz, 1H,5-H), 8.19 (dd, J = 9.4, 3.1 Hz, 1H, 7-H), 10.06 (s, 1H, CONH). 13C NMR: δ 13.5(CO2CH2CH3), 25.6 (C-3”’, C-5”’), 26.0 (C-3”), 32.5 (C-2”’, C-6”’), 32.6 (C-2”), 36.6
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(C-1”’), 62.7 (CO2CH2CH3), 68.3 (C-1”), 107.2-107.4 (C-7), 113.7 (C-2’), 117.1-117.4(C-5), 118.4 (C-4’), 119.6 (C-6’), 124.0 (C-3), 129.6 (C-6), 130.9 (Cq, C4a); 131.4 (Cq,C1?), 134.8 (C-8a), 140.6 (C-2), 142.2 (C-8), 158.8-165.0 (C-3’), 160.0 (CO2Et), 160.6(CONH), 201.7 (C-4). LC-MS (m/z): positive mode 512 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 78.0%. mp 145-147 ◦C.
5.2.22 3-(4-Cyclohexylbutoxy)-N-(naphthalen-1-yl)benzamide5.2.22.1 3-(4-Cyclohexylbutoxy)-N-(naphthalen-1-yl)benzamide 295 (ANM277)
NHO
O
The compound was synthesized according to GP-10 usingnaphthalen-1-amine (129 mg, 0.9 mmol) and 102 (332 mg, 1.2mmol). The precipitate was filtered off, washed three timeswith 1 mL of DCM each and dried in vacuum at 50 ◦C. Theproduct was isolated as a white solid (298 mg, 82% yield). 1HNMR: δ 0.82-0.80 (m, 2H, cyclohexyl), 1.03-1.31 (m, 6H, cyclohexyl, 4”-H), 1.39-1.52(m, 2H, 3”-H), 1.54-1.80 (m, 7H, 2”-H, cyclohexyl), 4.06 (t, J = 6.5 Hz, 2H, 1”-H), 7.16(dd, J = 8.1, 2.5 Hz, 1H, 2’-H), 7.45 (t, J = 7.9 Hz, 1H, 4’-H), 7.50-7.60 (m, 4H, 2-H,3-H, 5’-H, 6’-H), 7.60-7.68 (m, 2H, 6-H, 7-H), 7.86 (d, J = 7.9 Hz, 1H, 4-H), 7.93-7.99(m, 2H, 5-H, 8-H), 10.37 (s, 1H, CONH). 13C NMR: δ 25.9 (C-3”), 26.0 (C-3”’, C-5”’),26.3 (C-4”’), 29.1 (C-4”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.1 (C-1”’), 67.8 (C-1”), 113.6(C-2’), 118.1 (C-4’), 120.0 (C-6’), 123.5 (C-2), 124.1 (C-4), 125.6 (C-8), 126.1 (C-7),126.2 (C-6), 126.4 (C-3), 128.2 (C-5), 129.4 (C-8a), 129.7 (C-5’), 133.9-134.0 (C-4a, C-1’), 135.9 (C-1), 158.8 (C-3’), 166.0 (CONH). LC-MS (m/z): positive mode 402 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 99.3%. mp 136-137 ◦C.
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5.2.23 Ethyl 6-(4-aminophenyl)-8-(4-((4-fluorobenzyl)oxy)benza-mido)-4-oxo-4H-chromene-2-carboxylate5.2.23.1 Ethyl 6-(4-aminophenyl)-8-(4-((4-fluorobenzyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 132(ANM198)
O
O
CO2Et
NHO
O
H2N
F
130 (487 mg, 0.75 mmol) was supended in 5 mL of THFand heated to 45 ◦C. Then a solution of HCl in Dioxan(4N, 10 mL) was added and the reaction mixture stirredovernight at rt. After removing the solvent under reducedpressure the solid was filtrated, washed twice with coldTHF (5 mL each) an dried in vacuum at 45 ◦C. The productwas isolated as an orange solid (393 mg, 95% yield). 1HNMR: δ 1.23-1.26 (m, 3H, CO2CH2CH3), 4.34 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 5.21 (s,2H, C4”’-NH), 7.02 (s, 1H, 3-H), 7.16-7.21 (m, 2H, 3’-H, 5’-H), 7.21-7.25 (m, 2H, 3”-H,5”-H), 7.35 (d, J = 8.0 Hz, 2H, 2”’-H, 6”’-H), 7.51-7.57 (m, 2H, 2”-H, 6”-H), 7.78-7.82(m, 2H, 3”’-H, 5”’-H), 8.01-8.07 (m, 2H, 2’-H, 6’-H), 8.07 (d, J = 2.3 Hz, 1H, 5-H), 8.40(d, J = 2.3 Hz, 1H, 7-H), 10.22 (s, 1H, CONH). 13C NMR: δ 13.8 (CO2CH2CH3), 62.8(CO2CH2CH3), 113.7 (C-3), 114.8 (C-3’, C-5’), 115.3-115.5 (C-3”, C-5”), 118.1 (C-7),122.1 (C-3”’, C-5”’), 124.7 (C-4a), 126.3 (C-1’), 128.2 (C-2”’, C-6”’), 128.6 (C-5), 129.3(C-8), 129.8 (C-2’, C-6’), 130.1-130.2 (C-2”, C-6”), 133.0 (C-1”, C-6), 136.8 (C-1”’),148.7 (C-8a), 151.8 (C-2), 159.9 (CO2Et), 161.0 (C-4”), 162.9 (C-4’), 164.9 (CONH),177.3 (C-4). LC-MS (m/z): positive mode 553 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 99.1%. mp 215-216 ◦C.
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5.2.24 Ethyl-8-(4-((4-fluorobenzyl)oxy)benzamido)-6-(4-hydroxy-phenyl)-4-oxo-4H-chromene-2-carboxylate5.2.24.1 Ethyl-8-(4-((4-fluorobenzyl)oxy)benzamido)-6-(4-hydroxyphenyl)-4-oxo-4H-chromene-2-carboxylate 131(ANM199)
O
O
CO2Et
NHO
O
HO
F
129 (294 mg, 0.44 mmol) was suspended in 10 mL of THF.After addition of 2 mL of conc. HCl the reaction mixturewas refluxed for 4 hours. The solvent was removed underreduced pressure and after addition of 5 mL of water theobtained precipitate was filtered of, washed with water anddried in vacuum at 45 ◦C. The product was isolated as ayellow solid (236 mg, 89% yield). 1H NMR: δ 1.25 (t, J =7.1 Hz, 3H, CH2CH3), 4.34 (q, J = 7.1 Hz, 2H, CH2CH3), 5.21 (s, 2H, CH2-O), 6.86-6.92(m, 2H, 3”’-H, 5”’-H), 6.99 (s, 1H, 3-H), 7.15-7.21 (m, 2H, 3’-H, 5’-H), 7.23 (t, J = 8.9Hz, 2H, 3”-H, 5”-H), 7.54 (dd, J = 5.1 Hz, 2H, 2”-H, 6”-H), 7.56-7.61 (m, 2H, 2”’-H,6”’-H), 7.98 (d, J = 2.3 Hz, 1H, 5-H), 8.00-8.05 (m, 2H, 2’-H, 6’-H), 8.33 (d, J = 2.3Hz, 1H, 7-H), 9.69 (s, 1H, OH), 10.13 (s, 1H, CONH). 13C NMR: δ 13.8 (CH2CH3),62.8 (CH2CH3), 68.9 (CH2-O), 113.5 (C-3), 114.8 (C-3’, C-5’), 115.3-115.5 (C-3”, C-5”),116.2 (C-3”’, C-5”’), 117.2 (C-5), 124.6 (C-4a), 126.4 (C-1’), 128.2 (C-2”’, C-6”’), 128.4(C-7), 128.9-129.0 (C-1”, C-8), 129.8 (C-2’, C-6’), 130.2 (C-2”, C-6”), 133.0 (C-6), 137.8(C-1”’), 148.1 (C-8a), 151.7 (C-2), 160.0 (C-4”’), 161.0 (C-4’), 161.3 (CO2Et), 162.9 (C-4”), 164.9 (CONH), 177.3 (C-4). LC-MS (m/z): positive mode 554 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 89.3%. mp 291-292 ◦C.
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5.2.25 Ethyl 6-bromo-8-(4-methoxy-N-methylbenzamido)-4-oxo-4H-chromene-2-carboxylate5.2.25.1 Ethyl 6-bromo-8-(4-methoxy-N-methylbenzamido)-4-oxo-4H-chro-mene-2-carboxylate 181(ANM76)
O
O
CO2Et
Br
NO
OCH3
CH3
103 (312 mg, 0.7 mmol) and K2CO3 (193 mg, 1.4 mmol) were sus-pended in 10 mL of DMF. After addition of methyliodide (0.056mL, 0.9 mmol) the reaction mixture was stirred for 2 days at rtunder an argon atmosphere. The reaction was stopped by addi-tion of 22 mL of water and the mixture was extracted 3 times with25 mL EtOAc. The product was separated by column chromatog-raphy on a column of silica gel (40% Cyclohexane in EtOAc) and dried in vacuum at50 ◦C. The product was isolated as a yellow solid (244 mg, 76% yield). 1H NMR:δ 1.36 (t, J = 7.1 Hz, 3H, CH2CH3), 3.39 (s, 3H, NCH3), 3.68 (s, 3H, OCH3), 4.41 (q,J = 7.1 Hz, 2H, CH2CH3), 6.74-6.78 (m, 2H, 3’-H, 5’-H), 6.94 (s, 1H, 3-H), 7.25-7.29(m, 2H, 2’-H, 6’-H), 7.96 (d, J = 2.4, 1H, 5-H), 8.11 (d, J = 2.5, 1H, 7-H). 13C NMR: δ14.0 (CH2CH3), 55.3 (CH, OCH3), 63.0 (CH2CH3), 113.3 (C-3’, C-5’), 113.8 (C-3), 118.0(C-6), 125.7 (C-5), 125.8 (C-4a), 127.4 (C-1’), 129.9 (C-2’, C-6’), 136.7 (C-7), 149.7(C-8a), 152.1 (C-2), 159.6 (C-4’), 160.5 (CO2Et), 169.8 (CON), 176.0 (C-4). LC-MS(m/z): positive mode 460 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.0%. Mp137-138 ◦C.
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5.2.26 Ethyl 8-(3-(4-hydroxyphenyl)ureido)-4-oxo-4H-chromene-2-carboxylate5.2.26.1 Ethyl8-(3-(4-hydroxyphenyl)ureido)-4-oxo-4H-chromene-2-carboxylate 182(THB19)
O
O
NH
CO2Et
HN
O
OH
Triphosgene (1.04 g, 3.5 mmol) was dissolved in 4 mL of DCM andcooled to 0-5 ◦C in an ice bath. Then a mixture of 19 (234 mg,1 mmol), DIPEA (0.375 mL) in 8.75 mL DCM was added slowlyover a period of 90 min under an argon atmosphere. After stirringfor further 5 min at 0-5 ◦C the reaction mixture was heated tort and added dropwise to a mixture of p-aminophenol (109 mg, 1mmol), DIPEA (0.212 mL) and 5 mL DCM under an argon atmosphere and stirredovernight at rt. The solvent was removed under reduced pressure and the crudesolid suspended in 30 mL of DCM. After addition of 1 mL of MeOH the product wascrystallized by removing half of the DCM and separated by column chromatographyon a column of silica gel (0.5% MeOH in DCM). The product was isolated as a whitesolid (219 mg, 66% yield). 1H NMR: δ 1.36 (t, J = 3.5 Hz, 3H, CH2CH3), 4.41-4.43(m, 2H, CH2CH3), 6.86 (s, 1H, 3-H), 7.16-7.28 (m, 4H, 2’-H, 3’-H, 5’-H, 6’-H), 7.44(t, J = 8.0 Hz, 1H, 6-H), 7.66 (dd, J = 1.5, 7.9 Hz, 1H, 5-H), 7.76 (dd, J = 1.5, 7.9Hz, 1H, 7-H), 8.21 (s, 1H, C1’-NH), 8.87 (s, 1H, C8-NH), 9.11 (s, 1H, OH). 13C NMR:δ 13.6 (CH2CH3), 62.6 (CH2CH3), 110.6 (C-3), 113.5 (C-5), 115.2 (C-3’, C-5’), 117.2(C-7), 120.9 (C-2’, C-6’), 124.0 (C-4a), 125.0 (C-6), 129.6 (C-8), 130.6 (C-8a), 146.0(C-1’), 151.6 (C-4’), 152.4 (NCN), 153.0 (C-2), 159.7 (CO2Et), 177.0 (C-4). LC-MS(m/z): positive mode 369 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 72.6%. Mp249-250 ◦C.
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5.2.27 Ethyl 8-(3-(4-(4-cyclohexylbutoxy)phenyl)thioureido)-4-oxo-4H-chromene-2-carboxylate5.2.27.1 Ethyl 8-(3-(4-(4-cyclohexylbutoxy)phenyl)thioureido)-4-oxo-4H-chro-mene-2-carboxylate 185(ANM179)
O
O
CO2Et
NHS
HN
O
184 (245 mg, 0.9 mmol) was dissolved in 3 mL of dry THFunder argon. Then 187 (333 mg, 1.35 mmol) in mL of dryTHF was added and the reaction mixture stirred overnightat rt. The product was separated by two column chro-matographies on a column of silica gel (1. 25 % cylcohex-ane in EtOAc, 2. 50 % cylcohexane in EtOAc). The productwas isolated as a yellow oil (210 mg, 40% yield). 1H NMR: δ 0.81-0.90 (m, 2H,Cyclohexyl), 1.33 (t, J = 7.1 Hz, 3H, CH2CH3), 1.37-1.43 (m, 2H, 3”-H), 1.61-1.70 (m,7H, 2”-H, Cyclohexyl), 3.94 (t, J = 6.5 Hz, 2H, 1”-H), 4.39 (q, J = 7.1 Hz, 2H CH2CH3),6.89-6.92 (m, 2H, 3’-H, 5’-H), 6.98 (s, 1H, 3-H), 7.32-7.37 (m, 2H, 2’-H, 6’-H), 7.50 (t,J = 7.9 Hz, 1H, 6-H), 7.90 (ddd, J = 1.6, 7.9 Hz, 2H, 5-H, 7-H), 9.41 (s, 1H, C1’-NH),9.89 (s, 1H, C2’-NH). 13C NMR: δ 14.0 (CH2CH3), 22.9 (C-4”), 26.0 (C-3”’, C-5”’), 26.3(C-4”’), 29.1 (C-3”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.1 (C-1”’), 62.9 (CH2CH3), 67.8(C-1”), 113.9 (C-3), 114.6 (C-3’, C-5’), 122.3 (C-5), 124.6 C-4a), 125.5 (C-7), 126.5 (C-2’,C-6’), 129.8 (C-8), 131.7 (C-1’), 133.6 (C-6), 150.7 (C-8a), 151.9 (C-2), 156.5 (C-4’),160.0 (CO2Et), 177.4 (C-4), 180.9 (C-5). LC-MS (m/z): positive mode 524 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 71.9%.
5.2.28 Diethyl 2-((2-(ethoxycarbonyl)-4-oxo-4H-chromen-8-yl)a-mino)fumarates5.2.28.1 General procedure for the synthesis of the diethyl2-((2-(ethoxycarbonyl)-4-oxo-4H-chromen-8-yl)amino)fumarates(GP-11)
The appropriate amine (4 mmol) was dissolved in MeOH (8 mL) and diethyl acety-lendicarboxylate (0.96 mL, 6 mmol) was added slowly over a period of 30 min. Thenthe reaction mixture was stirred overnight at room temperature and the precipitatedsolid was filtered, washed with MeOH and dried in vacuum at 50 ◦C.
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5.2.28.2 Diethyl 2-((6-bromo-2-(ethoxycarbonyl)-4-oxo-4H-chromen-8-yl)ami-no)fumarate 270(ANM360)
O
O
Br
NH
CO2Et
EtO2C
EtO2C
The compound was synthesized according to GP-11 using 17(1.98 g, 6.5 mmol). The solvent was removed by reduced pres-sure and the resulting solid was filtered and washed with coldMeOH. The product was isolated as a yellow solid (1.02 g,33% yield). 1H NMR: δ 1.14, 1.26 (t, J = 7.0 Hz, 6H, C1’-CO2CH2CH3, C2’-CO2CH2CH3), 1.39 (t, J = 7.1 Hz, 3H, C2-CO2CH2CH3), 4.20 (p,J = 6.9 Hz, 4H, C1’-CO2CH2CH3, C2’-CO2CH2CH3), 4.42 (q, J = 7.0 Hz, 2H, C2-CO2CH2CH3), 5.71 (s, 1H, 2’-H), 6.87-7.07 (m, 1H, 3-H), 7.53 (q, J = 2.9 Hz, 1H, 7-H),7.79 (q, J = 2.3 Hz, 1H, 5-H), 9.73 (s, 1H, NH). 13C NMR: δ 13.3 (C1’-CO2CH2CH3, C2’-CO2CH2CH3), 13.9 (C2-CO2CH2CH3), 59.9, 62.0 (C1’-CO2CH2CH3, C2’-CO2CH2CH3),62.6 (C2-CO2CH2CH3), 97.8 (C-2’), 113.6 (C-3), 117.6 (C-6), 120.8 (C-5), 125.2 (C-4a),127.5 (C-7), 132.5 (C-8), 144.6 (C-1’), 146.6 (C-8a), 151.7 (C-2), 159.2 (C2-CO2Et),162.4 (C1’-CO2Et), 167.4 (C2’-CO2Et), 175.5 (C-4). LC-MS (m/z): positive mode 482[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 90.2%. Mp 111-112 ◦C.
5.2.28.3 Diethyl 2-((2-(ethoxycarbonyl)-6-methyl-4-oxo-4H-chromen-8-yl)ami-no)fumarate 271(ANM377)
O
O
H3C
NH
CO2Et
EtO2C
EtO2C
The compound was synthesized according to GP-11 using 23(1.0 g, 4 mmol). The solvent was removed by reduced pres-sure and the resulting solid was filtered and washed with coldMeOH. The product was isolated as a yellow solid (1.29 g,77% yield). 1H NMR: δ 1.05, 1.23 (t, J = 7.1 Hz, 6H, C1’-CO2CH2CH3, C2’-CO2CH2CH3), 1.36 (t, J = 7.1 Hz, 3H, C2-CO2CH2CH3), 2.37 (s, 3H,C6-CH3), 4.14 (dq, emphJ = 7.1 Hz, 4H, C1’-CO2CH2CH3, C2’-CO2CH2CH3), 4.37 (q, J= 7.1 Hz, 2H, C2-CO2CH2CH3), 5.56 (s, 1H, 2’-H), 6.92 (s, 1H, 3-H), 7.16.7.24 (m, J =2.1 Hz, 1H, 7-H), 7.53 (dd, J = 2.0, 1.0 Hz, 1H, 5-H), 9.82 (s, 1H, NH). 13C NMR: δ 13.6-13.8 (C1’-CO2CH2CH3, C2’-CO2CH2CH3), 14.3 (C2-CO2CH2CH3), 20.7 (C6-CH3), 60.1,62.2 (C1’-CO2CH2CH3, C2’-CO2CH2CH3), 62.8 (C2-CO2CH2CH3), 95.6 (C-2’), 113.6(C-3), 119.0 (C-5), 124.1 (C-6), 126.8 (C-7), 130.7 (C-4a), 135.7 (C-8), 145.9 (C-8a),146.4 (C-1’), 151.6 (C-2), 159.6 (C2-CO2Et), 162.9 (C1’-CO2Et), 168.3 (C2’-CO2Et),
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177.1 (C-4). LC-MS (m/z): positive mode 418 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 84.5%. Mp 100-101 ◦C.
5.2.28.4 (E)-tetramethyl 2,2’-((4-methyl-1,3-phenylene)bis(azanediyl))dimaleate276 (ANM363)
CH3 H
N
NH
CO2Me
MeO2C
CO2Me
CO2Me
The compound was synthesized according to GP-11 us-ing diaminotoluene (4.88 mg, 40 mmol). The solvent wasremoved by reduced pressure and the resulting yellow oilwas separated by column chromatography on a column ofsilica gel (gradient: 20% EtOAc in cyclohexane). The product was isolated as a palewhite solid (8.58 mg, 63% yield). 1H NMR: δ 2.20 (s, 3H, C1-CH3), 3.64-3.67 (m, 12H,CO2CH3), 5.26-5.33 (m, 2H, 2’-H, 2”-H), 6.37 (d, J = 2.2 Hz, 1H, 3-H), 6.59 (dd, J = 8.1,2.3 Hz, 1H, 5-H), 7.13 (dd, J = 8.1, 0.9 Hz, 1H, 6-H), 9.45-9.49 (m, 2H, NH). 13C NMR:δ 16.9 (C1-CH3), 51.2, 51.3, 53.0, 53.1 (CO2CH3), 91.91, 93.69 (C-2’, C-2”), 113.5 (C-3),116.7 (C-5), 125.5 (C-1), 131.1 (C-6), 139.0, 139.3 (C-2, C-4), 147.2, 147.3 (C-1’, C-1”),163.9, 164.4 (C1’-CO2CH3, C1”-CO2CH3), 168.5, 169.2 (C2’-CO2CH3, C2”-CO2CH3).LC-MS (m/z): positive mode 343 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:97.4%. Mp 104-106 ◦C.
5.2.29 Diethyl 4,7-dioxo-7,10-dihydro-4H-pyrano[3,2-h]quinoline-2,9-dicarboxylates5.2.29.1 General procedure for the synthesis of the diethyl4,7-dioxo-7,10-dihydro-4H-pyrano[3,2-h]quinoline-2,9-dicarboxylates(GP-12)
The appropriate dimethylaminomaleate or diethylaminomaleate was added to boil-ing Dowtherm A R© (2 mL/g) and stirred for 2-30 min at 250 ◦C. After cooling themixture to room temperature the poduct precipitated, was filtered off, washed withacetone and dried in oven at 60 ◦C.
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5.2.29.2 Diethyl 6-bromo-4,7-dioxo-7,10-dihydro-4H-pyrano[3,2-h]quinoline-2,9-dicarboxylate 274(ANM366)
O
O
CO2Et
Br
NH
O
CO2Et
The compound was synthesized according to GP-12 using 270(964 mg, 2 mmol) and was isolated as a yellow solid (245 mg,28% yield). 1H NMR: δ 1.40 (td, J = 7.1 Hz, 6H, CO2CH2CH3),4.42 (dq, J = 7.1 Hz, 4H, CO2CH2CH3), 7.11 (s, 2H, 3-H, 8-H),8.04 (s, 1H, 5H). 13C nicht gelöst! LC-MS (m/z): positive mode 436 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 98.8%. Mp 236-237 ◦C.
5.2.29.3 Diethyl 6-methyl-4,7-dioxo-7,10-dihydro-4H-pyrano[3,2-h]quinoline-2,9-dicarboxylate 275(ANM378)
O
O
CO2Et
H3C
NH
O
CO2Et
The compound was synthesized according to GP-12 using 271(1.25 g, 3 mmol) and was isolated as a yellow solid (220 mg, 20%yield). 1H NMR: δ 1.36-1.44 (m, 6H, CO2CH2CH3), 2.85 (s, 3H,CH3), 4.40-4.52 (m, 2H, CO2CH2CH3), 7.08 (s, 1H, 3-H), 7.69 (s,2H, 5-H, 8-H). 13C NMR: δ 14.0 (CO2CH2CH3), 24.0 (CH3), 61.6, 62.8 (CO2CH2CH3),108.8 (C-8), 115.1 (C-3), 121.0 (C-5), 123.1-124.0 (C-4a, C-6a), 133.4 (C-9), 141.4 (C-6), 151.3, 152.8 (C-10a, C-10b), 160.1 (C-2), 160.1 (CO2Et), 176.9 (C-4, C-7). LC-MS(m/z): positive mode 372 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.9%. Mp199-200 ◦C.
5.2.30 4,10-Dioxo-1,4,7,10-tetrahydro-1,7-phenanthroline-2,8-di-carboxylicacids5.2.30.1 General procedure for the synthesis of the4,10-dioxo-1,4,7,10-tetrahydro-1,7-phenanthroline-2,8-dicarboxylicacids (GP-13)The ester (0.44 mmol) was suspended in THF (12 mL) and EtOH (3 mL). Then 1 NNaOH was added (0.5 mL) and the reaction mixture was stirred for 5 min at rt. Afteraddition of 2 N HCl until a pH of 2 was reached, the precipitated solid was filtered,recrystallized in acetone and dried in vacuum at 50 ◦C.
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5.2.30.2 6-Bromo-4,7-dioxo-7,10-dihydro-4H-pyrano[3,2-h]quinoline-2,9-dicar-boxylic acid 272(ANM367)
O
O
CO2H
Br
NH
O
CO2H
The compound was synthesized according to GP-13 using 274(191 mg, 0.44 mmol) and was isolated as a yellow solid (87mg, 52% yield). 1H NMR: δ 7.03, 7.07 (s, 1H, 3-H, 8-H), 7.97(s, 1H, 5-H). 13C NMR: δ 111.8 (C-8), 114.0 (C-3), 114.3 (C-6),123.2 (C-5), 123.4, 123.9 (C-4a, C-6a), 135.6 (C-9), 155.2 (C-10a, C-10b), 160.6 (C-2),163.2 (CO2H), 175.8 (C-4, C-7). LC-MS (m/z): positive mode 382 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 98.5%. Mp > 300◦C.
5.2.30.3 6-Methyl-4,7-dioxo-7,10-dihydro-4H-pyrano[3,2-h]quinoline-2,9-dicar-boxylic acid 273(ANM379)
O
O
CO2H
H3C
NH
O
CO2H
The compound was synthesized according to GP-13 using 275(163 mg, 0.44 mmol) and was isolated as yellow solid (98 mg,71% yield). 1H NMR: δ 2.83 (s, 3H, CH3), 7.04 (s, 1H, 3-H), 7.58(s, 2H, 5-H, 8-H). 13C nicht gelöst! LC-MS (m/z): positive mode316 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.1%. Mp > 300◦C.
5.2.30.4 6-Methyl-4,10-dioxo-1,4,7,10-tetrahydro-1,7-phenanthroline-2,8-dicar-boxylic acid 277(ANM365)233
N
H
O
H3C
HN
O
CO2H
HO2C
276 (5.16 g, 15 mmol) was added to boiling Dowtherm A R©and stirred for 30 min. After cooling the solid was filteredand washed with acetone. Without further purification thesolid was dissolved 4 mL of NaOH (1N) and stirred for 5 minat rt. After addition of 2 N HCl until a pH of 2 was reached, the precipitated solidwas filtered, recrystallized in acetone and dried in vacuum at 50 ◦C. The productwas isolated as a brown solid (46 mg, 1% yield). 1H NMR: δ 2.69 (s, 3H, C6-CH3),7.11, 7.15 (s, 2H, 3-H, 9-H), 8.21 (s, 1H, 5-H). 13C nicht gelöst! LC-MS (m/z): positivemode 315 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.3%. Mp > 300◦C.
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5.2.31 6-Bromo-4-oxo-8-(1H-tetrazol-5-yl)-4H-chromene-2-car-boxylicacid5.2.31.1 6-Bromo-4-oxo-8-(1H-tetrazol-5-yl)-4H-chromene-2-carboxylic acid268 (ANM386)
Br
O
O
CO2H
N
N N
NH
267 (588 mg, 2 mmol) was dissolved in 12 mL of dry DMF underan argon atmosphere and NH4Cl (300 mg, 5.6 mmol) was added.Then the reaction mixture was heated to 35 ◦C and NaN3 (500 mg,7.7 mmol) were added. After stirring for 1.5 h at rt the reactionmixture was poured on 30 mL of 2 N HCl and the precipitated solid was filteredoff. The solid was recrystallized from concd. HCl and the product was isolated asa yellow-white solid (328 mg, 49% yield). 1H NMR: δ 7.01 (s, 1H, 3-H), 8.31 (d, J= 2.5 Hz, 1H, 5-H), 8.44 (d, J = 2.5 Hz, 1H, 7-H). 13C NMR: δ 113.8 (C-3), 118.4(C-6), 122.5 (extremely weak signal, C-8), 126.0 (C-4a), 130.0 (C-5), 137.7 (C-7),151.5 (C-8a), 153.8 (C-2), 158.4 (extremely weak signal, C-tetrazole), 161.1 (CO2H),176.0 (C-4). LC-MS (m/z): positive mode 339 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 97.7%. Mp 265-266 ◦C.
5.2.32 4-Oxo-4H-chromene-2-carboxylic acids5.2.32.1 General procedure for the synthesis of the4-oxo-4H-chromene-2-carboxylic acids (GP-14)
A solution of potassium carbonate (79 mg, 0.57 mmol) in water (4.5 mL) was slowlyadded to a suspension of the appropriate ethyl 4-oxo-4H-chromene-2-carboxylates(0.44 mmol) in THF (12 mL) and EtOH (3 mL). The reaction mixture was stirred at rtfor 16-24 h until a clear solution was obtained. After addition of water (4 mL), themixture was acidified with diluted aq HCl solution (2 N) until a pH ≤ 2 was reached.The solvents THF and EtOH were removed under reduced pressure. The obtainedprecipitate was filtered off, washed with 15 mL of water, and dried in vacuum at 45◦C. In some cases, further purification was necessary (see individual compounds).
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5.2.32.2 6-Bromo-8-(2,4-dimethoxybenzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 203(ANM47)
O
O
CO2H
Br
NHO
OCH3
OCH3
The compound was synthesized according to GP-14 using 109(210 mg, 0.44 mmol) and was isolated as a white solid (162mg, 82% yield). 1H NMR: δ 3.88 (s, 3H, C4’OCH3), 4.15 (s, 3H,C2’OCH3), 6.73 (dd, J = 8.8, 2.3 Hz, 1H, 5’-H), 6.77 (d, J = 2.3 Hz,1H, 3’-H), 6.97 (s, 1H, 3-H), 7.78 (d, J = 2.4 Hz, 1H, 5-H), 8.05 (d,J = 8.8 Hz, 1H, 6’-H), 9.09 (d, J = 2.4 Hz, 1H, 7-H), 10.52 (s, 1H,NH). 13C NMR: δ 55.6 (C2’-OCH3), 56.7 (C4’-OCH3), 98.6 (C-3’), 106.9 (C-5’), 112.8(C-6), 113.5 (C-3), 118.1 (C-1’), 120.0 (C-7), 124.9 (C-4a), 126.0 (C-5), 130.4 (C-8),133.3 (C-6’), 144.5 (C-8a), 152.9 (C-2), 159.9 (C-2’), 160.7 (CO2H); 162.9 (C-4’), 164.3(CO-NH), 175.8 (C-4). LC-MS (m/z): positive mode 450 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.5%. mp 284-285 ◦C.
5.2.32.3 8-(4-Methoxybenzamido)-4-oxo-6-(trifluoromethoxy)-4H-chromene-2-carboxylic acid 204(ANM68)
O
O
CO2H
F3CO
NHO
OCH3
The compound was synthesized according to GP-14 using 110(40 mg, 0.09 mmol), and was isolated as a white solid (37 mg,96% yield). 1H NMR: δ 3.86 (s, 3H, OCH3), 6.99 (s, 1H, 3-H),7.08-7.12 (m, 2H, 3’-H, 5’-H), 7.68-7.74 (m, 1H, 5-H), 7.99-8.02(m, 2H, 2’-H, 6’-H), 8.21-8.25 (m, 1H, 7-H), 10.18 (s, 1H, NH).13C NMR: δ 55.7 (O-CH3), 111.7 (C-5), 113.2 (C-3), 114.1 (C-3’,C-5’), 119.2 (O-CF3), 121.2 (C-7), 124.9 (C-4a), 125.7 (C-1’), 129.9 (C-2’, C-6’), 131.0(C-8), 145.0 (C-8a), 147.3 (C-6), 153.4 (C-2), 161.1 (C-4’), 162.7 (CO2H), 165.0 (CO-NH), 176.8 (C-4). LC-MS (m/z): positive mode 424 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.3%. mp 270-271 ◦C.
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5.2.32.4 8-(4-Methoxybenzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylicacid 205 (ANM77)
O
O
CO2H
NHO
OCH3
The compound was synthesized according to GP-14 using 111(195 mg, 0.44 mmol), and was isolated as a white solid (176 mg,96% yield). 1H NMR: δ 3.86 (s, 3H, OCH3), 6.98 (s, 1H, 3-H),7.08-7.12 (m, 2H, 3’-H, 5’-H), 7.43-7.45 (m, 1H, 4’-H), 7.50-7.56(m, 2H, 3’-H, 5’-H), 7.74-7.78 (m, 2H, 2’-H, 6’-H), 8.01-8.08 (m,2H, 2’-H, 6’-H), 8.08 (d, 1H, J = 2.3, 5-H), 8.42 (d, 1H, J = 2.4,7-H), 10.15 (s, 1H, NH). 13C NMR: δ 55.6 (OCH3), 113.5 (C-3),114.0 (C-3’, C-5’), 118.4 (C-5), 124.7 (C-4a), 126.1 (C-1’), 127.0 (C-2”, C-6”), 128.4 (C-4”), 129.0 (C-7), 129.3 (C-8), 129.4 (C-3”, C-5”), 129.8 (C-2’, C-6’), 137.5 (C-6), 138.4(C-1”), 148.8 (C-8a), 153.1 (C-2), 161.3 (CO2H), 162.4 (C-4’), 165.1 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode 416 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:100.0%. mp 270-272 ◦C.
5.2.32.5 6-Bromo-8-(4-methoxy-N-methylbenzamido)-4-oxo-4H-chromene-2-carboxylic acid 211(ANM78)
O
O
CO2H
Br
NO
OCH3
CH3
The compound was synthesized according to GP-14 using 181(202 mg, 0.44 mmol), and was isolated as a white solid (188 mg,99% yield). 1H NMR: δ 3.38 (s, 3H, NCH), 3.67 (s, 3H, OCH3),6.72-6.76 (m, 2H, 3’-H, 5’-H), 6.89 (s, 1H, 3-H); 7.23-7.27 (m, 2H,2’-H, 6’-H), 7.95 (d, 1H, J = 2.5, 5-H), 8.08 (d, 1H, J = 2.5, 7-H). 13C NMR: δ 55.3 (OCH3), 113.2 (C-3’, C-5’), 113.6 (C-3), 117.8(C-6), 125.8 (C-5), 125.8 (C-4a), 127.5 (C-1’), 129.8 (C-2’, C-6’), 136.7 (C-7), 149.8(C-8a), 153.3 (C-2), 160.4 (C-4’), 161.0 (CO2H), 169.8 (CONH), 176.3 (C-4). LC-MS(m/z): positive mode 432 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%.mp 146-148 ◦C.
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5.2.32.6 6-Ethyl-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylicacid 206 (ANM172)
O
O
CO2H
NHO
OCH3
H3C
The compound was synthesized according to GP-14 using 112(173 mg, 0.44 mmol), and was isolated as a white solid (139mg, 86% yield). 1H NMR: δ 1.24 (t, J = 7.6 Hz, 3H, C6-CH2CH3),2.76 (q, J = 7.6 Hz, 2H, C6-CH2CH3), 3.85 (s, 3H, O-CH3), 6.92(s, 1H, 3-H), 7.07-7.11 (m, 2H, 3’-H, 5’-H), 7.69-7.73 (m, 1H, 5-H), 7.96 (d, J = 2.2 Hz, 1H, 7-H), 7.99-8.03 (m, 2H, 2’-H, 6’-H),10.01 (s, 1H, NH). 13C NMR: δ 15.4 (C6-CH2CH3), 27.8 (C6-CH2CH3), 55.6 (O-CH3),113.4 (C-3), 114.0 (C-3’, C-5’), 119.5 (C-5), 124.2 (C-4a), 126.2 (C-1’), 128.4 (C-8),129.7 (C-2’, C-6’), 130.9 (C-7), 141.9 (C-6), 147.9 (C-8a), 152.9 (C-2), 161.4 (CO2H),162.4 (C-4’), 165.0 (CONH), 177.5 (C-4). LC-MS (m/z): positive mode 368 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 277-278 ◦C.
5.2.32.7 6-Bromo-8-(carboxyformamido)-4-oxo-4H-chromene-2-carboxylic acid188 (ANM183)
O
O
CO2H
Br
NHO
O OH
The compound was synthesized according to GP-14 using 120(181 mg, 0.44 mmol), and was isolated as a white solid (150 mg,96% yield). 1H NMR: δ 6.94 (s, 1H, 3-H), 7.87 (d, J = 2.4 Hz, 1H,5-H), 8.58 (d, J = 2.5 Hz, 1H, 7-H), 10.35 (s, 1H, NH). 13C NMR:δ 113.4 (C-3), 117.9 (C-6), 122.2 (C-7), 125.3 (C-4a), 127.6 (C-5),129.3 (C-8), 145.9 (C-8a), 153.8 (C-2), 158.4 (CONH), 161.0 (CO2H), 176.3 (C-4). LC-MS (m/z): positive mode 356 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.5%.mp 246-247 ◦C.
5.2.32.8 6-Bromo-8-(4-ethylbenzamido)-4-oxo-4H-chromene-2-carboxylic acid207 (ANM190)
O
O
CO2H
Br
NHO
CH3
The compound was synthesized according to GP-14 using 113(196 mg, 0.44 mmol), and was isolated as a white solid (173 mg,94% yield). 1H NMR: δ 1.23 (t, J = 7.5 Hz, 3H, C4?-CH2CH3), 2.70(q, J = 7.6 Hz, 2H, C4’-CH2CH3), 6.97 (s, 1H, 3-H), 7.40 (d, J =8.1 Hz, 2H, 3’-H, 5’-H), 7.92-7.96 (m, 3H, 2’-H, 6’-H, 5-H), 8.33 (d,J = 2.5 Hz, 1H, 7-H), 10.19 (s, 1H, NH). 13C NMR: δ 15.4 (C4’-CH2CH3), 28.2 (C4’-CH2CH3), 113.6 (C-3), 117.8 (C-6), 123.1 (C-5),
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125.5 (C-4a), 128.0 (C-2’, C-3’, C-5’, C-6’), 130.4 (C-8), 131.2 (C-1’), 132.1 (C-7), 148.1(C-4’),148.7 (C-8a), 153.2 (C-2), 161.1 (CO2H); 165.5 (CONH), 176.4 (C-4). LC-MS(m/z): positive mode 417 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%.mp 297-298 ◦C.
5.2.32.9 6-(4-Chlorophenyl)-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid 208(ANM196)
O
O
CO2H
NHO
OCH3
Cl The compound was synthesized according to GP-14 using114 (156 mg, 0.33 mmol), and was isolated as a white solid(125 mg, 84% yield). 1H NMR: δ 3.86 (s, 3H, OCH3), 6.97(s, 1H, 3-H), 7.08-7.12 (m, 2H, 3’-H, 5’-H), 7.54-7.57 (m, 2H,3”-H, 5”-H), 7.76-7.80 (m, 2H, 2”-H, 6”-H), 8.01-8.05 (m, 2H,2’-H, 6’-H), 8.07 (d, J = 2.3 Hz, 1H, 5-H), 8.41 (d, J = 2.3Hz, 1H, 7-H), 10.14 (s, 1H, NH). 13C NMR: δ 55.7 (OCH3),113.6 (C-3), 114.0 (C-3’, C-5’), 118.5 (C-5), 124.7 (C-4a), 126.1 (C-1), 128.8 (C-7), 128.8(C-2’, C-6’), 129.3 (C-3”, C-5”), 129.4 (C-8), 129.8 (C-2”, C-6”), 133.3 (C-4’), 136.2 (C-6), 137.2 (C-1’), 148.9 (C-8a), 153.1 (C-2), 161.3 (CO2H), 162.5 (C4”), 165.1 (CONH),177.5 (C-2). LC-MS (m/z): positive mode 450 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 99.3%. mp 291-292 ◦C.
5.2.32.10 6-Bromo-8-(4-(methylthio)benzamido)-4-oxo-4H-chromene-2-carbo-xylic acid 209(THB10)
Br
O
O CO2H
NHO
SCH3
The compound was synthesized according to GP-14 using 115(187 mg, 0.40 mmol), and was isolated as a white solid (140 mg,80% yield). 1H NMR: δ 2.55 (s, 3H, S-CH3), 6.97 (s, 1H, 3-H),7.39?7.45 (m, 2H, 3’-H, 5’-H), 7.90?7.98 (m, 3H, 5-H, 2’-H, 6’-H),8.31 (d, J = 2.5 Hz, 1H, 7-H), 10.24 (s, 1H, NH). 13C NMR: δ 14.3(S-CH3), 113.7 (C-3’, C-5’), 117.8 (C-6), 123.3 (C-3), 125.2 (C-5) (C-5’, C-3’), 125.6 (C-4a), 128.4 (C-2’, C-6’), 129.6 (C-1’), 130.3 (C-8), 132.4 (C-7), 144.3(C-8a), 148.3 (C-2), 153.3 (CO2H), 161.1 (C-4’), 165.1 (CONH), 176.4 (C-4). LC-MS(m/z): positive mode 435 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.7%. mp285-286 ◦C.
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5.2.32.11 8-(Carboxyformamido)-4-oxo-4H-chromene-2-carboxylic acid 189(THB12)
O
O CO2H
NHO
OHO
The compound was synthesized according to GP-14 using 121(281 mg, 0.84 mmol), and was isolated as a red solid (192 mg, 81%yield). 1H NMR: δ 6.94 (s, 1H, 3-H), 7.54 (t, J = 7.9 Hz, 1H, 6-H),7.86 (dd, J = 1.5, 8.0 Hz, 1H, 5-H), 8.30 (dd, J = 1.3, 7.8 Hz, 1H,7-H), 10.28 (s, 1H, NH). 13C NMR: δ 113.7 (C-3), 121.3 (C-5), 124.2(C-4a), 125.8 (C-7), 127.0 (C-8), 127.5 (C-6), 147.5 (C-8a), 152.8 (C-2), 156.6 (CONH),161.2 (CO2H), 161.3 (CO2H), 177.4 (C-4). LC-MS (m/z): positive mode 278 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 97.9%. mp 245-249 ◦C.
5.2.32.12 8-(3-(4-Hydroxyphenyl)ureido)-4-oxo-4H-chromene-2-carboxylic acid263 (THB22)
O CO2H
O
NHO
HN
OH
The compound was synthesized accroding to GP-14 using 182(201 mg, 0.54 mmol). The obtained crude solid was suspended in5 mL of EtOH and dissolved by addition of 2 mL NaOH (2N). Afteraddition of HCl (6N) the poduct crystallized, was filtrated, driedin vacuum at 50 ◦C and was isolated as a green solid (14 mg, 8%yield). 1H NMR: δ 6.71 (d, J = 8.8 Hz, 2H, 3’-H, 5’-H), 6.92 (s, 1H,3-H), 7.26 (d, J = 8.8 Hz, 3H, 5-H, 2’-H, 6’-H), 7.43 (t, J = 8.0 Hz, 1H, 6-H), 7.63 (d,J = 7.9 Hz, 1H, 7-H), 8.36 (s, 1H, C8N-H), 8.43 (d, J = 6.9 Hz, 1H, C1’N-H), 9.34 (s,1H, OH). 13C NMR: δ 113.5 (C-3), 115.4 (C-3’, C-5’), 117.1 (C-5), 120.8 (C-2’, C-6’),124.1 (C-4a), 124.6 (C-7), 125.7 (C-6), 129.8 (C-8), 130.9 (C-8a), 145.9 (C-1), 152.5(CONH, C-4’), 153.0 (C-2), 161.5 (CO2H), 177.7 (C-4). LC-MS (m/z): positive mode341 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.0%. mp 240-241 ◦C.
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5.2.32.13 8-(2,6-Difluoro-4-methoxybenzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylic acid 210(THB28)
O CO2H
O
NHO
F F
OCH3
The compound was synthesized according to GP-14 using 116(216 mg, 0.44 mmol), and was isolated as a yellow solid (189mg, 95% yield). 1H NMR: δ 3.86 (s, 3H, O-CH3), 6.90 (d, J =10.1 Hz, 2H, 3”-H, 5”-H), 6.98 (s, 1H, 3-H), 7.44 (t, J = 7.4 Hz,1H, 4’-H), 7.53 (t, J = 7.6 Hz, 2H, 3’-H, 5’-H), 7.74 (d, J = 7.5 Hz,2H, 2’-H, 6’-H), 8.08 (d, J = 2.3 Hz, 1H, 7-H), 8.46 (s, 1H, 5-H),10.59 (s, 1H, NH). 13C NMR: δ 56.6 (OCH3), 98.7-98.9 (C-3’, C-5’), 107.2 (C-1’), 113.6 (C-3), 118.7 (C-5), 124.8 (C-4a), 127.1 (C-2”, C-6”), 127.8 (C-7),128.2 (C-8), 128.5 (C-4”), 129.4 (C-3”, C-5”), 137.7 (C-6), 138.3 (C-1”), 147.9 (C-8a),153.3 (C-2), 159.1 (C-4’), 159.4 (C-2’, C-6’), 161.2 (CO2H), 162.4 (CONH), 177.4 (C-4).LC-MS (m/z): positive mode 452 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:96.4%. mp 267-268 ◦C.
5.2.32.14 6-Bromo-8-(4-methoxybenzamido)-4-thioxo-4H-chromene-2-carboxy-lic acid 212(ANM279)
O
S
CO2H
Br
NHO
OCH3
The compound was synthesized according to GP-14 using 119(166 mg, 0.36 mmol), and was isolated as a green solid (136 mg,87% yield). 1H NMR: δ 3.87 (s, 3H, OCH3), 7.06-7.14 (m, 2H, 3’-H,5’-H), 7.67 (s, 1H, 3-H), 7.96-8.02 (m, 2H, 2’-H, 6’-H), 8.24 (d, 1H, J= 2.4 Hz, 5-H), 8.44 (d, 1H, J = 2.4 Hz, 7-H), 9.88 (s, 1H, NH). 13CNMR: δ 55.4 (OCH3), 113.9 (C-3’, C-5’), 119.2 (C-6), 124.5 (C-3,C-5), 125.7 (C-1’), 129.5 (C-2’, C-6’), 130.8 (C-8), 131.0 (C-7), 131.6 (C-4a), 143.2 (C-2,C-8a), 161.1 (CO2H), 162.5 (C-4’), 164.7 (CONH), 201.4 (C-4). LC-MS (m/z): positivemode 435 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.7%. mp 272-273 ◦C.
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5.2.32.15 8-(Carboxyformamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylicacid 190 (ANM287)
O COOH
NH
O
O
OHO
The compound was synthesized according to GP-14 using 122(180 mg, 0.44 mmol), and was isolated as a white solid (123mg, 79% yield). 1H NMR: δ 6.98 (s, 1H, 3-H), 7.39-7.46 (m, 1H,4’-H), 7.48-7.55 (m, 2H, 3’-H, 5’-H), 7.66-7.72 (m, 2H, 2’-H, 6’-H), 7.96 (d, 1H, J = 2.2 Hz, 5-H), 8.84 (d, 1H, J = 2.4 Hz, 7-H),10.38 (s, 1H, NH). 13C NMR: δ 112.3 (C-3), 116.6 (C-5), 122.6 (C-7), 124.1 (C-4a),126.6 (C-2’, C-6’), 127.9 (C-4’), 128.3 (C-8), 128.9 (C-3’, C-5’), 137.3 (C-6), 138.6 (C-1’), 145.6 (C-8a), 155.3 (C-2), 160.3 (CONH), 160.8-161.1 (CO2H), 177.3 (C-4). LC-MS(m/z): positive mode 354 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97.6%. mp> 300 ◦C.
5.2.32.16 8-(Carboxyformamido)-6-fluoro-4-oxo-4H-chromene-2-carboxylic acid191 (ANM295)
F
O COOH
NH
O
O
OHO
The compound was synthesized according to GP-14 using 123(154 mg, 0.44 mmol), and was isolated as a white solid (111 mg,85% yield). 1H NMR: δ 6.95 (s, 1H, 3-H), 7.54 (dd, 1H, J = 3.1,8.0 Hz, 5-H), 8.25 (dd, 1H, J = 3.1, 9.8 Hz, 7-H), 10.28 (s, 1H,NH). 13C NMR: δ 105.4 (C-5), 113.0 (C-3), 114.4 (C-7), 125.0 (C-4a), 129.1 (C-8), 143.8 (C-8a), 153.0 (C-2), 156.7-157.6 (C-6), 159.6 (CONH), 161.0(CO2H), 176.7 (C-4). LC-MS (m/z): positive mode 296 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.4%. mp 254-256 ◦C.
5.2.32.17 8-(Carboxyformamido)-6-chloro-4-oxo-4H-chromene-2-carboxylicacid 192 (ANM296)
Cl
O COOH
NH
O
O
OHO
The compound was synthesized according to GP-14 using 124(63 mg, 0.17 mmol), and was isolated as a white solid (44 mg,83% yield). 1H NMR: δ 6.97 (s, 1H, 3-H), 7.79 (d, 1H, J = 2.6 Hz,5-H), 8.38 (d, 1H, J = 2.6 Hz, 7-H), 10.29 (s, 1H, NH). 13C NMR:δ 113.7 (C-3), 119.8 (C-5), 125.1 (C-4a), 126.0 (C-7), 128.9 (C-8),130.2 (C-6), 146.0 (C-8a), 153.1 (C-2), 156.8 (CONH), 161.0 (CO2H), 176.3 (C-4). LC-MS (m/z): positive mode 312 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.6%.mp 242-244 ◦C.
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5.2.32.18 8-(Carboxyformamido)-6-methoxy-4-oxo-4H-chromene-2-carboxylicacid 193 (ANM297)
H3CO
O CO2H
NH
O
O
OHO
The compound was synthesized according to GP-14 using 125(60 mg, 0.17 mmol), and was isolated as a white solid (43 mg,82% yield). 1H NMR: δ 3.86 (s, 3H, OCH3), 6.91 (s, 1H, 3-H),7.23 (d, 1H, J = 3.1 Hz, 5-H), 7.98 (d, 1H, J = 3.05 Hz, 7-H),10.19 (s, 1H, NH). 13C NMR: δ 56.08 (OCH3), 101.0 (C-5), 112.9(C-3), 115.9 (C-7), 124.8 (C-4a), 128.3 (C-8), 142.2 (C-8a), 152.5 (C-2), 156.6 (CONH,C-6), 161.2 (CO2H), 177.0 (C-4). LC-MS (m/z): positive mode 308 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 99.7%. mp 245-247 ◦C.
5.2.32.19 8-(Carboxyformamido)-6-methyl-4-oxo-4H-chromene-2-carboxylicacid 194 (ANM298)
H3C
O CO2H
NH
O
O
OHO
The compound was synthesized according to GP-14 using 126(100 mg, 0.29 mmol), and was isolated as a white solid (64 mg,76% yield). 1H NMR: δ 2.43 (s, 3H, CH3), 6.91 (s, 1H, 3-H), 7.66(d, 1H, J = 2.2 Hz, 5-H), 8.13 (d, 1H, J = 2.0 Hz, 7-H), 10.22 (s,1H, NH). 13C NMR: δ 20.9 (CH3), 113.6 (C-3), 120.7 (C-5), 124.0(C-4a), 126.7 (C-8), 128.4 (C-7), 135.7 (C-6), 145.9 (C-8a), 152.7 (C-2), 156.7 (CONH),161.3 (CO2H), 177.3 (C-4). LC-MS (m/z): positive mode 292 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 99.4%. mp 250-252 ◦C.
5.2.32.20 8-(Carboxyformamido)-6-ethyl-4-oxo-4H-chromene-2-carboxylic acid195 (ANM299)
O CO2H
NH
O
O
OHO
H3C
The compound was synthesized according to GP-14 using 127(108 mg, 0.3 mmol), and was isolated as a white solid (85 mg,93% yield). 1H NMR: δ 1.22 (t, 3H, J = 7.6 Hz, CH3), 2.74 (q,2H, J = 7.6 Hz, CH2), 6.92 (s, 1H, 3-H), 7.46-7.84 (m, 1H, 5-H),8.17 (d, 1H, J = 2.16 Hz, 7-H), 10.25 (s, 1H, NH). 13C NMR: δ15.4 (CH3), 27.9 (CH2), 113.6 (C-3), 119.5 (C-5), 124.1 (C-4a), 126.9 (C-8), 127.5 (C-7), 141.7 (C-6), 146.1 (C-8a), 152.7 (C-2), 156.7 (CONH), 161.3 (CO2H), 177.4 (C-4).LC-MS (m/z): positive mode 306 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.4%. mp 246-248 ◦C.
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5.2.32.21 6-Bromo-8-(carboxyformamido)-4-thioxo-4H-chromene-2-carboxylicacid 197 (ANM300)
Br
O CO2H
NH
S
O
OHO
The compound was synthesized according to GP-14 using 128(88.4 mg, 0.2 mmol), and was isolated as a green solid (36 mg,48% yield). 1H NMR: δ 7.65 (s, 1H, 3-H), 8.17 (d, 1H, J = 2.4 Hz,5-H), 8.64 (d, 1H, J = 2.4 Hz, 7-H), 10.41 (s, 1H, NH). 13C NMR: δ119.6 (C-6), 124.3 (C-7), 124.8 (C-5), 127.6 (C-8), 129.9 (C-3), 131.6(C-4a), 141.7 (C-8a), 161.0 (CONH), 161.3 (C2), 161.4 (CO2H), 201.5 (C-4). LC-MS(m/z): positive mode 372 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 95.6%. mp> 300 ◦C.
5.2.32.22 6-Bromo-8-cyano-4-oxo-4H-chromene-2-carboxylic acid 267(ANM384)
Br
CN
O
O
CO2H
The compound was synthesized according to GP-14 using 266(143 mg, 0.44 mmol), and was isolated as a white solid (111 mg,86% yield). 1H NMR: δ 7.02 (s, 1H, 3-H), 8.35 (d, J = 2.5 Hz, 1H,7-H), 8.69 (d, J = 2.5 Hz, 1H, 5-H). 13C NMR: δ 105.2 (C-8), 113.0 (CN), 114.5 (C-3),117.9 (C-6), 125.7 (C-4a), 132.6 (C-5), 141.7 (C-7), 153.5 (C-8a), 155.0 (C-2), 160.8(CO2H), 175.7 (C-4). LC-MS (m/z): positive mode 294 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 98.0%. mp 234-236 ◦C.
5.2.32.23 6-Bromo-8-(3-(4-fluorobenzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 227(ANM20)
O
O
COOH
Br
NHO
O
F
The compound was synthesized accroding to GP-14 using 146(189 mg, 0.35 mmol) and was isolated as a white solid (128 mg,71% yield). 1H NMR: δ 5.18 (s, 2H, CH2-O), 6.98 (s, 1H, 3-H),7.19-7.26 (m, 2H, 3”-H, 5”-H), 7.28 (dd, J = 8.2, 2.4 Hz, 1H, 4’-H), 7.49 (t, J = 7.9 Hz, 1H, 5’-H), 7.52-7.58 (m, 2H, 2”-H, 6”-H),7.58-7.62 (m, 1H, 2’-H), 7.63-7.67 (m, 1H, 6’-H), 7.97 (d, J = 2.4Hz, 1H, 5-H), 8.33 (d, J = 2.4 Hz, 1H, 7-H), 10.30 (s, 1H, NH).13C NMR: δ 69.0 (CH2-O), 113.7 (C-3), 114.1 (C-2’), 115.5 (C-3”, C-5”), 117.8 (C-6),119.0 (C-6’), 120.4 (C-4’), 123.3 (C-5), 125.6 (C-4a), 130.0 (C-5’), 130.2 (C-2”, C-6”),130.2 (C-8), 132.3 (C-7), 133.1 (C-1”), 135.2 (C-1’), 148.2 (C-8a), 153.3 (C-2), 158.5
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(C-3’), 161.1 (CO2H), 165.4 (CONH), 176.4 (C-4). LC-MS (m/z): negative mode 566[M-CO2H]-, positive mode 514 [M+H]+, 531 [M+NH4]+. Purity by HPLC-UV (254nm)-ESI-MS: 99.3%. mp 258-259 ◦C.
5.2.32.24 6-Bromo-8-(3-(4-bromobenzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 228(ANM21)
O
O
CO2H
Br
NHO
O
Br
The compound was synthesized according to GP-14 using 147(265 mg, 0.44 mmol) and was isolated as a white solid (74 mg,30% yield). 1H NMR: δ 5.19 (s, 2H, CH2-O), 6.96 (s, 1H, 3-H),7.28 (dd, J = 7.3, 2.2 Hz, 1H, 4’-H), 7.43-7.46 (m, 2H, 3’-H, 5’-H), 7.49 (t, J = 7.9 Hz, 1H, 5’-H), 7.58-7.62 (m, 3H, 2’-H, 2”-H,6”-H), 7.62-7.66 (m, 1H, 6’-H), 7.96 (d, J = 2.4 Hz, 1H, 5-H), 8.33(d, J = 2.4 Hz, 1H, 7-H), 10.30 (s, 1H, NH). 13C NMR: δ 68.9(CH2-O), 113.5 (C-3), 114.1 (C-2’), 117.8 (C-6), 119.0 (C-6’), 120.5 (C-4’), 121.2 (C-4”),123.3 (C-5), 125.6 (C-4a), 130.0 (C-2”, C-6”), 130.0 (C-5’), 130.18 (C-8), 131.6 (C-3”,C-5”), 132.2 (C-7), 135.2 (C-1’), 136.4 (C-1”), 148.2 (C-8a), 153.6 (C-2), 158.4 (C-3’),161.1 (CO2H), 165.33 (CONH), 176.4 (C-4). LC-MS (m/z): negative mode 572 [M-H]-.Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 232-233 ◦C.
5.2.32.25 6-Bromo-8-(3-(4-chlorobenzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 229(ANM22)
O
O
CO2H
Br
NHO
O
Cl
The compound was synthesized according to GP-14 using 148(116 mg, 0.22 mmol) and was isolated as a white solid (84 mg,72% yield). 1H NMR: δ 5.20 (s, 2H, CH2-O), 6.97 (s, 1H, 3-H),7.28 (dd, J = 7.9, 2.2 Hz, 1H, 4’-H), 7.45-7.53 (m, 5H, 5’-H, 2”-H,3”-H, 5”-H, 6”-H), 7.59-7.66 (m, 2H, 2’-H, 6’-H), 7.96 (d, J = 2.4Hz, 1H, 5-H), 8.33 (d, J = 2.4 Hz, 1H, 7-H), 10.30 (s, 1H, CONH).13C NMR: δ 68.8 (CH2-O), 113.6 (C-3), 114.1 (C-2’), 117.8 (C-6),119.0 (C-6’), 120.5 (C-4’), 123.3 (C-5), 125.6 (C-4a), 128.6 (C-3”, C5”), 129.7 (C-2”, C-6”), 130.0 (C-5’), 130.2 (C-8), 132.3 (C-7), 132.7 (C-1’), 135.2 (C-4”), 135.9 (C-1”), 148.2(C-8a), 153.4 (C-2), 158.4 (C-3?), 161.1 (CO2H), 165.3 (CONH), 176.4 (C-4). LC-MS(m/z): negative mode 484 [M-CO2H]-, 528 [M-H]-, positive mode 530 [M+H]+. Purity
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by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 202-203 ◦C.
5.2.32.26 6-Bromo-8-(2-(4-fluorobenzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 234(ANM23)
O
O
CO2H
Br
NHO
O
F
The compound was synthesized according to GP-14 using 153(238 mg, 0.44 mmol) and was isolated as a white solid (146 mg,65% yield). 1H NMR: δ 5.62 (s, 2H, CH2-O), 6.96 (s, 1H, 3-H),7.04-7.11 (m, 2H, 3”-H, 5”-H), 7.12-7.16 (m, 1H, 5’-H), 7.30 (d, J= 8.2 Hz, 1H, 3’-H), 7.46-7.51 (m, 2H, 2”-H, 6”-H), 7.52-7.57 (m,1H, 4”-H), 7.84 (d, J = 2.5 Hz, 1H, 5-H), 8.05 (dd, J = 7.8, 1.8Hz, 1H, 6’-H), 9.01 (s, 1H, 7-H), 10.73 (s, 1H, CONH). 13C NMR:δ 69.8 (CH2-O), 113.8 (C-3), 114.8 (C-3’), 115.4 (C-3”, C-5”), 118.3 (C-6), 121.0 (C-5’),121.4 (C-1’), 121.8 (C-5), 125.2 (C-4a), 127.1 (C-7), 129.8 (C-2”, C-6”), 130.4 (C-8),131.8 (C-6’), 132.7 (C-1”), 134.2 (C-4’), 145.2 (C-8a), 153.0 (C-2), 156.1 (C-2’), 160.9(CO2H), 161.1 (C-4”), 163.7 (CONH), 176.3 (C-4). LC-MS (m/z): negative mode 511[M-H]-, positive mode 513 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.4%.mp 257-258 ◦C.
5.2.32.27 8-(4-(4-Fluorobenzyloxy)benzamido)-6-methoxy-4-oxo-4H-chromene-2-carboxylic acid 213(ANM58)
O
O
COOH
H3CO
NHO
O
F
The compound was synthesized according to GP-14 using 133(108 mg, 0.22 mmol) and was isolated as a white solid (89 mg,87% yield). 1H NMR: δ 3.89 (s, 3H, O-CH3), 5.21 (s, 2H, CH2-O), 6.90 (s, 1H, 3-H), 7.15-7.18 (m, 2H, 3’-H, 5’-H), 7.18-7.23(m, 2H, 3”-H, 5”-H), 7.27 (d, J = 3.1 Hz, 1H, 5-H), 7.50-7.54 (m,2H, 2”-H, 6”-H), 7.85 (d, J = 3.1 Hz, 1H, 7-H), 7.97-8.01 (m, 2H,2’-H, 6’-H), 9.77 (s, 1H, CONH). 13C NMR: δ 55.8 (O-CH3), 68.9(CH2-O), 101.1 (C-5), 112.3 (C-3), 114.7 (C-3’, C-5’), 114.95-115.12 (C-3”, C-5”), 117.9(C-7), 124.6 (C-4a), 126.4 (C-1’), 129.4 (C-2’, C6’), 129.6-129.7 (C-2”, C-6”), 129.7 (C-8),132.7 (C-1”), 143.5 (C-8a), 152.5 (C-2), 156.4 (C-6), 160.9 (C-4’), 161.2 (CO2H), 162.7(C-4”), 164.7 (CONH), 176.8 (C-4). LC-MS (m/z): negative mode 462 [M-H]-, positivemode 464 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 274-278 ◦C.
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5.2.32.28 8-(4-(4-Fluorobenzyloxy)benzamido)-6-methyl-4-oxo-4H-chromene-2-carboxylic acid 214(ANM59)
O
O
CO2H
H3C
NHO
O
F
The compound was synthesized according to GP-14 using 134(105 mg, 0.22 mmol) and was isolated as a white solid (62 mg,63% yield). 1H NMR: δ 2.48 (s, 3H, CH3), 5.23 (s, 2H, CH2-O),6.91 (s, 1H, 3-H), 7.15-7.20 (m, 2H, 3’-H, 5’-H), 7.20-7.26 (m, 2H,3”-H, 5”-H), 7.51-7.57 (m, 2H, 2”-H, 6”-H), 7.70 (dd, J = 2.3 Hz,1H, 5-H), 7.96-8.04 (m, 3H, 7-H, 2’-H, 6’-H), 9.78 (s, 1H, CONH).13C NMR: δ 20.5 (CH3), 68.8 (CH2-O), 113.0 (C-3), 114.7 (C-3’,C-5’), 115.0-115.1 (C-3”, C-5”), 120.2 (C-5), 123.9 (C-4a), 126.5 (C-1’), 128.1 (C-8),129.3 (C-2’, C6’), 129.6-129.7 (C-2”, C6”), 130.7 (C-1”), 135.1 (C-6), 147.1 (C-8a), 152.7(C-2), 160.9 (CO2H), 161.1 (C-4’), 162.7 (C-4”), 164.7 (C-4”), 164.7 (CONH), 177.1 (C-4). LC-MS (m/z): negative mode 446 [M-H]-, positive mode 448 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 100.0%. mp 260-261 ◦C.
5.2.32.29 6-Ethyl-8-(4-(4-fluorobenzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 215(ANM97)
O
O
CO2H
NHO
O
F
H3C
The compound was synthesized according to GP-14 using 135(215 mg, 0.44 mmol) and was isolated as a white solid (193mg, 95% yield). 1H NMR: δ 1.24 (t, J = 7.6 Hz, 3H, CH2CH3),2.76 (q, J = 7.6 Hz, 2H, CH2CH3), 5.20 (s, 2H, CH2-O), 6.92 (s,1H, 3-H), 7.14-7.19 (m, 2H, 3’-H, 5’-H), 7.21-7.26 (m, 2H, 3”-H,5”-H), 7.52-7.58 (m, 2H, 2”-H, 6”-H), 7.71 (d, J = 2.1 Hz, 1H,5-H), 7.95 (d, J = 2.2 Hz, 1H, 7-H), 7.96-8.02 (m, 2H, 2’-H, 6’-H), 10.04 (s, 1H, CONH). 13C NMR: δ 15.8 (CH2CH3), 28.1 (CH2CH3), 69.2 (CH2-O),133.7 (C-3), 115.1 (C-3’, C-5’), 115.9 (C-3”, C-5”), 119.9 (C-5), 125.5 (C-4a), 126.8(C-1’), 128.7 (C-8a), 130.1 (C-2’, C-6’), 130.1 (C-2”, C-6”), 131.3 (C-7), 133.3 (C-1”),141.9 (C-6), 148.3 (C-8a), 153.2 (C-2), 161.5-161.8 (CO2H, C-4’), 163.1 (C-4”), 165.3(CONH), 177.9 (C-4). LC-MS (m/z): negative mode 460 [M-H]-, positive mode 462[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 258-259 ◦C.
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5.2.32.30 8-(4-(4-Fluorobenzyloxy)vbenzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylic acid 216(ANM98)
O
O
CO2H
NHO
O
F
The compound was synthesized according to GP-14 using 136(161 mg, 0.30 mmol) and was isolated as a white solid (150mg, 98% yield). 1H NMR: δ 5.20 (s, 2H, CH2-O), 6.98 (s, 1H,3-H), 7.16-7.21 (m, 2H, 3’-H, 5’-H), 7.21-7.26 (m, 2H, 3”-H, 5”-H), 7.41-7.46 (m, 1H, 4”’-H), 7.49-7.56 (m, 4H, 2”-H, 6”-H, 3”-H,5”-H), 7.74-7.78 (m, 2H, 2”’-H, 6”’-H), 8.01-8.06 (m, 2H, 2’-H,6’-H), 8.07-8.10 (d, J = 2.3 Hz, 1H, 5-H), 8.41 (d, J = 2.3 Hz,1H, 7-H), 10.17 (s, 1H, CONH). 13C NMR: δ 69.0 (CH2-O), 113.5 (C-3), 114.8 (C-3’,C-5’), 115.4-115.6 (C-3”, C-5”), 118.4 (C-5), 124.7 (C-4a), 126.4 (C-1”’), 127.0 (C-2”’,C-6”’), 128.4 (C-7), 129.0 (C-4”’), 129.2 (C-8), 129.4 (C-3”’, C-5”’), 129.9 (C-2’, C-6’),130.2-130.3 (C-2”, C-6”), 133.0 (C-1”), 137.6 (C-6), 138.4 (C-1’), 148.8 (C-8a), 153.1(C-2), 161.0-163.0 (C-4”), 161.4 (CO2H), 161.4 (C-4’), 165.1 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode 510 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.2%.mp 155-156 ◦C.
5.2.32.31 8-(4-(3,4-Difluorobenzyloxy)benzamido)-4-oxo-6-phenyl-4H-chro-mene-2-carboxylic acid 217(ANM130)
O
O
CO2H
NHO
O
F
F
The compound was synthesized according to GP-14 using 137(144 mg, 026 mmol) and was isolated as a white solid (93 mg,68% yield). 1H NMR: δ 5.21 (s, 2H, CH2-O), 6.98 (s, 1H, 3-H),7.17-7.21 (m, 2H, 3’-H, 5’-H), 7.33-7.37 (m, 1H, 6”-H), 7.41-7.61(m, 5H, 2”-H, 5”-H, 3”’-H, 4”’-H, 5”’-H), 7.74-7.78 (m, 2H, 2”’-H,6”’-H), 8.02-8.06 (m, 2H, 2’-H, 6’-H), 8.09 (d, J = 2.31 Hz, 1H,5-H), 8.41 (d, J = 2.3 Hz, 1H, 7-H), 10.17 (s, 1H, CONH). 13CNMR: δ 68.3 (CH2-O), 113.5 (C-3), 114.8 (C-3’, C-5’), 117.0-117.1 (C-2”), 117.7-117.8(C-5”), 118.4 (C-5), 124.7 (C-4a), 124.8-124.9 (C-6”), 126.6 (C-1”’), 127.0 (C-2”’, C6”’),128.4 (C-7), 129.0 (C-4”’), 129.2 (C-8), 129.4 (C-3”’, C-5”’), 129.9 (C-2’, C-6’), 134.5-134.6 (C-1”), 137.6 (C-6), 138.3 (C-2), 148.2-148.6 (C-4”), 148.8 (C-8a), 150.2-150.5(C-3”), 153.1 (C-2), 161.2 (C-4’), 161.3 (CO2H), 165.1 (CONH), 177.6 (C-4). LC-MS(m/z): negative mode 526 [M-H]-, positive mode 528 [M+H]+. Purity by HPLC-UV
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(254 nm)-ESI-MS: 100.0%. mp 281-282 ◦C.
5.2.32.32 8-(3-Chloro-4-(4-fluorobenzyloxy)benzamido)-4-oxo-6-phenyl-4H-chromene-2-carboxylic acid 219(ANM139)
O
O
CO2H
NHO
O
F
Cl
The compound was synthesized according to GP-14 using 139(92 mg, 0.16 mmol) and was isolated as a white solid (77 mg,89% yield). 1H NMR: δ 5.32 (s, 2H, CH2-O), 6.98 (s, 1H, 3-H),7.23-7.29 (m, 2H, 3”-H, 5”-H), 7.42-7.46 (m, 2H, 4”’-H, 5’-H),7.50-7.58 (m, 4H, 2”-H, 6”-H, 3”’-H, 5”’-H), 7.74-7.78 (m, 2H,2”’-H, 6”’-H), 8.02 (dd, J = 2.2, 8.7 Hz, 1H, 6’-H), 8.11 (d, J=2.3 Hz, 1H, 5-H), 8.16 (d, J = 2.2 Hz, 1H, 2’-H), 8.36 (d, J =2.3 Hz, 1H, 7-H), 10.36 (s, 1H, CONH). 13C NMR: δ 69.9 (CH2-O), 113.5 (C-3), 114.1(C-5’), 115.5-115.6 (C-3”, C-5”), 118.8 (C-5), 121.7 (C-3’), 124.7 (C-4a), 127.0 (C-2”’,C-6”’), 127.3 (C-1”’), 128.4 (C-7), 128.9 (C-8), 129.5 (C-2’), 129.7 (C-6’), 130.0-130.1(C-2”, C-6”), 132.5 (C-1”), 137.6 (C-6), 138.3 (C-1’), 149.1 (C-8a), 153.1 (C-2), 156.5(C-4’), 161.1 (C-4”), 151.4 (CO2H), 164.1 (CONH), 177.6 (C-4). LC-MS (m/z): negativemode 542 [M-H]-, positive mode 544 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.7%. mp 259-260 ◦C.
5.2.32.33 8-(4-(4-Fluorobenzyloxy)benzamido)-6-(4-fluorophenyl)-4-oxo-4H-chromene-2-carboxylic acid 220(ANM141)
O
O
CO2H
NHO
O
F
F The compound was synthesized according to GP-14 using140 (206 mg, 0.37 mmol) and was isolated as a white solid(170 mg, 87% yield). 1H NMR: δ 5.20 (s, 2H, CH2-O), 6.97(s, 1H, 3-H), 7.16-7.21 (m, 2H, 3’-H, 5’-H), 7.21-7.26 (m, 2H,3”-H, 5”-H), 7.31-7.37 (m, 2H, 3”’-H, 5”’-H), 7.51-7.56 (m, 2H,2”-H, 6”-H), 7.78-7.83 (m, 2H, 2”’-H, 6”’-H), 8.01-8.05 (m, 2H,2’-H, 6’-H), 8.06 (d, J = 2.3 Hz, 1H, 5-H), 8.39 (d, J = 2.3 Hz,1H, 7-H), 10.16 (s, 1H, CONH). 13C NMR: δ 69.0 (CH2-O), 113.5 (C-3), 114.8 (C-3’,C-5’), 115.4-115.6 (C-3”’, C5”’), 116.1-116.3 (C-3”, C-5”), 118.4 (C-5), 124.7 (C-4a),126.4 (C-1’), 129.0 (C-7), 129.2 (C-2”’, C-6”’), 129.3 (C-8), 129.9 (C-2’, C-6’), 130.2-130.3 (C-2”, C-6”), 133.0 (C-1”), 134.9 (C-6), 136.6 (C-1”’), 148.8 (C-8a), 153.1 (C-2),
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61.0-161.7 (C-4”’, CO2H), 163.0-163.4 (C-4’, C-4”), 165.1 (CONH), 177.6 (C-4). LC-MS(m/z): negative mode 526 [M-H]-, positive mode 528 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 100.0%. mp 264-265 ◦C.
5.2.32.34 8-(4-(4-Fluorobenzyloxy)benzamido)-6-(4-methoxyphenyl)-4-oxo-4H-chromene-2-carboxylic acid 221(ANM142)
O
O
CO2H
NHO
O
F
H3CO The compound was synthesized according to GP-14 using141 (261 mg, 0.46 mmol) and was isolated as a yellowsolid (226 mg, 91% yield). 1H NMR: δ 3.81 (s, 3H, O-CH3),5.20 (s, 2H, CH2-O), 6.96 (s, s, 1H, 3-H), 7.05-7.09 (m, 2H,3”’-H, 5”’-H), 7.16-7.20 (m, 2H, 3’-H, 5’-H), 7.20-7.26 (m,2H, 3”-H, 5”-H), 7.51-7.55 (m, 2H, 2”-H, 6”-H), 7.68-7.72(m, 2H, 2”’-H, 6”’-H), 8.01-8.03 (m, 2H, 2’-H, 6’-H), 8.04 (d,1H, 5-H), 8.36 (d, J = 2.3 Hz, 1H 7-H). 13C NMR: δ 55.4 (O-CH3), 69.0 (CH2-O), 113.4(C-3), 114.8 (C-3’, C5’, C3”’, C5”’), 115.4-115.6 (C-3”, C-5”), 117.6 (C-5), 124.7 (C-4a),126.5 (C-1”’), 128.2 (C-2”’, C-6”’), 128.6 (C-7), 129.1 (C-8), 129.9 (C-2’, C-6’), 130.2-130.3 (C-2”, C-6”), 130.6 (C-6), 133.3 (C-1”), 137.3 (C-1”’), 148.5 (C-8a), 153.1 (C-2),159.7 (CO2H), 161.4 (C-4’), 151.1-163.0 (C-4”), 165.1 (CONH), 177.6 (C-4). LC-MS(m/z): negative mode 538 [M-H]-, positive mode 540 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 100.0%. mp 264-265 ◦C.
5.2.32.35 8-(4-(4-Fluorobenzyloxy(benzamido)-4-oxo-6-p-tolyl-4H-chromene-2-carboxylic acid 222(ANM143)
O
O
CO2H
NHO
O
F
H3C The compound was synthesized according to GP-14 using142 (200 mg, 0.36 mmol) and was isolated as a white solid(172 mg, 91% yield). 1H NMR: δ 2.36 (s, 3H, CH3), 5.20(s, 2H, CH2-O), 6.97 (s, 1H, 3-H), 7.18 (d, J = 8.8 Hz, 2H,3’-H, 5’-H), 7.23 (t, J = 8.8 Hz, 2H, 3”-H, 5”-H), 7.33 (d, J= 8.1 Hz, 2H, 3”’-H, 5”’-H), 7.50-7.57 (m, 2H, 2”-H, 6”-H),7.65 (d, J = 8.1 Hz, 2H, 2”’-H, 6”’-H), 8.03 (d, J = 8.8 Hz,2H, 2’-H, 6’-H), 8.06 (d, J = 2.2 Hz, 1H, 5-H), 8.38 (d, J = 2.2 Hz, 1H, 7-H), 10.14s, 1H, CONH). 13C NMR: δ 20.8 (CH3), 69.0 (CH2-O), 113.5 (C-3), 114.8 (C-3’, C-5’),
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115.4-115.6 (C-3”, C-5”), 118.0 (C-5), 124.7 (C-4a), 126.4 (C-1”’), 126.8 (C-2”’. C-6”’),128.8 (C-7), 129.2 (C-8), 129.9 (C-2’, C-6’), 130.0 (C-3”’, C-5”’), 130.2-130.3 (C-2”, C-6”), 133.0 (C-1”), 135.4 (C-6), 137.5 (C-1”’), 137-9 (C-1’), 148.7 (C-8a), 153.0 (C-2),161.3 (C-4’), 161.4 (CO2H), 161.1-163.0 (C-4”), 177.6 (C-4). LC-MS (m/z): negativemode 522 [M-H]-, positive mode 524 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.9%. mp 268-269 ◦C.
5.2.32.36 6-(4-Chlorophenyl)-8-(4-(4-fluorobenzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 218(ANM138)
O
O
CO2H
NHO
O
F
Cl The compound was synthesized according to GP-14 using138 (166 mg, 0.29 mmol) and was isolated as a yellow solid(137 mg, 87% yield). 1H NMR: δ 5.20 (s, 2H, CH2-O), 6.98 (s,1H, 3-H), 7.14-7.28 (m, 4H, 3’-H, 5’-H, 3”-H, 5”-H), 7.50-7.60(m, 4H, 2”-H, 6”-H, 3”’-H, 5”’-H), 7.75-7.82 (m, 2H, 2”’-H,6”’-H), 8.00-8.06 (m, 2H, 2’-H, 6’-H), 8.08 (d, J = 2.3 Hz, 1H,5-H), 8.41 (d, J = 2.3 Hz, 1H, 7-H), 10.16 (s, 1H, CONH). 13CNMR: δ 69.0 (CH2-O), 113.5 (C-3), 114.8 (C-3’, C-5’), 115.4-115.5 (C-3”, C-5”), 118.5(C-5), 124.7 (C-4a), 126.4 (C-8), 128.8-129.8 (C-2”’, C-6”’, C-2’, C-6’, C-3”’, C-5”’, C-7),130.2-130.3 (C-2”, C-6”), 133.0 (C-1”’), 133.3 (C-1”), 136.2 (C-6), 137.1 (C-1’), 149.0(C-8a), 153.1 (C-2), 161.0 (C-4”), 161.4 (CO2H), 163.0 (C-4’), 165.1 (CONH), 177.5 (C-4). LC-MS (m/z): positive mode 544 [M+H+. Purity by HPLC-UV (254 nm)-ESI-MS:98.3%. mp 264-265 ◦C.
5.2.32.37 8-(4-(3,4-Difluorobenzyloxy)benzamido)-6-(4-fluorophenyl)-4-oxo-4H-chromene-2-carboxylic acid 223(ANM151)
O
O
CO2H
NHO
O
F
F
F
The compound was synthesized according to GP-14 using143 (224 mg, 0.39 mg) and was isolated as a white solid(193 mg, 91% yield). 1H NMR: δ 5.21 (s, 2H, CH2-O), 6.97(s, 1H, 3-H), 7.16-7.21 (m, 2H, 3’-H, 5’-H), 7.30-7.38 (m, 3H,6”-H, 3”’-H, 5”’-H), 7.47 (dt, J = 8.4 Hz, 1H, 5”-H), 7.57 (ddd,J = 7.9, 2.1 Hz, 1H, 2”-H), 7.89 (m, 2H, 2”’-H, 6”’-H), 7.94-8.15(m, 3H, 5-H, 2’-H, 6’-H), 8.39 (d, J = 2.4 Hz, 1H, 7-H), 10.17
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(s, 1H, CONH). 13C NMR: δ 68.3 (CH2-O), 113.5 (C-3), 114.8 (C-3’, C-5’), 116.1-116.3(C-3”’, C5”’), 117.0-117.1 (C-2”), 117.7-117.8 (C-5”), 118.4 (C-7), 125.7 (C-4a), 124.8-124.9 (C-6”), 126.5 (C-1’), 128.9 (C-5), 129.1-129.2 (C-2”’, C-6”’), 129.2 (C-8), 129.8(C-2’, C-6’), 134.5 (C-1”), 134.8 (C-6), 136.5 (C-1”’), 148.2-148.6 (C-4”), 148.8 (C-8a),150.1-150.5 (C-3”), 153.1 (C-2), 161.2-161.3 (C-4”’), 161.4 (CO2H), 163.4 (C-4’), 165.0(CONH), 177.5 (C-4). LC-MS (m/z): positive mode 546 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.3%. mp 276-277 ◦C.
5.2.32.38 8-(3-Chloro-4-(3,4-difluorobenzyloxy)benzamido)-6-(4-fluorophenyl)-4-oxo-4H-chromene-2-carboxylic acid 224(ANM152)
O
O
CO2H
NHO
O
F
F
F
Cl
The compound was synthesized according to GP-14 using144 (386 mg, 0.63 mmol) and was isolated as a yellow solid(310 mg, 85% yield). 1H NMR: δ 5.32 (s, 2H, CH2-O), 6.97 (s,1H, 3-H), 7.29-7.40 (m, 3H, 3”’-H, 5”’-H, 6”’-H), 7.42 (d, J =8.7 Hz, 1H, 5’-H), 7.49 (dt, J = 8.4 Hz, 1H, 5”-H), 7.57 (ddd, J= 7.8, 2.1 Hz, 1H, 2”-H), 7.77-7.83 (m, 2H, 2”’-H, 6”’-H), 8.02(d, J = 8.7, 2.2 Hz, 1H, 6’-H), 8.07 (d, J = 2.3 Hz, 1H, 5-H),8.16 (d, J = 2.2 Hz, 1H, 2’-H), 8.34 (d, J = 2.3 Hz, 1H, 7-H), 10.36 (s, NH, CONH). 13CNMR: δ 69.2 (CH2-O), 113.5 (C-3), 114.0 (C-5’), 116.1-116.3 (C-3”’, C-5”’), 116.8-116.9(C-2”), 177.8-117.9 (C-5”), 118.8 (C-7), 121.7 (C-3’), 124.6 (C-6”), 124.7 (C-4a), 127.4(C-1’), 128.5-129.7 (C-2’, C-6’, C-5), 128.9 (C-8), 129.1-129.2 (C-2”’, C-6”’), 134.0-134.0(C-1”), 134.7 (C-6), 136.5 (C-1”’), 148.3-148.6 (C-4”), 149.0 (C-8a), 150.2-150.5 (C-3”),153.1 (C-2), 161.3 (C-4”’), 161.4 (CO2H), 163.4 (C-4’), 164.0 (CONH), 177.5 (C-4). LC-MS (m/z): positive mode 580 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.4%.mp 276-277 ◦C.
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5.2.32.39 8-(4-((4-Fluorobenzyl)oxy)benzamido)-6-(4-hydroxyphenyl)-4-oxo-4H-chromene-2-carboxylic acid 225(ANM203)
O
O
CO2H
NHO
O
HO
F
The compound was synthesized according to GP-14 using131 (221 mg, 0.40 mmol) and was isolated as a yellow solid(178 mg, 85% yield). 1H NMR: δ 5.20 (s, 2H, CH2-O), 6.87-6.93 (m, 2H, 3”’-H, 5”’-H), 6.95 (s, 1H, 3-H), 7.12-7.20 (m,2H, 3’-H, 5’-H), 7.20-7.27 (m, 3”-H, 5”-H), 7.48-7.56 (m, 2H,2”-H, 6”-H), 7.56-7.61 (m, 2H, 2”’-H, 6”’-H), 7.96-8.06 (m,3H, 2’-H, 6’-H, 5-H), 8.32 (d, J = 2.4 Hz, 1H, 7-H), 9.68 (s,1H, OH), 10.12 (s, 1H, CONH). 13C NMR: δ 69.0 (CH2-O), 113.4 (C-3), 114.8 (C-3’,C-5’), 115.4-115.5 (C-3”, C-5”), 116.2 (C-3”’, C-5”’), 117.3 (C-5), 124.7 (C-4a), 126.5(C-1’), 128.2 (C-2”’, C-6”’), 128.5 (C-7), 129.8 (C-2’, C-6’), 130.2-130.3 (C-2”, C-6”),133.0 (C-6, C-1”), 137.7 (C-1”’), 148.3 (C-8a), 153.0 (C-2), 158.0 (C-4”’), 161.0 (C-4’),161.4 (CO2H), 163.0 (C-4”), 165.1 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode580 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.2%. mp > 300 ◦C.
5.2.32.40 8-(3-Fluor-4-(4-fluorbenzyloxy)benzamido)-4-oxo-6-phenyl-4H-chro-mene-2-carboxylic acid 226(THB27)
O CO2H
NH
O
O
O
F
F
The compound was synthesized according to GP-14 using 145(343 mg, 0.61 mmol) and was isolated as a yellow solid (301mg, 94% yield). 1H NMR: δ 5.29 (s, 2H, CH2-O), 6.98 (s, 1H, 3-H), 7.19-7.31 (m, 2H, 3”’-H, 5”’-H), 7.41-7.50 (m, 3H, 4’-H, 2”’-H,6”’-H), 7.50-7.57 (m, 4H, 2’-H, 3’-H, 5’-H, 6’-H), 7.70-7.82 (m,2H, 5”-H, 6”-H), 7.86-7.94 (m, 1H, 2”-H), 8.10 (d, J = 2.3 Hz,1H, 7-H), 8.37 (d, J = 2.3 Hz, 1H, 5-H), 10.30 (s, 1H, CONH).13C NMR: δ 69.9 (CH2-O), 133.5 (C-3), 115.1 (C-5”), 115.4-115.7 (C-3”’, C-5”’), 118.8(C-5), 124.7 (C-3”), 125.0 (C-7), 126.8 (C-4a), 127.0 (C-2’, C-6’), 128.4 (C-4’), 128.9 (C-8), 129.4 (C-3’, C-5’), 130.4 (C-2”, C-6”), 130.4 (C-2”’, C-6”’), 132.5 (C-1’), 137.5 (C-1”’),138.2 (C-6), 149.0-149.4 (C-1”), 150.3 (C-8a), 152.3 (C-2), 153.1 (C-4”), 161.3 (C-4”’),163.1 (C-4”’), 163.1 (CO2H), 164.1 (CONH), 177.5 (C-4). LC-MS (m/z): positive mode528 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 97%. mp 262-263 ◦C.
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5.2.32.41 6-Bromo-8-(2-fluoro-4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid 198(ANM6)65
O
O
CO2H
Br
NHO
F
OCH3
The compound was synthesized according to GP-14 using 104(204 mg, 0.44 mmol). Recrystallization from 1:1 acetone/ ethanolafforded the product as a white solid (170 mg, 95% yield). 1HNMR: δ 3.87 (s, 3H, OCH3), 6.96-7.04 (m, 3H, 3-H, 5’-H, 3’-H),7.88 (d, J = 2.4 Hz, 1H, 5-H), 7.92 (dd, J = 8.9 Hz, 1H, 6’-H), 8.68(d , J = 2.4 Hz, 1H, 7-H), 9.81 (d, J = 10.2 Hz, 1H, CONH). 13CNMR: δ 56.4 (OCH3), 102.1 (C-3’), 111.6 (C-5’), 113.4 (C-1’), 113.6 (C-3), 118.1 (C-6),121.9 (C-5), 125.3 (C-4a), 128.7 (C-7), 130.1 (C-8), 132.5 (C-6’), 146.2 (C-8a), 153.3(C-2), 161.0 (CO2H), 161.2 (C-2’), 161.7 (C-4’), 164.1 (CONH), 176.3 (C4). LC-MS (m/z): negative mode 390 [M-CO2H]-, 434 [M-H]-, positive mode 436 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 100.0%. mp 289-290 ◦C.
5.2.32.42 6-Bromo-8-(2,6-difluoro-4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid 199(ANM7)65
O
O
CO2H
Br
NHO
F
OCH3
F
The compound was synthesized according to GP-14 using 105(97 mg, 0.20 mmol). Recrystallization from 1:1 acetone/ ethanolafforded the product as a white solid (83 mg, 91% yield). 1HNMR: δ 3.85 (s, 3H, OCH3), 6.89 (d, J = 10.0 Hz, 2H, 3’-H, 5’-H),6.97 (s, 1H, 3-H), 7.95 (d, J = 2.4 Hz, 1H, 5-H), 8.40 (s 1H, 7-H),10.62 (s, 1H, CONH). 13C NMR: δ 56.7 (OCH3), 98.9 (C-3’, C-5’),106.6?106.9 (C-1’), 113.8 (C-3), 117.9 (C-6), 123.3 (C-5), 125.7 (C-4a), 129.4 (C-8),130.9 (C-7), 147.3 (C-8a), 153.4 (C-2), 159.1 (C-4’), 160.4 (C-2’, C-6’), 161.0 (CO2H),162.6 (CONH), 176.2 (C4). LC-MS (m/z): negative mode 408 [M-CO2H]-, 452 [M-H]-, positive mode 456 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0%. mp296-297 ◦C.
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5.2.32.43 6-Bromo-8-(3-fluoro-4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxylic acid 200(ANM27)65
O
O
CO2H
Br
NHO
OCH3
F
The compound was synthesized according to GP-14 using 106(204 mg, 0.44 mmol). Recrystallization from 1:1 acetone/ ethanolafforded the product as a white solid (144 mg, 75% yield). 1HNMR: δ 3.94 (s, 3H, OCH3), 6.97 (s, 1H, 3-H), 7.36 (dd, J = 8.5Hz, 1H, 5’-H), 7.84?7.89 (m, 2H, 2’-H, 6’-H), 7.96 (d, J = 2.4 Hz,1H, 5-H), 8.28 (d, J = 2.4 Hz, 1H, 7-H), 10.27 (s, 1H, CONH). 13CNMR: δ 56.5 (OCH3), 113.6 (C-3 or C-6’), 113.7 (C-3 or C-6’), 115.5 (C-2’), 117.8(C-6), 123.4 (C-5), 125.3 (C-5’), 125.6 (C-4a), 126.0 (C-1’), 130.2 (C-8), 132.6 (C-7),148.4 (C-8a), 150.6 (C-4’), 151.0 (C-3’), 153.3 (C-2), 161.1 (CO2H), 164.1 (CONH),176.4 (C4). LC-MS (m/z): negative mode 390 [M-CO2H]-, 434 [M-H]-, positive mode438 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.8%. mp 296-297 ◦C.
5.2.32.44 8-(4-Methoxybenzamido)-6-methyl-4-oxo-4H-chromene-2-carboxylicacid 201 (ANM34)65
O
O
CO2H
H3C
NHO
OCH3
The compound was synthesized according to GP-14 using 107(168 mg, 0.44 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (134 mg, 86% yield). 1HNMR: δ 2.45 (s, 3H, ArCH3), 3.85 (s, 3H, OCH3), 6.91 (s, 1H, 3-H),7.09 (d, J = 9.1 Hz, 2H, 3’-H, 5’-H), 7.68?7.69 (m, 1H, 5-H), 7.92(d, J = 2.2 Hz, 1H, 7-H), 8.00 (d, J = 8.8 Hz, 2H, 2’-H, 6’- H),10.00 (s, 1H, CONH). 13C NMR: δ 20.8 (ArCH3), 55.6 (OCH3), 113.4 (C-3), 114.0 (C-3’,C-5’), 120.7 (C-5), 124.1 (C-4a), 126.2 (C-1’), 128.3 (C-8), 129.7 (C-2’, C-6’), 131.9 (C-7), 135.5 (C-6), 147.7 (C-8a), 152.9 (C-2), 161.4 (CO2H), 162.4 (C-4’), 165.0 (CONH),177.5 (C4). LC-MS (m/z): negative mode 308 [M-CO2H]-, 352 [M-H]-, positive mode354 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.7%. mp 283-284 ◦C.
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5.2.32.45 6-Methoxy-8-(4-methoxybenzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 202(ANM40)65
O
O
CO2H
H3CO
NHO
OCH3
The compound was synthesized according to GP-14 using 108(175 mg, 0.44 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (151 mg, 93% yield). 1HNMR: δ 3.85 (s, 3H, 6-OCH3 or 4’-OCH3), 3.88 (s, 3H, 6-OCH3or 4’-OCH3), 6.91 (s, 1H, 3-H), 7.09 (d, J = 8.9 Hz, 2H, 3’-H, 5’-H), 7.27 (d, J = 3.1 Hz, 1H, 5-H), 7.77 (d, J = 3.1 Hz, 1H, 7-H),8.00 (d, J = 8.9 Hz, 2H, 2’-H, 6’-H), 10.01 (s, 1H, CONH). 13C NMR: δ 55.7 (6-OCH3or 4’-OCH3), 56.1 (6-OCH3 or 4’-OCH3), 101.2 (C-5), 112.7 (C-3), 114.0 (C-3’, C-5’),119.1 (C-7), 124.9 (C-4a), 126.1 (C-1’), 129.8 (C-2’, C-6’), 129.9 (C-8), 144.2 (C-8a),152.7 (C-2), 156.6 (C-6), 161.4 (CO2H), 162.5 (C-4’), 165.0 (CONH), 177.2 (C4). LC-MS(m/z): negative mode 324 [M-CO2H]-, 368 [M-H]-, positive mode 370 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 100.0%. mp 276-277 ◦C.
5.2.32.46 6-Bromo-8-(4-(3-cyclohexylpropoxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 254(ANM26)
O
O
CO2H
Br
NHO
O
The compound was synthesized according to GP-14 using 172(1952998221 mg, 0.35 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (167 mg, 90%yield). 1H NMR: δ 0.89-1.76 (m, 15H, Cyclohexyl-H, 2”-H, 3”-H), 4.07 (t, J = 6.5 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H), 7.07 (m, 2H,3’-H, 5’-H), 7.93 (d, J = 2.4 Hz, 1H, 5-H), 7.90-7.89 (m, 2H, 2’-H, 6’-H), 8.39 (d, J = 2.4 Hz, 1H, 7-H), 9.86 (s, 1H, CONH). 13CNMR: δ 25.6-26.0 (C-2”, C-3”’, C-4”’, C-5”’), 32.6 (C-2”’, C-6”’), 32.9 (C-3”), 68.3 (CH,O-CH ), 113.2 (C-3), 114.3 (C-3’, C-5’), 117.5 (C-6), 122.3 (C-5), 125.3 (C-1’), 125.6(C-4a), 129.5 (C-2’, C-6’), 130.4 (C-8), 130.8 (C-7), 147.5 (C-8a), 153.2 (C-2), 160.6(C-4’), 161.9 (CO2H), 164.8 (CONH), 175.9 (Cq, C-4). LC-MS (m/z): negative mode482 [M-CO2H]-, 528 [M-H]-, positive mode 530 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 100.0%. mp 246-247 ◦C.
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5.2.32.47 8-(4-(4-Cyclohexylbutoxy)benzamido)-6-methoxy-4-oxo-4H-chro-mene-2-carboxylic acid 255(ANM123)
O
O
CO2H
H3CO
NHO
O
The compound was synthesized according to GP-14 using173 (117 mg, 0.22 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (100 mg,92% yield). 1H NMR: δ 1.29-1.41 (m, 17H, 2”-H, 3”-H, 4”-H,1”’-H, 2”’-H, 3”’-H, 4”’-H, 5”’-H, 6”’-H), 3.88 (s, 3H, OCH3), 4.06(t, J = 6.5 Hz, 2H, 1”-H), 6.91 (s, 1H, 3-H), 7.01-7.15 (m, 2H,3’-H, 5’-H), 7.26 (d, J = 3.1 Hz, 1H, 5-H), 7.77 (d, J = 3.1 Hz,1H, 7-H), 7.90-7.99 (m, 2H, 2’-H, 6’-H), 9.99 (s, 1H, CONH). 13C NMR: δ 22.9 (C-3”),26.0 (C-3”’, C-5”’), 26.4 (C-4”’), 29.0 (C-2”), 33.0 (C-2”’, C-6”’), 36.7 (C-4”), 37.2 (C-1”’),56.0 (OCH3), 68.0 (C-1”), 101.1 (C-5), 112.7 (C-3), 114.4 (C-3’, C-5’), 119.0 (C-7), 124.9(C-4a), 125.9 (C-1’), 129.8 (C-2’, C-6’), 129.9 (C-8), 144.1 (C-8a), 152.7 (C-6), 156.6(C-2), 161.4 (CO2H), 161.9 (C-4’), 165.0 (CONH), 177.2 (C-4). LC-MS (m/z): negativemode 492 [M-H]-, positive mode 494 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:99.8%. mp 223-224 ◦C.
5.2.32.48 8-(4-((5-Cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chromene-2-car-boxylic acid 260(ANM158)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using 178(117 mg, 0.35 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (132 mg, 79% yield). 1HNMR: δ 0.86-0.95 (m, 2H, Cyclohexyl), 1.08-1.27 (m, 6H, Cy-clohexyl, 5”-H), 1.32-1.50 (m, 4H, 4”-H, 3”-H), 1.60-1.78 (m, 7H,2”-H, Cyclohexyl), 4.00-4.22 (m, 2H, 1’-H), 6.92 (s, 1H, 3-H), 7.04-7.14 (m, 2H, 3’-H, 5’-H), 7.53 (t, J = 7.9 Hz, 1H, 6-H), 7.88 (dd,J = 1.6, 8.0 Hz, 1H, 5-H), 7.90-7.99 (m, 2H, 2’-H, 6’-H), 8.16 (dd, J = 1.58, 7.8 Hz,1H, 7-H), 9.76 (s, 1H, CONH). 13C NMR: δ 25.6 (C-3”’, C-4”’), 25.8-26.0 (C-5”, C-4”),28.4 (C-3”), 32.7 (C-2”’, C-6”’), 36.5 (C-2”), 36.8 (C-1”’), 67.9 (C-1”), 113.1 (C-3), 113.2(C-3’, C-5’), 120.6 (C-5), 124.1 (C-4a), 125.2 (C-7), 126.0 (C-1’), 128.4 (C-8), 129.3(C-2’, C-6’), 129.5 (C-6), 148.7 (C-8a), 152.8 (C-2), 160.9 (CO2H), 161.6 (C-4’), 164.7(CONH), 177.2 (C-4). LC-MS (m/z): positive mode 478 [M+H]+. Purity by HPLC-UV
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(254 nm)-ESI-MS: 100%. mp 231-232 ◦C.
5.2.32.49 6-Chloro-8-(4-(4-cyclohexylbutoxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 257(ANM170)
O
O
CO2H
NHO
O
Cl
The compound was synthesized according to GP-14 using 175(200 mg, 0.38 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (177 mg, 94% yield). 1HNMR: δ 0.86-0.95 (m, 2H, Cyclohexyl), 1.10-1.33 (m, 6H, Cyclo-hexyl, 4”-H), 1.37-1.51 (m, 2H, 3”-H), 1.55-1.82 (m, 7H, 2”-H, Cy-clohexyl), 4.08 (t, J = 6.5 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H), 7.04-7.10(m, 2H, 3’-H, 5’-H), 7.79 (d, J = 2.6 Hz, 1H, 5-H), 7.94-8.11 (m,2H, 2’-H, 6’-H), 8.27 (d, J = 2.6 Hz, 1H, 7-H), 9.87 (s, 1H, CONH).13C NMR: δ 22.5 (C-4”), 25.6 (C-3”’, C5”’), 26.0 (C-4”’), 28.7 (C-3”), 32.6 (C-2”’, C-6”’), 36.2 (C-2”), 36.8 (C-1”’), 67.9 (C-1”), 113.1 (C-3), 114.3 (C-3’, C-5’), 124.9 (C-7),124.9 (C-4a), 125.5 (C-1’), 128.1 (C-5), 129.4 (C-2’, C-6’), 129.8-130.3 (C-8, C-6), 147.1(C-8a), 153.1 (C-2), 160.6 (CO2H), 161.9 (C-4’), 164.7 (CONH), 176.1 (C-4). LC-MS(m/z): positive mode 498 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.7%. mp219-220 ◦C.
5.2.32.50 8-(4-(4-Cyclohexylbutoxy)benzamido)-6-methyl-4-oxo-4H-chromene-2-carboxylic acid 256(ANM173)
O
O
CO2H
NHO
O
H3C
The compound was synthesized according to GP-14 using 174(192 mg, 0.38 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (172 mg, 95% yield). 1HNMR: δ 0.86-0.95 (m, 2H, Cyclohexyl), 1.10-1.33 (m, 6H, Cy-clohexyl, 4”-H), 1.36-1.51 (m, 2H, 3”-H), 1.54-1.81 (m, 7H, 2”-H,Cyclohexyl), 2.44 (s, 3H, CH3), 4.06 (t, J = 6.5 Hz, 2H, 1”-H), 6.91(s, 1H, 3-H), 7.03-7.10 (m, 2H, 3’-H, 5’-H), 7.69 (dd, J = 2.2 Hz,1H, 5-H), 7.92 (d, J = 2.2 Hz, 2H, 7-H), 7.93-8.02 (m, 2H, 2’-H,6’-H), 9.98 (s, 1H, CONH). 13C NMR: δ 20.8 (CH3), 22.9 (C-4”), 26.0 (C-3”’, C5”’),26.3 (C-4”’), 29.0 (C-3”), 32.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.1 (C-1”’), 68.0 (C-1”), 113.4(C-3), 114.4 (C-3’, C-5’), 120.7 (C-5), 124.1 (C-4a), 126.0 (C-1’), 128.3 (C-8), 129.7
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(C-2’, C-6’), 131.8 (C-7), 135.4 (C-6), 147.7 (C-8a), 152.9 (C-2), 161.4 (CO2H), 161.8(C-4’), 165.0 (CONH), 177.5 (C-4). LC-MS (m/z): positive mode 478 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 99.9%. mp 223-225 ◦C.
5.2.32.51 8-(4-(4-Cyclohexylbutoxy)benzamido)-6-fluoro-4-oxo-4H-chromene-2-carboxylic acid 258(ANM177)
O
O
CO2H
NHO
O
F
The compound was synthesized according to GP-14 using 176(178 mg, 0.35 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (138 mg, 82% yield). 1HNMR: δ 0.86-0.96 (m, 2H, Cyclohexyl), 1.11-1.34 (m, 6H, Cyclo-hexyl, 4”-H), 1.36-1.50 (m, 2H, 3”-H), 1.53-1.80 (m, 7H, 2”-H, Cy-clohexyl), 4.05-4.11 (m, 2H, 1”-H), 6.93 (s, 1H, 3-H), 7.03-7.10 (m,2H, 3’-H, 5’-H), 7.52 (dd, J = 3.1, 8.0 Hz, 1H, 5-H), 7.94-8.02 (m, 2H,2’-H, 6’-H), 8.15 (dd, J = 3.1, 9.9 Hz, 1H, 7-H), 9.86 (s, 1H, CONH).13C NMR: δ 22.9 (C-4”), 26.0 (C-3”’, C5”’), 26.3 (C-4”’), 29.0 (C-3”), 33.0 (C-2”’, C-6”’),36.7 (C-2”), 37.1 (C-1”’), 68.0 (C-1”), 105.2 (C-5), 112.8 (C-3), 114.5 (C-3’, C-5’), 117.4-117.6 (C-7), 125.1 (C-4a), 125.6 (C-1’), 129.9 (C-2’, C-6’), 130.8 (C-8), 145.5 (C-8a),153.3 (C-2), 155.8 (C-6), 159.6 (CO2H), 161.2 (C-4’), 162.1 (CONH), 177.9 (C-4). LC-MS (m/z): positive mode 482 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.5%.mp 243-244 ◦C.
5.2.32.52 8-(3-(4-Cyclohexylbutoxy)benzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 240(ANM178)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using159 (162 mg, 0.33 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (120 mg,83% yield). 1H NMR: δ 0.82-0.89 (m, 2H, Cyclohexyl), 1.09-1.20 (m, 6H, Cyclohexyl, 4”-H), 1.36-1.50 (m, 2H, 3”-H), 1.51-1.78 (m, 7H, 2”-H, Cyclohexyl), 4.02-4.09 (m, 2H, 1”-H), 6.95 (s,1H, 3-H), 7.17 (dd, J = 2.5, 8.2 Hz, 1H, 2’-H), 7.45 (t, J = 7.9 Hz, 1H, 6-H), 7.50-7.60(m, 3H, 4’-H, 5’-H, 6’-H), 7.91 (dd, J = 1.6, 8.0 Hz, 1H, 5-H), 8.08 (dd, J = 1.7, 7.8Hz, 1H, 7-H), 10.19 (s, 1H, CONH). 13C NMR: δ 22.9 (C-4”), 26.0 (C-3”’, C5”’), 26.3
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(C-4”’), 29.1 (C-3”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.1 (C-1”’), 67.9 (C-1”), 113.5 (C-3, C-2’), 118.4-119.9 (C-4’, C-6’), 121.6 (C-5), 124.5 (C-8), 125.7 (C-7), 128.3 (C-4a),129.9 (C-5’), 131.0 (C-6), 135.5 (C-1’), 149.4 (C-8a), 153.1 (C-2), 158.9 (C-3’), 161.4(CO2H), 165.4 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode 464 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 100%. mp 201-202 ◦C.
5.2.32.53 8-(3-(4-Cyclohexylbutoxy)benzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 264(ANM182)
O
O
CO2H
NHS
HN
O
The compound was synthesized according to GP-14 us-ing 185 (173 mg, 0.33 mmol). Recrystallization from 1:1acetone/ethanol afforded the product as a white solid (89mg, 56% yield). 1H NMR: δ 0.82-0.89 (m, 2H, Cyclohexyl),1.09-1.21 (m, 6H, Cyclohexyl, 4”-H), 1.36-1.46 (m, 2H, 3”-H), 1.51-1.78 (m, 7H, 2”-H, Cyclohexyl), 3.94 (t, J = 6.5 Hz,2H, 1”-H), 6.86-6.92 (s, 2H, 3’-H, 5’-H), 6.93 (s, 1H, 3-H), 7.34-7.40 (m, 2H, 2’-H,6’-H), 7.49 (t, J = 7.9 Hz, 1H, 6-H), 7.89 (dd, J = 1.6, 7.9 Hz, 1H, 7-H), 7.97 (dd, J= 1.6, 7.8 Hz, 1H, 5-H), 9.41 (s, 1H, 1’-NH), 9.91 (s, 1H, 8-NH). 13C NMR: δ 22.9(C-4”), 26.0 (C-3”’, C5”’), 26.3 (C-4”’), 29.1 (C-3”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.1(C-1”’), 67.8 (C-1”), 113.6 (C-3), 114.6 (C-3’, C-5’), 122.1 (C-5), 124.6 (C-4a), 125.3 (C-7), 126.5 (C-2’, C-6’), 129.7 (C-8), 131.7 (C-1’), 133.4 (C-6), 150.6 (C-8a), 153.1 (C-2),156.5 (C-4’), 161.5 (CO2H), 177.7 (C-4), 180.7 (CS). LC-MS (m/z): positive mode 495[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98%. mp 148-150 ◦C.
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5.2.32.54 8-(4-(4-Cyclohexylbutoxy)benzamido)-6-ethyl-4-oxo-4H-chromene-2-carboxylic acid 259(ANM217)
O
O
CO2H
NHO
O
H3C
The compound was synthesized according to GP-14 using177 (228 mg, 0.44 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (208 mg,96% yield). 1H NMR: δ 0.82-0.89 (m, 2H, Cyclohexyl), 1.10-1.22 (m, 9H, Cyclohexyl, 4”-H, 6-CH2CH3), 1.36-1.46 (m, 2H,3”-H), 1.53-1.78 (m, 7H, 2”-H, Cyclohexyl), 2.76 (q, J = 7.6 Hz,2H, 6-CH2CH3), 4.06 (t, J = 6.5 Hz, 2H, 1”-H), 6.92 (s, 1H, 3-H),7.02-7.11 (m, 2H, 3’-H, 5’-H), 7.71 (d, J = 2.2 Hz, 1H, 5-H), 7.96(d, J = 2.2 Hz, 1H, 7-H), 7.98 (d, J = 8.7 Hz, 2H, 2’-H, 6’-H), 10.00 (s, 1H, CONH).13C NMR: δ 15.4 (6-CH2CH3), 22.9 (C-4”), 26.0 (C-3”’, C-5”’), 27.0 (C-4”’), 27.8 (6-CH2CH3), 29.0 (C-3”), 36.7 (C-2”), 37.1 (C-1”’), 67.9 (C-1”), 113.3 (C-3), 114.3 (C-3’,C-5’), 119.4 (C-5), 124.2 (C-4a), 126.0 (C-1’), 128.4 (C-8), 129.7 (C-2’, C-6’), 130.8(C-7), 141.5 (C-6), 147.9 (C-8a), 152.9 (C-2), 161.4 (CO2), 161.8 (C-4’), 165.0 (CONH),177.6 (C-4). LC-MS (m/z): positive mode 492 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 100%. mp 220-221 ◦C.
5.2.32.55 6-Bromo-8-(3-((3-bromobenzyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 233(ANMDOT6)
O
O
CO2H
NHO
O
Br
Br
The compound was synthesized according to GP-14 using 152(258 mg, 0.44 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (215 mg, 85% yield). 1HNMR: δ 5.21 (s, 2H, CH2), 6.98 (s, 1H, 3-H), 7.29 (ddd, J = 0.9,2.6, 8.2 Hz, 1H, 4’-H), 7.38 (t, J = 7.8 Hz, 1H, 5”-H), 7.45-7.56 (m,3H, 5’-H, 2”-H, 6”-H), 7.61 (dt, J = 1.1, 7.8 Hz, 1H, 2’-H), 7.65(dd, J = 1.6, 2.6 Hz, 1H, 6’-H), 7.65-7.72 (m, 1H, 4”-H), 7.97 (d,J = 2.4 Hz, 1H, 5-H), 8.32 (d, J = 2.4 Hz, 1H, 7-H), 10.32 (s, 1H, CONH). 13C NMR:δ 68.7 (CH2), 113.7 (C-3), 114.1 (C-2’), 117.8 (C-6), 119.0 (C-6’), 120.5 (C-4’), 121.9(C-3”), 123.4 (C-5), 125.6 (C-4a), 126.8 (C-6”), 130.1 (C-5’), 130.2 (C-8), 130.4 (C-5”),130.9 (C-4”), 130.9 (C-2”), 132.3 (C-7), 135.2 (C-1’), 139.7 (C-1”), 148.3 (C-8a), 153.3(C-2), 158.3 (C-3’), 161.1 (CO2H), 165.3 (CONH), 176.4 (C-4). LC-MS (m/z): positive
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mode 575 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100%. mp 253-254 ◦C.
5.2.32.56 8-(3-((4-Methylbenzyl)oxy)benzamido)-4-oxo-4H-chromene-2-carbo-xylic acid 230(ANM234)
O
O
CO2H
NHO
O
CH3
The compound was synthesized according to GP-14 using 149(137 mg, 0.30 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (74 mg, 57% yield). 1HNMR: δ 2.30 (s, 3H, CH3), 5.15 (s, 2H, CH2), 6.94 (s, 1H, 3-H),7.21 (d, J = 7.7 Hz, 2H, 2”-H, 6”-H), 7.25 (dd, J = 2.6, 8.2 Hz, 1H,4’-H), 7.36 (d, J = 7.8 Hz, 2H, 3”-H, 5”-H), 7.47 (t, J = 7.9 Hz,1H, 6-H), 7.55 (t, J = 7.9 Hz, 1H, 5’-H), 7.58-7.63 (m, 1H, 2’-H),7.65 (t, J = 2.0 Hz, 1H, 6’-H), 7.91 (dd, J = 1.6, 8.0 Hz, 1H, 5-H), 8.09 (dd, J = 1.6, 7.9Hz, 1H, 7-H), 10.20 (s, 1H, CONH). 13C NMR: δ 20.9 (CH3), 69.6 (CH2), 113.6 (C-3),114.0 (C-2’), 118.8 (C-6’), 120.2 (C-4’), 121.6 (C-5), 124.5 (C-8), 125.7 (C-7), 128.0(C-2”, C-6”), 128.3 (C-4a), 129.2 (C-3”, C-5”), 129.9 (C-5’), 130.9 (C-6), 133.9 (C-4”),135.5 (C-1’), 137.3 (C-1”), 149.4 (C-8a), 153.1 (C-2), 158.6 (C-3’), 161.4 (CO2H), 165.4(CONH), 177.6 (C-4). LC-MS (m/z): positive mode 430 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.8%. mp 229-231 ◦C.
5.2.32.57 6-Bromo-8-(3-((4-methylbenzyl)oxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 231(ANM235)
O
O
CO2H
NHO
O
Br
CH3
The compound was synthesized according to GP-14 using150 (40 mg, 0.075 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (29 mg, 75%yield). 1H NMR: δ 2.0 (s, 3H, CH3), 5.15 (s, 2H, CH2), 6.97 (s,1H, 3-H), 7.21 (d, J = 7.7 Hz, 2H, 2”-H, 6”-H), 7.27 (dd, J = 2.5,8.2 Hz, 1H, 4’-H), 7.33-7.40 (m, 2H, 3”-H, 5”-H), 7.48 (t, J = 7.9Hz, 1H, 5’-H), 7.56-7.62 (m, 1H, 2’-H), 7.61-7.65 (m, 1H, 6’-H),7.96 (d, J = 2.5 Hz, 1H, 5-H), 8.33 (d, J = 2.5 Hz, 1H, 7-H), 10.30 (s, 1H, CONH). 13CNMR: δ 20.9 (CH3), 69.6 (CH2), 113.6 (C-3), 114.1 (C-2’), 117.8 (C-6), 119.0 (C-6’),120.3 (C-4’), 123.3 (C-5), 125.6 (C-8), 128.0 (C-2”, C-6”), 129.2 (C-3”, C5”), 130.0 (C-5’),130.2 (C-4a), 132.3 (C-7), 133.8 (C-4”), 135.2 (C-1’), 137.4 (C-1”), 148.2 (C-8a), 153.3
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(C-2), 158.6 (C-3’), 161.1 (CO2H), 165.4 (CONH), 176.4 (C-4). LC-MS (m/z): positivemode 509 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.0%. mp 245-246 ◦C.
5.2.32.58 8-(3-((3-Bromobenzyl)oxy)benzamido)-4-oxo-4H-chromene-2-carbo-xylic acid 232(ANM236)
O
O
CO2H
NHO
O
Br
The compound was synthesized according to GP-14 using 151(157 mg, 0.30 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (148 mg, 99% yield). 1HNMR: δ 5.21 (s, 2H, CH2), 6.95 (s, 1H, 3-H), 7.28 (dd, J =2.6, 8.3Hz, 1H, 4’-H), 7.38 (t, J = 7.8 Hz, 1H, 5”-H), 7.46-7.59 (m, 4H, 6-H,5’-H, 2”-H, 6”-H), 7.60-7.71 (m, 3H, 2’-H, 6’-H, 4”-H), 7.91 (td, J= 1.4, 8.2 Hz, 1H, 5-H), 8.09 (dd, J = 1.7, 7.6 Hz, 1H, 7-H), 10.22(s, 1H, CONH). 13C NMR: δ 68.7 (CH2), 113.6 (C-3), 114.1 (C-2’), 118.7 (C-6’), 120.5(C-4’), 121.7 (C-5), 121.9 (C-3”), 124.5 (C-8), 125.7 (C-7), 126.8 (C-6”), 128.3 (C-4a),129.9 (C-5’), 130.4 (C-3”), 130.9 (C-4”, C-2”), 131.0 (C-6), 135.6 (C-1’), 139.8 (C-1”),149.5 (C-8a), 153.1 (C-2), 158.4 (C-3’), 161.4 (CO2H), 165.3 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode 495 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.9%.mp 256-257 ◦C.
5.2.32.59 6-Bromo-4-oxo-8-(4-((5-phenylpentyl)oxy)benzamido)-4H-chromene-2-carboxylic acid 261(THB47)
Br
O
O
CO2H
NH
O
O
The compound was synthesized according to GP-14 using179 (198 mg, 0.34 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (166 mg,89% yield). 1H NMR: δ 1.38-1.52 (m, 2H, 3”-H), 1.58-1.72 (m,2H, 4”-H), 1.78 (p, J = 6.8 Hz, 2H, 2”-H), 2.60 (t, J = 7.7 Hz, 2H,5”-H), 4.06 (t, J = 6.5 Hz, 2H, 1”-H), 6.97 (s, 1H, 3-H), 7.03-7.11(m, 2H, 3’-H, 5’-H), 7.12-7.1 (m, 5H, 2”’-H, 3”’-H, 4”’-H, 5”’-H,6”’-H), 7.89-8.01 (m, 3H, 2’-H, 6’-H, 5-H), 8.33 (d, J = 2.5 Hz, 1H, 7-H), 10.10 (s,1H, CONH). 13C NMR: δ 25.3 (C-2”), 28.5 (C-3”), 30.8 (C-5”), 35.2 (C-4”), 67.9 (C-1”), 113.6 (C-3), 114.4 (C-3’, C-5’), 117.8 (C-6), 122.9 (C-5), 125.5 (C-4a, C-1’), 125.7(C-4”’), 128.3 (C-2’, C-6’, C-2”’, C-6”’), 129.8 (C-3”’, C-5”’), 130.5 (C-8), 132.0 (C-7),
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142.3 (C-1”’), 148.1 (C-8a), 153.3 (C-2), 161.1 (C-4’), 162.0 (CO2H), 165.0 (CONH),176.4 (C-4). LC-MS (m/z): positive mode 552 [M+H]+. Purity by HPLC-UV (254nm)-ESI-MS: 99.7%. mp 223-224 ◦C.
5.2.32.60 4-Oxo-8-(3-(4-phenylbutoxy)benzamido)-4H-chromene-2-carboxylicacid 252 (THB49)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using170 (182 mg, 0.37 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (137 mg,81% yield). 1H NMR: δ 1.76 (dq, J = 3.4, 7.4 Hz, 4H, 2”-H,3”-H), 2.59-2.70 (m, 2H, 4”-H), 3.88-4.23 (m, 2H, 1”-H), 6.95(s, 1H, 3-H), 7.13-7.31 (m, 6H, 2’-H, 2”’-H, 3”’-H, 4”’-H, 5”’-H,6”’-H), 7.45 (t, J = 7.9 Hz, 1H, 6-H), 7.51-7.61 (m, 3H, 4’-H, 5’-H, 6’-H), 7.91 (dd, J= 1.6, 8.0 Hz, 1H, 5-H), 8.08 (dd, J = 1.6, 7.7 Hz, 1H, 7-H), 10.17 (s, 1H, CONH).13C NMR: δ 27.5 (C-2”), 28.4 (C-3”), 34.9 (C-4”), 67.7 (C-1”), 113.5 (C-3), 118.4-119.9(C-4’, C-6’), 121.6 (C-5), 124.3 (C-8), 125.7 (C-4”’), 125.8 (C-2”’, C-6”’), 128.4 (C-4a),128.4 (C-7, C-3”’, C-5”’), 129.8 (C-5’), 130.9 (C-6), 135.5 (C-1’), 142.1 (C-1”’), 149.4(C-8a), 153.01 (C-2), 158.8 (C-3’), 161.3 (CO2H), 165.4 (CONH), 177.6 (C-4). LC-MS(m/z): positive mode 458 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.5%. mp213-214 ◦C.
5.2.32.61 8-(3-(4-Cyclohexylbutoxy)benzamido)-6-fluoro-4-oxo-4H-chromene-2-carboxylic acid 242(THB71)
O
O
CO2H
F
O
NHO
The compound was synthesized according to GP-14 using161 (94 mg, 0.18 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (31 mg,36% yield). 1H NMR: δ 0.78-0.93 (m, 2H, Cyclohexyl), 1.03-1.30 (m, 6H, Cyclohexyl, 4”-H), 1.43 (dt, J = 6.8 Hz, 2H, 3”-H),1.54-1.77 (m, 7H, 2”-H, Cyclo- hexyl), 4.05 (t, J = 6.4 Hz, 2H,1”-H), 6.95 (s, 1H, 3-H), 7.09-7.29 (m, 1H, 2’-H), 7.46 (t, J = 7.9 Hz, 1H, 5’-H), 7.51-7.60 (m, 3H, 5-H, 4’-H, 6’-H), 8.10 (dd, J = 3.1, 9.7 Hz, 1H, 7-H), 10.26 (s, 1H, CONH).13C NMR: δ 22.9 (C-4”), 26.0 (C-3”’, C-5”’), 26.3 (C-4”’), 29.1 (C-3”), 33.0 (C-2”’, C-6”’),36.7 (C-2”), 37.1 (C-1”’), 67.9 (C-1”), 105.8 (C-5), 112.8 (C-2’), 113.5 (C-3), 117.7 (C-7),
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118.7-119.9 (C-4’, C-6’), 125.1 (C-4a), 129.9 (C-5’), 130.5 (C-8), 135.1 (C-1’), 145.6(C-8a), 153.2 (C-2), 153.2 (C-2), 157.6-159.6 (C-6), 158.9 (C-3’), 161.4 (CO2H), 165.4(CONH), 176.9 (C-4). LC-MS (m/z): positive mode 482 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.7%. mp 218-219 ◦C.
5.2.32.62 6-Chloro-8-(3-(4-cyclohexylbutoxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 241(THB72)
O
O
CO2H
Cl
O
NHO
The compound was synthesized according to GP-14 using160 (206 mg, 0.39 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (155 mg,80% yield). 1H NMR: δ 0.78-0.93 (m, 2H, Cyclohexyl), 1.02-1.27 (m, 6H, Cyclohexyl, 4”-H), 1.38-1.49 (m, 2H, 3”-H), 1.54-1.77 (m, 7H, 2”-H, Cyclo- hexyl), 4.04 (t, J = 6.4 Hz, 2H, 1”-H),6.97 (s, 1H, 3-H), 7.18 (ddd, J = 1.0, 2.6, 8.3 Hz, 1H, 2’-H), 7.46 (t, J =7.9 Hz, 1H,5’-H), 7.51-7.59 (m, 2H, 4’-H, 6’-H), 7.83 (d, J = 2.6 Hz, 1H, 5-H), 8.21 (d, J = 2.6Hz, 1H, 7-H), 10.27 (s, 1H, CONH). 13C NMR: δ 22.9 (C-4”), 26.0 (C-3”’, C-5”’), 26.3(C-4”’), 29.1 (C-3”), 33.0 (C-2”’, C-6”’), 36.7 (C-2”), 37.1 (C-1”’), 67.9 (C-1”), 113.5 (C-3,C-2’), 118.7 (C-7), 120.0-120.1 (C-4’, C-6’), 125.2 (C-4a), 129.5 (C-5), 130.0 (C-8, C-6),130.1 (C-5’), 15.1 (C-1’), 147.8 (C-8a), 153.3 (C-2), 158.9 (C-3’), 161.1 (CO2H), 165.4(CONH), 176.5 (C-4). LC-MS (m/z): positive mode 498 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.7%. mp 219-220 ◦C.
5.2.32.63 8-(3-(3-Cyclohexylpropoxy)benzamido)-6-fluoro-4-oxo-4H-chromene-2-carboxylic acid 239(THB73)
O
O
CO2H
F
O
NHO
The compound was synthesized according to GP-14 using 158(241 mg, 0.49 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (132 mg, 58% yield). 1HNMR: δ 0.80-0.95 (m, 2H, Cyclohexyl), 1.07-1.38 (m, 6H, Cyclo-hexyl, 3”-H), 1.54-1.81 (m, 7H, 2”-H, Cyclo- hexyl), 4.03 (t, J =6.4 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H), 7.19 (ddd, J = 1.0, 2.6, 8.0Hz, 1H, 2’-H), 7.46 (t, J = 7.9 Hz, 1H, 5’-H), 7.51-7.62 (m, 3H, 5-H, 4’-H, 6’-H), 8.10(dd, J = 3.1, 9.6 Hz, 1H, 7-H), 10.26 (s, 1H, CONH). 13C NMR: δ 26.3 (C-3”’, C-5”’,
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C-4”’. C-3”), 32.9 (C-2”’, C-6”’), 33.3 (C-2”), 36.9 (C-1”’), 68.2 (C-1”), 105.6 (C-5), 112.8(C-2’), 113.5 (C-3), 117.7 (C-7), 118.7-119.9 (C-4’, C-6’), 125.1 (C-4a), 129.9 (C-5’),130.5 (C-8), 135.1 (C-1’), 145.6 (C-8a), 153.2 (C-2), 153.2 (C-2), 157.6-159.6 (C-6),158.9 (C-3’), 161.4 (CO2H), 165.4 (CONH), 176.9 (C-4). LC-MS (m/z): positive mode468 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.6%. mp 230-231 ◦C.
5.2.32.64 6-Chloro-8-(3-(3-cyclohexylpropoxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 238(THB74)
O
O
CO2H
NH
Cl
O
O
The compound was synthesized according to GP-14 using 157(235 mg, 0.46 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (144 mg, 65% yield). 1HNMR: δ 0.79-0.96 (m, 2H, Cyclohexyl), 1.01-1.39 (m, 6H, Cyclo-hexyl, 3”-H), 1.54-1.81 (m, 7H, 2”-H, Cyclo- hexyl), 4.03 (t, J =6.4 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H), 7.18 (ddd, J = 1.0, 2.6, 8.3Hz, 1H, 2’-H), 7.46 (t, J =7.9 Hz, 1H, 5’-H), 7.49-7.60 (m, 2H, 4’-H, 6’-H), 7.82 (d, J =2.6 Hz, 1H, 5-H), 8.21 (d, J = 2.6 Hz, 1H, 7-H), 10.26 (s, 1H, CONH). 13C NMR: δ 26.3(C-3”’, C-5”’, C-4”’. C-3”), 32.9 (C-2”’, C-6”’), 33.3 (C-2”), 37.0 (C-1”’), 68.2 (C-1”), 113.6(C-3, C-2’), 118.7 (C-7), 120.0-120.1 (C-4’, C-6’), 125.2 (C-4a), 129.5 (C-5), 129.9 (C-8,C-6), 130.2 (C-5’), 15.1 (C-1’), 147.8 (C-8a), 153.2 (C-2), 158.9 (C-3’), 161.1 (CO2H),165.4 (CONH), 176.5 (C-4). LC-MS (m/z): positive mode 484 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 99.5%. mp 239-240 ◦C.
5.2.32.65 8-(3-(3-Cyclohexylpropoxy)benzamido)-4-oxo-4H-chromene-2-carbo-xylic acid 237(THB75)
O
O
CO2H
NH
O
O
The compound was synthesized according to GP-14 using 156(188 mg, 0.39 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (109 mg, 62% yield). 1HNMR: δ 0.78-0.96 (m, 2H, Cyclohexyl), 1.00-1.39 (m, 6H, Cyclo-hexyl, 3”-H), 1.52-1.82 (m, 7H, 2”-H, Cyclo- hexyl), 4.03 (t, J =6.4 Hz, 2H, 1”-H), 6.94 (s, 1H, 3-H), 7.09-7.32 (m, 1H, 2’-H), 7.45(t, J = 7.9 Hz, 1H, 6-H), 7.51-7.60 (m, 3H, 4’-H, 5’-H, 6’-H), 7.91 (dd, J = 1.6, 8.0Hz, 1H, 5-H), 8.08 (dd, J = 1.7, 7.8 Hz, 1H, 7-H), 10.19 (s, 1H, CONH). 13C NMR: δ
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26.0-26.4 (C-3”’, C-5”’, C-4”’. C-3”), 33.0 (C-2”’, C-6”’), 33.4 (C-2”), 37.0 (C-1”’), 68.3(C-1”), 113.5 (C-3, C-2’), 118.4-119.9 (C-4’, C-6’), 121.6 (C-5), 124.5 (C-8), 125.7 (C-7),128.3 (C-4a), 129.9 (C-5’), 131.0 (C-6), 135.5 (C-1’), 149.4 (C-8a), 153.1 (C-2), 158.9(C-3’), 161.4 (CO2H), 165.4 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode 450[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 98.9%. mp 220-221 ◦C.
5.2.32.66 8-(3-((5-Cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chromene-2-car-boxylic acid 243(ANM250)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using162 (222 mg, 0.44 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (191 mg,91% yield). 1H NMR: δ 0.78-0.90 (m, 2H, Cyclohexyl), 1.06-1.23 (m, 6H, 5”-H, Cyclohexyl), 1.55-1.78 (m, 7H, 2”-H, Cy-clohexyl), 4.05 (t, J = 6.5 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H),7.17 (dd, J = 8.3, 2.5 Hz, 1H, 4’-H), 7.45 (t, J = 7.9 Hz, 1H,2’-H), 7.52- 7.60 (m, 3H, 5’-H, 6’-H, 6-H), 7.91 (dd, J = 8.1, 2.5 Hz, 1H, 5-H), 8.08(dd, J = 7.7, 1.6 Hz, 1H, 7-H), 10.17 (s, 1H, CONH). 13C NMR: δ 26.0 (C-5”, C-4”,C-3”’, C-5”’), 26.0 (C-4”’), 28.8 (C-3”), 33.0 (C-2”’, C-6”’), 37.0 (C-2”), 37.1 (C-1”’), 67.9(C-1”’), 113.5 (C-3, C-2’), 118.5 (C-4’), 119.9 (C-5), 121.6 (C-6’), 124.5 (C-4a), 125.7(C-7), 128.3 (C-8), 129.9 (C-6), 130.9 (C-5’), 135.5 (C-1’), 149.4 (C-8a), 153.0 (C-2),158.9 (C-4”), 161.4 (CO2H), 165.4 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode478 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.2%. mp 239-240 ◦C.
5.2.32.67 6-Chloro-8-(3-((5-cyclohexylpentyl)oxy)benzamido)-4-oxo-4H-chro-mene-2-carboxylic acid 244(ANM251)
O
O
CO2H
NHO
O
Cl
The compound was synthesized according to GP-14 using163 (187 mg, 0.35 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (165 mg,92% yield). 1H NMR: δ 0.81-0.94 (m, 2H, Cyclohexyl), 1.03-1.27 (m, 6H, Cyclohexyl, 5”-H), 1.30-1.49 (m, 4H, 3”-H, 4”-H),1.54-1.81 (m, 7H, 2”-H, Cyclohexyl), 4.07 (t, J = 6.5 Hz, 2H,1”-H), 6.95 (s, 1H, 3-H), 7.18 (dd, J = 8.0 Hz, 1H, 4’-H), 7.45
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(t, J = 7.9 Hz, 1H, 2’-H), 7.50-7.60 (m, 2H, 5’-H, 6’-H), 7.81 (d, J = 2.5 Hz, 1H, 5-H),8.26 (d, J = 2.6 Hz, 1H, 7-H), 10.01 (s, 1H, CONH). 13C NMR: δ 25.7 (C-4”, C-5”,C-3”’, C-5”’), 26.1 (C-4”’), 28.6 (C-3”), 32.8 (C-2”’, C-6”’), 36.6 (C-2”), 36.9 (C-1”’), 67.9(C-1”), 113.2 (C-2’, C-3), 118.6 (C-4’), 119.7 (C-5, C-6’), 125.0 (C-4a), 128.5 (C-7),129.7 (C-5’), 130.0 (C-8), 134.0 (C-1’), 147.3 (C-8a), 153.2 (C-2), 158.8 (C-4”), 160.7(C2H), 165.3 (CONH), 176.2 (C-4). LC-MS (m/z): positive mode 512 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 99.8%. mp 230-231 ◦C.
5.2.32.68 8-(3-((5-Cyclohexylpentyl)oxy)benzamido)-6-fluoro-4-oxo-4H-chro-mene-2-carboxylic acid 245(ANM252)
O
O
CO2H
NHO
O
F
The compound was synthesized according to GP-14 using164 (172 mg, 0.33 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (142 mg,87% yield). 1H NMR: δ 0.83-0.90 (m, 2H, Cyclohexyl), 1.01-1.27 (m, 6H, Cyclohexyl, 5”-H), 1.27-1.46 (m, 4H, 3”-H, 4”-H),1.52-1.80 (m, 7H, 2”-H, Cyclohexyl), 4.05 (t, J = 6.5 Hz, 2H,1”-H), 6.95 (s, 1H, 3-H), 7.19 (dd, J = 8.3 Hz, 1H, 4’-H), 7.46(t, J = 8.0 Hz, 1H, 2’-H), 7.50-7.61 (m, 3H, 5’-H, 6’-H, 5-H), 8.10 (d, J = 3.2 Hz, 1H,7-H), 10.27 (s, 1H, CONH). 13C NMR: δ 26.0 (C-4”, C-5”, C-3”’, C-5”’), 26.0 (C-4”’),28.8 (C-3”), 33.0 (C-2”’, C-6”’), 37.0 (C-2”), 37.1 (C-1”’), 67.9 (C-1”), 105.6-105.8 (C-7),112.9 (C-2’), 113.5 (C-3), 117.7-117.9 (C-5), 118.8 (C-4’), 120.0 (C-6’), 125.1 (C-4a),130.0 (C-5’), 130.5 (C-8), 135.1 (C-1’), 145.6 (C-8a), 153.2 (C-2), 157.8-159.4 (C-6),158.9 (C-4”), 161.2 (CO2H), 165.4 (CONH). LC-MS (m/z): positive mode 496 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 99.8%. mp 227-228 ◦C.
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5.2.32.69 8-(3-(Cyclohexylmethoxy)benzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 235(ANM263)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using 154(198 mg, 0.44 mm32292229ol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (177 mg, 95%yield). 1H NMR: δ 0.99-1.14 (m, 2H, Cyclohexyl), 1.14-1.35 (m, 3H,Cyclohexyl), 1.61-1.89 (m, 7H, Cyclohexyl), 3.87 (d, J = 6.1 Hz, 2H,1”-H), 6.95 (s, 1H, 3-H), 7.14-7.23 (m, 1H, 4’-H), 7.45 (t, J = 7.8 Hz,1H, 2’-H), 7.50-7.61 (m, 3H, 5’-H, 6’-H, 6-H), 7.91 (dd, J = 8.0, 1.7Hz, 1H, 5-H), 8.08 (dd, J = 7.7, 1.7 Hz, 1H, 7-H), 10.18 (s, 1H, CONH). 13C NMR: δ25.4 (C-3”’, C-5”’), 26.2 (C-4”’), 29.4 (C-2”’, C-6”’), 37.3 (CH, C-1”’), 73.2 (C-1”), 113.5(C-3, C-2’), 118.5 (C-4’), 120.0 (C-5), 121.7 (C-6’), 124.5 (C-4a), 125.7 (C-8), 129.9(C-6), 131.0 (C-5’), 135.5 (C-1’), 149.5 (C-8a), 153.1 (C-2), 159.1 (C-4”), 161.4 (CO2H),165.4 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode 422 [M+H]+. Purity byHPLC-UV (254 nm)-ESI-MS: 99.8%. mp 254-255 ◦C.
5.2.32.70 8-(3-(Benzyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid249 (ANM264)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using 167(195 mg, 0.44 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (158 mg, 87% yield). 1HNMR: δ 5.20 (s, 2H, OCH2), 6.95 (s, 1H, 3-H), 7.27 (dd, J = 8.3 Hz,2H, 4’-H), 7.30-7.37 (m, 1H, 4”’-H), 7.37-7.44 (m, 2H, C-3”’, C-5”’),7.45-7.52 (m, 3H, 2”’-H, 6”’-H, 2’-H), 7.55 (t, J = 7.9 Hz, 1H, 6-H),7.58-7.64 (m, 1H, 5’-H), 7.68 (dd, J = 2.7 Hz, 1H, 6’-H), 7.91 (dd,J = 8.0, 1.6 Hz, 1H, 5-H), 8.09 (dd, J = 7.8, 1.6 Hz, 1H, 7-H), 10.22 (s, 1H, CONH).13C NMR: δ 69.7 (OCH2), 113.5 (C-3), 114.0 (C-2’), 118.8 (C-4’), 120.3 (C-5), 121.6(C-6’), 123.7 (C-4a), 125.8 (C-7), 127.9 (C-2”’, C-6”’, C-5”’), 128.1 (C-8), 128.6 (C-3”’,C-5”’), 129.9 (C-6), 130.9 (C-5’), 135.6 (C-1’), 136.9 (C-1”’), 149.4 (C-8a), 153.1 (C-2),158.6 (C-4”), 161.4 (CO2H), 165.3 (CONH), 177.6 (C4). LC-MS (m/z): positive mode416 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.9%. mp 243-244 ◦C.
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5.2.32.71 4-Oxo-8-(3-(3-phenylpropoxy)benzamido)-4H-chromene-2-carboxylicacid 251 (ANM265)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using 169(132 mg, 0.28 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a pale-yellow solid (99 mg, 80% yield).1H NMR: δ 1.88-2.20 (m, 2H, 3”-H), 2.63-2.90 (m, 2H, 2”-H), 4.07(t, J = 6.3 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H), 7.14-7.33 (m, 6H,4’-H, 4”’-H, 3”’-H, 5”’-H, 2”’-H, 6”’-H), 7.46 (t, J = 7.9 Hz, 1H,6-H), 7.51-7.62 (m, 2H, 5’-H, 6’-H), 7.91 (dd, J = 8.0, 1.6 Hz, 1H,5-H), 8.09 (dd, J = 7.8, 1.6 Hz, 1H, 7-H), 10.20 (s, 1H, CONH). 13C NMR: δ 30.5(C-2”), 120.1 (C-5), 121.6 (C-6’), 124.4 (C-4a), 125.7 (C-7), 128.3 (C-8), 128.5 (C-2”’,C-3”, C-4”’, C-5”’, C-6”’), 129.9 (C-6), 130.9 (C-5’), 135.5 (C-1”’), 141.5 (C-1’), 149.4(C-8a), 153.0 (C-2), 158.8 (C-4”), 161.4 (CO2H), 165.4 (CONH), 177.6 (C-4). LC-MS(m/z): positive mode 444 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.9%. mp222-223 ◦C.
5.2.32.72 8-(3-(2-Cyclohexylethoxy)benzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 236(ANM267)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using 155(203 mg, 0.44 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (185 mg, 97% yield). 1HNMR: δ 0.88-1.02 (m, 2H, Cyclohexyl), 1.07-1.30 (m, 2H, Cyclo-hexyl), 1.50-1.60 (m, 2H, Cyclohexyl), 1.56-1.79 (m, 7H, Cyclohexyl,2”-H), 4.09 (t, J = 6.6 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H), 7.18 (ddd, J= 8.2, 2.6, 1.0 Hz, 1H, 4’-H), 7.45 (t, J = 7.9 Hz, 1H, 2’-H), 7.50-7.62 (m, 3H, 6-H, 5’-H,6’-H), 7.91 (dd, J = 8.0, 1.6 Hz, 1H, 5-H), 8.08 (dd, J = 7.7, 1.6 Hz, 1H, 7-H), 10.17(s, 1H, CONH). 13C NMR: δ 25.9 (C-3”’, C-5”’), 26.2 (C-4”’), 32.9 (C-2”’, C-6”’), 34.2(C-1”’), 36.2 (C-2”), 66.0 (C-1”), 113.6 (C-2’, C-3),118.4 (C-4’), 120.0 (C-5), 121.7 (C-6’),124.5 (C-4a), 125.7 (C-7), 128.4 (C-8), 129.9 (C-6), 131.0 (C-5’), 135.5 (C-1’), 149.5(C-8a), 153.1 (C-2), 158.9 (C-4”), 161.4 (CO2H), 165.4 (CONH), 176.6 (C-4). LC-MS(m/z): positive mode 436 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 100%. mp230-231 ◦C.
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5.2.32.73 4-Oxo-8-(3-phenethoxybenzamido)-4H-chromene-2-carboxylic acid250 (ANM270)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using 168(174 mg, 0.38 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a pale-yellow solid (142 mg, 87% yield).1H NMR: δ 3.08 (t, J = 6.8 Hz, 2H, 2”-H), 4.30 (t, J = 6.8 Hz, 2H,1”-H), 6.94 (s, 1H, 3-H), 7.15-7.25 (m, 2H, 4’-H, 4”’-H), 7.28-7.38(m, 4H, 2”’-H, 3”’-H, 5”’-H, 6”’-H), 7.42-7.49 (m, 1H, 6-H), 7.51-7.61(m, 3H, 2’-H, 5’-H, 6’-H), 7.91 (dd, J = 8.0, 1.6 Hz, 1H, 5-H), 8.07 (dd, J = 7.8 Hz,1.6 Hz, 1H, 7-H), 10.19 (s, 1H, CONH). 13C NMR: δ 35.0 (C-2”), 68.5 (C-1”), 113.5(C-2’, C-3), 118.4 (C-4’), 120.1 (C-5), 121.6 (C-6’), 124.5 (C-4a), 125.7 (C-7), 126.4(C-4”’), 128.4 (C-8), 128.4 (C-2”’, C-6”’), 129.1 (C-3”’, C-5”’), 129.9 (C-6), 131.0 (C-5’),135.5 (C-1’), 138.4 (C-1”’), 149.5 (C-8a), 153.0 (C-2), 158.6 (C-4”), 161.3 (CO2H), 165.3(CONH), 177.6 (C-4). LC-MS (m/z): positive mode 430 [M+H]+. Purity by HPLC-UV(254 nm)-ESI-MS: 99.2%. mp 230-231 ◦C.
5.2.32.74 4-Oxo-8-(3-((5-phenylpentyl)oxy)benzamido)-4H-chromene-2-carbo-xylic acid 253(ANM280)
O
O
CO2H
NHO
O
The compound was synthesized according to GP-14 using171 (138 mg, 0.28 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (123 mg,93% yield). 1H NMR: δ 1.40-1.52 (m, 2H, 2”-H), 1.59-1.70 (m,2H, 3”-H), 1.71-1.83 (m, 2H, 5”-H), 2.56-2.64 (m, 2H, 4”-H),4.05 (t, J = 6.4 Hz, 2H, 1”-H), 6.95 (s, 1H, 3-H), 7.11-7.22 (m,4H, 4’-H, 3”’-H, 4”’-H, 5”’-H), 7.22-7.29 (m, 2H, 2”’-H, 6”’-H), 7.45 (t, J = 7.9 Hz, 1H,6-H), 7.51-7.61 (m, 3H, 5’-H, 6’-H, 2’-H), 7.91 (dd, J = 8.0, 1.6 Hz, 1H, 5-H), 8.08 (dd,J = 7.7, 1.6 Hz, 1H, 7-H), 10.17 (s, 1H, CONH). 13C NMR: δ 25.4 (C-2”), 28.6 (C-3”),30.9 (C-5”), 35.2 (C-4”), 67.8 (C-1”), 113.5 (C-3, C-2’), 118.5 (C-4’), 120.0 (C-5), 121.6(C-6’), 124.5 (C-4a), 125.7 (C-7), 128.3 (C-8), 128.4 (C-2”’, C-3”’, C-4”’, C-5”’, C-6”’),129.9 (C-6), 130.9 (C-5’), 135.5 (C-1’), 142.3 (C-1”’), 149.4 (C-8a), 153.0 (C-2), 158.9(C-4”), 161.4 (CO2H), 165.4 (CONH), 177.6 (C-4). LC-MS (m/z): positive mode 472[M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.6%. mp 206-207 ◦C.
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5.2.32.75 6-Chloro-8-(3-(hexyloxy)benzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 246(ANM334)
O
O
CO2H
NHO
O CH3
Cl
The compound was synthesized according to GP-14 using165 (40 mg, 0.10 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (34 mg,95% yield). 1H NMR: δ 0.84-0.91 (m, 3H, 6”-H), 1.19-1.37 (m,4H, 5”-H, 4”-H), 1.37-1.50 (m, 2H, 3”-H), 1.65-1.80 (m, 2H, 2”-H), 4.05 (t, J = 6.5 Hz, 2H, 1”-H), 6.97 (s, 1H, 3-H), 7.19 (dd, J= 2.5, 8.2Hz, 1H, 4’-H), 7.46 (td, J = 7.9 Hz, 1H, 5’-H), 7.52-7.62 (m, 2H, 2’-H, 6’-H),7.83 (d, J = 2.6 Hz, 1H, 5-H), 8.21 (d, J = 2.6 Hz, 1H, 7-H), 10.28 (s, 1H, CONH). 13CNMR: δ 14.1 (C-6”), 22.2 (C-5”), 25.3 (C-4”), 28.8 (C-3”), 31.2 (C-2”), 67.9 (C-1”), 113.5(C-2’), 113.6 (C-3), 118.7 (C-4’), 120.0 (C-6’), 120.2 (C-5), 125.2 (C-4a), 130.0 (C-7),130.0 (C-6, C-1’), 130.2 (C-5’), 135.1 (C-8), 147.9 (C-8a), 153.3 (C-2), 158.9 (C-3’),161.1 (CONH), 165.4 (C2H), 176.5 (C-4). LC-MS (m/z): positive mode 444 [M+H]+.Purity by HPLC-UV (254 nm)-ESI-MS: 95.0%. mp 228-230 ◦C.
5.2.32.76 6-Chloro-8-(3-(octyloxy)benzamido)-4-oxo-4H-chromene-2-carboxylicacid 248 (ANM335)
O
O
CO2H
NHO
O
Cl
CH3
The compound was synthesized according to GP-14 using294 (219 mg, 0.44 mmol). Recrystallization from 1:1 ace-tone/ethanol afforded the product as a white solid (118mg, 57% yield). 1H NMR: δ 0.80-0.90 (m, 3H, 8”-H), 1.18-1.39 (m, 10H, 7”-H, 6”-H, 5”-H, 4”-H), 1.38-1.50 (m, 2H,3”-H), 1.72-1.76 (m, 2H, 2”-H), 4.05 (t, J = 6.4 Hz, 2H,1”-H), 6.97 (s, 1H, 3-H), 7.19 (ddd, J = 8.2, 1.0 Hz, 1H, 4’-H), 7.46 (t, J = 7.9 Hz, 1H,5’-H), 7.51-7.59 (m, 2H, 2’-H, 6’-H), 7.83 (d, J = 2.6 Hz, 1H, 5-H), 8.21 (d, J = 2.6Hz, 1H, 7-H), 10.27 (s, 1H, CONH). 13C NMR: δ 14.1 (C-8”), 22.2 (C-7”), 25.7 (C-6”),28.8 (C-3”, C-4”, C-5”), 31.4 (C-2”), 67.9 (C-1”), 113.5 (C-2’, C-3), 118.7 (C-4’), 120.0(C-6’), 120.2 (C-5), 125.2 (C-4a), 129.6 (C-7), 130.0 (C-5’), 130.2 (C-6, C-1’), 147.9(C-8a), 153.3 (C-2), 158.9 (C-3’), 161.1 (CONH), 165.4 (CO2H), 176.5 (C-4). LC-MS(m/z): positive mode 472 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.7%. mp221-224 ◦C.
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5.2.32.77 6-Chloro-8-(3-(heptyloxy)benzamido)-4-oxo-4H-chromene-2-carboxy-lic acid 247(ANM337)
O
O
CO2H
NHO
O
Cl
CH3
The compound was synthesized according to GP-14 us-ing 166 (213 mg, 0.44 mmol). Recrystallization from 1:1acetone/ethanol afforded the product as a white solid (101mg, 50% yield). 1H NMR: δ 0.86 (t, J = 6.8 Hz, 3H, 7”-H),1.22-1.38 (m, 8H, 6”-H, 5”-H, 4”-H), 1.39-1.47 (m, 2H, 3”-H),1.72-1.76 (m, 2H, 2”-H), 4.05 (t, J = 6.4 Hz, 2H, 1”-H), 6.97(s, 1H, 3-H), 7.19 (dd, J = 8.3, 2.5 Hz, 1H, 4’-H), 7.46 (t, J = 7.9 Hz, 1H, 5’-H), 7.51-7.59 (m, 2H, 2’-H, 6’-H), 7.83 (d, J = 2.6 Hz, 1H, 5-H), 8.21 (d, J = 2.6 Hz, 1H, 7-H),10.28 (s, 1H, CONH). 13C NMR: δ 140.1 (C-7”), 22.2 (C-6”), 25.6 (C-5”), 28.6 (C-3”,C-4”), 31.4 (C-2”), 67.9 (C-1”), 113.5 (C-2’, C-3), 118.7 (C-4’), 120.0 (C-6’, C-5), 125.2(C-4a), 129.9 (C-7), 130.0 (C-3’), 130.1 (C-6, C-1’), 135.1 (C-8), 147.8 (C-8a), 153.2(C-2), 158.9 (C-3’), 161.1 (CONH), 165.3 (CO2H), 176.5 (C-4). LC-MS (m/z): positivemode 458 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS: 99.3%. mp 222-224 ◦C.
5.2.32.78 8-(3-(3-Cyclohexylpropoxy)benzamido)-6-fluoro-4-thioxo-4H-chro-mene-2-carboxylic acid 262(ANM346)
O
S
F
NH
CO2H
O
O
The compound was synthesized according to GP-14 using 180(85 mg, 0.16 mmol). Recrystallization from 1:1 acetone/ethanolafforded the product as a white solid (43 mg, 56% yield). 1HNMR: δ 0.80-0.95 (m, 2H, Cyclohexyl), 1.06-1.39 (m, 6H, Cyclo-hexyl, 3”-H), 1.57-1.82 (m, 7H, 2”-H, Cyclohexyl), 4.04 (t, J = 6.4Hz, 2H, 1”-H), 7.20 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H, 2’-H), 7.47 (t,J = 7.9 Hz, 1H, 5’-H), 7.52-7.61 (m, 2H, 4’-H, 6’-H), 7.68 (s, 1H,3-H), 7.86 (dd, J = 9.0, 3.1 Hz, 1H, 5-H), 8.17 (dd, J = 9.4, 3.1 Hz, 1H, 7-H), 10.32 (s,1H, CONH). 13C NMR: δ 26.0-26.3 (C-3”’, C-5”’, C-4”’. C-3”), 33.0 (C-2”’, C-6”’, C-2”),37.0 (C-1”’), 68.3 (C-1”), 107.8-108.0 (C-5), 113.5 (C-2’), 118.1-118.3 (C-7), 118.7 (C-4’), 120.0 (C-6’), 124.1 (C-3), 130.0 (C-5’), 131.1 (C-8), 131.5 (C-4a),135.0 (C-1’), 141.3(C-8a), 143.6 (C-2), 158.9 (C-3’), 160.7 (C-6), 161.6 (CO2H), 165.4 (CONH), 202.0 (C-4). LC-MS (m/z): positive mode 484 [M+H]+. Purity by HPLC-UV (254 nm)-ESI-MS:95.0%. mp 212-214 ◦C.
308
5.2 Synthesis and characterization Dissertation, Universität Bonn 2016
5.2.33 6-Butyl-8-(carboxyformamido)-4-oxo-4H-chromene-2-car-boxylicacid5.2.33.1 6-Butyl-8-(carboxyformamido)-4-oxo-4H-chromene-2-carboxylic acid196 (ANM383)
NH
O
O
CO2H
O
O OH
33 (20 mg, 0.069 mmol) was dissolved in DCM (2 mL) andone drop of THF under an argon atmosphere. After additionof DIPEA (0.05 mL, 0.069 mmol) and ethyl chlorooxoacetate(0.21 mL, 0.19 mmol) the reaction mixture was stirred at rt for2 days. After removing the solvent under reduced pressurea solution of potassium carbonate (10 mg, 0.089 mmol) in water (0.7 mL) was slowlyadded to a suspension of the obtained crude ester in THF (2 mL) and EtOH (0.5 mL).The reaction mixture was stirred at rt overnight until a clear solution was obtained.The mixture was acidified with diluted aq. HCl solution (2 N) until a pH ≤ 2 wasreached. The solvents THF and EtOH were removed under reduced pressure andthe product was filtered and washed with water. The product was isolated as awhite solid (18 mg, 78% yield). 1H NMR: δ 0.90 (t, J = 7.3 Hz, 3H, 4’-H), 1.12-1.44(m, 2H, 4’-H), 1.48-1.74 (m, 2H, 2’-H), 2.71 (t, J = 7.6 Hz, 2H, 1’-H), 6.91 (s, 1H,3-H), 7.66 (d, J = 2.2 Hz, 1H, 5-H), 8.16 (d, J = 2.2 Hz, 1H, 7-H), 10.23 (s, 1H, NH).13C NMR: δ 13.8 (C-4’), 21.7 (C-3’), 32.9 (C-2’), 34.4 (C-1’), 113.5 (C-3), 120.0 (C-5),124.0 (C-4a), 126.8 (C-8), 127.8 (C-7), 140.3 (C-1’), 146.0 (C-8a), 152.7 (C-2), 156.7(CONH), 161.3 (CO2H), 177.3 (C-4). LC-MS (m/z): positive mode 334 [M+H]+. Purityby HPLC-UV (254 nm)-ESI-MS: 95.1%. mp 224-225 ◦C.
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5.3 Biological Evaluation
5.3.1 Pharmacological testing of chromenon-4-one-2-carboxylicacid derivatives5.3.1.1 Calcium assayThe receptor (GPR17) was expressed in 1321N1 astocytoma cells. Cells of two 175cm2 culture flasks with a confluence of 70-80% were incubated for 45 min in 30 mL ofculture medium in an incubator. Then the cells were sedimented at 200g for 5 minand the supernatant was discarded. The cells were taken up in 994 µL potassiumhydrogen phthalate (KHP)-buffer und pipetted into an Eppendorf tube containing3 µL of Oregon Green R©BAPTA(1,2-bis(o-aminophenoxy)ethane-N,N,N,N-tetraaceticacid)-1/AM- and 3 µL of Pluronic R© F127 solution. The cells were then incubatedfor two hours under light exclusion at rt and 200 rpm. Meanwhile 2 µL of theantagonist (different concentrations; in DMSO, final concentration 1%) was pipettedin a 96 well plate. After incubation the cells were sedimented for 1 min at 2000 rpm,the supernatant removed, washed twice with 1 mL of KHP buffer each, and taken upin 1 mL KHP buffer. Then they were isolated and diluted with 19 mL of KHP buffer.178 µL of cell suspension were added to the antagonist solution per well. After30 min incubation a validation was performed using the NOVOstar R© fluoremeter.Then 20 µL of the agonist solution in DMSO/KHP buffer (1µM MDL29.951234) wasadded automatically by the NOVOstar R© fluorometer to the wells. Fluorescence wasmeasured for 36 s (excitation: 485 nm, emission: 520 nm). Concentration-inhibitioncurves were performed in 3 independent experiments.These experiments were performed by Dr. Aliaa Abdelrahman.
5.3.1.2 β-Arrestin recruitment assayThe experiments were performed using thePathhunter β-Arrestin recruitment sys-tem. For the β-arrestin assays specially modified CHO cells were used. Thosecells express fusion proteins, which consist of β-arrestin and a N-terminal dele-tion mutant of β-galactosidase. Furthermore a receptor was expressed which hasan enzyme fragment fused to its C-terminal domain. Cell lines transfected withhGPR18, hGPR35, hGPR55 or hGPR84 were commercially available or prepared inour group. For the generation of cell lines expressing the murine GPR35 receptors,
310
5.3 Biological Evaluation Dissertation, Universität Bonn 2016
Pathhunter β-Arrestin parental cell lines were transfected with the correspondingplasmids. For each experiment 20000 cells were plated in 90 µL cell plating 2reagent or F12 medium supplemented with fetal calf serum (FCS) (10%), PenicillinG (100 U/mL) and Streptomycin (100 µg/mL) on a 96 well plate one day in advance.After 24 h incubation at 37 ◦C and 5% CO2 the F12 medium was exchanged formedium without FCS (approximately 3 hours prior to the assay). The assay wasstarted by the addition of 10 µL of the agonist solution to each well (10% DMSOin cell plating 2 reagent). For the antagonist assay 5 µL of the antagonist solution(10% DMSO in cell plating medium 2 each) was added 30 min before 5 µL of theagonist were added (hGPR18: 10 µM THC, hGPR35: 5 µM Zaprinast, hGPR55:1 µM LPI, hGPR84: 20 µM Embelin). After 90 min incubation 50 µL of detec-tion reagent (hGPR18 and GPR35: Pathhunter, DiscoverX; GPR35 and hGPR55:Galacton-Star R© (2mM), Emerald-IITM and lysis buffer 1:5:19) was added followed byfurther incubation for 60 min. Then luminescence was measured for 1 min (TopcountNXT). Concentration-inhibition curves were performed in 3-4 separate independentexperiments.These experiments were performed by Dr. Dominik Thimm (GPR35), Clara Schoeder(GPR18, GPR55) and Dr. Meryem Köse (GPR84).
5.3.1.3 Membrane preparation for radioligand binding assaysCHO cells were transfected using a retroviral transfection system.235 GP+envAM12packaging cells were transfected with the plasmide pLXSN, in which the humanGPR35 was inserted. After pseudotyped retroviruses were formed the virus-containingsupernatant was sterile-filtered and added to the CHO cells. Selection of succes-fully transfected cells lasted one week (DMEM/F-12 medium, Invitrogen, Carlsbad,CA; 10% FCS; 100 U/mL Penicillin G; 100 µg/mL Streptomycin, 0.8 mg/mL G418).Then the cells were cultured in the same medium containing a reduced concentra-tion of G418 (0.2 mg/mL). After removing the culture medium the cells were washedwith phosphate-buffered saline (PBS) buffer and frozen to -20 ◦C. In a sterile buffercontaining 5 mM Tris-HCl and 2 mM ethylenediaminetetraacetic acid (EDTA) (pH= 7.4) the cells were detached followed by mechanical lysis, homogenisation us-ing an Ultra Turrax (11000 UpM, 15 s) and centrifugation (10 min, 1000g, 4 ◦C).The membranes in the supernatant were sedimented for 1 h at 48000g and 4 ◦C.
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Then the pellet was resuspended in sterile 50 mM Tris-HCl buffer (pH = 7.4). Themembrane suspension was homogenized, aliquoted and stored at -80 ◦C.236 Proteinconcentration was determined following the method of Lowry.237These experiments were performed by Dr. Dominik Thimm.
5.3.1.4 Radioligand binding assayRadioligand binding assays were carried out using [3H]PSB-1325365 in a final vol-ume of 400 µL (10 µL DMSO or test compound dissolved in 100% DMSO, 190 µLbuffer (sterile 50 mM Tris-HCl, 10 mM MgCl2, pH = 7.4), 100 µL radioligand solu-tion (final concentration 5 nM), 100 µL membrane preparation (10 µg protein)). Themembrane preparations were diluted with a sterile buffer (50 mM Tris-HCl and 10mM MgCl2, pH = 7.4). For the competitive studies the assay solution was incubatedfor 100 min followed by filtration through a GF-B filter using a Brandel Harvester(Brandel, Gaithersburg, MD). The filters were washed three times with 2-3 mL ofice-cold 50 mM Tris-HCl buffer (pH = 7.4) and the radioactivity was measured byscintillation counting using a Tri-Carb 1810 TR (Perkin-Elmer, Waltham, MA) Threeto four separate experiment were performed in duplicates.These experiments were performed by Dr. Dominik Thimm.
5.3.1.5 cAMP accumulation assayCHO cells expressing hGPR84 were cultured for 2 days on 24 well plates. Afterremoving the culture medium the cells were washed with HBSS! (HBSS!) (pH =7.4). Then the cAMP accumulation assay was performed (final assay volume 500 µL).After addition of 300 µL HBSS in each well 50 µL Ro20-1724 as phosphodiesteraseinhibitor was pipetted followed by an incubation of 10 min at 37 ◦C. 50 µL of theantagonist solution (100 % DMSO) (or 50 µL HBSS to the controls with forskolin ordecanoic acid) were added and further incubated for 60 min. Then 50 µL decanoicacid as agonist (or 50 µL HBSS containing 10% DMSO as control with forskolin)were added. After an incubation of exactly 5 min 50 µL of forskolin were added forthe stimulation of the cellular cAMP production and after further 15 min of incubationthe reaction was stopped by removing the reaction buffer and addition of hot lysisbuffer (500 µL, 90 ◦C, 4 mM EDTA, 0.01% TritonTM X-100, pH = 7.4, Sigma, München).
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After cooling down for 5 min the 24 well plates were frozen at -20 ◦C.Before the assay was continued the cell lysate was thawed up and homogenizedwith the pipette. To determine the cAMP concentration 50 µL of the cell lysate wasincubated with 30 µL [3H]cAMP (3 nM) and 40 µL cAMP binding protein (cAMPdependend protein kinase238) diluted in lysis buffer for 1 h at 4 ◦C followed byfiltration through a GF/B filter using a Brandel Harvester (Brandel, Gaithersburg,MD). The radioactivity was measured by scintillation counting using a Tri-Carb 1810TR (Perkin-Elmer, Waltham, MA). Three to four separate experiment were performed.These experiments were performed by Dr. Meryem Köse.
5.3.2 Biological testing of ecto-5’-nucleotidase (CD73) inhibitors5.3.2.1 Radiometric TLC eN assayHuman blood was taken from healthy volunteers by venipuncture and was allowedto clot at room temperature for 30 min. Blood samples were centrifuged for 15min at 2000 g followed by freezing of the serum at -70 ◦C. The enzyme assayswith cultured cell lines (MDA-MB-231 and HUVEC)222 were carried out in 96 wellplates. Serum samples (4-7 µL), or recombinant human eN (purified as previouslydescribed),224 or cells, respectively, were incubated for 1 h at 37 ◦C. The enzymeassays were carried out in a final volume of 80 µL of RPMI-1640 medium containing5 mM β-glycerophosphate and 40 µM, 40 µM, 400 µM and 200 µM of unlabeledAMP for recombinant eN, human serum eN, MDA-MB-231 and HUVEC, respectively,containing tracer [2-3H]AMP (18.6 Ci/mmol; Amersham, Little Chalfont, UK) as asubstrate. The products were separated by TLC on Alugram SIL G/UV254 plates(Machery-Nagel, Düren, Germany) (eluent: 1-butanol 1.5 eq.; isoamylalcohol 1 eq.;diethyleneglycol monoethylether 3 eq.; ammonia solution 1.5 eq.; pure water 2.5 eq.)and quantified by scintillation β-counting as previously described.223 Concentration-inhibition curves were performed in 2-4 separate experiments.
5.3.2.2 Lead-nitrate stainingFrozen human tonsil and mouse spleen sections, thawed to room temperature, werepreincubated for 45 min at room temperature with Trizma maleate buffer containingsucrose (40 mM Trizma maleate, 0.25 M sucrose, pH 7.4), alkaline phosphatase
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inhibitor tetramisole (3 mM) and in case of inhibitor treatment Ecto-5’-nucleotidaseinhibitor (600 nM) or AOPCP (20 µM). After addition of Pb(NO)3 (2 mM), AMP (1mM)and CaCl2 (0.5 mM) the enzyme reaction was performed for 90 min at 37 ◦C. Afterincubation of the tissue sections for 30 sec in 0.5% NH4S and mounting with VectaMount (Vector Laboratories, Burlingame, CA) images were taken using an OlympusBX60 microscope.225
5.3.2.3 Haematoxylin-Eosin stainingFrozen human tonsil and mouse spleen sections, thawed to room temperature, werepreincubated for 10 min with Mayers Hematoxylin solution. After washing withwater the sections were washed for 30 sec with Milli Q water followed by incubationfor 40 sec in eosin solution. Then the sections were washed twice in 70%, 96%, and99% EtOH for 30 sec each. After fixing twice in xylene for 5 min each, the sectionswere mounted with Aquatex (Merck).
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6 List of abbreviations
GPCR G protein-coupled receptor
7TM-receptor 7-transmembrane receptor
CALCR calcitonin receptor
CRHR corticotropin-releasing hormone receptor
GCGR glucagon receptor
GRM metabotropic glutamate receptor
GABA γ-aminobutyric acid
CASR calcium-sensing receptor
MECA melanocortin, endothelial differentiation sphingolipid, cannabinoid, adeno-sine
SOG somatostatin, chemokine, galanin
MCH melanin-concentrating hormone
GEF guanosine triphosphate exchange factor
GDP guanosine diphosphate
GTP guanosine triphosphate
AC adenylate cyclase
ATP adenosine triphosphate
cAMP cyclic adenosine monophosphate
PKA protein kinase A
CREB responsive element binding protein
PKB phosphorylase kinase B
PLC phospholipase C
315
Anne Meyer 6 List of abbreviations
PIP2 phosphatidylinositol-4,5-bisphosphate
IP3 inositol trisphosphate
DAG diacylglycerol
CAMK Ca2+/calmodulin-dependent protein kinase
PKC protein kinase C
RhoGEF Rho guanine nucleotide exchange factors
GRK G protein-coupled receptor-kinase
AP-2 β2-adaptin
IUPHAR International Union of Basic and Clinical Pharmacology
5HT1A receptor 5-hydroxytryptamine receptor
AMP adenosine 5’-monophosphate
ADP adenosine 5’-diphosphate
UTP uridine triphosphate
UDP uridine diphosphate
MS multiple sclerosis
CNS central nervous system
cDNA complementary DNA
RT-PCR reverse transcription polymerase chain reaction
CysLT1 cysteinyl-leukotriene receptor 1
CysLT2 cysteinyl-leukotriene receptor 2
CysLT cysteinyl-leukotriene receptor
LTD4 leukotriene D4
LTC4 leukotriene C4
LTE4 leukotriene E4
ERK extracellular-signal regulated kinase
SCI spinal cord injury
bHLH basic helix-loop-helix
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OPC oligodentrocyte precursor cell
NGF neuronal growth factor
siRNA small interfering RNA
SAR structure-activity relationship
SNP single nucleotide polymorphism
IBD inflammatory bowel disease
iNKT invariant natural killer T cell
TRPV1 transient receptor potential vanilloid 1
LPA lysophosphatidic acid
PDE phosphodiesterase
AEA anandamide
2-AG 2-arachidonylglycerol
CB cannabinoid
EST expressed sequence tag
PCR polymerase chain reaction
mRNA messenger RNA
LPI lysophosphatidylinositol
BMI body mass index
DSS dextran sulfate sodium
TNBS trinitrobenzene sulfonic acid
THC tetrahydrocannabinol
MEA methanandamide
DRG dorsal root ganglion
MCFFA medium-chain free fatty acid
SCFFA short-chain free fatty acid
LCFFA long-chain free fatty acid
DIM diindolylmethane
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LPS lipopolysaccharide
IL interleukin
TNF-α tumor necrosis factor-α
EAE experimental autoimmune encephalomyelitis
HFC high-fat chow
ADSC adipose-derived stem cell
6-OAU 6-n-octylaminouracil
PMN polymorphonuclear neutrophil
LSC leukemic stem cell
AML acute myeloid leukemia
MLL mixed lineage leukemia
AD Alzheimer’s disease
GERD gastroesophageal reflux disease
eNPP ecto-nucleotide pyrophosphatases/phosphodiesterase
eNTPDase ecto-nucleoside triphosphate diphosphohydrolase
AP alkaline phosphatase
eN ecto-5’-nucleotidase
ADA ecto-adenosine deaminase
PNP purine nucleoside phosphorylase
NTP nucleoside triphosphate
NMP nucleoside monophosphate
NDP nucleoside diphosphate
GPI glycosylphosphatidylinositol
AOPCP α ,β-methylene-ADP
rt room temperature
mp melting point
DMF dimethylformamide
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TBDMS tert-butyldimethylsilyl
aq. aquaous
NBS N-bromosuccinimide
AIBN azobisisobutyronitrile
THF tetrahydrofurane
DMF dichlormethane
DIPEA N,N-diisopropylethylamine
Boc tert-butyloxycarbonyl
EtOAc ethyl acetate
TLC thin-layer chromatography
EA enzyme acceptor
HUVEC human umbilical vein endothelial cell
DMSO dimethylsulfoxide
ESI electrospray ionization
LC-MS liquid chromatography-mass spectrometry
HPLC high-performance liquid chromatography
UV ultraviolet
mp melting point
KHP potassium hydrogen phthalate
FCS fetal calf serum
PBS phosphate-buffered saline
EDTA ethylenediaminetetraacetic acid
PNL partial sciatic nerve ligation
DCM dichloromethane
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